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Alzheimer´s disease (AD) biomarkers that can detect and track disease progression at 
its earliest stages to aid the critical search for a disease modifying therapy is much 
needed. Markers of in vivo amyloid-beta (Aβ) deposition (e.g. 11C-PiB) combined 
with positron emission tomography (PET) or cerebrospinal fluid (CSF) examination 
are becoming widely utilised as essential criterion for AD prevention trials. Although 
necessary, this is likely to come at a great cost and will restrict the progression of 
some trials. The inexpensive and accessible nature of a blood-based prediction for 
AD risk would be of considerable value in a population screening process. The 
traditional “case versus control” design frequently disregards the clinical 
heterogeneity in AD, with active preclinical neuropathology overlooked. Therefore, 
deriving biologically relevant markers associated with in vivo surrogates of AD 
pathology is considered a superior approach. Here, we aimed to identify single and 
multi-analyte plasma biomarkers associated with neocortical Aβ burden (NAB) using 
two proteomic approaches.  
One dimensional gel electrophoresis (1DGE) coupled with Mass Spectrometry was 
performed on 78 individuals with extreme ranges of NAB. Immunoassay-based 
techniques were utilised to validate protein candidates in independent cohorts. 
Further to this, an improved proteomic strategy incorporating high-resolution peptide 
separation was able to increase the number of quantifiable targets and widen plasma 
proteome coverage. This enhanced methodology was applied to 297 individuals from 
two cohorts stratified by Aβ PET. In both discoveries, the relationship between 
plasma protein levels and NAB modalities was examined, with an attempt to build 
multi-modal predictions of NAB. 
In the first discovery study, several candidates associated with NAB were selected 
for technical replication. Plasma FGγ models predicted NAB with a sensitivity of 
59% and specificity of 78%. FGγ was further shown to associate with Aβ using core 
CSF biomarkers as surrogate measures. The secondary discovery study demonstrated 
a larger number of single markers associated with NAB, along with the verification 
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of brain-derived proteins found to be present in plasma. A machine learning analysis 
built a multi-analyte panel for NAB prediction which was shown to replicate, in an 
independent cognitively normal cohort, with an accuracy of 86.6%. This predictive 
panel indicated the convergence of pathways related to coagulation, APP processing, 
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The identification of 468 highly expressed cerebral cortex protein groups that have 
peptide spectral evidence (at 5% FDR) of plasma expression in the OGE-9 
methodology highlighted in Chapter 4. A total of 311/468 protein groups have been 
described as “Grouped Enriched” (n = 88) or “Tissue Enhanced” (n = 223) by 
Human Protein Atlas. These are protein groups that have five-fold higher expression 







C-PiB Pittsburgh compound B  
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AD Alzheimer's disease 
AGC Automatic Gain Control 
AGP α1-Acid glycoprotein  
AIBL 
Australian Imaging, Biomarkers and Lifestyle Flagship Study of 
Ageing  
ALS Amyotrophic lateral sclerosis 
Ambic Ammonium Bicarbonate 
ANM AddNeuroMed study 
ANOVA Analysis of variance 
apo(a) apolipoprotein(a)  
apoA1 apolipoprotein A-I  
apoA2 apolipoprotein A-II 
apoA4 apolipoprotein A-IV 
ApoE apolipoprotein E (protein) 
APOE apolipoprotein E (gene) 
apoL1 apolipoprotein L1  
APP amyloid precursor protein 
APP Amyloid precursor protein (gene) 
AUC Area Under the Curve 
Aβ Amyloid-beta 
BACE1 β-secretase 
BBB Blood-brain barrier 
BDP Brain-derived protein 
C18 C18-bonded silica 
C4α complement C4-A  
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CAA Cerebral amyloid angiopathy 
CART Classification and Regression Trees  
CC3 complement C3 
CDR Clinical Dementia Rating  
CFB complement factor B 
CFH complement factor H  
CJD Creutzfeldt-Jakob disease 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CSF Aβ1-42- Cerebrospinal fluid beta-amyloid negative 
CSF Aβ1-42+ Cerebrospinal fluid beta-amyloid positive 
CV Coefficient of Variation 
Da Daltons 
DAVID Database for Annotation, Visualization and Integrated Discovery 
ddH20 Double distilled water 
DIAN Dominantly Inherited Alzheimer Network 
DLB Dementia with Lewy Bodies 
DS Down Syndrome 
DTT Dithiothreitol 
ELISA Enzyme-linked immunosorbent assay 
EMIF European Medical Informatics Framework 
EMIF-AD European Medical Informatics Framework for Alzheimer’s disease 
ENO2 neuron specific enolase 
EOAD Early onset Alzheimer’s disease  
FA Formic acid 
FDA Food and Drug Administration 
FDG Fludeoxyglucose 
FDR False discovery rate 
FGα fibrinogen α chain  
FGβ fibrinogen β chain  
FGγ fibrinogen γ chain  
FHR-1 complement factor H related protein 1  
FTD Frontotemporal Dementia 
FTLD Frontotemporal lobar degeneration  
x g Acceleration due to gravity 
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GFAP glial fibrillary acidic protein 
GLM Generalised linear model 
GWAS Genome-wide association study 
h Hours 
HA Heterophilic antibodies 
HCD Higher Collision induced Dissociation 
HD Huntington's disease 
HEC Healthy elderly control 
HPA Human Protein Atlas 
HRG histidine-rich glycoprotein  
HRP Horseradish peroxidase 
IAA Iodoacetamide 
IDE Insulin degrading enzyme 
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IgA Immunoglobulin A 
IgG Immunoglobulin G 
IGHA1 Ig alpha-1 chain C region 
IgM Immunoglobulin M 
IPG Immobilised pH gradient 
IV Intravenous 
kDa Kilodaltons 
KEGG Kyoto Encyclopedia of Genes and Genomes  
kVh Kilo voltage hours 
LASSO Least absolute shrinkage and selection operator 
LC Liquid chromatography 
LC-MS/MS Liquid chromatography – tandem mass spectrometry 
LOAD Late onset Alzheimer’s disease 
LOD Limit of detection 
LP Lumbar puncture  
LTQ Linear Trap Quadrupole  
M Molar 
m/z  Mass-to-charge ratio 
MBL Mannose-binding lectin  






MMSE Mini Mental State Examination 
MOG myelin-oligodendrocyte glycoprotein 
MRI Magnetic resonance imaging 
MS Mass spectrometry  
MS/MS Tandem mass spectrometry 
MSA Multiple system atrophy 
MSD Mesoscale discovery 
MTL Medial temporal lobe  
MW Molecular weight 
n Number 
NAB Neocortical amyloid burden  
NaCl Sodium chloride 
NDEs Neuronal-derived exosomes 
NEFL neurofilament light 
NFT Neurofibrillary tangles  




NPV Negative predcitive value 
NRGN neurogranin 
Qalb CSF/plasma albumin ratio 
OGE OFFGEL fractionation  
OPALIN oligodendrocytic myelin paranodal and inner loop protein 
OR Odds ratio 
pAGC predictive automatic gain control 
PARK7 protein deglycase DJ-1 
PBS Phosphate buffered saline 
PCA Principle component analysis 
PD Parkinsons disease 
PDD Parkinsons disease dementia 
PET Positron emmision tomography 
pH Potential of Hydrogen 
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PiB- Pittsburgh compound B negative 
PiB+ Pittsburgh compound B positive 
PLP1 proteolipid Protein 1 
PPD Plasma Proteome Database 
ppm Parts per million 
PPV Postivie predictive value 
PPY pancreatic polypeptide  
PRQ-1 Pre-processing for Relative Quantification 1 
PRQ-2 Pre-processing for Relative Quantification 2 
PSEN1 Presenilin 1 (gene) 
PSEN2 Presenilin 2 (gene) 
PSM Peptide spectral matches 
PSP Progressive supranuclear palsy 
PTM Post translational modification  
QC Quality control 
RBM Rules-Based Medicine 
RF Random Forest 
ROC Receiver Operator Characteristic 
ROI Region of interest 
rpm Revolutions per minute 
RT Room temperature 
S.D Standard deviation 
S100B S100 calcium-binding protein B 
SCX Strong cation exchange 
SDS Sodium dodecyl sulfate 
SIMOA Single-molecule enzyme-linked immunosorbent assay 
SMC Subjective memory complaints 
SNAP Suspected Non Amyloid Pathology 
SNAP-25 synaptosome associated protein 25kDa 
SNCA α-synuclein  
SNCB β-synuclein  
SNP Single nucleotide polymorphism 
SRM Selection reaction monitoring 
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TFA Trifluoroacetic acid 
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V Voltage 
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1.1 A brief history of dementia: Auguste Deter to present day   
In 1906, Alois Alzheimer presented for the first time a form of dementia that was 
later acknowledged as Alzheimer’s disease (AD). Alzheimer described the rapid 
clinical decline of his patient, Auguste Deter, who had shown progressive cognitive 
impairment, memory loss, delusional behaviour and psychosocial difficulties. Upon 
post mortem examination, Alzheimer demonstrated the extensive atrophy of the 
cerebral cortex as well as extracellular and intracellular protein aggregates. Although 
these observations had been previously reported by other scientists, it was the young 
age and rapid decline of Auguste Deter that made this case so unique.    
Since Alzheimer’s first account of Auguste Deter, significant discoveries and 
breakthroughs for AD have been hard to come by. It wasn’t until 1984 when the 
extracellular protein deposits that Alzheimer described in Auguste Deter were found 
to be amyloid-beta (Aβ) and in 1985, researchers discovered that the key component 
of the intracellular tangles was hyperphosphorylated tau. Genetic studies identified 
the first gene for inherited familial AD (amyloid precursor protein; APP) in 1987, 
with the first major risk factor gene (apolipoprotein ε4; APOE ε4) being identified in 
1993. The first drug approved by the Food and Drug Administration (FDA) for the 
symptomatic treatment of AD was made in 1996, with three further symptomatic 
only treatments approved since. The discovery of the imaging agent Pittsburgh 
Compound B (PiB) in 2004 was a major breakthrough in disease monitoring and 
early detection by the in vivo assessment of neocortical Aβ deposition. This 
contributed to the development of a hypothetical model being published in 2010, 
based upon growing evidence, that changes in AD related pathology occurs decades 
before clinical onset (Aβ being the earliest). New criteria and guidelines for AD 
diagnosis quickly followed. The first major Phase III preventive trials that targeted 
Aβ production and clearance commenced in 2008, with several others underway and 
concluded since.  
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While in recent year’s major landmark breakthroughs for the cause and 
understanding of AD have been deduced, there is still no disease modifying 
treatment. Since the description of Auguste Deter in 1906, the prevalence and 
concern for AD has grown immeasurably. In 1976, AD was for the first time 
declared the most common cause of dementia and a major public health concern for 
the future. At that time, the estimated prevalence of AD was thought to be between 
880,000 – 1.2 million 1. 
Today, there are more than 40 million worldwide dementia sufferers, mostly older 
than 60 years of age, which is expected to rise to 115 million by 2050 
2
. Of major 
concern, these projected increases in dementia prevalence are proportionally much 
higher for developing countries than for Western Europe and the USA, which already 
have a much older populations 
3
. The global economic burden of dementia care is 
currently estimated at $604 billion and like prevalence rates this figure is set to 
exponentially increase with a projected 85% rise in costs within the next 20 years. 
These figures can be revised if interventions are found to delay or prevent the clinical 
onset of dementia. AD is the main cause of dementia and accounts for around 60-
80% of all cases. AD has therefore been highlighted as a major global priority to 




1.2 Alzheimer’s disease pathology 
AD is primarily characterised by two neuropathological hallmarks; extracellular 
deposits of senile plaques and intracellular neurofibrillary tangles (NFTs). Senile 
plaques exist in various morphological forms including diffuse (‘pre-amyloid’), 
primitive neuritic, classic (‘dense-cored’) plaques 4. The major component of senile 
plaques is amyloid-beta (Aβ), a 38-43 amino acid peptide, which is derived by the 
secretase cleavage of the amyloid precursor protein (APP) 
5
. A variety of Aβ 
peptides are present within these plaques with the most common peptide being 
Aβ42/43, whereas the more soluble Aβ40 is also found in association with blood 
vessels 
6. Diffuse plaques contain Aβ42/43 as well as APP fragments lacking the C-
terminus while more mature classic plaques contain Aβ40 in addition to Aβ42/43 
7
. 
While senile plaques are primarily composed of the Aβ peptides, a host of 
‘secondary’ constituents have been colocalised with Aβ in the AD brain, this 
includes; proteoglycans, inflammatory molecules (e.g. acute phase proteins, 
cytokines, chemokines, complement proteins and immunoglobins), serum related 
molecules (e.g. amyloid-P), metal ions, protease and clearance related elements (e.g. 
alpha-1-antichymotrypsin), antioxidant defense proteins (e.g. ferritin and 
ceruloplasmin) as well as apolipoprotein E and the multifactoral protein clusterin 
(reviewed in 
8-7
).    
The cleavage of APP predominately occurs by the action of α-secretase followed by 
γ-secretase to produce non-amyloidogenic products. The cleavage of α-secretase 
releases a large soluble ectodomain of APP (sAPPα) and a carboxyl terminal 
fragment (αCTF) 9. The γ-secretase cleavage of αCTF produces APP interacellular 
cytoplasmic domain (AICD) and soluble peptide P3 
10
.  However, a proportion of 
APP is cleaved by β-secretase (BACE1) rather than α-secretase to produce sAPPβ 
and βCTF. The following cleavage by γ-secretase produces an Aβ fragment and 
AICD which are transported, via exocytosis, in the extracellular space 
9, 11-12
 (Figure 
1-1). The predominate forms of Aβ produced by the amyloidogenic pathway are Aβ1-
40 and Aβ1-42, of which the latter is considered to be the more neurotoxic and tends to 
aggregate into oligomers, protofibers and fibrils 
13-14. Subsequent diffuse Aβ plaque 
formation leads to localised microglial activation, cytokine release, astrocytosis and a 





Three forms of APP have been described
 
and are referred to as APP695, APP751 and 
APP770, reflecting the number of amino acids encoded for by their respective 
complementary DNAs 
17
. The two larger APPs contain a 57-amino-acid addition 
with striking homology to the Kunitz family of protease inhibitors 
18-19
. It has been 
shown that the deduced amino-terminal sequence of APP is identical to the sequence 
of a cell-secreted protease inhibitor, protease nexin-II (PN-II).
 
Nexin-II potently 
inhibits serine proteases, including trypsin and coagulation factors 
20
. This 
identification of APP as a secreted protease nexin has offered new insights into the 
pathogensis of AD; not only is the protease activities of APP are of importance but 
also the reuptake and degradation APP-protease complexes.  
The “amyloid cascade hypothesis”, supported by genetics, has been the prevailing 
theory to explain AD pathogenesis. This model suggests that APP mismetabolism 
and subsequently the increased production then deposition of toxic Aβ acts as a 
pathological trigger that leads to neurotic injury, NFT formation and cell death which 
underpin neurodegeneration in AD 
21
. This has been further supported by substantial 
genetic, biochemical and pathological evidence 
22
. Recent evidence suggests that the 
failure or imbalance of A clearance, rather than excess formation, is the major 
contributor to toxic deposition 
23-24
. This would attribute mechanisms implicated in 
the degradation of toxic Aβ (i.e. neprilysin, insulin degrading enzyme (IDE), 
intracellular lysosomal degradation and microglia activation) a central importance in 




Figure 0-1: Sequential cleavage of the amyloid precursor protein (APP) occurs by two 
main pathways. The non-amyloidogenic processing of APP involves α-secretase 
followed by γ-secretase. The amyloidogenic processing of APP involves BACE1 
followed by γ-secretase. Both processes generate soluble ectodomains (sAPPα and 
sAPPβ) and identical intracellular C-terminal fragments (AICD).  
Although Aβ peptides are produced in high amounts in pathological conditions, they 
are also present at low levels in normal brains, particularly during synaptic activity. It 
was thought for many years that Aβ was a bi-product of APP catabolism and had no 
non-pathological role. APP is an essential membrane protein with high affinity to 
copper which is ubiquitously expressed 
26
. It has been reported that APP is involved 
in neurodevelopment and is required for neuronal growth 
26
, synaptogenesis and cell 
adhesion 
27
. At nanomolar and micromolar concentrations Aβ causes neurotoxicity 
and cell death, however at picomolar levels Aβ has been shown to act as a key 
growth factor and modulator synaptic activity and plasticity, with relation to memory 
and learning highly important for normal individuals 
28-29
. This is supported by anti-
APP antibodies being shown to block memory formation 
30
. Furthermore, low 
concentrations of Aβ could work as antioxidants, due to its ability to capture redox 
metals, such as Copper, Iron and Zinc, and therefore, preventing their participation in 
redox cycling with other ligands 
31
. Considering the positive or negative effects of Aβ 
at differing concentrations, it is proposed that the peptide exhibits dual effects: 
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The hyperphosphorylation of the microtubule-associated protein tau causes the 
production of NFTs in the intracellular space 
32-33
. Neurodegeneration, synaptic loss 
and cognitive symptoms observed in AD patients are more associated with the 
density and distribution of NFT pathology than Aβ deposition 34. In the adult brain, 
six tau isoforms are coded for by a single gene located on chromosome 17 
35
. A 
prominent feature of the primary structure of tau is the three or four repeat of an 18 
amino acid sequence located at the C-terminal half (3R and 4R tau). This 
microtubule binding domain is involved in the microtubule polymerisation and 
stabilisation 
36
. In neurons, the cytoskeleton undergoes continuous change and tau 
protein regulates this process. The abnormal hyperphosphorylation of tau prevents 
the primary function of tau binding to microtubules and ultimately causes cell death 
by leading to the destabilisation of axons, impairment of axonal transport, axonal 
degeneration and neuronal dysfunction 
37
. Hyperphosphorylated tau also forms 
insoluble aggregates, paired helical filaments (PHF), the foremost constituent of 
NFTs found in AD and other tauopathies 
38
. Tau isolated from AD brains has a 4-
fold increase in phosphorylation 
39
 and all tau isoforms are found to be aggregated in 
PHFs 
40
. Contrary to this causative role, recent evidence from mouse models also 
points towards a protective element of tau in early AD. This is by the specific 
phosphorylation of threonine-205 at post-synaptic terminals 
41
. 
There is growing evidence of the direct or indirect interaction of Aβ pathology and 
tau to accelerate NFT formation. The dominant view is that Aβ precedes and initiates 
a cascade that results in NFT and other pathologies 
42
. Evidence from genetic studies 
that increase Aβ production demonstrates the enhanced development of tau 
pathology 
43
 and whilst hyperphosphorylation of tau promotes aggregation and NFT 
formation, tau kinase activation can be induced by Aβ 43-44. Furthermore, 
inflammatory cytokine activation and impairment of degrading enzymes that increase 
tau phosphorylation can be modulated by Aβ 43.  
Although the relationship of Aβ accumulation and tau pathology remain unclear they 
both finally converge to cause widespread and progressive cell death and neuronal 
loss. Post mortem analysis indicates the medial temporal lobe (MTL), including the 
hippocampus, parahippocampus and entorhinal cortex, to be the first affected by AD 
pathology 
45
. In addition, extensive degeneration of cholinergic processes from the 
43 
 
basal nucleus of Meynert to the neocortex is an early observation in the disease 
process 
45
. As the disease progresses, significant neuronal loss in the cerebral cortex, 
specifically the lateral temporal and medial parietal lobes are observed, followed by 
atrophy of the lateral parietal and frontal lobes 
46
. Upon clinical presentation, an AD 
sufferer will have extensive atrophy of the temporal, parietal and frontal cortices with 
relative preservation of the primary occipital and primary sensor-motor cortex 
45, 47
. 
The extent of clinic symptoms due to AD is more strongly correlated with the 
anatomical extent and number of NFTs in the cortex 
48
. This observation has led to 
the “tau propagation” hypothesis where tau may systemically develop and progress 
independently throughout the brain 
49
. Investigations using animal models strongly 






1.3 Genetic, epigenetic and lifestyle risks  
1.3.1 Genetics of Alzheimer’s disease  
Early onset Alzheimer’s disease (EOAD) and genetic risk 
EOAD compromises the minority of all AD cases (5-10%) with an onset normally 
between 30-65 years of age. EOAD can be categorised by a classic Mendelian 
inheritance pattern, usually autosomal-dominant, however it can present without any 
family history (“sporadic” EOAD). Although autosomal-dominant AD is very rare 
(<1%), discovery of the causative mutations is the basis of unravelling the 




Figure 0-2: Three genes implicated in early onset AD; amyloid precursor protein 
(APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2). 
Highly-penetrant mutations in three genes are considered the main risk factors for 




 and PSEN2 
57
. These mutations have 
been shown to alter A production to increase the A1-42 to A1-40 ratio leading to 
dementia 
58-60
. PSEN1 mutations are the most common and most severe cause of 
autosomal-dominant AD with full penetrance and the age of onset occuring as early 
as 25 years of age 
61







Figure 0-3: The age onset of Alzheimer’s disease depending on the different 
involvement of genes. 
Late onset Alzheimer’s disease (LOAD) and genetic risk 
Late onset AD is considered to be a multifactorial disease; nonetheless, there is a 
considerable genetic contribution. The APOE gene, located on chromosome 19, is an 
important genetic risk factor for LOAD. Apolipoprotein E (ApoE) protein is the 
major cholesterol carrier in the brain and has key roles in neuronal growth, tissue 
injury repair and immunoregulation. ApoE binds to numerous cell surface receptors 
which are implicated in lipid delivery and transport as well as mitochondrial function 
and glucose metabolism. Three predominate allelic variations are found in the APOE 
gene (ε2, ε3 and ε4) encoding for different protein isoforms that differ in two sites of 
the amino acid sequence 
62
. APOE ε3 is the most common variant (77%), while ε2 
(8%) and ε4 (15%) alleles are less common 63. Conversely, the frequency of ε4 
carriers in the AD population is much larger, approximately 60% 
64
 and substantially 
increases the risk in both familial AD and sporadic AD 
65-66
. Typically, ApoE binds 
to Aβ peptides and effectuates the clearance of soluble Aβ and its aggregates 67-68 
however the APOE ε4 variant is less efficient in the clearance of Aβ 68. Furthermore, 
transgenic mouse models that express APOE ε4 show a disinhibition of cyclophlin A 
signalling in the pericytes of the brain-blood vessels and this results in degeneration 
of these vessel and leakage of the blood-brain barrier (BBB) and neurodegeneration 
independent of A 69. Nonetheless, the presence of the APOE ε4 allele alone is not 
sufficient for the development of AD pathology 
66.  Not only has the ε4 allele found 
to increase risk but it is also implicated in the reduction in the age of onset 
62, 70
 and 
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increases the rate of cognitive decline 
71-72
. The APOE ε4 allele has also been found 
to have a stronger association with risk in women than in men 
73-74
. The disease risk 
effect in heterozygous ε4 carriers is estimated at 3-fold whereas a 15-fold risk is 
reported in homozygous ε4 carriers 62, 65, 67. The APOE ε2 allele is considered to be 
protective and to delay disease onset 
66, 75-76
, although in certain populations APOE 
ε2 has been shown not to have protective effect in relation to AD 77. More recent 
evidence suggests a protective mechanism whereby APOE ε2 allele reduces the 
accumulation of Aβ pathology in the ageing brain 78.  
Genome wide association studies (GWAS) have identified a number of novel loci for 
late onset AD, including polymorphisms in: SORL1, BIN1, CR1, CLU and PICALM 
(Table 1-1) 
79-85
. This analysis approach has so far highlighted pathways related to 
cholesterol and lipid metabolism, energy metabolism,  immune system, inflammatory 
responses, endosomal vesicle cycling and risk genes connected with Aβ and Tau 
pathology (Table 1-1). On-going large meta-analyses continue to be published and 
identify new susceptibility genes adding further weight to the implicated pathways in 
AD 
86
. Moreover, GWAS studies have revealed several additional susceptibility loci 
located in gene dense regions; MS4A6A locus, HLA-DRB5 locus, ZCWPW1 locus, 
SLC24A4/RIN3 locus, NME8 locus and CELF1 locus 
64
. It is yet to be determined 
which gene in these regions is responsible for the association. More recently, GWAS 
studies have indentified novel genetic loci associated with hippocampal volume 
87
 
and novel AD loci encoding in proximity to the gene that encoded for tau (MAPT) 
88
. 
None of these indentified risk loci attain the magnitude of APOE ε4, yet they provide 









Table 0-1: Overview of the single locus susceptibility genes identified for AD by GWAS 
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Immune system and 
inflammatory response 
Aβ clearance 
Abbreviations: CI, Confidence interval; OR, Odds ratio. 
Recent next-generation sequencing (NGS) studies and GWAS on very large cohorts 
have revealed rare variants associated with AD. Multiple rare, missense variants in 
TREM2 (1-2% frequency) have been reported to increase the risk for late onset AD 
89-91
 and FTD 
92
. People homozygous for TREM2 variants develop Nasu-Hakola 
48 
 
disease characterised by early onset cognitive problems and with bone fractures and 
cysts.  The most common disease-associated variant in TREM2 (R47H) is found 
within European populations and is reported to have an effect size comparable to 
APOE 4. TREM2 is a highly expressed receptor in microglia where it is thought to 




Epigenetics refers to the change in gene regulation caused by modifications to the 
DNA’s packaging protein or the DNA molecules themselves without changing the 
underlying nucleotide sequence 
94-95
. Epigenetic modifications have found to be a 
cause of phenotypic plasticity loss associated with the ageing process 
96
. Since 
ageing is the biggest risk factor for AD and other neurodegenerative diseases, it is 
hypothesised that epigenetic modifications play a prominent role in disease 
pathogenesis 
97-98
. At the molecular level two dominant epigenetic modifications are 
known: direct methylation of DNA or modification of the histones that package 
DNA 
99-100
. There have been several reports of a genome-wide change in DNA 
methylation in AD patients 
101-103
; whereas epigenome-wide association studies 
(EWAS) have identified hypermethylated genes (SORBS3 and ANK1) in AD 
vulnerable brain regions 
104-106
. The less studied histone modifications have been 
shown to be decreased 
107
 and increased 
108
 in AD post mortem studies.  
Pharmacologically targeting DNA methylation or histone acetylation maybe of 
potential benefit to AD sufferers. Folic acid and Vitamin B12 influence DNA 
methylation through their role in 1-Carbon metabolism 
109
 whereas histone 
deacetylase (HDAC) modifiers (2-valproate) have been used to target histone 
acetylation 
110
.    
1.3.3 Lifestyle and vascular risk factors 





 and head injury 
113
. However, given that AD develops over a 
long preclinical period of several decades; modifiable lifestyle choices may have a 
large impact in the development and onset of AD.  Sufficient evidence points 
towards physical activity and exercise 
114-116











 and smoking 
121-122
 being the most crucial 
modifiable risk factors for AD.  
Regular physical exercise has been shown to delay the onset of AD with even low 
intensity activity shown to be beneficial 
115-116
. Exercise was shown to enhance 
hippocampal neurogenesis 
123
 and learning in rodents 
124
. Moreover, a significant 
protective effect of regular exercise was found in persons with APOE ε4 risk 125. 
Higher BMI in middle aged is a risk factor for many dementias 
117, 126
 and many 
studies link midlife obesity to cognitive decline and directly to AD 
127-128
. 
Conversely, in the elderly, a significant decrease in BMI was associated with the 
onset of AD within 5-6 years 
129-130
.  Alcohol consumption is a widely recognised 
risk for dementia. Middle-aged heavy drinkers are at a 3-fold greater risk to develop 
AD later in life 
131
. There is a significant reduction in risk for light and moderate 
consumers 
132-133
 however, alcohol consumption at all levels has been found to be 
related to brain atrophy and volume loss 
134
. Meta-analysis and systemic review of 
large datasets have shown that enhanced cognitive reserve (a model combing 
education, mental activity and occupation) may have a protective mechanism in 
delaying the onset of dementia 
135
 with education being the most influencing factor 
135
. A number of studies assessing smoking on cognitive health concluded that a 
current smoker was 1.5-fold more likely to develop AD 
122
, with the risk greater in 
APOE ε4 non-carriers 122. 
The lifestyle factors mentioned above may contribute to the development of treatable 





, type 2 diabetes 
139-141
, midlife hypertentsion 
142-143
 and midlife 
hypercholesterolaemia 
144-146
 have been associated with an increased risk of AD. 
Evidence from the Rotterdam study suggests that a 30% reduction in the incidence of 




A number of intervention studies addressing modifiable risk factors to address the 
development of AD have been conducted, with variable results. Many studies link 
hypertension to increased brain atrophy and NFT generation 
147
 however randomised 
controlled trials addressing hypertension have shown little benefit in reducing the 
50 
 
incidence of dementia 
148
. There is also insufficient evidence to support dietary 
supplements in reducing the incidence of AD 
149-150
 and similarly vitamin 
supplements do not seem to be effective 
151
. However, there is continued support for 
the components of a Mediterranean diet in a having an encouraging effect on 
cognition 
152-153
. Furthermore, a moderate benefit of applying cognitive stimulation 
in older adults has been observed 
135, 154
. Many modifiable risk factors of AD do 
overlap, explaining why altering one lifestyle strategy alone has made little impact in 
reducing the incidence of AD. It has been postulated that a more general approach to 
promote healthy living, with a focus on exercise, is the most promising approach 
14
 





1.4 Clinical timeline of symptom development  
1.4.1 Clinical Alzheimer’s disease 
A definitive AD diagnosis can only be made at post mortem and only a “probable” 
diagnosis of AD can be made clinically. AD is characterised by multiple cognitive 
deficits and memory decline which is assessed by a detailed history (by patient and 
carer) to determine the impact on social or occupational functioning 
14
. The National 
Institute on Neurological and Communicative Disorders and Stroke and Alzheimer 
Related Disorders Association (NINCDS/ADRDA) proposed the criteria for the 
diagnosis of AD 
155
 with later revisions made to incorporate advancements in 
clinical, imaging and fluids assessments 
24, 156-158
. The revised NINCDS/ADRDA 
criteria in 2011 recognised that the clinical diagnosis of AD could only be designated 
as “probable” while the patient was alive and could not be made “definite” 
until AD pathology had been confirmed post mortem. The recent NINCDS/ADRDA 
criteria also addressed the development of in vivo assessment of AD pathology. The 
clinical guidelines alone demonstrated a good sensitivity and specificity (>80%) of 
distinguishing AD patients from non-demented individuals 
159
 but were inconsistent 
in separating the subtypes of dementia 
159
.  
More recent criteria set out by the International Working Group (IWG) for New 
Research Criteria for the Diagnosis of Alzheimer's Disease (AD) proposed criteria 
that is reliant on the in vivo biomarker evidence of pathophysiology indicative of AD 
(discussed further in section 1.7) 
158
. Nonetheless the clinical criteria set out for AD 
remains important for clinics without advanced neuroimaging or cerebrospinal fluid 
testing. 
The initial presentation of cognitive impairment follows a long preclinical phase of 
AD pathology 
160
. Individuals with early AD may present clinically normal with only 
slight impediment of daily living. The decline of cognitive impairment is variable but 
often slow in the early symptomatic phase. Significant decline in short term memory 
are the main complaints by the individual or informant but symptoms of aphasia or 
spatial disorientation are commonly described 
161
. Individuals with early AD 
experience difficulty with executive function and reduced verbal fluency. Subtle 
mood changes occur in 20-30% of early AD patients, with behavioural and 
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personality changes observed in 25-50% of cases 
162
. Conversely, agitation, 
psychosis and anxiety are rare in early AD but the frequency tends to increase as the 
disease develops 
163
. Moderate to severe AD has significant impact on daily living 
with functional impairment and dependency on others. Individuals with moderate to 
severe AD have extreme difficulty in retaining new information, develop 
prosopagnosia (deficit in recognising familiar people) and executive function is 
significantly deteriorated. Behavioural symptoms (hallunications, delusions, 
aggression and anxiety) are not always apparent but are increased in the advanced 
stages of AD.  Basic motor functions (dysphagia) can become impaired and almost 
all cognitive functions are lost in severe AD with individuals completely dependent 
on comprehensive care.  
1.4.2 Differential clinical diagnosis  
AD accounts for between 60-80% of dementia cases seen in clinical practice, which 
has been confirmed by post mortem studies 
164-166
. In pathological studies, 
approximately half of post mortem confirmed AD cases have a “pure AD” 
pathological phenotype; the remainder have substantial pathology relating to other 
dementias (i.e DLB or VaD) 
165
. Conversely, a considerable proportion of cases 
diagnosed with non-AD dementia still demonstrate classical AD pathology; DLB 
(66%-70%) and VaD (74%) 
164, 166
. Given this large overlap between the pathological 
presentation of AD and other dementias, neurological evidence that can be derived 
within clinics to suggest differential causes should be pursued. 
Dementia with Lewy Bodies (DLB) is widely considered to be the second most 
common form of dementia, with 30-40% of post mortem dementia cases having 
sufficient pathology to be diagnosed with DLB 
167-168
. In addition to the symptoms of 
dementia, core DLB indicators are visual hallucinations (42%), spontaneous 
Parkinsonism (55%) and cognitive fluctuations 
169
. Sleep disorders, neuroleptic 
sensitivity, repeated falls, syncope (temporary loss of consciousness), autonomic 
dysfunction and depression are also suggestive features of DLB 
169. A “definite” 
DLB clinical diagnosis is made with the presence of at least 2/3 core features, 
whereas a “probable DLB” diagnosis is made with one core feature with the addition 
of a suggestive feature. Compared with AD, a DLB patient is more likely to be 
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impaired in executive, visuoperceptual and psychomotor functions 
170
 and less likely 
to have verbal recall disruption 
171
. Furthermore, early psychiatric symptoms 
(hallucinations and delusions) and passive personality traits are more apparent in 
DLB 
172-173
. Vascular dementia (VaD) is a heterogeneous phenotype resulting from a 
wide variety of vascular pathologies and there is no single clinical profile indicative 
of VaD 
174
. Nevertheless, abstract thinking, information processing and working 
memory seem to be more affected in VaD 
175
. The decline of cognition is generally 
slower 
174
, with a preserved verbal memory 
176
 while increased mortality rates are 
observed compared with AD 
174
. However, vascular abnormalities do contribute to 
the pathological development of AD, particularly cerebrovascular lesions in the early 
stages. As a consequence VaD is considered to be over diagnosed as a direct cause of 
dementia 
164
. Frontotemporal lobar degeneration (FTLD) typically presents between 
the ages of 45-65 and in this demographic proportion has equal prevalence as AD 
177
. 
FTLD is characterised as a progressive neurodegeneration in the frontal and anterior 
temporal cortices and has three subtypes: Frontotemporal lobar degeneration (FTD), 
semantic dementia and non-fluent aphasia. FTD typically presents with behavioural 
and personality changes including disinhibition, apathy, executive dysfunction as a 
result of right frontal lobe involvement. Semantic dementia characteristically 
presents anomia and deficits in empathy whereas non-fluent aphasia displays with 
phonological errors and speech apraxia. The distinction between AD and advanced 
FTLD is not challenging clinically, however is harder to differentiate in the mild 
stages of development. Imaging biomarkers measuring hypometabolism and Aβ have 
helped with this distinction (Discussed in 1.7).  The clinical presentation of 
depression can mirror early features observed in AD. AD and depression can 
overlap, with 20% of early stage AD patients displaying clinical depression 
178
. 
Pronounced memory complaints with minor cognitive deficits along with apathy are 
commonly observed with depression in the elderly 
178
. However, focal deficits such 
as apraxia and aphasia should point towards a diagnosis of dementia and not 
depression.  
1.4.3 Mild Cognitive Impairment  
Individuals classified with Mild Cognitive impairment (MCI) are regularly included 
in AD research studies as an opportunity to investigate prodromal AD, with MCI 
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seen as the intermediate state between normal ageing and AD. Indeed MCI patients 
are known to have an increased risk for developing AD with an annual conversion 
rate of 10-15% compared to 1-2% in nondemented individuals 
165
. However a meta-
analysis of 41 research studies, documenting the clinical conversion to AD from an 
MCI state, revealed that only 30-34% of MCI individuals progressed to AD within 
10 years 
179
. Therefore, the original criteria for MCI diagnosis 
180
 were changed to 
recognise impairment other than memory deficits, leading to the creation of amnestic 
MCI (including memory impairment) and nonamnestic 
181-182
. Amnestic MCI has 
many common behavioural and neurobiological features with AD 
183
 as well as in 
vivo biomarkers similarities 
184
.      
1.4.4 Healthy cognitive ageing  
Several cognitive changes are associated with increasing age however without 
significant underlying pathology these changes are sporadic, inconsistent and not 
progressive. The speed of mental processing, reaction and perception time decline 
the most compared with young individuals however in the absence of a dementia 
they do not have a significant functional impact 
165
. Short-term memory loss without 
immediate and long memory loss is reported in the healthy elderly. Decline in verbal 
fluency is expected with all other language characteristics unimpaired 
185
. Unlike 
AD, insight, social engagement and visuospatial functions are retained 
186
 and the 
ability of learning new tasks is reserved. Longitudinal studies investigating the 
healthy elderly have been difficult to conduct due to the number of subjects with 
asymptomatic dementias researched as healthy elderly. However successful studies 
have demonstrated that the healthy elderly generally have a flat cognitive trajectory 






1.5 Therapeutic interventions for Alzheimer’s disease 
1.5.1 Symptomatic treatment 
There is currently no cure or preventative treatment for AD, however treatments that 
help ameliorate the cognitive and behavioural symptoms are available. Their clinical 
effects are largely palliative however the use of symptomatic relief in combination 
with disease-modifying treatments has yet to be explored. There are two main groups 
of classes of drugs approved for AD treatment: Acetylcholinesterase inhibitors and 
NMDA receptor antagonists. 
Acetylcholinesterase inhibitors  
Acetylcholine (ACh) modulation plays a central role in facilitating learning and 
memory. The cholinergic hypothesis describes the degeneration of cholinergic 
neurons and loss of cholinergic neurotransmission to the neocortex and hippocampus 
that contribute significantly to the decline in cognitive function in AD. Several post 
mortem studies have demonstrated decreases in acetyltransferase (ChAT) and ACh 
release in the cerebral cortex and hippocampus of AD patients 
188
. 
Acetylcholinesterase inhibitors act by promoting the availability of ACh at the 
synapse by deterring the enzyme that degrades ACh 
189
. Currently three approved 
acetylcholinesterase inhibitors are routinely used in clinic for the symptomatic relief 
for AD: Rivastigmine, galantamine and donepezil 
190
. Furthermore, tacrine, 
xanthostigmine, para-aminobenzoic acid, coumarin, flavonoid and pyrroloisoxazole 
are also being studied in relation to AD and cognition. Ladostigil is an 
acetylcholinesterase inhibitor currently in Phase II clinical trials as a reversible 
inhibitor of ACh that also promote antidepressant effects by the inhibition of 
monoamine oxidases A and B 
191-192
. Recent reports show that ladostigil failed to 
reach its primary endpoint but trended in the direction of a treatment benefit. In 
general, acetylcholinesterase inhibitors are well tolerated by patients and the adverse 
effects are dose-dependent 
193
.   
N-Methyl-D-Aspartate (NMDA) receptor antagonists 
NMDA receptor antagonists act to block glutamate-mediated excitotoxicity. This 
overstimulation is known to trigger calcium overload and mitochondrial dysfunction 
causing neuronal apoptosis by the elevated generation of nitric oxide. Memantine 
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acts to decreases glycogen synthase kinase (GSK-3), therefore reducing tau 
phosphorylation and protecting neurons.  Memantine was approved by the FDA for 
the treatment of moderate-severe AD but is also shown to have small or no impact on 
cognition in mild AD 
194-195
. NMDA receptor antagonists can be prescription alone or 
in combination with acetylcholinesterase inhibitors 
196
, although combination therapy 
has yet to show a positive clinical benefit 
190
. 
Other neurotransmitter systems 
Serotonin and histamine receptors are also expressed ubiquitously in brain regions 
involved in memory and learning. The inhibition of the 5-HT6 serotonin receptors 
has shown to stimulate ACh release 
197
, which have cognitive benefit in animals 
studies 
198
. It has been postulated that 5-HT6 antagonists would be of benefit to mild 
AD patients 
191
. Similarly, H3 receptor antagonists may improve cholinergic 




1.5.2 Disease modifying therapies  
The search for disease-modifying interventions is largely focused on targeting Aβ, 
based on the amyloid cascade hypothesis. Intervention strategies are focused upon 
(1) the inhibition of A production and plaque formation and (2) to promote the 
removal of A deposits and plaques to successfully halt or slow the progression of 
the disease. Finally, an alternative to an Aβ focused strategy would be to target the 
formation of insoluble PHF which form NFTs which have a greater correlation with 
cognitive decline.  
Modulators and inhibitors of secretases 
The generation of A from APP occurs by the initial cleavage of either -secretase 
or -secretase. The resulting fragments are finally processed by -secretase. The over 
activation of -secretase or -secretase and the age-dependent decline in -secretase 




The development of -secretase (BACE1) inhibitors can lead to significant side 
effects. BACE1 targets many other substrates in the CNS, including proteins of 
myelin metabolism. However, during the past few years much progress had been 
made on the development of BACE1 inhibitors, which have been shown to have 
positive effects in experimental animal models. GRL-8234 was shown to rescue age-
related cognitive decline in transgenic APP mice (Tg2576) 
200
. Human trials of 
BACE1 inhibitors (E2609, MK8931, LY3314814 and LY2886721) have all shown 
to reduce A production of up to 90% 201-202. Yet, no BACE1 inhibitor has 
successfully been approved for the use in AD. In a similar fashion -secretase 
inhibitors secondary off-target effects are a major concern. A key target of -
secretase is Notch signalling which has central roles in regulating cell proliferation, 
development and cellular communication 
203-204
. Clinical studies of -secretases 
(Semagacestat and Avagacestat) were discounted as a result of serious adverse 
effects and lack of efficacy 
205-206
. Selective -secretase modulators (SGSM) are 
currently being investigated which aim to block the process of APP processing while 
preserving other signalling pathways 
207
. Lastly, the up regulation of 
metalloproteinases (ADAM10 and ADAM17), key enzymes in the proteolytic 
processing of -secretase, have been studied to prevent A generation 208. In AD 
transgenic mice the overexpression of metalloproteinases has been shown to prevent 
cognitive decline 
209
. Furthermore, melatonin also encourages -secretase activity by 
the positive regulation of ADAM10 and AMAM17 
210
.    
Inhibition of A peptide aggregation  
Given the overproduction of toxic A due to faulty activity of , , -secretases, 
compounds that prevent the formation A aggregates have been widely investigated. 
The only inhibitor of A aggregation that has reached Phase III trials is Tramiprosate 
211-212
, with three other small molecules investigated in phase II clinical trials 




. Although these 
agents effectively prevented A fibril formation they failed to pass phase II and III 





Anti-A immunotherapy  
Active and passive immunotherapy attempts to promote Aβ clearance in AD patients, 
with the aim of reducing Aβ load and thereby slowing cognitive decline. Active 
immunotherapy uses A1-42 or synthetic fragments to stimulate an immune response 
that produce anti-Aβ antibodies. Initial results from active immunotherapy phase II 
clinical trials (AN1792) demonstrated Aβ plaque clearance, a reduction in CSF tau 
and minor cognitive benefits. However, serious adverse effects of AN1792 lead to 
the halting of the clinical trial due to 6% of the participants developing aseptic 
meningoencephalitis as a result of T cell-mediated autoimmune response 
216
. Second 
generation vaccines have been designed using shorter A peptides (A1-6 and A1-15) 
and have shown to be free from adverse inflammatory reactions. Phase II clinical 
trials investigating these immunotherapies are currently ongoing 
191, 217
.  
Passive immunotherapy is the direct administration of monoclonal or polyclonal 
antibodies directed against A. A potential advantage of passive immunotherapy 
over active immunotherapy is to prevent a potential proinflammatory immune 
response 
191
. The passive A immunotherapies investigated for AD are summarised 
in Table 1.2. Solanezumab and Bapineuzumab are monoclonal antibodies that have 
both reached Phase III clinical trials for AD, however they both lacked clinical 
efficacy in patients with mild-moderate AD 
218-219
. Solanezumab is directed to the 
mid-domain of the A peptide (A12-28) binding only soluble A species that are 
directly toxic to synaptic function. The Solanezumab trial indicated a promising 
effect on mild AD patients, albeit statistical significance was not achieved 
219
. 
Solanezumab continues to be trialled in cognitively normal older individuals who are 
at risk for AD. Bapineuzumab binds to fibrillar and soluble A promoting its 
clearance as well as microglial phagocytosis and cytokine activation. Bapineuzumab 
failed to produce a positive change in cognitive function despite demonstrating 
significant reduction in A plaques and positive changes in core CSF biomarkers 220.  
Gantenerumab, Crenezumab, Aducanumab and BAN2401 are also monoclonal 
antibodies that act by prompting microglia recruitment that will act to dissemble and 
degradation A 221 and are currently in on-going Phase III clinical trials. 
Gantenerumab, alongside Solanezumab, trials are being investigated patients with 
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risk of A accumulation due to genetic mutation, A accumulators who are 
cognitively normal and mild AD 
222-225
.   
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Promoting A degrading enzymes 
Another mechanism that would promote the removal of A is addressing the reduced 
activity of enzymes that degrade A aggregates and plaques which has been 
extensively observed in AD 
226-227
. There are number of proteases that act to degrade 
A plaques (neprilysin, plasmin, angiotensin and endothelin converting enzyme) 
however strategy with this mode of action has not reached advanced clinical trials.  
Therapeutic strategies focused on Tau  
Another potential therapeutic strategy distinct from Aβ-based interventions is the 
prevention of tau hyperphosphorylation and aggregation. Tau active immunotherapy 
has been developed (AADvacl and ACI-35) with phase II clinical trials currently 
underway 
189
. Both immunotherapies have produced positive results in relation to 
cognition within rodent models with no adverse affects 
189, 228
. Inhibitors of tau 
phosphorylation (i.e. tideglusib) have been investigated with no significant benefits 
observed 
189
. There have been successes in identifying molecules that act as good 
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inhibitors of tau aggregation. Leucomethylthioninium (LMTX) and 
methylthioninium chloride (MTC) have been shown to reduce tau aggregation and 
restore cognition in transgenic mice 
229
. However, recent reports have shown that 
LMTX has failed to slow cognitive decline in two recent AD trials.   
Participant recruitment for therapeutic trials  
Multiple failures in drugs trials, mainly targeting the Aβ pathway, have been 
disappointing and there are several suggested reasons for such failures: (1) 
Approximately 20% of trial participants recruited into Solanezumab and 
Bapineuzumab Phase III trials had little or no A when studied later using 
retrospective neuroimaging 
218, 230
. This is a concern for such trials when a large 
minority of trial subjects fail to have the primary target pathology (A or tau), which 
may mask positive outcomes in pathology positive subjects. (2) Participants recruited 
for Phase III clinical trials are in the advanced stages of the disease and intervention 
is unlikely to have an effect. This has prompted clinical trials to target individuals in 
the early stages of AD, with little or no cognitive deficits.   
Successful recruitment of individuals of preclinical AD with the target pathology will 
be a key factor for these preventative clinical trials and the use of biomarkers for 
subject selection is imperative.  Current imaging methods to detect AD pathology in 
cognitively healthy individuals will substantially increase the cost of these trials, 
whereas CSF biomarkers may not be suitable for widespread implementation and 
repeated sampling. A more practical approach would be to use a blood-based 
indicator of AD pathology. A relatively accurate blood test implemented as a trial 
entry criterion would be minimally invasive, easy to implement and could also be 
used to help triage subjects to further testing using imaging methods. However, to 




1.6 Pathological timeline of Alzheimer’s disease 
The clinical presentation of AD is thought to be the end result of 10-20 years of 
gradual unseen changes in various pathological processes. The timeline of AD 
development can be generally divided into three stages: preclinical, prodromal and 
dementia. The study of clinical development, although progressive and informative, 
is now thought to be at an advanced stage of disease. Preclinical and prodromal 
development can now be investigated with established biomarkers to measure in vivo 
AD pathology; for example A (11C-PiB PET) and glucose metabolism imaging 
tracers imaging (FDG PET), structural imaging (MRI), and CSF protein measures.  
These studies have shown that AD biomarker abnormalities do precede clinical onset 
with A accumulation (measured by A PET and CSF Aβ1-42) being the earliest 
abnormal change 
231-237
. These changes are followed by subsequent markers of NFT 
formation (CSF tau measures and FDG PET) 
234-238
 and subtle changes using MRI 
becoming apparent before clinical onset occurs 
239-240
. These biomarkers enhance 
with disease severity, with each biomarker developing at different rates and reaching 
differing plateau points. A theoretical time-dependant in vivo staging established AD 
biomarkers was first proposed in 2010 
241
 and later revised in 2013 
242
 which 
describes that AD biomarkers become abnormal in a temporally ordered manner 
(Figure 1-4). This model is now an accepted but simplified version of typical AD 
development, hypothesising asymptomatic individuals with underlying pathology 
would eventually develop clinical AD. Evidence generated from several studies has 
concluded that a sigmoidal trajectory of A, tau and glucose metabolism biomarkers 
occurs and approaches a plateau at different disease phases 
242
. The model also 
recognises that AD risks factors (genetics, life style and diminished cognitive 




Figure 0-4: An in vivo model of the AD pathological cascade, taken from Jack CR et al., 
2013. The theoretical model is based on imaging, biofluid and autopsy studies and 
describes an initial change in CSF Aβ1-42 followed by Aβ PET in preclinical AD. CSF 
tau, FDG PET and MRI changes are observed before the clinical onset of dementia. 
Cross-sectional comparisons in healthy ageing, MCI and AD patients by in vivo A 
imaging revealed that ~20% of healthy ageing individuals had an equivalent A level 
as AD patients. Conversely, there was minimal overlap of the clinical groups when 
comparing hippocampal volume with structural imaging by magnetic resonance 
imaging (MRI) 
243
. This is evidence to suggest that substantial plaque deposition 
occurs prior to neurodegeneration with significant Aβ load accumulated in pre-
symptomatic subjects. Reduced CSF Aβ1-42 measures in pre-symptomatic individuals 
have also been shown to reflect this increased Aβ load 244.  Longitudinal studies have 
shown that rate of change in Aβ biomarkers do not change between clinical group 
whereas biomarkers observed with MRI (ventricular volume and hippocampal 
atrophy) are more associated with MCI and AD 
245
. This implies that changes in 
cognition are more associated with neurodegenerative processes than with Aβ 
accumulation. This supports the theory that Aβ initiates a series of events that lead to 
neurodegeneration. Reports from the dominantly inherited Alzheimer’s network 
(DIAN) 
246
 support the concept of Aβ being the initiating event in the pre-
symptomatic stage but with CSF Aβ1-42 preceding Aβ imaging biomarkers.   
CSF tau measures have been shown to be elevated in cognitively healthy and MCI, 
assumed to reflect NFT formation, although these have been shown to be less evident 
and later in the disease course than CSF Aβ1-42 
247-249
. Patients with early AD and 
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individuals who are cognitively normal that later convert to dementia, have marked 
brain metabolic reduction, as measured by FDG PET 
250
 demonstrating that FDG 
PET changes occur in the early stages of the disease. However on several occasions 
this has been shown to occur after Aβ biomarkers 249, 251 with hypometabolism being 
more pronounced in the later stages of the disease 
252
. Furthermore, FDG PET 
measures correlate highly with CSF tau biomarkers 
253
 but abnormal CSF tau 
measures precede FDG PET biomarkers 
246
. Subtle brain atrophy at the preclinical 




 however, these changes observed by MRI are 
more associated with the clinical severity of AD and therefore a biomarker of 
established disease rather than prodromal or preclinical AD 
240
. MRI is also superior 






1.7 Biomarkers – Neuroimaging  
The current role for neuroimaging in AD is the exclusion of another disease that may 
be the primary cause of cognitive decline. The two types of neuroimaging most 
commonly used as AD biomarkers include Magnetic Resonance Imaging (MRI) and 
Positron Emission Tomography (PET). MRI is predominantly utilised to investigate 
in vivo structural changes in an AD setting and is preferred to computed tomography 
(CT) due to its superior resolution of tissues. PET is generally coupled to radio-
labelled ligands which measure in vivo metabolic and neurochemical processes. In 
AD research, two types of PET ligands are primarily exploited: (1) 
18
F-
fluorodeoxyglucose (FDG), which measures brain metabolism and (2) Aβ tracers 
which bind to fibrillar Aβ plaques.    
1.7.1 Aβ imaging in Alzheimer’s disease  
The development of PET tracers for Aβ aggregates has allowed the in vivo evaluation 
of Aβ pathology. Several hundred Aβ PET studies have been published since the first 
human study was reported in 2004 
231
, improving our knowledge on the 
accumulation pattern, variability and timing of Aβ deposition in the human brain. 
Quantitative PET studies using diverse range of Aβ tracers have consistently 
demonstrated a significant increase in retention between AD and elderly controls, 
with the binding particularly elevated in the frontal, cingulate, precuneus, striatum, 
parietal and lateral temporal cortices 
255
. PET imaging also presents an accumulation 
pattern that is representative of the Aβ deposition at post mortem 231, 256. Longitudinal 
studies examining Aβ accumulation have shown that it is slow and relatively stable 
measure across early clinical stages, but tends to accelerate with increasing Aβ load 
and plateau at the late stages of amyloidosis 
242, 257
.   
11
C-PiB – Pittsburgh Compound B 
Initial investigation in mouse models demonstrated the rapid neocortical uptake of 
11
C-PiB upon intravenous injection. 
11
C-PiB also demonstrated rapid clearance from 




C-PiB was the 
first radiotracer to be developed for binding with fibrillar Aβ plaques in humans 231 





C-PiB in vivo signal demonstrates excellent neuropathological 
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concordance with in vitro measures of Aβ in post mortem brain 261-262. Compared 
with elderly controls, 
11
C-PiB PET scans of AD patients show higher overall 





comparison, 60% of clinically defined MCI cases and 25-30% of cognitively normal 




. The regional distribution of 
11
C-PiB 
is known to contain large amounts of Aβ plaques 231, 260, 262. This distinct pattern can 
aid the differential diagnosis from other neurodegenerative diseases 
260
 but not all 
233, 
259
. Longitudinal studies with 
11
C-PiB have shown that significant changes in Aβ 




C has a half-life (t1/2) of 20 minutes, limiting its use to facilities capable of onsite 
isotope production. 
18
F labelled radiotracers for Aβ, with a longer t1/2 (110 minutes), 
may foster greater utility and a number are being used within clinical trials.    
18
F-GE067 – Flutemetamol  
Flutemetamol is the structural analogue of 
11
C-PiB and therefore it is unsurprising 
that the neuronal uptake and Aβ affinity of this radiotracer closely resembles 11C-PiB 
266-267
. However, it has been demonstrated that higher non-specific white matter 
background can be visualised with Flutemetamol even in healthy controls 
232
. This 
may lead to the false assignment of an Aβ positive (Aβ+) diagnosis.  
18
F-AV-45 – Florbetapir 
Florbetapir is the first 
18
F radiotracer to be approved by the FDA for the clinical 
investigation of patients with suspecting AD. Florbetapir has been able to accurately 




 with a high affinity for Aβ plaques and 
encouraging pharmacokinetics 
269
. Florbetapir rapidly enters the brain, and clears 
circulation illustrating clear Aβ positivity or negativity within 20 minutes of injection 
270
. Phase III clinical trials utilising Florbetapir are currently in use demonstrating a 





F-BAY94-9172 – Florbetapen 
Florbetapen (
18
FBB) is used for the examination of Aβ aggregates in AD and other 
dementias. The cortical distribution of 
18









FBB has been able to distinguish DLB patients from AD despite the 
similar pattern of Aβ pathology 233 thus it may prove useful in the differential 
diagnosis of other dementias and amyloidopathies.  
18
F-FDDNP  
FDDNP was initially developed for the visualisation of senile plaques in AD 
however, it also binds to NFTs 
272
. Early studies using FDDNP demonstrated 
significant binding of regions consistent with Aβ plaques but also NFTs, later 
confirmed by post mortem examination 
273
. Therefore, uptake in the MTC, which is 
among the first areas to develop NFTs, is relatively high when compared with 
11
C-
PiB. In contrast to other Aβ radiotracers, the clearance time of FDDNP maybe 
inversely correlated with the degree of cognitive impairment 
272
.     
Table 0-3: List of radiotracers designed for PET analysis of AD pathology 
Radiotracer t1/2 Specificity Disease Condition 
11
C-PiB (Pittsburgh Compound B) 20 minutes Aβ AD 
11
C-AZD2184 20 minutes Aβ AD 
18
F-AV-45 (Florbetapir) 110 minutes Aβ AD 
18




FBB) 110 minutes Aβ AD 
18
F-GE067 (Flutemetamol) 110 minutes Aβ AD 
18
F-AZD4694 110 minutes Aβ AD 
11
C-BF-227 20 minutes Aβ AD 
11
C-SB-13 20 minutes Aβ AD 
18
F-THK523 110 minutes Tau tauopathies 
18
F-THK5105 110 minutes Tau tauopathies 
18
F-THK5107 110 minutes Tau tauopathies 
18
F-T807 110 minutes Tau tauopathies 
18
F-T808 110 minutes Tau tauopathies 
11




























20 minutes I2BS Neuroinflammation 
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1.7.2 Aβ imaging in other disorders 
The investigation of Aβ imaging across a wide spectrum of neurodegenerative 
disorders has allowed the assessment of the pattern of Aβ presence or absence as a 
biomarker in differing conditions.   
Co-pathology of A, tau and -synuclein is present in several neurodegenerative 
diseases, including AD, Parkinson’s (PD), Parkinson’s dementia (PDD), DLB and 
Multiple system atrophy (MSA).  Cortical 
11
C-PiB retention in DLB is more subtle 
and variable than AD 
274
. Post mortem studies have confirmed that 50-80% of DLB 
cases have cortical Aβ deposits with a distribution pattern similar to AD 275 and that a 
pure -synuclein DLB is relatively uncommon. DLB patients with negative A scans 
have been neuropathologically confirmed to have little diffuse A plaques 276. An 
overlap in early cognitive signs with AD makes a differential diagnosis of DLB 
difficult and with a mixed DLB/AD pathology commonly found, A imaging maybe 
only useful in identifying pure DLB cases. Despite this, 
18
F A tracers are beginning 
to show the sensitivity to distinguish between AD and DLB 
233
. Furthermore, DLB, 
PD and PDD patients have been described to have higher 
11
C-PiB retention in the 
occipital lobe when compared with AD 
274
. No differences between DLB and PDD 
global 
11





C-PiB has also been used successfully as a tool to separate 
DLB and MSA patients given the similar clinical presentations 
278
.   
FTD can also be extremely difficult to be clinically distinguished from AD. A 
deposition is not a common pathological trait of FTD and three intraneuronal 
inclusions are often found: tau, TDP-43 and FUS 
279
. It has been widely shown that 
A imaging is helpful in the differential diagnosis between FTD and AD 280. 
Cerebral amyloid angiopathy (CAA) is characterised by A build-up around small 




C-PiB in patients with CAA has 
demonstrated a distinct pattern of A, specifically in the occipital regions, that can be 
distinguishable from AD 
282
. No cortical 
11
C-PiB retention is found in sporadic prion 
diseases like Creutzfeldt-Jakob disease (CJD) 
283
. Given the rapid phase of the 
symptomatic illness, plaque formation is unlikely to occur although sub-types of CJD 
68 
 
have been shown to have small synaptic and perivascular A deposits 284.  A PET 
imaging can distinguish other spongiform encephalopathies and CJD 
285
. 
Patients with Down Syndrome (DS) have an extremely high incidence of early-onset 
dementia and this is likely due to the overexpression of the APP gene by 




F A tracers have all concluded 
an age-dependant accumulation of A in age brain of DS patients 286. A imaging in 
DS patients has been used as a model of the natural history of A deposition. The 
early detection of A accumulation is critical in the development of anti-A 
therapies, in which DS patients may benefit. With little influence from contaminant 
diseases such as VaD, dementia formed in DS patients is likely to be A driven. 
Thus, Aβ PET imaging studies in DS patients would help study the role of APP and 
A accumulation in the pathogenesis of AD 287.    
1.7.3 FDG imaging in Alzheimer’s disease 
FDG PET measures brain glucose metabolism and investigations have shown that in 
AD a decline in glucose consumption is progressive and correlates with disease 
severity. The typical “AD pattern” in FDG PET studies demonstrate posterior 
cingulate, parietal, temporal, and prefrontal cortex hypometabolism with relative 
sparing of the basal ganglia, thalamus, cerebellum and primary sensorimotor cortex 
288
. A similar pattern of hypometabolism has been reported in MCI 
289
 and 
asymptomatic subjects with mutations in APP, PSEN1 and PSEN2 genes 
290
. Glucose 
metabolism abnormalities identified using FDG PET also have been found to 
successfully predict conversion from MCI to AD with very early metabolic deficits 
reported in the medial parietal cortex 
291
. Reviews on FDG PET have reported an 
average diagnostic accuracy of 93% in differentiating AD from healthy controls and 
can discriminate AD from other dementias with an accuracy of 94% 
291-292
.   
The relationship between A imaging and FDG PET 
On the whole, no relationship can be found between FDG PET and A imaging in 
AD subjects 
293
. There are conflicting reports in the non-demented group with 
correlations in the parietal and temporal cortices with 
11
C-PiB and FDG PET 
231, 294
 
whereas others have reported no correlations in any brain regions 
291, 295
. A study 
69 
 
conducted in a large group of participants concluded that there was no association 
between regional fibrillar A and hypometabolism in clinically defined AD and 




1.7.4 MRI in Alzheimer’s disease 
Brain atrophy measured by structural MRI is repeatedly reported as an AD 
biomarker. While brain atrophy is not specific to AD, many studies have associated 
the atrophy of structures in the MTL and ventricular enlargement with changes in 
cognition and disease progression 
240, 297
. Notably, atrophy of the entorhinal cortex 
and hippocampus are of considerable value in predicting conversion from cognitively 
normal to MCI and MCI to AD 
297
. Hippocampal volume is reduced in AD patients 
by up to 40%, with a 15% reduction in MCI patients 
298
. Serial MRI measures from a 
preclinical stage through to moderate dementia show a non-linear relationship 
between cognition and brain atrophy, with the rate of atrophy increasing with disease 
severity 
254
. AD patients have an atrophy rate of 4-6% each year, whereas aged-
matched controls typically have a decline of 1-2% per year 
299
.  This demonstrates 
that although MRI has the ability as a diagnostic pre-clinical biomarker, its main 
strength lies after the onset of clinical symptoms to follow cognitive decline. 
Other structural MRI techniques include Diffusion Weighted Imaging (DWI) and 
Magnetisation Transfer Imaging (MTI). DWI is used to investigate white matter 
changes in the temporal lobe and hippocampus in relation to AD 
300
. MTI is able to 
detect structural changes reflecting tissues homogeneity from pathological changes 
associated with AD 
301
. Functional MRI (fMRI) can assess the decline of neuronal 
activity and connectivity as a consequence of neuropathology. These images are 
determined by changes in cerebral blood flow or changes revealed by blood oxygen 
level (BOLD) effect 
300
. Compared to controls, AD patients exhibit a decreased 
hippocampal and parahippocampal activity as well as a disruption in the default 
mode network (DMN) 
302





The relationship between A imaging and MRI 
The relationship between Aβ deposition and atrophy is inconclusive. In AD, no 
direct association between hippocampal Aβ load and hippocampal atrophy has been 
found 
303
, although other regional relationships between Aβ load and atrophy have 
been reported at certain stages of the disease 
304
. In the cognitively normal, some 





while others did not 
305
. Furthermore, an inverse relationship between temporal lobe 
volume and Aβ load (larger temporal volume and high Aβ deposition) has been 
implicated as a sign of resistance, as these individuals seem to have the ability to 
have a greater tolerance to the presence of Aβ plaques 304.     
1.7.5 Tau imaging in Alzheimer’s disease   
The limitation of Aβ imaging is that presence of Aβ plaques alone is not sufficient 
for complete diagnosis of AD, whereas a PET Tau tracer would aid and affirm this 
diagnosis. The development of Tau radiotracers is somewhat more difficult given the 
intracellular location of tau aggregation. A successful PET tau tracer would have 
selective binding to PHF over Aβ, high permeability to the BBB, low metabolism 
and non-specific binding to white matter.  
Initial studies of the radiotracer 
18
F-THK523 demonstrated high affinity to PHFs 
compared to Aβ 306 and does not have an association with any Aβ radiotracers 307. 
Regional retention of THK523 has been found in the hippocampus, orbitofrontal, 





F-THK5105 has been shown to have retention in the lateral 
mesial temporal lobes, areas known to have a high accumulation of NFTs 
309
. Further 
to this, the intensity of the radiotracer in these regions is seen to be correlated with 




F-T807 has very weak selectivity 
to Aβ and human studies demonstrate excellent concordance of radiotracer retention 




F-T807 also has favourable kinetics, 
rapid delivery into the brain and clearance from the white matter 
311
. The initial 
success of 
18
F-T807 has moved this radiotracer into Phase II clinical trials of AD and 
other tauopathies and will likely be used to monitor the ability of tau-targeted 
therapeutics that are in development. 
71 
 
1.7.6 Neuroinflammation imaging in Alzheimer’s disease 
Neuroinflammation is a significant process in the progression in all 
neurodegenerative diseases. Inflammation is associated with microglial activation 
that is triggered by neuronal degradation in the early stages of AD. Therefore, 
molecular imaging that could detect and monitor neuroinflammation would be of 
considerable use in further characterising AD. 
11
C-PK11195 is the leading PET 
based radiotracer for neuroinflammation and specifically binds TSPO, an 18kDa 
translocator protein. TSPO is upregulated in response to inflammatory microglia 
activation; therefore 
11
C-PK11195 could act as a putative biomarker for 
neuroinflammation 
312
. Indeed, initial studies have demonstrated notably high 
retention of 
11
C-PK11195 in AD patients compared with aged matched controls 
313
. 
However, due to increased reports of nonspecific binding 
11
C-PK11195 may have 





more recently their equivalent F
18
 ligands, have shown a decreased likelihood of 
nonspecific neuronal interaction and are sensitive to subtle TSPO expression due to 







been developed for the imaging of imidazoline 2 binding sites (I2BS) 
314
. The 
increased expression of I2BS is a prominent hallmark of astrocytosis, another key 
feature of neuroinflammation and neurodegeneration.  
The relation of neuroinflammation imaging and Aβ imaging  
Most reports have reported no association between A retention and microglia 









. Similarly, no regional association between PET 
astrocytosis and 
11






1.8 Fluid Biomarkers – Cerebrospinal Fluid  
CSF is in direct contact with the extracellular space of the brain and serves as a 
substrate for biochemical changes related to brain pathology. The single cell 
epithelium layer that separates the two compartments allows an almost unimpeded 
flow of molecules from the brain towards the CSF.  
 
A lumbar puncture (LP) must be performed to obtain CSF. The perceived invasive 
nature of an LP has made the routine implementation of CSF analysis in AD 
diagnostics and research troublesome. However, several large prospective studies 
have demonstrated that the incidence of post-LP complications is very low in the 
elderly 
318-319
.  International collaborative efforts have standardised the use of small 
gauge needles and atraumatic techniques in CSF sampling to further reduce the 
concerns of post-LP headache. Particular attention has been paid to the 
standardisation of pre-analytical treatment of CSF 
320
 and measurements of core CSF 
AD biomarkers given the reported large inter-laboratory variation in concentrations 
321-324
. The results have produced fully validated mass-spectrometry references for 
CSF A1-42 
325
 and automated assays that are reproducible between laboratories 
3
.  
This global effort in standardisation and safety has made CSF analysis a rapidly 
expanding research field. The direct interaction with the disease organ and cost 
effective alternative to neuroimaging biomarkers has ensured the introduction of CSF 
analysis routinely implemented into AD diagnostics.  
1.8.1 Core CSF biomarkers 
The core CSF biomarkers for AD are A1-42, total tau (t-tau) and phosphorylated tau 
(p-tau) and these markers are thought to reflect cortical Aβ deposition, neuronal loss 
and neurofibrillary tangles respectively 
326
. These biomarkers are now included in 
AD diagnostic guidelines to help increase the accuracy of an early preclinical or 
prodromal AD diagnosis for a research setting 
327-328
.  
CSF A1-42 concentrations are widely reported to be reduced in AD patients, where 
an approximate decrease of 50% is expected when compared to healthy controls 
329
. 
The inverse relationship of CSF A1-42 and cortical 
11
C-PiB binding suggest that this 
73 
 
CSF measure is a strong surrogate marker for in vivo neocortical Aβ burden (NAB) 
247
. Autopsy investigations also demonstrated reduced CSF A1-42 is correlated with 
neuropathological A 
330
. In the preclinical phase of the disease, a reduction in CSF 
A1-42 has been shown to predict subsequent conversion to dementia 
331
. 
Furthermore, a significant change in CSF A1-42 
332-333
 but not t-tau or p-tau 
334
 in 
cognitively normal participants were more likely to later develop AD. 
Increases in CSF t-tau and p-tau have been associated with neocortical 
neurofibrillary pathology, cognition and temporal lobe hypometabolism. CSF t-tau 
assays, that detect all tau isoforms independent of phosphorylation site, have shown 
increases of 50-300% in AD subjects 
335
. Although increases in CSF p-tau 
concentrations are somewhat less dramatic between clinical classifications than CSF 
t-tau, p-tau is thought to be a more accurate reflection of neuronal degeneration, with 
sensitivity for AD reported at 85% 
235, 336
. Both t-tau and p-tau have demonstrated 
correlation with 
11
C-PiB binding in the healthy subjects but the relationship is 




. Abnormal CSF concentrations 
of tau have been reported before the clinical presentation of AD, indicating an ability 
of future conversion to dementia 
336
.  
Ratios of the core AD CSF markers have also been identified as useful AD 
biomarkers. The diagnostic performance of the core CSF biomarkers to discriminate 
AD from non-demented older adults is extremely accurate (~85-90%). During life 
CSF measures combined with neuropathological conformation demonstrated that 
CSF core measures had a specificity of 96% for AD 
235, 337
. Normal CSF levels with 
cognitive symptoms could be indicative of depression or PD, whereas p-tau aids to 
differentiate AD from FTD and DLB 
338
. CSF Aβ1-42/t-tau has been identified as a 
good predictive marker of future conversion from MCI to AD 
240, 326
. Later studies 
with comprehensive clinical follow-up demonstrated than combinations of the core 
CSF biomarkers (t-tau, p-tau and Aβ1-42) have a predictive ability of 95% to 
differentiate MCI cases into stable, converting and other underlying pathology 
339
. 
The uses of these markers to identify prodromal AD have been confirmed in other 
large studies 
236-237
. Studies investigating CSF Aβ1-42/t-tau and Aβ1-42/p-tau also show 





1.8.2 Novel CSF biomarkers 
The pathobiological variance observed in AD precludes any biomarker from having a 
diagnostic accuracy of 100%. However, additional biomarkers of the pathogenic 
processes that can further differentiate AD from healthy controls and other dementias 
would be of considerable value.  Synaptic dysfunction and degeneration is an early 
pathological event 
340
 and is likely the direct cause of cognitive deterioration in AD 
341
. High CSF concentrations of the post-synaptic protein neurogranin (NRGN) 
predict progression from MCI to AD and correlate with rapid cognitive decline 
342-
344
. Additionally, the pre-synaptic protein synaptosome associated protein 25kDa 
(SNAP25) increases substantially during the prodromal stage of the disease 
345
. 
Neurofilament light (NEFL) is a global marker of axonal damage and is shown to be 
increased in AD compared with controls 
346
. However, high levels of CSF NEFL 
have also shown to be associated with FTD 
347-348
 with the highest levels associated 
Amyotrophic lateral sclerosis (ALS) 
349
. A recent CSF biomarker meta-analysis by 
Olsson and colleagues 
350
 demonstrated that CSF NEFL had the second highest effect 
size (2.35) at discriminating AD subjects from control after t-tau.  The same analysis 
highlighted that CSF measures neuron specific enolase (ENO2), visinin-like protein 
1 (VLP-1), heart fatty acid binding protein (HFABP) and chitinase-3-like protein 1 
(YKL-40) to moderately distinguish AD from healthy controls 
350
. Further to this, 
early changes in CSF TREM2 levels have recently been reported 
351
. This study 
points towards the activation of microglial before the clinical onset, but after CSF Aβ 




1.9 Fluid Biomarkers – Blood 
1.9.1 Proteomic approaches for blood-based biomarker discovery   
The difficultly and complexity of discovering blood-based measures indicative of 
AD and its pathology is reflected in the number of analytical approaches that are 
routinely employed. To date, single and multi-analyte immunocapture and to a lesser 
extent Mass Spectrometry (MS) have been utilised. These approaches have 
advantages and disadvantages which will be discussed further. More recently, 
advanced multi-analyte and ultra-sensitive assays have been developed for targeted 
proteomics.  
Immunocapture assays 
The most commonly used method for soluble protein quantification is a “sandwich” 
or “in-direct” ELISA but this method only allows the measurement of one analyte 
per assay. There is a need to maximise the use of valuable clinical samples and 
therefore multiplexing immunocapture assays are a rapidly developing field.  
Mesoscale discovery (MSD) and Luminex xMAP technology are in principle 
sandwich ELISAs but with modifications that allow the measurement of multiple 
analytes. For the MSD assay, capture antibodies for multi-targets are coated onto the 
base of the microtitre plates. Electrochemiluminescence (SULFO-TAG) labels are 
then bound to the detection antibody and upon electrical stimulation the SULFO-
TAG emits light signals that are unique to the protein of interest. Alternatively, 
Luminex xMAP employ a microsphere technology. The capture antibody and 
fluorescently labelled detection antibody are coated onto microsphere beads 
(polystyrene or magnetic) in suspension. This will allow for microspheres to be 
labelled with differing capture antibodies. Luminex xMAP technology has a greater 
capacity for multiplexing than MSD.  Blood-based investigations in AD using MSD 
and Luminex xMAP have been conducted 
352-357
. More recently, the ultra-sensitive 
single molecule arrays (SIMOA) divides samples into femtoliter-size chambers and 
allows higher detection of signal to background 
358
. This assay has been shown to 
detect tau in plasma with a sensitivity of 0.02pg/mL far superior than other 
immunocapture assays 
359-361
. SIMOA has also been used to successfully detect other 
76 
 
neurodegenerative markers in blood; Aβ 362 and NEFL 363-364. However, at this time, 
the numbers of multiplex assays available for SIMOA are limited.  
Whichever approach is selected these methods are solely reliant on the availability, 
quality and binding characteristics of the antibodies being used. Immunocapture 
assays are useful tools for targeted or semi-targeted investigations where a protein or 
pathway is of particular interest and are not feasible for unbiased hypothesis 
generating experiments. Additionally, protein quantification will largely depend on 
the epitope determined by the capture antibody. This is important to note when 
comparing results generated by other immunocapture assays and antibody-free 
technologies such as MS.    
Aptamer-based multiplexing  
Aptamers are single-stranded oligomucleotides, which recognise and bind target 
proteins with high affinity 
365
. Somalogic™ have developed a panel of >1300 
analytes that can be targeted in a single sample, making this approach ideal for 
clinical samples with limited volume. However, just as with antibody-based 
approaches, aptamer arrays are limited to those which have been designed. Aptamer 
studies in blood related to AD phenotypes have been conducted 
366-367
.   
Mass Spectrometry 
At the discovery level, MS has a key advantage of measuring features present within 
a sample having without prior knowledge of its contents. This enables MS to be a 
hypothesis-generating tool which can be confirmed using targeted approaches. 
Multiple variants in MS-based proteomics can be employed but typically plasma 
proteins undergo enzymatic digestion. The resulting peptides are resolved using 
reserve-phase liquid chromatography (LC) and analysed by MS. The peptides 
sequences identified are probability matched to unique protein groups by databases. 
The development of isobaric chemical labelling (TMT and iTRAQ) for peptides or 
proteins has enabled multiplexing of clinical samples within one MS analysis, 
increasing throughput, with relative quantitation 
368
. An obvious disadvantage of 
MS-based studies is the inability to detect low abundant proteins within plasma. 
Plasma is a highly complex biofluid but is constituted by 20 highly abundant proteins 
including albumin, immunoglobulins, transferrin and haptoglobin, which make up 
77 
 
99% of the total protein content 
369
. Therefore, upfront fractionation, in addition to 
reserve-phase chromatography, is required to divide plasma into manageable 
portions. Furthermore, immunodepletion of the most highly abundant proteins has 
been widely explored.    
There have been several blood-based biomarker studies for AD utilising MS with 
fractionation and isobaric labelling, typically but not exclusively employing a case-
control design 
370-375
. Blood-based biomarker discovery employing protein and 
peptide isobaric labelling, upfront fractionation and immunodepletion in an 
endophenotype fashion are discussed in Chapters 3, 4 and 5 of this thesis.      
1.9.2 Blood-based measures of A and Tau 
Due to the central importance of A and tau in the neuropathology of AD and with 
the successful translation of CSF A1-42, p-tau and t-tau in classifying AD from 
healthy controls, it is unsurprising that there has been a substantial focus on 
measuring these targets within blood. 
A1-40 and A1-42 as blood-based biomarkers 
To date, A1-40 and A1-42 have been the predominant A species investigated in 
blood. However, contradictory and largely unsuccessful results have been reported in 
several studies. Large systematic reviews and meta-analyses of blood A1-40 and A1-
42 have reported significant findings 
376-377
. Koyama and colleagues 
377
 conducted a 
meta-analysis of 10,303 subjects, which demonstrated significant association of A1-
40/A1-42 ratios in the development of AD. However, this study also showed that 
stand-alone measures of A1-40 and A1-42 blood measures were not associated with 
AD. Similar conclusions were made by Song and colleagues with the addition of a 
non-significant decrease in A1-42 in AD subjects. Furthermore, a recent meta-
analysis investigating all potential fluid biomarkers for AD found no significant 
differences between plasma or serum concentration of Aβ markers in AD and 
controls 
378
. Due to the wide confidence intervals created by large inter study 
variability these studies concluded that blood A1-40, A1-42 and ratios are unlikely to 
be useful in the classification of AD from healthy controls.  
78 
 
In relation to disease progression, decreased plasma A1-42 has been correlated with 
rapid cognitive decline 
379
, conversion from healthy to MCI 
380
 and MCI to AD 
381
. In 
contrast to this, other studies have reported opposite results to these findings, 
demonstrating that an increase in plasma A1-42 is a significant factor in disease 
conversion 
382-383
. However, a large longitudinal community-based study of plasma 
A1-40 and A1-42 conducted in 2,000 cognitively healthy individuals reported that 
decreased plasma A1-42 was associated with the development of AD 
384
. Given the 
size and duration of the study, this may be the most promising blood A result to 
date. The results of blood A1-40 are less promising than A1-42, given the 
contradictory reports. Both increased serum A1-40 and decreased plasma A1-40 have 
been reported in AD individuals 
385-386
. A decrease in plasma A1-40 has been 
attributed to rapid cognitive decline 
379
 however the majority of studies report no 
change in plasma A1-40 in relation to a range of AD modalities 
381, 384
. The 
conflicting reports in A studies may suggest that A measures are unsuitable or 
time dependant 
382
. Blasko and colleagues 
382
 demonstrated that A1-42 levels were a 
good measure in predicting the conversion from healthy elderly to MCI but not 
conversion to AD. This is supported by A1-42 appearing to be a predictive marker of 
AD development in an 8-year longitudinal study in cognitively healthy individuals. 
The clearance of CSF A into the blood 
387
 gives the reasonable assumption that 
plasma A1-42 would follow the same disease related trend as CSF A1-42. However, 
most investigations into the relationship between plasma and CSF A measures 
report poor correlations 
246
. The relationship between plasma A and neuropathology 
is also inconclusive. Levels of plasma A1-40 and A1-42 taken 1 year prior to post 
mortem did not correlate with A1-40 and A1-42 burden at post mortem examination 
388
. However, a link between plasma A1-40/A1-42 ratios and in vivo A imaging 
have been reported 
380, 389-390
. 
The results discussed above point toward a potential use of blood A in disease 
classification or in relation to disease pathology but the huge discrepancy in findings 
highlighted by individual studies and large meta-analysis suggest further work is 
needed. The most promising studies have been described in preclinical stages of AD, 
suggesting that disease-stage testing of plasma A is critical. In addition, technical 
79 
 
challenges in plasma A measurements will invariably account for a substantial 
proportion of the variation. Large intra-subject variability in A plasma measures 
were reported in plasma samples from the same individuals obtained four weeks 
apart 
385
. A show signs of a circadian rhythm in its levels 391 and therefore 
standardisation of sampling times for A need to be considered 365. Further to this, 
the standardisation of assays used to measure plasma A in clinical studies needs to 
be addressed. For example, the influence of heterophilic antibodies (HAs) in Aβ 
assays for CSF but particualrly blood needs to be made uniform 
392
. Plasma A 
studies routinely use commercial and in-house ELISA 
246, 379, 381-383, 385, 388-389
, 
Luminex xMAP assay 
380, 384, 393
 and immunomagnetic reduction (IMR) assays 
390
 
which all use a range of antibodies that recognise differing epitopes of A.  
Tau as a blood-based biomarker 
Plasma tau is a brain-specific axonal protein that is expected to be transferred to the 
peripheral system from brain interstitial fluid 
360
. It is therefore a prime candidate for 
a reflection of centralised AD pathology however low abundances in plasma have 
made it a great challenge to report consistent results 
365
. Studies on hypoxic brain 
injury describe a rapid clearance of plasma tau from blood stream, again highlighting 
a difficulty in applying plasma tau as reliable biomarker 
394
. The vast majority of 
plasma tau studies have been underpowered and reported contradictory results. 
Substantially elevated and mild elevations of plasma tau in AD individuals have been 
reported 
390, 395-396
. Conversely, reduced plasma tau in AD 
397-398
 and no change 
compared with healthy controls have also been reported 
399
. Efforts have been made 
to develop more sensitive assays for the detection and quantification of plasma tau. 
Firstly, a measurement of specific tau fragments (Tau-A and Tau-C) using an ELISA 
method was correlated with cognitive decline in AD. However, this was not 
associated with CSF tau measures 
400
. Likewise, a digital array technology (SiMoA) 
demonstrated elevated plasma tau in AD subjects with no correlation with CSF tau 
359
. A large replication study in two cohorts confirmed the increase in plasma tau 
with SiMoA in the AD population with mild association with CSF biomarkers but 
with significant cohort differences 
360
. Lastly, SQUID-IMR technology also verified 
the increased levels of plasma tau in AD subjects with significant correlations with 





1.9.3 Blood-based biomarkers of AD: case versus control design 
The blood-brain barrier (BBB) dysfunction described in AD, the movement of 
content from the CSF into the blood and the failure to consistently demonstrate blood 
A and tau as biomarkers are all reasons why the field is now focused on the 
detection of novel blood markers of AD. An enormous amount of effort, using a 
wide range of proteomic techniques, has been dedicated to discover single blood 
markers that can differentiate AD individuals from healthy controls or MCI 
370, 401-
411
. One of the first large-scale AD plasma studies discovered several differences in 
the blood of AD individuals 
372
. Most notably complement factor H (CFH), an innate 
immunity marker, which has been replicated by several research groups 
412-414
.  
It was soon apparent that a single protein marker in blood is unlikely to achieve the 
sensitivity or specificity required for clinical implementation. A multi-variate 
signature approach has been taken by many research groups 




 identified a panel of 18 cytokines which illustrated a diagnostic 
accuracy of 90%. This multi-analyte signature pointed towards the dysregulation of 
immune response, neuronal support and apoptosis 
422
. However, subsequent 
validation attempts in independent cohorts have been unsuccessful 
423-425
. These 
studies comparing established disease to healthy individuals have clearly 
demonstrated that a signature of AD and/or dementia in blood does exist. However, a 
more constructive signature would be one of prodromal disease and therefore a 
signature of MCI patients that later convert to AD compared with stable MCI and 
healthy ageing has been investigated 
426-427
. Hye and colleagues 
357
 demonstrated a 
10 protein panel with an accuracy of 87% to predict future conversion from MCI to 
AD. Replication studies in multiple cohorts are examining this panel further. 
A major concern for the field has been the lack of reproducibility in plasma markers 
of AD diagnosis or disease progression. Technical, assay, sampling and cohort 
variation might explain these discrepancies however it is likely that the heterogeneity 
of AD is partially accountable for the failure of replication using a “case versus 
control” design. Such approaches are inherently flawed in AD, as a considerable 
proportion of cognitively unimpaired individuals will be in the prodromal phase of 
the disease where substantial pathology has accumulated without clinical 
81 
 
presentation. Therefore, in a “case versus control” design individuals in the 
prodromal phase of the disease would be incorrectly classified as “control”. 
Furthermore, the recent failure in Phase III anti-Aβ clinical trials has shown that a 
considerable proportion of AD subjects do not exhibit Aβ pathology 218, 220 and this 
highlights the importance of participant selection based upon neuropathology 
biomarkers. The inevitable triage based on CSF measures and/or neuroimaging is 
likely to be costly and unfeasible to widely implement given the expected failure 
rates. Therefore, a minimally invasive and accessible blood-based measure of AD 
pathology could be of considerable use in early diagnosis and reducing screen failure 
rates for therapeutic trials. 
1.9.4 Blood-based biomarkers of AD: endophenotype design 
Increasingly, blood-based biomarker studies are increasingly using other variables, 
besides clinical outcome, to discover markers reflecting AD. The endophenotype 
approach has utilised measures of brain atrophy (MRI), cognitive decline and NAB 
(Aβ PET) to investigate disease activity and pathology, including preclinical disease.    
Blood-based biomarkers of cognitive decline and brain atrophy 
Thambisetty and colleagues reported the first results from an endophenotype 
approach, which investigated plasma biomarkers of brain atrophy and rate of clinical 
progression 
373
. A panel of 7 proteins (complement C3 (CC3), fibrinogen gamma 
(FGγ), albumin, complement factor-I (CFI), alpha-1-macroglobin (α1m), clusterin 
and serum amyloid-P (SAP)) were found to explain 34% of the variance in 
hippocampal atrophy 
373
. This was later replicated in an independent cohort 
428
. In the 
same discovery investigation, 5 proteins were able to classify “fast” and “slow” 
cognitive decliners (complement C4-A (C4α), complement C8, clusterin, 
apolipoprotein A1 (apoA1) and transthyretin) 
373
. Transthyretin was more recently 
replicated in an independent cohort to be plasma biomarker of faster cognitive 
decline 
429
. Plasma clusterin (also known as apolioprotein J) was found to be 
important in the panels of both hippocampal atrophy and cognitive decline 
373
. Since 
these initial discoveries, additional studies have further implicated plasma Clusterin 
in cognitive decline 
366, 430-431
, brain atrophy 
357, 432





Other studies have investigated the role of inflammatory plasma proteins in AD 
356, 
434
. A five protein panel (IL-1ra, IL-6, IL-10, TNFα and IL-13) was able to 
distinguish “high” and “low” atrophy measures 356 whereas a panel of six proteins 
(Il-4, IL-10, G-CSF, IL-2, IFN-γ and PDGF) were associated with the rate of 
cognitive decline 
356
. Further to this, inflammatory proteins CCL3 and chromogranin 
A were found to be related to brain atrophy 
435
.   
Blood-based biomarkers of neocortical A 
The inconclusive findings of A species as blood markers for AD or correlation with 
A pathology has meant that novel peripheral markers of neocortical Aβ (determined 
by A PET) have been investigated. The initial studies utilising this endophenotype 
approach used a range of technologies: two-dimensional gel electrophoresis (2DGE) 
373
 and Rules-Based Medicine (RBM) 
436-437
. The first study to utilise an unbiased 
Mass Spectrometry discovery approach and the subsequent immunoassay-based 
verification for the detection of plasma biomarkers of neocortical A is presented in 
detail in Chapter 3 
374
. This study is also the first to use CSF Aβ1-42 measure in an 
endophenotype design.   
Thambisetty and colleagues 
373
 demonstrated a panel of six plasma proteins (ApoE, 
CC3, albumin, plasminogen, haptoglobin and IgG C chain receptor) to distinguish 
individuals with elevated neocortical A burden (NAB) from those without using 
11
C-PiB. A further validation study only confirmed the association of ApoE with 
NAB 
428
. Kiddle and colleagues 
436
 used a commercially available platform (RBM) to 
identify a panel of 13 proteins that predict elevated NAB at a sensitivity and 
specificity of 92% and 55% respectively. Burnham and colleagues 
437
 also utilised 
the RBM panel to produce a biomarkers signature that achieve a sensitivity of 79% 
and specificity of 78% 
437
. Despite the same discovery platform employed, only 





Table 0-4: The findings from initial blood-based discovery studies of Aβ PET 
endophenotypes. 
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2DGE 373 
C-peptide, fibrinogen, α1AT, PPY, 
CC3, vitronectin, cortisol, AXL 
receptor kinase, IL-3, IL-13, MMP9, 
apoE and IgE 
 
(with age, APOE predicts NAB with 








Aβ1-42, CXCL-13, IL-17, IgM-1, PPY 
and VCAM-1 
 
(with age, APOE predicts NAB with 











α2m, FHR-1 and FGγ 
 













Abbreviations: apoE, apolipoprotein E; CC3, complement C3; A1AT, α1-antitrypsin; PPY, pancreatic 
polypeptide; IL-3, interleukin-3; IL-13, interleukin-13; MMP9, matrix metalloproteinase-9; IgE, 
Immunoglobulin E; CXCL-13, chemokine ligand 13; IL-17, interleukin-17; IgM-1, Immunoglobulin 
M; VCAM-1, vascular cell adhesion protein; α2m; alpha-2-macroglobin; FHR-1, complement factor 
related protein-1; FGγ, fibrinogen gamma chain.  
Since these original investigations, other studies have reported blood-based 
signatures of NAB. Plasma IL-6 receptor, clusterin and apoE together with clinical, 
MRI imaging and demographic data revealed a 79% and 83% sensitivity and 
specificity for NAB 
427
. A reduced level plasma BDNF was also related to 
widespread brain amyloidosis 
438
. Westwood and colleagues 
375
 presented a number 
of plasma proteins associated with longitudinal 
11
C-PiB in cognitively normal 
individuals using a 2DGE methodology. Proteins that were associated with three 
separate time-points were α2m, albumin, apoA1, CC3, complement C4-B, 
haptoglobin and Ig kappa chain C region. Despite platform differences across all 
these studies, commonalities in candidate proteins related to NAB do exist (PPY, 
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CC3, apoE, fibrinogen, α2m and haptoglobin). An effort was made to replicate 
targets using a SOMAscan platform in an independent cohort. This work confirmed 
the association of two proteins with NAB: PPY and IgM 
439
. This was a 
disappointing replication finding; however, the lack of translation between multiple 
platforms (Mass Spectrometry, immunocapture and SOMAscan) is unsurprising. 
The endophenotype approach to biomarker discovery is still in its infancy but has 
already yielded promising results. However, it is likely that these markers will be 
more variable than CSF measures. Firstly, proximity and reduced interaction with the 
diseases organ is far greater and secondly, blood-biomarker standardisation of 
sample pre-analytics and assay choice are at the preliminary stage 
440
. In addition, the 
majority of blood-based endophenotype studies have utilised 
11
C-PiB as the 
surrogate measure A pathology. 11C-PiB detects insoluble fibrillary A and not the 
neurotoxic insoluble oligomeric A. It is then critical that the reproducibility and 
robustness of plasma proteins associated with NAB are assessed in (1) large 
independent cohorts, (2) multiple technical platforms and (3) alternative measures of 
NAB (
18
F PET tracers or CSF A1-42).       
Other endophenotype approaches  
Other types of biomarkers within blood have been investigated in AD individuals. 
Metabolomic 
407, 441-443
 and transcriptomic markers 
444
 have shown promise but have 
predominantly used a case-control design. A recent metabolomic study demonstrated 
a 5 analyte panel that could predict elevated NAB with 72% accuracy with increased 
accuracy shown with the addition of proteomic results discovered in this thesis 
445
. 
Further research is needed to examine how these markers relate to disease 
endophenotypes and if in combination with proteomic markers can improve the 




1.10 Conclusion  
Biomarkers for AD are dynamic with disease development. These changes start at an 
early preclinical stage and progress until clinical symptoms manifest in the later 
stages of the disease. Biochemical changes measured by neuroimaging and CSF 
sampling have been successful in tracking AD pathology but will prove difficult to 
implement as population screening tools for clinical application and clinical trial 
selection. The most suitable application for biomarker investigation at all stages of 
disease is venipuncture for blood analysis. The reduced cost, simplicity, accessibility 
and perceived non-invasive nature of blood testing compared with CSF sampling and 
neuroimaging will allow for large nondemented and demented populations to be 
extensively studied and followed longitudinally. The complexity of blood makes the 
search for these biomarkers a challenging task and in-depth unbiased profiling to 
discover protein markers at high and more importantly low abundances are required. 
Multiple pre-analytical procedures as well as varying technical platforms may need 
to be utilised in combination to provide a comprehensive coverage of the proteome 
for the discovery and validation of blood biomarkers. 
This work will therefore investigate multiple proteomic platforms, focusing primarily 
on LC-MS/MS, for the unbiased identification, replication and validation of single 
and multi-analyte panels predictive of elevated Aβ pathology at the preclinical to 
advanced stages of AD. An endophenotype approach will be taken so that individuals 










1.11 Aims and Objectives 
Overall aim 
To investigate blood-based markers of neocortical Aβ burden (NAB) to establish 
plasma derived protein signatures of for Alzheimer’s disease (AD) pathology that 
could be used as a population screening tool for therapeutic trials. 
Specific aims 
1. To use established proteomic approaches to investigate abundant plasma proteins 
that are associated with elevated NAB using an extreme endophenotype research 
design.  
a. LC-MS/MS discovery will be used to relate proteins with elevated NAB 
as determined by Pittsburgh compound B (
11
C-PiB) PET. 
b. To select and target proteins from LC-MS/MS discovery phase and 
replicate the findings by immunoassay in independent cohorts of differing 
NAB modalities: 
i. 11C-PiB PET imaging 
ii. Core CSF biomarkers (A1-42, p-tau and t-tau)  
2. To review, assess and improve upon current plasma proteomic LC-MS/MS 
approaches for the investigation of plasma biomarkers. Several modalities 
coupled to LC-MS/MS will be investigated including immunodepletion, 
fractionation and isobaric labelling methods. Outcomes of each methodology will 
be assessed by comparing; 
a. The total numbers of quantified protein groups and peptides.  
b. The number of protein groups of low abundance (<100ng/mL). 
c. The identification of brain specific protein groups and protein groups 
related to neurodegenerative pathogenesis. 
3. To apply the developed LC-MS/MS methodology to two larger, predominately 
cognitively normal, cohorts to discover single and multi-analyte protein panels 
that can predict elevated NAB as measured by A PET neuroimaging (11C-PiB 
and 
18




CHAPTER 2  
MATERIALS AND METHODOLOGY 
 
2.1 Participants 
2.1.1 The Australian Imaging, Biomarkers and Lifestyle Flagship Study of 
Ageing  
The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) 
study was initiated in 2006 with the view to recruit participants, over the age of 60, 
for the primary purpose of prospective research into AD. AIBL is one of the largest 
longitudinal studies of ageing (>1000 participants) that incorporates neuroimaging, 
fluid biomarkers, lifestyle, clinical and neuropsychological assessment. The AIBL 
study was approved by the institutional ethics committees of Austin Health, St. 
Vincent’s Health, Hollywood Private Hospital and Edith Cowan Univeristy. All 
volunteers gave written consent before participating in the study 
446
.  
In this work, two distinct AIBL populations were selected as discovery cohorts. 
AIBL-1 (Chapter 3) consisted of plasma samples from 78 participants selected on the 
premise of an extreme endophenotype approach based on measures by 
11
C-PiB PET 
imaging. AIBL-2 (Chapter 5) was a larger cohort which consisted of plasma samples 
from 190 individuals. Here, participants were selected based upon baseline 
11
C-PiB 
PET neuroimaging but an extreme endophenotype was not used. AIBL-2 was 
enriched to principally include cognitively normal individuals with longitudinal Aβ 
PET and cognitive examinations. 
Positron emission tomography (PET) acquisition and analysis 
An initial T1-weighted MRI for screening and co-registration with the PET images 
was initially performed on all participants. Within 11 ±22 days of the 
neuropsychological assessment all participants (AIBL-1 and AIBL-2) received an 
11
C-PiB PET scan, which has been previously described 
447
. In brief, individuals 
received ~370 MBq 
11
C-PiB PET IV over 1 minute. Imaging was performed on a 
Phillips Allegro PET camera. A rotation transmission sinogram acquisition was 
88 
 
performed before the injection of the radiotracer for attenuation correction. A 90-
minute list-mode emission acquisition was performed in 3D mode after injection of 
PiB. List-mode raw data were classified off line into four 30-seconds, nine 1-minute, 
three 3-minute, ten 6-minute, and two 10-minute frames. Classified sinograms were 
reconstructed using a 3D RAMLA algorithm 
448
. PET standardized uptake values 
(SUV) were acquired 40–70 minutes post-PiB injection and were summed and 
normalised to the cerebellar cortex SUV, resulting in a region to cerebellar ratio 
termed the SUV ratio (SUVR). The cerebellar cortex was used as a reference region 
as it is relatively devoid of senile plaques and shows no PiB binding in controls or 
AD 
448
. Regions of interest (ROIs) were determined by the individual’s MRI. Mean 
radioactivity values were obtained from ROIs for cortical, subcortical and cerebellar 
regions. Neocortical Aβ burden (NAB) was expressed as the average SUVR of the 
area-weighted mean for the following cortical ROIs. ROC’s were performed to 
establish the most accurate cut-off value to distinguish AD from Healthy. This 
approach generated a cut-off value for 
11
C-PIB SUVR of 1.3 for AIBL-1 and 1.5 for 
AIBL-2, which was used to categorise participants into those with ‘AD-like’ (PiB 
positive (PiB+) images or those with ‘Control’ (PiB-negative (PiB-) 447. 
Cognitive assessment  
Various cognitive assessments were implemented based on internationally 
recognised literature. The full battery comprised of Mini Mental State Examination 
(MMSE) 
449
, California Verbal Learning Test (CVLT-II), 30-item Boston Naming 
Test (BNT), Wechsler Test of Adult Reading (WTAR), Digit Span and Digit 
Symbol-Coding subtests of the Wechsler Adult Intelligence Scale (WAIS-III), the 
Stroop task and the Rey Complex Figure Test (RCFT) 
446
.  In addition, participants 
also completed the CogState battery examination (www.cogstate.com). The Hospital 
Anxiety and Depression Scale (HADS) were also completed to complement the GDS 
performed at screening 
446
. 
For participants with a diagnosis of MCI or AD, an informant was asked to provide 
supplementary information about the functional performance of the research 
participant and to complete the Informant Questionnaire on Cognitive Decline 
(IQCODE). Dementia severity was assessed by the Clinical Dementia Rating scale 
(CDR) 
450
. CDR assesses six categories of function (memory, orientation, problem 
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solving, home and hobbies, community affairs, self-care) and is scored to indicate 
whether dementia is absent (CDR = 0), questionable (CDR = 0.5), mild (CDR = 1), 
moderate (CDR = 2) or severe (CDR = 3). This decision is made from retrospective 
information obtained from the cognitive testing and from an informant and/or from 
the participants’ clinician. 
Blood sampling 
All sampling took place in the morning with participants required to fast overnight. 
Whole blood was collected by venipuncture at two separate sampling sites within 
Australia (Melbourne and Perth). Samples were inverted several times and incubated 
on an orbital shaker for approximately 15 minutes at room temperature (RT) prior to 
being fractionated. For plasma preparation, whole blood was spun at 200 x g, at 
20°C, for 10 minutes. The resulting supernatant was transferred to a new 15mL tube 
and spun at 800 x g at 20°C for 15 minutes, to obtain the platelet depleted plasma. 
Resulting plasma was then aliquoted into 1mL polypropylene tubes and immediately 
frozen on dry ice before long term storage in liquid nitrogen vapour tanks 
446
. 
2.1.2 The University of California, San Francisco Memory and Ageing Cohort  
The University of California, San Francisco (UCSF), Memory and Aging Centre 
(MAC) is a tertiary care dementia clinic and research program. Established in 1985, 
the primary focuses at UCSF-MAC were to conduct longitudinal research in the 
clinical, genetic, neuroimaging, emotional and diagnostic features of MCI, AD and 
non-AD dementias. Written informed consent was obtained from all patients (or 
guardians of patients) participating in the study. Biomarkers studies were approved 
by the University of California (San Francisco and Berkeley) and Lawrence Berkeley 
National Laboratory institutional review boards for human research. 
In this study, the UCSF cohort was utilised as an independent replication in Chapter 
3. UCSF participants predominantly were given an FTD diagnosis but this 
replication utilised brain Aβ measures that had been obtained and not a clinical 
represtnation. A total of 79 participants were selected based upon an extreme 
endophenotype approach using either 
11
C-PiB PET SUVR or 
11
C-PiB visual 
examination to categorise subjects into PiB- or PiB+ groups. UCSF participants must 
also have had APOE genotyping, neurological and cognitive investigations. 
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Positron emission tomography (PET) acquisition and analysis 
Subjects underwent 
11
C-PiB on a Siemens ECAT EXACT HR scanner at Lawrence 





C-PiB was injected as a bolus into an antecubital vein and dynamic 
acquisition frames were obtained for 90 minutes. Thirty minutes of emission data 
was collected at 30-60 minutes after tracer injection. Ten minute transmission scans 
for attenuation correction were obtained immediately after each PiB scan. PET data 
were reconstructed using an ordered subset expectation maximisation algorithm with 
weighted attenuation 
451
. Image processing and analysis was performed using 
Statistical Parametric Mapping software (www.fil.ion.ucl.ac.uk). As with AIBL, the 
cerebellum was utilised as a reference region to create SUVR’s and a PiB+ cut-off 
was set 1.5.  
Patient 
11
C-PiB PET scans were also visually rated by two experienced investigators 
(Professor Howard Rosen and Professor William Jagust) blinded to clinical data. 
11
C-
PiB scans were rated as “PiB-positive (PiB+)” if tracer binding was thought to be 
greater in cortical gray matter than in white matter and as “PiB-negative (PiB-)” if 
only nonspecific white matter binding was observed 
451
. 
Cognitive assessment  
All UCSF participants underwent standardised cognitive and behavioural testing. 
Cognitive testing was obtained within three months of the participants’ blood draw 
and neuroimaging scan 
452
. As with AIBL, a CDR was completed for each patient 
based on an interview with their informant and/or from the participants’ clinician. 
Face-to-face neuropsychological testing that overlapped with AIBL included the 




Whole blood was collected by venipuncture. The blood was centrifuged at 2000 g at 
room temperature for 15 minutes. Plasma was carefully collected, aliquoted and 





2.1.3 European Medical Informatics Framework  
The European Medical Informatics Framework (EMIF; www.imi.europa.eu) project 
aims to develop a common information framework of data to facilitate access to 
medical and research cohorts. The EMIF-AD platform provides a catalogue on study 
characteristics of AD cohorts in Europe that can be accessed by other research 
groups. To date EMIF-AD consists on information on 23 cohort studies. These 
cohorts have accessible to data for 4,000 subjects with normal cognition, 1,500 with 
subjective memory complaints (SMC), 5,000 with MCI and 3,000 with AD.  
In this work, the EMIF-AD cohort was used as an independent replication and in 
Chapter 3.  EMIF-AD consisted of plasma samples from 489 participants from three 
European centres selected on the primary premise of CSF Aβ1-42 stratified as CSF 
Aβ1-42+ (high NAB) or CSF Aβ1-42- (low NAB). Furthermore, participants were also 
stratified by CSF t-tau, p-tau and a CSF algorithm which incorporated all three 
measures 
454
. EMIF-AD participants must also have had APOE genotyping, 
neurological and cognitive investigations.   
Cerebrospinal fluid (CSF) sampling and analysis 
CSF was obtained by LP using a 25-gauge needle and collected in 10mL 
polypropylene tubes. CSF samples were centrifuged at 1800 × g for 10 minutes at 
4°C within 2 h of collection. CSF was aliquoted in polypropylene tubes of 0.5 or 
1 ml and stored at −80 °C until further analysis. CSF Aβ1-42, t-tau, and p-tau were 
measured with INNOTEST ELISA at each cohort site. The inter-assay coefficient of 
variation (CV) was under 12% for all analytes at all sites.  
Cognitive assessment  
All EMID-AD participants underwent a different battery of cognitive assessment at 
different cohort sites. Consistent with AIBL and UCSF, a CDR was completed for 
each patient and face-to-face neuropsychological testing included MMSE and GDS. 
Blood sampling 
All EMIF-AD cohorts all followed a similar blood processing pipeline. Blood 
samples were obtained in the morning after an overnight fast, centrifuged at 2000 x g 
for 30 min at 4°C. Plasma was collected and stored in 1.5ml aliquots at -80◦C.  
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2.1.4 The McCusker Kerr Ageing Research cohort     
The McCusker Kerr Anglican Retirement Village Initiative in Ageing Health 
Research cohort (KARVIAH) study is a two year health and lifestyle evaluation 
incorporating a one year curcumin intervention focused on AD prevention (Martins 
R et al., unpublished). The study includes a two stage design to evaluate the health 
and risk factors of older people (65-90 yrs) living in independent living retirement 
complexes. Stage 1 will involve a physical assessment including blood collection, 
neuropsychological assessment and the completion of lifestyle questionnaires. 
Eligible participants, based on the defined inclusion / exclusion criteria, will progress 
to Stage 2 of the study where the participants will in addition to the preceding 
investigations, undergo retinal and brain imaging. At the completion of the Stage 2 
baseline assessment, the participant will then be provided with either the intervention 
Biocurcumax™ or placebo, through a double blind, randomly allocated process. The 
participants will be assessed at three monthly intervals for two years. 
In this study, the 94 KARVIAH participants were utilised as an independent 
replication cohort in Chapter 5. It was not the intention to investigative the affects of 
curcumin and therefore only baseline plasma samples, before intervention, were 
utilised. Selection was dependant on the availability of 
18
FBB images for each 
subject. All KARVIAH participants were categorised as Aβ+ and Aβ- however all 
were clinically defined as healthy controls. Cognitive assessments as well as APOE 
genotyping needed to be available for inclusion into this study.    
Positron emission tomography (PET) acquisition and analysis 
All participants receiving PET scans also underwent an anatomical MRI procedure 
for anatomical localisation of ROIs. All KARVIAH participants underwent PET 
imaging using the ligand 
18
FBB within three months of blood collection, at the 
Macquarie Medical Imaging centre in Macquarie University Hospital, Sydney, 
Australia. Participants were administered an IV bolus of 
18
FBB over 30 seconds at 
resting state. Images were acquired over a 20 minute scan beginning 50 minutes post 
18
FBB injection. NAB was calculated as the mean SUVR of the frontal, superior 
parietal, lateral temporal, lateral occipital, and anterior and posterior cingulate. An 
SUVR cut-off value of 1.35 was utilised to categorise participants into Aβ+ and Aβ-. 
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Cognitive assessment  
The battery of neuropsychological tasks followed the same protocol as the AIBL 
study 
446
. As with AIBL, only MMSE and CDR assessments were utilised in this 
study. 
Blood sampling 
Whole blood was collected by venipuncture and followed the same plasma 







The following is a list of reagents and the suppliers they were acquired.    
Reagent Supplier Catalogue # 








Ammonium Bicarbonate (Ambic) Sigma A6141 












apolipoprotein(a) (apo(a)) Human ELISA kit Cusabio 
CSB-
E15088h 












complement factor B (CFB) Human ELISA kit Abcam ab137973 
complement factor H (CFH) Human ELISA kit Abcam ab137975 





Dithiothreitol (DTT) Sigma D5545 
























Glycercol Sigma G5516 
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haptoglobin Human ELISA kit Genway 17Q1 








Hydroxylamine solution Sigma 438227 




Iodoacetamide (IAA) Sigma I1149 




Methanol, hypergrade for LC-MS Sigma 34966 
Minerial Oil Sigma M3516 




NuPAGE® Novex 10% Bis-Tris 1.5 mm Invitrogen NP0316BOX 
Phosphate buffered saline (PBS) Sigma P4417 










Sample Buffer, Laemmli 2× Concentrate Sigma S3401 




Sodium dodecyl sulfate (SDS) Sigma 5030 




Tetraethylammonium bromide (TEAB) Sigma T7408 












Tris (2-carboxyethyl) phosphine (TCEP) Sigma C4706 
Trypsin, Modified Sequencing Grade Roche 11418025001 




All solutions were made up with 18MΩcm ultra-pure water (ddH20) unless stated 
otherwise. 
Stock Procedure 




1mL 100mM Ambic 
Hydroxylamine 5 
20µL Hydroxylamine 50% 




LC-MS/MS sample solution (2% 




OGE rehydration solution (24 well 
frame) 
960µL OGE peptide stock solution 
240µL ddH20 
OGE rehydration solution (12 well 
frame) 
560µL OGE peptide stock solution 
140µL ddH20 
OGE peptide stock solution 
600µL OGE buffer 
Glyercol 6mL 
43.4mL ddH20 
OGE peptide sample (24 well frame) 
1mg TMT10plex dried sample 
360µL ddH20 
1.44mL OGE peptide stock solution 
OGE peptide sample (12 well frame) 
1mg TMT10plex dried sample 
720µL ddH20 










70µL 0.5M TCEP 
70µL ddH20 
35µL 1M TEAB 
TEAB 200mM 
600µL 1M TEAB 
2.4mL ddH20 
Trypsin 0.1% TFA 





2.4 Methodology for Chapter 3 
 
Figure 2-1: Schematic diagram of the LC-MS/MS workflow applied to AIBL-1 cohort 
in Chapter 3. 
2.4.1 Tandem Mass Tag 6plex (TMT6plex) protein labelling  
TMT tags were utilised for multiplexing clinical samples and relative quantification 
against a study reference. TMT chemical tags contain four regions; a mass reporter 
region, a cleavable linker region, a mass normalisation region and a protein reactive 
group (Figure 2-2). Although chemically identical, each TMT tag has isotope 
replacements at differing locations. This ensures that the mass normaliser and mass 
reporter have differing molecular masses in each tag. As the full structure and 
molecular weight of each TMT tag is identical, the differing TMT labels cannot be 
distinguished during protein fractionation, liquid chromatography (LC) or MS1 
fragmentation. Fragmentation is achieved upon MS2 (MS/MS) by high energy 
collision dissociation (HCD), cleavage of the peptide back bone and linker give rise 




Figure 2-2: Functional regions of TMT tag structure including MS/MS fragmentation 
sites by higher energy collision dissociation (HCD). During MS2 fractionation by HCD 
the cleavable linker is broken to give produce a unique Mass Reporter. 
Total protein quantification was determined by a NanoDrop™ 1000 
Spectrophotometer (Thermo Scientific) and 100µg of protein from each sample was 
extracted for TMT6plex protein labelling. Each sample was randomly assigned and 
labelled with an amine reactive TMT reagent (TMT-127, TMT-128, TMT-129, 
TMT-130 and TMT-131) with TMT-126 being used to label the study reference, an 
equal pool of the plasma obtained from all samples included in the study (Figure 2-
1).  
One hundred micrograms of lyophilised plasma sample was solubilised in 200mM 
Tetraethylammonium bromide (TEAB) and 2% SDS, reduced in 200mM tris (2-
carboxyethyl) phosphine (TCEP) for 1 h at 55˚C and then alkylated in 150mM 
iodoacetamide (IAA). The TMT6plex protein reagents were reconstituted in 24µL 
acetonitrile (ACN) and 18.5µL was added to the appropriate pre-designated sample 
and incubated at RT for 1 hour.  Plasma samples were then quenched with 4µL of 
5% hydroxylamine and incubated at RT for a further 15 minutes. The TMT6plex’s 
were completed by combining one of each sample with a TMT-127, TMT-128, 
TMT-129, TMT-130 and TMT-131 reagent, plus a study reference (TMT-126). The 
resulted in the formation of 16 TMT6plex’s, each with a total of 600µg of protein, 
were further treated with 8µL of 5% hydroxylamine before being divided into 100µg 
aliquots, frozen at -80˚C and lyophilised until completion. 
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2.4.2 One dimensional gel electrophoresis (1DGE) 
One hundred micrograms of each TMT6plex were reconstituted in 15µL 50mM 
TEAB. An equal volume of 2x sample buffer (4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromphenol blue and 0.125 M Tris HCl, pH ~6.8) was 
added to the TEAB sample and incubated at 90˚C for 10 minutes. TMT6plex protein 
samples were loaded onto a single NuPAGE® Novex 10% Bis-Tris 1.5 mm precast 
gel. To avoid overloading only 4 TMT6plex’s were run on one 1DGE gel. Gels were 
run at constant 150V for 90 minutes, stained with Imperial™ Protein stain (Thermo 
Scientific) for 2 h and destained with ddH20 overnight.  A pre-stained reference 
(SeeBlue® Plus2 Pre-stained Protein Standard) was run on each gel. All gel lanes 
were cut manually into 10 equal sized fractions (Figure 2-3) and frozen at -80˚C. 
 
Figure 2-3: A schematic diagram demonstrating the equal fractions excised for 
enzymatic digestion for all 16 TMT6plex groups. Four representative TMT6plex’s are 
shown. 
2.4.3 Enzymatic digestion  
Excised gel fractions were further cut into ~2mm
3
 cubes and washed firstly with 
100mM of ammonium bicarbonate (ambic) for 5 minutes and then decanted. ACN 
was added in excess, decanted, and then the same volume was added to fully and 























cubes were vacuum dried for 15 minutes. The gel cubes were reduced in 10mM 
Dithiothreitol (DTT), incubated at 56˚C for 1 h before being dehydrated by two 
rounds of ACN washes before being vacuum dried for 10-15 minutes. Next 55mM 
IAA was added to alkylate the gel cubes and incubated at RT for 20 minutes, 
protected from light. Three further washes included 100mM ambic, 50% ACN and 
100% ACN with a final vacuum stage. Trypsin solution was prepared by adding 
200µL of ambic to each aliquot containing 0.1% Trifluoroacetic acid (TFA) to give a 
final concentration of 13ng/µL trypsin. Gel cubes were fully submersed in the trypsin 
solution and incubated at 4˚C for 20 minutes. Finally, 20µL of 50mM ambic was 
added to the gel pieces, to keep moist during enzyme cleavage and incubated at 37˚C 
for 4 hours then overnight at RT. 
2.4.4 Peptide extraction  
Supernatant from the overnight tryptic digestion was decanted and collected into a 
new Eppendorf tube (primary collection).  A minimal volume of 50mM Ambic 
(enough to cover the gel cubes) was added to each gel fraction and incubated on a 
heat shaker (37˚C) for 5 minutes. The supernatant was collected and added to the 
primary collection. Gel cubes were next dehydrated with ACN for 10 minutes at 
37˚C, after which the supernatant was again decanted and into the primary collection 
Eppendorf tube. The rehydrating and dehydrating step was repeated once more, with 
the supernatant being added to the primary collection Eppendorf tube each time. The 
pooled supernatant of tryptic peptides was then frozen and vacuum dried to 
completion prior to MS analysis. 
2.4.5 Liquid Chromatography – Tandem Mass Spectrometry acquisition  
Prior to LC-MS/MS analysis, peptide extracts from all 160 gel fractions were 
reconstituted in 0.1% formic acid (FA), 2% ACN and de-ionised water then shaken 
at 37˚C, vortexed and centrifuged thoroughly. Each peptide extract was reconstituted 
to a concentration of 0.5µg/µL with retrospective protein concentration of peptide 





Figure 2-4: Method of chromatographic separation for TMT6plex labelled peptides in 
AIBL-1. A linear increase of 5% solvent B (0.1% FA in 100% ACN) was run for 100 
minutes before a 5 minute wash at 80% solvent B.    
Chromatographic separation was achieved by a two column configuration; 4µL of 
sample (~2µg) was injected first onto a 0.1 × 20 mm pre-column (Thermo Scientific) 
packed with octadecyl carbon chain C18-bonded silica (C18) using the Thermo 
Scientific Proxeon EASY-nLC II system. Peptides were then resolved using a linear 
gradient of 0.1% FA in ACN (10% to 65% over 115 minutes) through a 0.075 × 150 
mm C18 analytical column (Thermo Scientific) at a flow rate of 300nL/min (Figure 
2-4). Mass spectra were acquired on a Thermo Scientific LTQ Orbitrap Velos 
instrument throughout the chromatographic run which operated in data-dependent 
mode to automatically switch between full scan MS and MS/MS acquisition. 
Instrument control was through Tune 2.6.0 and Xcalibur 2.1 (Thermo Scientific). A 
Higher Collision induced Dissociation (HCD) Top10 method was used; survey full 
scan MS spectra (from m/z 400–2,000) were acquired in the Orbitrap system with 
resolution at 30,000 after accumulation to an Automatic Gain Control (AGC) ion 
injection target value of 1x10
6
 (500ms max injection time). The ten most intense 
peptide ions, with charge states >2, were sequentially isolated to an AGC target value 
of 50,000 (250ms max ion injection time). Selected ions were then put on a dynamic 
exclusion list for 30secs (10 ppm m/z window). Fragmentation in the HCD collision 
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cell was achieved with normalised collision energy of 40%. The resulting fragments 
were detected in the Orbitrap system with resolution of 7,500. Real-time calibration 
and therefore greater mass accuracy was achieved using the polysiloxane peak at 
445.120024 m/z as a lock-mass. Other standard MS conditions for all experiments 
were as described in Olsen and colleagues 
455
; spray voltage, 2.2 kV; no sheath and 
auxiliary gas flow; heated capillary temperature, 200°C; predictive automatic gain 
control (pAGC) enabled and an S-lens RF level of 50–60%. 
2.4.6 Computational Mass Spectrometry  
Pre-processing of LC-MS/MS data 
Raw data files produced in Xcalibur software 2.1 were processed using Proteome 
Discoverer, (ver. 1.3; Thermo Scientific) to determine peptide identification (Figure 
2-5); the subsequent Mascot (ver. 2.3; available at: http://www.matrixscience.com) 
output file was used for additional pre-processing and analysis. 
Prior to database searching a spectrum selector threshold was applied; minimum 700 
Da and maximum 10000 Da. Within Mascot, mass spectra were searched against the 
uniprot/Swiss-prot database (ver. 4.11), taxonomy was set to human with precursor 
and fragment mass tolerances were set to ±5ppm and 0.5 Da respectively. Dynamic 
modifications included TMT6plex modification of the lysine residue (TMT (K)), 
TMT6plex modification of the peptide N-Terminus (TMT (N-Term)), deamidation 
(NQ) and oxidation of the methionines. Additionally, carbamidomethylation of 
cysteine residues was set as a fixed modification and three miss cleavages were 
allowed. The results of this database search were further filtered to include peptides 
with an “ion score” >15 and those described by mascot as “Bold Red” (at least one 
top-scoring peptide appearing for the first time in a protein; 
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). The LC-MS/MS 
peak lists were further processed to pull out the six TMT reporter ion intensities for 
each peptide that passed the criteria mentioned above; this was generated by a 






Figure 2-5: Proteome Discoverer workflow for database searching of MS/MS spectra in 
Chapter 3. Spectrum selector thresholds were set as 700Da-10000 Da. In Mascot, 
precursor and fragment tolerances were set to ±5ppm and 0.5 Da. Modifications 
included TMT (K), TMT (N-Term), deamidation (NQ), oxidation (M) and 
carbamidomethylation (C) of cysteine residues. Three miss cleavages were allowed.  
Pre-processing for Relative Quantification (PRQ-1) 
A script was written in R to complete the pre-processing of LC-MS/MS data 
acquired. The script, named Pre-processing for Relative Quantification (PRQ-1) can 
be viewed in Supplementary Material 1. PRQ-1 performs (1) median ratio 
normalisation 
456
, (2) calculates within TMT6plex ratios for each peptide, (3) derives 
within TMT6plex protein level data from all corresponding peptide scores, and (4) 
collects the protein group scores across all TMT6plex experiments. A protein group 
is defined as the number of protein identification in which this peptide is found.  
Median normalisation to correct for TMT6plex labelling and MS-run variation (Step 
1) is performed within each sample and gel fraction. This involves calculating the 
median of the ratios of all peptide intensities from one sample versus the 
corresponding intensities measured in the reference sample. All intensities relating to 
that sample and gel fraction are then divided by the median ratio. Ratio scores for 
each peptide are then calculated (Step 2) by taking the ratios of the normalised data 
for each peptide by dividing it to the reference intensity. Ratios corresponding to the 
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same source protein, peptide sequence and gel fraction are then summed. Protein 
level data is derived from these summed peptide scores (Step 3) by taking either the 
mean or median of all peptide scores from the same source protein and gel fraction. 
This protein level data is then collected across all sixplexs (Step 4).  
Post PRQ-1 data clean up included the removal of all non-TMT peptides. The 
isobaric multiplex approach applied subsequently meant that only proteins with full 
quantifiable TMT information were carried forward for statistical evaluation. In 
addition, only protein data with information from >50% of subjects were considered 
a reliable measurement of plasma protein expression. In the instance of LC-MS/MS 
data separated with 1DGE a single protein can be observed in multiple fractions. 
These mass differences could be explained by Post-Translational Modifications 
(PTM), single nucleotide polymorphism (SNP), proteolytic cleavage, alternative 
splicing or terminal fragments of a protein sequence. Therefore, identical protein 
identifications observed in different fractions were considered as separate entities 
known as protein group molecular weight (MW) isoforms.  
Manual assessment of MS spectra  
Manual examination of assigned spectra in Proteome Discoverer was only performed 
for significantly associated proteins. The manual examination of MS/MS spectra is 
subjective; however it is an essential step when confirming the identity of a peptide 
sequence, especially at a relaxed assignment criterion (5% FDR) or for proteins of 
lower abundance. MS/MS spectra would typically be confirmed by the presence of 
overlapping b and y ions that give full coverage of the peptide sequence (good 
quality, Figure 2-6) or significant coverage series of b or y ions with strings of 
adjacent b or y ions being identified together (moderate quality, Figure 2-7). The 
criterion set out by Tabb and colleagues 
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Figure 2-6: Example of a good quality MS/MS spectrum identified at 5% FDR. There is a large intensity ion count and full series of overlapping b 
and y ions are indentified. TMT reporter region is not contributing to peptide score in Mascot. MS/MS spectrum of m/z 605.98 for the 
[M+3H]
3+





Figure 2-7: Example of a moderate quality MS/MS spectrum identified at 5% FDR. There is a large intensity ion count and the majority but not all b 
and y ions are accounted for. TMT reporter region is contributing small proportion to peptide score in Mascot and a small amount of the precursor 
ion remains. MS/MS spectrum of m/z 588.65 for the [M+3H]
3+
 molecular ion for a peptide of 1763.95 Da with corresponding sequence 






Figure 2-8: Example of a poor quality MS/MS spectrum identified at 5% FDR. There is a large intensity ion count which is caused by the non-
fragmented precursor ion. Only one y ion matched with no subsequent b ions matched. MS/MS spectrum of m/z 545.64 for the [M+3H]3+ molecular 
ion for a peptide of 1634.92 Da with corresponding sequence DEGKASSAKQR unique to hemopexin. 
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2.4.7 Technical verification and validation: Enzyme-linked Immunoabsorbent 
assays (ELISA) 
Candidate markers discovered by LC-MS/MS underwent technical verification using 
commercially available ELISAs. Technical verification was performed in the same 
78 subjects from the AIBL-1 imaging sub-cohort, as we sought to translate our 
discovery findings to a simple-to-use format. Further validation in independent 
cohorts (UCSF and EMIF-AD) was performed using the same commercial ELISA as 
the technical verification. 
Sandwich ELISA 
Plasma samples were tested for optimal dilution by testing each kit using a pool of 
elderly control and AD plasma all standards were diluted as recommended in the 
protocol for each ELISA kit (Table 2-1). All kit components and samples were 
brought to RT (18-25˚C) before use. The variations between assay protocols were 
minimal and differences in volumes, incubation times/temperatures are indicated in 
Table 2-1. In general, 100µL of the standard and diluted plasma samples were added 
to the appropriate wells and incubated for 2 h at 37˚C with agitation on an orbital 
shaker. The liquid from each well was aspirated and 100µL of detection antibody 
was added, and incubated for 1 h at 37˚C. The plate was then washed 3 times with 
350µL of wash buffer by an automated plate washer (Bio-Rad) and incubated for 30 
minutes with 100µL secondary antibody. The plate was further washed 5 times as 
before and 90µL 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate solution was 
added to each well and incubate at 37˚C for 5-20 minutes (protected from the light). 
Finally, 50µL of stop solution was added to each well and the absorbance at 450nm 
was measured on a micro plate reader (PHERAStar FS). The plate was also read at 
595nm to account for background interference.  
Before statistical analysis, the performance of each assay was examined using 
quality checks (QC; Table 2-3). Sample replicates were averaged and standard 
values were exported into Sigma plot (Systat Software; version 12) for estimation of 
protein concentrations using a 5-parameter logistic curve fitting method. Any sample 
that recorded a coefficient of variation (CV) >15% for either duplicate was 
eliminated; if both duplicates were out of range then both data points were excluded. 
Ideally, a spike and recovery assessment should be performed on each commercial 
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assay to determine its performace. In spike and recovery, a known amount of analyte 
is added (spiked) into the natural test sample matrix. Then the assay (ELISA) is run 
to measure the response (recovery) of the spiked sample matrix compared to an 
identical spike in the standard diluent. This was not performed for commercial 
assays displayed in Table 2-1.  
Table 2-1: Sandwich ELISA protocol variations for proteins selected for technical 
replication and validation.  

























Sciences Inc.  
40,000 2 (37°C) 100µL (1)  
100µL 
(0.5)  















Sciences Inc.  








Sciences Inc.  
1000+  2 (37°C) 100µL (1)  
100µL 
(0.5)  




Sciences Inc.  
500+  2 (37°C) 100µL (1)  
100µL 
(0.5)  
90µL (15)  
clusterin  
USCN Life 
Sciences Inc.  
10,000 2 (37°C) 100µL (1)  
100µL 
(0.5)  




Sciences Inc.  
10,000 2 (37°C) 100µL (1)  
100µL 
(0.5)  




Sciences Inc.  






factor B (CFB) 
Abcam  5,000 2 (37°C) 
50µL  
(1)  
50µL (0.5)  50µL (12)  
complement 
factor H (CFH) 
Abcam  200,000 2 (37°C) 
50µL  
(1)  




Sciences Inc.  
25+  2 (37°C) 10 µL (1)  
100µL 
(30)  




Sciences Inc.  
10,000 2 (37°C) 100µL (1)  
100µL 
(30)  
90µL (10)  
geloslin 
USCN Life 
Sciences Inc.  
250+  2 (37°C) 100µL (1)  
100µL 
(30)  
90µL (15)  
haptoglobin  GenWay  50,000 0.25 (25°C) 
100µL 
(0.25)  
N/A  100µL (5)  
histidine-rich 
glycoprotein 
(HRG)   
USCN Life 
Sciences Inc.  
20,000 2 (37°C) 100µL (1)  
100µL 
(30)  




Sciences Inc.  
200,000 2 (37°C) 100µL (1)  
100µL 
(30)  
90µL (12)  
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Table 2-2: Immunoassay quality control (QC) criteria (adapted from Hye A et al., 
2014). Analytes were assessed for quality by applying rank according to the assay 
performance and defined using a scoring system based on four criteria as follows. All 
plasma analytes passed these criteria.  
  
1- Standard Curve Rank 
1 = Good quality – samples within linear section on standard 
curve.  
2 = Moderate quality – samples spread across the linear 
section on standard curve. 
3 = Poor quality – not on linear section at all. 
2- Intra-assay CV 
Intra-assay CV (%) for assay standards 1-4, CV<15% 
accepted.  
3- Inter-assay CV 
Inter-assay CV (%) for in-house pooled sample (master mix), 
CV<20% accepted. 
4- Missing data 
Missing data defined as samples that could not be reliably 
extrapolated from the standard curve.  
(1) OD values outside the quantifiable range.  
(2) Technical failure resulting in no OD value being 
generated. 
 
Competitive ELISA: complement Factor H related protein 1 (FHR-1) 
For FHR-1, a competitive ELISA was utilised. Briefly, 50µL of standards and 
diluted plasma (1 in 400) were added to a pre-coated 96 well micro plate pre-coated. 
Immediately, 50µL of the HRP-conjugate (FHR-1) secondary antibody is added to 
each well and then incubated for 1 hr at 37˚C.  The plate was then washed 5 times 
with 200µL of wash buffer by an automated plate washer, allowing standing for 2 
minutes after each wash. Then, 90µL of TMB substrate was added to each well and 
incubated at 37˚C and after 20 mins 50µL stop solution was added. FHR-1 plates 
were measured in the same fashion as a sandwich ELISA. 
With a competitive ELISA, analyte concentration is measured by noting the extent of 
the signal reduction. If there is a high concentration of antigen in the sample, then 
there will be a significant reduction in signal output of the assay. Conversely, if there 
is little analyte in the sample, there will be minimal reduction in signal and the HRP-
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conjugate with bind to the capture antibody. A competitive ELISA is often used 
when only one antibody is available to the antigen of interest or when the analyte is 
small and cannot be bound by two different antibodies. On the other hand, a 
sandwich ELISA is considered to be highly specific as two antibodies are used to 
capture and detected the antigen and therefore more suitable for complex samples. 
 
Figure 2-9: A schematic diagram illustrating the differences between a sandwich and 
competitive ELISA. The sandwich ELISA measures an analyte by two primary 
antibodies – the capture antibody and the detection antibody. For a competitive ELISA 
unlabelled antigen from the sample and the HRP labelled antigen compete for binding 
to the capture antibody. A decrease in signal from purified antigen indicates the 
presence of the antigen in samples. 
2.4.8 Statistical analysis  
All statistical analyses were performed in SPSS (version 21) and R statistical 
packages. For Logistic and Linear regressions, age, gender and presence of APOE ε4 
allele were used as standard confounding factors upon the data (covariates). 
For LC-MS/MS discovery data in AIBL-1, each protein group MW isoform 
underwent four statistical tests for either correlation with 
11
C-PiB SUVR 
(Spearman’s Rank Correlation and Linear Regression) or to assess association with 
11
C-PiB SUVR as an extreme endophenotype (PiB-, PiB+;
 
Mann Whitney-U and 
Logistic Regression). These statistical tests were performed on both median and 
mean protein roll up methods (PRQ-1; Step 3). Benjamini-Hochberg Q values were 
calculated as a multiple testing correction.  
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For the ELISA analysis of technical replication (AIBL-1) and validation (UCSF) 
studies, data outliers were excluded (±3 standard deviations). Protein values were 
log10 transformed to achieve normal distribution. Again, protein values were assessed 
for their association with 
11
C-PiB SUVR as a continuous and binary measure. Only 
Linear Regression and Logistics Regressions were performed with a fourth 
covariate, assay plate, being added. PET scanner type was added as an additional 
covariate for only the UCSF data. Multiple testing corrections were calculated using 
Benjamini-Hochberg Q values. The package ‘CARET’ 458, with default parameters, 
was used to perform Random Forest and partitioning multivariate classifications. 
The package ‘ROCR’ 459 was used to calculate classifier performance.  
For the ELISA analysis in the EMIF-AD cohort there was no confounding affect of 
age or gender. However, EMIF-AD is a multi-centre cohort and therefore, protein 
values were adjusted by a Generalised Linear Model (GLM) for cohort differences as 
well as assay plate difference. The residuals produced from the GLM, for each 
individual sample, were added to mean of raw protein value. Protein values were 
assessed with CSF Aβ1-42, p-tau, t-tau and CSF algorithm as continuous and 
endophenotype binary measures. APOE ε4 was added as a covariate separately. The 
identical protein model developed in AIBL-1 and UCSF was tested in EMIF-AD. 
The package ‘CARET’ was used to create confusion matrices to calculate negative 
predictive value (NPV), positive predictive value (PPV), sensitivity and specificity.  
Pathway analysis was performed using the Database for Annotation, Visualization 
and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/) 
460-461
, based on 
Kyoto Encyclopedia of Genes and Genomes (KEGG) annotations 
462
.Methodology 
for Chapter 4 
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Figure 2-10: Schematic flow diagram represents the 15 proteomic workflows 
investigated to establish a workflow to detect a broad range, low abundant and brain 
derived plasma proteins circulating within plasma. 
2.4.9 Immunodepletion  
Two commercially available immuodepletion kits were investigated: The 
ProteoPrep
®
 Immunoaffinity Albumin and IgG Depletion Kit (PROTIA, Sigma-
Aldrich, Saint Louis, USA) and Pierce™ Top12 Abundant Protein Depletion Spin 
columns (Pierce Biotechnology, Rockford, USA). 
ProteoPrep
®
 Immunoaffinity Albumin and IgG Depletion 
The depletion spin columns were brought to RT and 30µL (~1.8mg) of plasma was 
diluted in 70μl of equilibration buffer before performing the depletion process. After 
column preparation and equilibration (as per manufactures instructions), diluted 
plasma was loaded onto the column and incubated for 15 minutes at RT. Samples 
were then collected by centrifugation 8000 x g for 60 seconds. The eluate collected 
was then re-applied to the medium bed and incubated for a further 10 minutes. The 
twice depleted plasma was centrifuged again at 8000 x g for 1 minute. Finally, 125µl 
of equilibration buffer was added to the medium bed and centrifuged for 60 seconds 
to wash through any remaining unbound proteins from the spin column. Total 
protein quantification of the “twice depleted” sample was determined by a 
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NanoDrop™ 2000 Spectrophotometer for further downstream fractionation or 
analysis. 
Pierce™ Top12 Abundant Protein Depletion 
The Pierce™ Top12 Abundant Protein Depletion spin columns was utilised to 
remove 12 highly abundant proteins from plasma to assist the identification and 
quantitation of low abundant proteins 
Table 2-3: The Top 12 proteins removed by the Pierce™ Top12 Abundant Protein 
Depletion spin columns 
alpha-1-Acid glycoprotein (AGP) fibrinogen 
alpha-1-Antitrypsin (α1AT) haptoglobin 
alpha-2-Macroglobulin (α2m) Immunoglobulin A (IgA) 
albumin Immunoglobulin G (IgG) 
apolipoprotein A-I (apoA1) Immunoglobulin M (IgM) 
apolipoprotein A-II (apoA2) transferrin 
 
The depletion spin column was brought to RT and 10µL (~600µg) of plasma was 
added directly to the resin slurry. The column was inverted several times until the 
resin was completely suspended in the solution. The sample was then further 
incubated for 60 minutes on an end-over-end mixer at RT. The column was then 
centrifuged for 2 minutes at 1000 x g and the flow through collected in separated 
tube. The sample, depleted of the top 12 proteins, is in a solution of 10mM PBS, 
0.15M NaCl, 0.02%. The sample was frozen and vacuum dried to completion for 
further downstream fractionation or analysis. 
2.4.10 Tandem Mass Tag 10plex (TMT10plex) labelling 
TMT10plex labelling utilise the same reporter regions as TMT6plex however an 
elemental isotope different of 0.0063 Da in tags 127, 128, 129 and 130 created four 
additional tags for multiplexing.  
 
TMT10plex protein labelling 
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The process of TMT10plex protein labelling followed the same technical process as 
TMT6plex protein labelling (see Chapter 2.4.1). Each sample was randomly 
assigned amine-reactive TMT10plex tag (TMT-127N, TMT-127C, TMT-128N, 
TMT-128C, TMT-129N, TMT-129C, TMT-130N, TMT-130C and TMT-131) with 
TMT-126 assigned as a static study reference. 
 
TMT10plex peptide labelling and in-solution digests 
TMT10plex peptide labelling commences following in-solution tryptic digestion. 
Briefly, for in-solution digests, 100g of each plasma sample was initially dried to 
completion and incubated with 100mM TEAB and 0.1% SDS [w/v]. Reduction and 
alkylation was achieved in 1mM tris (2-carboxyethyl) phosphine (TCEP) for 1 hour 
at 55˚C followed by incubation in 7.5mM iodoacetamide (IAA). Proteins were 
digested overnight in 4µg trypsin (sequencing grade) reconstituted in 100mM TEAB. 
TMT10plex reagents were reconstituted in ACN then added to the appropriate 
sample to reach a final concentration of 15mM and incubated for 1 h at RT.  Plasma 
samples were treated with 5% hydroxylamine (0.25% [w/v]) and incubated at RT for 
15 minutes. After combining all samples together, the samples were incubated at RT 
for a further 15 minutes.  Again, each sample was randomly assigned amine-reactive 
TMT10plex tag with TMT-126 assigned as the study reference. 
2.4.11 One dimensional gel electrophoresis (1DGE) 
All information on the 1DGE procedure is outlined in Chapter 2.4.2. After 
destaining, gel lanes were cut manually and frozen at -80˚C. For methods that 
required 10 fractions (1DGE-4 and 1DGE-5) or 20 fractions (1DGE-7 and 1DGE-8) 
gel pieces were excised to maximise gel bands displayed by protein staining and was 
kept uniform across all replicates (Figure 2-11, Figure 2-12, Figure 2-13 and Figure 
2-14). The process of enzymatic digestion (2.5.3) and peptide extraction (2.5.4) was 




Figure 2-11: A schematic diagram demonstrating the fractions excised for enzymatic 
digestion for undepleted TMT10plex groups with 10 fractions (1DGE-4). 
 
Figure 2-12: A schematic diagram demonstrating the fractions excised for enzymatic 












































Figure 2-13:  A schematic diagram demonstrating the fractions excised for enzymatic 
digestion for undepleted TMT10plex groups with 20 fractions (1DGE-7). 
 
Figure 2-14: A schematic diagram demonstrating the fractions excised for enzymatic 































































2.4.12 OFFGEL (OGE) fractionation 
OFFGEL fractionation (OGE) technology enables separation based on immobilised 
pH gradient (IPG) strips. Unlike the traditional workflow of gel electrophoresis, 
protein/peptides present in the liquid phase are forced to migrate through the gel 
from one compartment to another until reaching their isoelectric point (pI). These 
molecules are then retained in the solution as their net charge equals zero and 
therefore enabling the recovery of protein/peptides from the liquid phase (Figure 2-
15).  
Isoelectric point-based (pI) OGE for peptides was carried out as specified by 
manufacturer’s instructions. In brief, 1mg of TMT10plex labelled peptides were 
dried to completion and re-suspended in OGE stock solution (1.25X). Prior to 
separation, each IPG strip was rehydrated with 40µL (per well) OGE rehydration 
solution for 15 minutes. Peptides were separated using both a 12-multiwell and 24-
multiwell format encompassing IPG strips (pH 3-10, 13cm; pH 3-10, 24cm), focused 
for 50kVh with a maximum current of 50µA and maximum voltage of 4500 V. Upon 
completion peptide fractions were held at 500 V and current of 20μA prior to 
collection. Liquid fractions (12 and 24) were collected into separate Eppendorf tubes 
(passive recovery). To extract larger peptides retained in the IPG strips, 150μL of 
50% ACN/0.1% FA was added in each compartment and incubated for 30 minutes. 
The solution (second recovery) was retrieved and added to extract from the passive 
recovery. Peripheral fractions (1-3 and 22-24) were combined to emulate the number 
of fractions as included in 1DGE methods and each fraction was cleaned by a SOLA 
HRP solid phase extraction cartridge (Thermo Scientific). Each fraction was 
vacuum-dried to completion and re-suspended in 2% ACN/0.1% FA at concentration 




Figure 2-15: Schematic diagram to demonstrate the process of OFFGEL fractionation. 
Protein/peptide sample is evenly distributed across all compartment of the IPG strip. 
In response to high voltage, molecules move through the compartment until their 
isoelectric point is found. Protein/peptides are removed in a liquid fraction ready for 
LC-MS/MS analysis.  
Diagram has been adapted with permission from Agilent Technologies.   
2.4.13 Liquid Chromatography – Tandem Mass Spectrometry acquisition  
All LC-MS/MS acquisition was performed in an identical manner, regardless of 
proteomic workflow employed. As previous (Chapter 2.4.5), chromatographic 
separation was achieved by a two column configuration and mass spectra were 
acquired on a Thermo Scientific LTQ Orbitrap Velos instrument controlled through 
Tune 2.6.0 and Xcalibur 2.1 (Thermo Scientific). There were two major 
modifications made to the LC-MS/MS acquisition that differed from the 
methodology used in Chapter 2.4.5.  
1. Peptides were resolved using a modified linear gradient of 0.1% FA in 
ACN (10% to 65% over 115 minutes) through a 0.075 × 150 mm C18 
analytical column (Thermo Scientific) at a flow rate of 300nL/min (Figure 2-
16).    
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2. A HCD Top10 method was used; survey full scan MS spectra (from m/z 400–
2,000) were acquired in the Orbitrap system with resolution 60,000 after 
accumulation to an AGC ion injection target value of 1x10
6
 (500ms max 
injection time). The higher resolution was needed for the incorporation of 
TMT10plex. 
 
Figure 2-16: Method of chromatographic separation for TMT10plex labelled peptides. 
A modified linear gradient of 0.1% FA in ACN (10% to 65% over 115 minutes) was 
applied to peptide extracts from all methodologies. 
2.4.14 Computational Mass Spectrometry and statistical analysis  
Raw data files produced in Excalibur software (Thermo Scientific) were processed 
using Proteome Discoverer (ver. 1.4) to determine peptide identification and 
quantitation. All methods underwent a sequential database searching, where all 
individual fraction(s) were processed as separate entities and merged to create one 
file. In addition, methodologies with multiple fractions (4-9) also underwent MudPIT 
database searching where all fractions were merged prior to pre-processing 
indentified as 4b, 5b, 6b, 7b, 8b and 9b (Figure 2-10). Within Proteome Discoverer, 
mass spectra were searched against two sequence databases side-by-side (Figure 2-
17). For Mascot based searching against the uniprot/Swiss-prot database (ver. 4.11) 
taxonomy was set to human and precursor and fragment mass tolerances were set to 
122 
 
±5ppm and 0.5Da respectively. Dynamic modifications included TMTPlex 
modification of the lysine residue (TMT (K)), TMTPlex modification of the peptide 
N-Terminus (TMT (N-Term)), deamidation (NQ) and oxidation of the methionines. 
Additionally, carbamidomethylation of cysteine residues was set as a fixed 
modification and three missed cleavages were allowed.  Sequest HT searching 
parameters were identical to Mascot. Validation of merged Mascot and Sequest 
database results were conducted by Percolator at FDR of 0.05.  
 
Figure 2-17: Proteome Discoverer workflow for database searching of MS/MS spectra 
for methods in Chapter 4 and 5. Two database search engines were utilised (Mascot 
and Sequest HT) with identical parameters.   
LC-MS/MS peak lists with TMT reporter raw intensities were exported from 
Proteome Discoverer. Each methodology reported the number of proteins groups, 
unique peptides, PSMs (peptide spectral matches) and spectral yield (unique 
peptides/PSMs) at 1% and 5% FDR to assess the number of indentified features for 
each methodology.  
To assess the depth of proteome coverage, each workflow was compared with the 
Plasma Proteome Database (PPD, www.plasmaproteomedatabase.org) that has 
reported the concentrations of >1,200 proteins 
463
. Protein concentrations in PPD 
matched with our LC-MS/MS peak lists were extracted and log2 transformed to 
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achieve a normal distribution. In SPSS (ver. 22), an Analysis of variance (ANOVA) 
was used to compare the mean differences of protein concentration between each 
method and illustrated with a box plot (to demonstrate range) with vertical bins (to 
demonstrate frequency) was created in R.  The Human Protein Atlas (HPA) 
(http://www.proteinatlas.org/; download date from HPA 20/10/2016) was utilised to 
assess brain-derived proteins (BDP) present within plasma. The “Tissue Enriched” 
category in HPA (>five-fold increased expression in the cerebral cortex compared 
with all other tissues) was used as an indication of a BDP and compared with our 
LC-MS/MS plasma protein list. Spectra of LC-MS/MS plasma proteins that matched 
in HPA were manually assessed to confirm the database identification (same criteria 
as 2.4.6).  
For TMT quantification, a threshold of >50 counts was applied to all PSM (as 
applied by PRQ-1), therefore <50 was considered to be background noise and 
removed as a TMT assignment. Any PSM with >4/10 TMT reporter channels present 
was also removed from the TMT analysis. The assessment TMT quantification for 
each method was reported as a percentage of total identified PSMs that could be 




2.5 Methodology for Chapter 5 
The LC-MS/MS based proteomic workflow utilised in this study is outlined in 
Figure 2-18. This method has been shown to produce a superior coverage of the 
plasma proteome over other conventional proteomic methodologies (Chapter 4). The 
process of immunodepletion, enzymatic digestion, OGE fractionation and LC-
MS/MS acquisition were perform as described in either Chapter 2.5.  
 
Figure 2-18: Methodology workflow employed in to examine plasma samples from 
AIBL-2 and KARVIAH in Chapter 5. 
Plasma samples (30µL) 
Immunodepletion
(ProteoPrep Immunoaffinity Albumin and IgG 
Depletion Kit )
TMT10plex peptide labelling
OGE Fractionation (1mg) 
(24 fractions)
Digestion (100µg)




2.5.1 Tandem Mass Tag 10plex (TMT10plex) peptide labelling 
TMT10plex peptide labelling was performed identically as described above. In a 
different manner to previous TMT methodologies, Chapter 5 employed a dynamic 
study reference. Previously, a TMT study reference had been made static, usually 
TMT-126 being assigned as the study reference channel. Here, the study reference 
channel was randomly assigned in each TMT10plex group and therefore reducing 
any bias toward a chemical label.   
2.5.2 Computational Mass Spectrometry  
Raw data files produced in Excalibur software (Thermo Scientific) were processed 
using Proteome Discoverer (ver. 1.4) to determine peptide identification and 
quantitation as previously described (Figure 2-17). The use of peptide isoelectric 
focusing based fractionation means that protein MW isoforms cannot be studied. 
Therefore, for each TMT10plex the database search results for all OGE fractions can 
be merged in one file for analysis. This requires a differing but more simplified 
script for LC-MS/MS pre-processing than PRQ-1.    
As with PRQ-1, this modified script (PRQ-2; Supplementary Material 2) performs 
median ratio normalisation and calculates within TMT10plex ratios for each peptide. 
However, this is performed across all fractions simultaneously rather than within 
each fraction. PRQ-2 then continues to derive within TMT10plex protein level data 
from all corresponding peptide scores and then collects protein scores across all 
TMT10plex experiments. A protein matrix table was then produced with all 
identified protein groups and their corresponding TMT scores for each individual 
within the study. This was done so that “missingness” and technical variability could 
be assessed by principle component analysis (PCA).  
2.5.3 Statistical analysis  
All statistical analyses were performed in SPSS (version 22) and R statistical 
packages. TMT ratios were log10 transformed to achieve normal distribution. Only 
protein groups extracted by PRQ-2 with >50% participant data, BDPs from HPA and 
specific proteins of interest in disease pathogenesis were extracted from the protein 
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matrix table for further analysis. Covariates including age, gender, cohort and 
technical variables (TMT10plex group, TMT10plex label, OGE fractionation date, 
depletion date and MS analysis date) were investigated. We found that a large 
proportion of protein groups were affected by these covariates and therefore a GLM 
was used to adjust the data. The function “glm” in R package “STATS” was used to 
performed this. All subsequent analysis was performed on residuals from GLM 
adjusted data.  
Univariate analysis was performed in SPSS (version 22). A Mann Whitney-U test 
was performed to examine the association of all protein group GLM adjusted data 
with APOE genotype. Spearman’s Rank Correlation was used to examine 
associations of protein groups with PET SUVR as a continuous measure. 
Furthermore, a partial correlation (adjusting for APOE genotype) was performed on 
protein groups found to be significant from this analysis that were also associated 
with APOE genotype. Protein groups were also examined individually in an 
endophenotype group-wise analysis (Aβ- versus Aβ+) using a Mann Whitney-U test. 
A modified GLM, including APOE genotype, was performed on protein groups 
found to be significantly associated with both APOE genotype and group-wise 
analysis. Benjamini-Hochberg Q values were calculated as a multiple testing 
correction. Classification analysis was performed in R. Functions “svm” and 
“glmnet” from packages “MASS”, “e1071” and “glmnet” were utilised. Missing 
values were imputed by using the average score of the protein group. Protein groups 
were assessed by LASSO (Least Absolute Shrinkage and Selection Operator) with 
10,000 iterations. Supervised learning models (Support Vector Machine (SVM)) 
were built using protein groups in the AIBL-2 dataset and assessed by 100 repeats of 
a 5-fold cross validation. The performance of a classifier was assessed in KARVIAH 




CHAPTER 3  
BLOOD PROTEIN PREDICTORS OF NEOCORTICAL 
AMYLOID PATHOLOGY FOR ENRICHMENT IN 
THERAPEUTIC TRIALS 
 
3.1 Introduction  
The diagnosis of AD can only be confirmed, with certainty, by histological 
examination of brain tissue at autopsy. This inspection should demonstrate 
substantial evidence of the classical pathological hallmarks of AD. Although an age-
related disease usually affecting people over the age of 65 it is believed the 
accumulation of Aβ plaques begins 15-20 years prior to clinical presentation 233 and 
plateaus when cognitive, functional and behavioural decline occurs 
464
. As elevated 
brain Aβ is an important risk factor for AD, it has become critical to identify 
individuals at the early stages of Aβ deposition to recruit into clinical trials of 
potentially disease-modifying therapeutics.  
At present neuroimaging and CSF biomarkers are the accepted standards used to 
provide evidence of on-going AD pathophysiology related to Aβ plaques. 11C-PiB 
coupled with PET is widely used in research in measuring in vivo Aβ deposition as 
its uptake in AD correlates with Aβ plaques measured neuropathologically in the 
same brains 
261
. The availability of longer lived 
18









 could foster wider utilisation in 
clinical use 
466
.  Several large studies have shown that 
11
C-PiB PET could 
discriminate between AD and non-Aβ dementias 260, 448, 451. Some, but not all 467-468, 
studies also show that Aβ deposition as measured using 11C-PiB PET either predicts 
decline in cognitive measures or tracks with such 
233, 257
.  
Disease modifying therapeutics that are being developed target primarily Aβ 
generation, deposition or clearance 
469
.  Recent Phase III trials targeting Aβ reported 
that  approximately 20% of trial participants actually had little or no A when 
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studied later using retrospective PET imaging (Suspected Non Amyloid Pathology; 
SNAP) 
218
. This is a concern for such trials when a large minority of trial subjects 
fail to have the primary target pathology. A solution is to use Aβ PET imaging to 
ensure primary target pathology for patient stratification or recruitment. The first 
study to use this strategy is the anti-Aβ in Asymptomatic AD (A4) prevention trial 
470
.  In A4, the screen failure rate is anticipated to be even higher (~66%) due to the 
use of only asymptomatic subjects. The great expense of the anticipated Aβ PET 
screen failure rates for clinical and prevention anti-Aβ trials means that a blood test, 
with even relatively low predictive accuracy for neocortical Aβ burden (NAB), has 
the potential to greatly reduce costs. This would work by applying the blood tests to 
large numbers of potentially eligible subjects and only performing neuroimaging or 
CSF measures on those whose blood tests are positive. This would reduce the screen 
failure rates as well as reducing costs and recruitment time as the blood test would be 
inexpensive comparatively and more widely accessible. Therefore, a blood-based 
measure that correlates with NAB would be of considerable value as an enrichment 
filter for clinical trials.  
The obvious blood candidate biomarker of NAB would be Aβ itself but numerous 
studies, examining the correlation between Aβ plasma levels and NAB, have 
produced conflicting results 
377
. There has been considerable effort in the search for 
AD blood-based biomarkers. Most studies use a “case versus control” design, based 
on a clinical diagnosis of AD as determined by medical history, cognitive 
assessments and clinical examination. This classical approach has identified a large 
number of putative plasma biomarkers. However, such approaches are intrinsically 
flawed in the context of AD where a considerable proportion of cognitively 
unimpaired controls will be in the prodromal phase of AD, e.g. asymptomatic but 
with elevated NAB. An approach to overcome this is to use a non-apparent measure 
of disease activity (endophenotype paradigm). The endophenotype approach is 
increasingly being adopted for a range of modalities related to AD 
357, 366, 370, 430, 432, 
471
. More recently, blood-based biomarkers of NAB, as measured by 
11
C-PiB PET, 
have been reported by utilising the Rules-Based Medicine (RBM) panel of 190 
analytes 
436-437
.  In a different approach, 2DGE coupled with Mass Spectrometry 
(MS) was utilised to identify protein spots associating with NAB in an unbiased 
fashion 
373
. This study identified 6 proteins from spots associated with NAB, 
129 
 
including ApoE and CC3 which were independently replicated in the Kiddle and 
colleagues study 
436
. 2DGE is a well established technique for blood biomarker 
research and offers many advantages. 2DGE enables the separation of proteins in a 
complex sample according to charge (pH/pI) in the first dimension followed by 
molecular weight (MW) in the second dimension. However, it is restricted by a 
lengthy procedure with poor reproducibility that can only identify a small number of 
“candidate spots” in limited sample sets.    
In this study we employed a methodology (Figure 3-1) that combines the unbiased 
approach of gel-based proteomics (1DGE) with high-throughput multiplex 
technology (TMT). Isobaric labelling is a critical step in LC-MS/MS discovery 
primarily because of its application in measuring multiple samples in a single 
acquisition. This is fundamental to drive down cost, reduce analytical time and 
increase sample size consequently improving statistical power. Coupled to high-
resolution MS instrumentation this method has enabled the identification of several 
hundred proteins, comparable to most panel based arrays, without losing the key 
advantages of unbiased gel-based discovery. This is the first application of this 
approach to identify blood-based biomarkers of NAB, and was applied to a subset of 
patients from the AIBL-1 cohort with either high or low NAB. These results were 






To use 1DGE, isobaric TMT protein labelling and LC-MS/MS to identify proteins 
predictive of neocortical Aβ burden (NAB). An extreme endophenotype approach 
has been employed to stratify participants as “high Aβ (PiB+)” or “low Aβ (PiB-)” 
as determined by 
11
C-PiB PET. Replication of LC-MS/MS candidates by an 
orthogonal platform was performed in the same discovery cohort (technical 
replication) to confirm the proteins most predictive of NAB. The most associated 
candidates were further examined in two independent cohorts (UCSF and EMIF-AD) 
that reflect NAB by differing surrogate measures (1) 
11
C-PiB PET and (2) CSF Aβ1-




3.3 Methodological Overview  
The LC-MS/MS proteomic workflow utilised in this study is outlined in Figure 3-1. 
The detailed methodological protocols for each procedure are outlined in Chapter 
2.4. 
This MS-based proteomic workflow utilises TMT6plex protein isobaric tagging for 
LC–MS/MS based quantification. 1DGE was utilised for the pre-fractionation of 
TMT6plex labelled proteins prior to LC-MS/MS acquisition. Each protein gel was 
divided into 10 equal fractions, digested and resulting peptides were extracted for 
LC-MS/MS analysis. This was performed on 16 TMT6plex groups, which included 
78 individual from the Australian Imaging, Biomarkers and Lifestyle Flagship Study 
of Ageing (AIBL-1). All peptides extracts were resolved using on a liquid 
chromatography (LC) linear gradient for 115 minutes through a C18 analytical 
column and mass spectra were acquired on a LTQ Orbitrap Velos instrument.  
Candidate markers discovered by LC-MS/MS underwent technical replication 
(AIBL-1 cohort) and further replication and validation (UCSF and EMIF-AD 
cohorts) using commercially available ELISAs (Table 2-1).   
 
Figure 3-1: Methodological Overview: Schematic flow diagram represents the LC-
MS/MS proteomic workflow applied to the discovery cohort (AIBL-1) in Chapter 3.  
TMT-126
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3.4.1 Demographic characteristics 
Discovery and technical replication cohort (AIBL-1) 
Participants (n = 78) were selected from the Australian Imaging, Biomarkers and 
Lifestyle Flagship Study of Ageing (AIBL-1) imaging sub-cohort previously 
described (Chapter 2.1.1) and by Ellis and colleagues 
446
. These individuals must 
have undergone baseline 
11
C-PiB PET, cognitive assessment and APOE genotyping 
to be included in the study. A standardised uptake value ratio (SUVR) was calculated 
and a cut-off of 1.3 was used to classify subjects as belonging to Aβ positive (PiB+) 
or Aβ negative (PiB-) groups. Subjects were selected by an extreme endophenotype 
strategy and enriched for clear cases of PiB PET negativity and positivity (Figure 3-
2). Table 3-1 summarises the full demographic characteristics of subjects selected for 
the AIBL-1 cohort. 







Number of subjects (n) 38 40 
 
11
C-PiB PET SUVR (mean 
(S.D) ) 
1.11 (0.06) 2.34 (0.33) 2.4 x10-25 
Gender; females (n (%)) 18 (47%) 20 (50%) 0.830 
Age in years (mean (S.D)) 75.8 (6.53) 80.9 (8.22) 0.004 
Clinical diagnosis (n (%)) 
HEC: 13 (34%) HEC: 6 (15%) 
0.004 
SMC: 18 (47%) SMC: 13 (40%) 
MCI: 7 (19%) MCI: 16 (30%) 
AD: 0 (0%) AD: 6 (15%) 
APOE ε4 carrier (n (%)) 14 (37) 25 (63) 0.360 
MMSE (mean (S.D)) 28.3 (1.8) 26.8 (4.1) 0.038 
Abbreviations: HEC, Healthy elderly control; SMC, Subjective memory complaints; MCI, Mild 
cognitive impairment; AD, Alzheimer’s disease; SUVR, Standardized uptake values ratio; S.D; 




Subjects were matched for gender and APOE ε4 but a significant difference was 
observed between the two groups for age, diagnosis and consequently MMSE. 
Figure 3-2 shows the distribution of 
11
C-PiB PET SUVR values across selected 
subjects from the AIBL-1 imaging cohort. This histogram displays the two distinct 
populations of 
11
C-PiB PET SUVR values included in the study. The PiB- group 
SUVR range from 0.95–1.21 whereas the more diverse PiB+ group range from 1.82–
3.18. 
 
Figure 3-2: Histogram displaying the distribution of 
11
C-PiB PET SUVR values for 78 
participants selected from the AIBL-1 imaging cohort. 
Aβ endophenotype replication cohort (UCSF) 
The replication cohort consisted of plasma samples from participants (n = 79) 
enrolled in the University of California, San Francisco (UCSF) memory and ageing 
centre (Table 3-2) which has been previously described (Chapter 2.1.2). All subjects 
underwent APOE genotyping, neurological and cognitive assessments 
451
, as well as 
plasma collection and storage as previously described 
452
. Clinical diagnoses of AD, 
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Although a mixed diagnosis cohort that differs in dementias from AIBL-1, the UCSF 
cohort was utilised as a replication of Aβ positivity and not clinical diagnosis. All 
subjects underwent 
11
C-PiB PET at Lawrence Berkeley National Laboratory on 
either a Siemens ECAT EXACT HR PET (n = 70) or Biograph Truepoint 6 PET/CT 
(n = 9) 
262
. Scans were also visually rated as PiB+ or PiB- by two experienced 
physicians blinded to clinical data 
262
. The UCSF endophenotype design differed to 
AIBL-1 by having an 
11
C-PiB PET SUVR cut-off at 1.5. Figure 3-3 shows the 
distribution of 
11
C-PiB PET SUVR values and visual classification of 
11
C-PiB PET 
images in the UCSF cohort. There is a relatively good concordance between the two 
assessments, with only three subjects visually classified as PiB+ having an SUVR of 
<1.5 and only one subject visually classified as PiB- with an SUVR of >1.5. Three 
UCSF subjects did not have quantifiable SUVR values recorded and are not included 
in Table 3-2; however a visual examination was completed on these subjects (1 = 
PiB-, 2 = PiB+). As with AIBL-1, gender did not affect the two PiB groups however 
there was a significant difference between APOE genotype as well as diagnostic 
status and MMSE. There was no significant difference between ages (Table 3-2). 







Number of subjects (n) 47 32 
 
11
C-PiB PET SUVR (mean 
(S.D) [missing]) 
1.2 (0.12) [1] 2.2 (0.35) [2] 4.2 x10-16 
Gender; females (n (%)) 18 (38%) 14 (44%) 0.650 
Age in years (mean (S.D)) 65 (8.8) 64 (8.4) 0.610 
Clinical diagnosis (n (%)) 
HEC: 2 (4.3%) HEC: 1 (3.1%) 
1.9 x10
-10 
MCI: 1 (2.1%) MCI: 1 (3.1%) 
AD: 2 (4.3%) AD: 23 (72%) 
FTD: 42 (89.3%) FTD: 7 (21.8%) 
APOE ε4 carrier (n (%)) 8 (17%) 13 (41%) 0.036 
MMSE (mean (S.D)) 26 (4.3) 21 (6.9) 0.001 
Abbreviations: HEC, Healthy elderly control; MCI, Mild cognitive impairment; AD, Alzheimer’s 
disease;  FTD, Frontotemporal dementia; SUVR, Standardized uptake values ratio; S.D; Standard 




Figure 3-3: Scatter plot demonstrating the distribution of 
11
C-PiB PET SUVR for the 
UCSF imaging cohort. The individual SUVR values are coded by the visual 
classification of the PET images; PiB- (blue) or PiB+ (green). 
Validation cohort (EMIF-AD) 
An original 510 participants were recruited from the European Medical Informatics 
Framework (EMIF-AD) previously described (Chapter 2.1.3); however 21 
participants were removed from this study for not having the basic demographics 
available (APOE genotype, cognitive scores or CSF measures).  
Participants were categorised into two groups (Table 3-3; Figure 3-4); CSF Aβ1-42 
negative (CSF Aβ1-42- (550.5 – 2066 pg/mL)) and CSF Aβ1-42 positive (CSF Aβ1-42+ 
(151 – 550 pg/mL)). A low CSF Aβ1-42 measure (CSF Aβ1-42+) is indicative, but not 
exclusively, of PiB+ subjects. We also examined CSF Aβ1-42 as a continuous 
measure. CSF t-tau and p-tau were also classified into endophenotype groups based 
upon their individual measures (Figure 3-5 and Figure 3-6). The CSF t-tau- group 
ranged from 15 – 372 pg/mL (n = 262), with the CSF t-tau+ groups ranging from 
377 – 2114 pg/mL (n = 227; Figure 3-5). The CSF p-tau- group ranged from 9 – 52 
pg/mL (n = 209), with the CSF t-tau+ groups ranging from 52.5 – 328 pg/mL (n = 















A CSF algorithm that incorporated Aβ1-42, t-tau and p-tau measures was also 
investigated in this study 
454
. A low CSF algorithm score is considered to be more 
healthy (CSF algorithm–; 0.47 – 0.997) whereas a high CSF algorithm score is a 
more high risk group (CSF algorithm+; 1.00 – 9.166). An overlap of CSF algorithm 
values when stratifying by CSF Aβ group is observed and this is because of the 
inclusion of CSF t-tau and p-tau measures in the algorithm (Table 3-3; Figure 3-7). If 
subjects were stratified by CSF algorithm (CSF algorithm- and CSF algorithm+) we 
can see a number of CSF Aβ1-42+ subjects would be classed as CSF algorithm- 
(Figure 3-7). However, there was still a highly significant correlation between the 
CSF algorithm and all modalities, with CSF Aβ1-42 being the most significant 
association (Figure 3-8; Rho = -0.915, P = 2.097 x10
-195
).  
As with AIBL-1 and UCSF there was no significant difference of gender with the 
two groups. However, age, clinical diagnosis and APOE ε4 carrier status were vastly 
different (Table 3-3).  









Number of subjects (n) 268 221 
 
CSF Aβ1-42 pg/mL 







CSF algorithm  







Gender; females (n (%)) 146 (55%) 131 (59%) 0.388 
Age in years (mean (S.D)) 66.8 (10.1) 70.3 (7.9) 2.90 x10-5 
Clinical diagnosis (n (%)) 
HEC: 82 (30.6%) HEC: 12 (5.4%) 
4.16 x10
-36 MCI: 158 (59%) MCI: 76 (34.4%) 
AD: 28 (10.4%) AD: 133 (49.1%)  
APOE ε4 carrier (n (%)) 74 (27.6%) 115 (52.2%) 2.21 x10-8 
Abbreviations: HEC, Healthy elderly control; MCI, Mild cognitive impairment; AD, Alzheimer’s 
disease; SUVR, Standardized uptake values ratio; S.D; Standard deviation; MMSE, Mini mental state 




Figure 3-4: Scatter plot demonstrating the CSF Aβ1-42 distribution of the selected 
subjects from the EMIF-AD cohort. The EMIF-AD individuals are colour coded by 
CSF Aβ1-42 category alone; CSF Aβ1-42- (blue) or CSF Aβ1-42+ (green). 
 
Figure 3-5: Scatter plot demonstrating the CSF t-tau distribution of the selected 
subjects from the EMIF-AD cohort. The EMIF-AD individuals are colour coded by 


























Figure 3-6: Scatter plot demonstrating the CSF p-tau distribution of the selected 
subjects from the EMIF-AD cohort. The EMIF-AD individuals are colour coded by 
CSF p-tau category alone; CSF p-tau- (grey) or CSF p-tau+ (orange). 
 
Figure 3-7: Scatter plot demonstrating the CSF algorithm (CSF Aβ1-42, t-tau and p-tau) 
distribution of the selected subjects from the EMIF-AD cohort. The EMIF-AD 



























Figure 3-8: Scatter plot demonstrating the CSF algorithm correlation with Aβ1-42 
measures (P = 2.097 x10
-195
) of the selected subjects from the EMIF-AD cohort. The 
EMIF-AD individuals are colour coded by CSF algorithm category alone; CSF 
algorithm – (blue) or CSF algorithm+ (green). 
3.4.2 LC-MS/MS performed on AIBL-1 subjects 
TMT protein labelling, gel-based proteomics and LC-MS/MS analysis (Chapter 2.4) 
was performed on plasma samples from 78 subjects from the AIBL-1 imaging 
cohort, whose demographics are shown in Table 3-1. Technical variance was 
assessed by the sum of MS/MS events for each TMT6plex experiment (Table 3-4). 
MS/MS events are an indication of how many MS1 precursor ions has been selected 
for subsequent fragmentation. A lower number of MS/MS events may indicate a 






















Table 3-4: The number of MS/MS events acquired for each TMT6plex included in the 




events   
  1 55638 9 71399 
2 74521 10 72816 
3 72141 11 67710 
4 62419 12 74161 
5 77941 13 73276 
6 83123 14 76425 
7 85936 15 73884 






Variation (CV %) 
72751.31 7130.38 9.80% 
 
A CV of <10% for MS/MS events across all 16 TMT6plex experiments signifies 
consistent sample preparation and instrument performance. The number of MS/MS 
events is directly proportional to the number peptide spectral matches (PSM) and 
therefore related to the number of unique peptides and protein groups that will be 
assigned by a database. Features inconsistently measured across several experiments 
would be rejected from downstream analysis and therefore it is imperative to keep 
the number of identifications reliable across each TMT6plex. TMT6plex 1 had a 
reduced number of MS/MS events in comparison to all other experiments and this is 
reflected in the number of PSM assignments (Figure 3-9). Despite this, the resulting 
number of unique peptides and protein groups, although the lowest in the study, was 
not out of the norm when compared to all other experiments (Table 3-5 and Table 3-




Figure 3-9: A visualisation of the number of MS/MS events (blue) compared to number 
of peptide spectral matches (PSMs; red) for each TMT6plex experiment.  
The number of protein groups, peptides, PSMs and spectral yield rates of each 
TMT6plex at 5% FDR were examined (Table 3-5) and contrasted this to 1% FDR 
(Table 3-6). As expected, on average there was a reduction in protein groups (6.8%), 
peptides (8.6%), PSMs (6.7%) and spectral yield performance when applying a more 
stringent FDR to the dataset. For discovery proteomics and to maximise potential 
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TMT6plex experiment 




Table 3-5: The performance of each TMT6plex by number of protein groups, peptides, 










1 221 1082 5893 0.11 
2 319 1405 8553 0.11 
3 258 1198 7573 0.10 
4 221 1012 5057 0.08 
5 250 1280 8656 0.11 
6 308 1424 9209 0.11 
7 292 1459 8675 0.10 
8 285 1415 8754 0.12 
9 277 1364 7770 0.11 
10 326 1480 7966 0.11 
11 340 1489 8454 0.12 
12 275 1261 6624 0.09 
13 270 1282 6620 0.09 
14 278 1330 6827 0.09 
15 268 1281 6985 0.09 
16 262 1326 6911 0.10 
Mean 278.13 1318.00 7532.94 0.10 
Standard Dev. 33.75 135.89 1173.73 0.01 
Coefficient of 
Variation (CV %) 
12.13% 10.31% 15.58% 12.35% 
Table 3-6: The performance of each TMT6plex by number of protein groups, peptides, 










1 209 995 5554 0.10 
2 298 1287 8043 0.11 
3 240 1096 7037 0.10 
4 208 901 4579 0.07 
5 235 1157 8061 0.10 
6 286 1297 8695 0.10 
7 262 1330 8144 0.09 
8 264 1279 8143 0.12 
9 256 1244 7159 0.10 
10 304 1334 7391 0.10 
11 318 1365 7863 0.12 
12 254 1135 6050 0.08 
13 255 1199 6152 0.08 
14 261 1227 6454 0.08 
15 251 1219 6548 0.09 
16 247 1221 6499 0.09 
Mean 259.25 1205.38 7023.25 0.10 
Standard Dev. 30.65 125.60 1123.82 0.01 
Coefficient of 
Variation (CV %) 
11.82% 10.42% 16.00% 12.66% 
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Combining data from all MS/MS acquisitions, 4,518 unique peptides sequences were 
identified that corresponded to 789 unique protein groups at 5% FDR. The statistical 
pipeline Pre-processing for Relative Quantification (PRQ-1; Chapter 2.4.6) extracted 
2,319 unique TMT peptides, 1,139 protein group MW isoforms and 379 unique 
protein groups (Supplementary Material 3). In the instance of LC-MS/MS data 
separated by 1DGE a single protein group can be observed in multiple fractions. 
Therefore, identical protein identifications observed in different fractions were 
considered as separate entities and termed molecular weight (MW) protein group 
isoforms. This list of unique protein groups further reduced to 116 confidently 
annotated unique protein groups when applying post-PRQ-1 restrictions (Figure 3-
10); this consisted of 381 protein MW group isoforms (Appendix 1) which 
underwent statistical analysis in relation to 
11
C-PiB retention.  
Figure 3-10: (A) Schematic diagram demonstrating the selection process of unique 
protein groups and protein group MW isoforms for statistical analysis. Pie charts 
illustrate (B) the percentage of all peptides identified by Mascot that could be 
quantified by TMT and (C) the percentage all protein groups identified by mascot 
could be quantified by TMT. 
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3.4.3 Plasma protein markers associated with 11C-PiB PET in AIBL-1  
Each of the identified 381 protein group MW isoforms (Appendix 1) was 
investigated by Mann-Whitney U tests and Logistic Regression to compare PiB+ and 
PiB- groups. In addition, Spearman Rank Correlation and Linear Regression were 
used to correlate protein group MW isoform levels against 
11
C-PiB retention as a 
continuous measure. This was completed for both the mean and median protein roll-
up methods separately (described in Chapter 2.4.6), giving a total of eight statistical 
tests per protein group MW isoform. The significant protein group MW isoforms 
using the mean protein roll-up method are displayed in Table 3-7 and Table 3-8. The 
significant protein group MW isoforms using the median protein roll-up method are 
presented in Table 3-9 and Table 3-10. A summary of these results ranked by the 
number of statistical tests that each protein group MW isoform passes is displayed in 
Table 3-11. 
Table 3-7: Protein group MW isoforms measured by LC-MS/MS significantly 
associated with NAB groups (PiB- and PiB+) when applying a “mean of all peptides” 
method.  For regressions age, gender and presence of APOE ε4 was used as covariates. 
Protein group MW isoforms that passed a significance of P = <0.05 are highlighted 
(green). All multiple testing corrections = Q > 0.75. 
 


















P01876 IGHA1 4 93.75 -0.863 0.008 -0.410 0.058 
P02647 APOA1 10 68.75 -0.877 0.014 -0.173 0.070 
P00738 HP 8 81.25 -0.932 0.015 -0.331 0.011 
P00738 HP 5 100 -0.728 0.023 -0.521 0.017 
P01700 n/a 7 81.25 -0.747 0.024 -0.195 0.050 
P00747 PLG 1 62.50 0.901 0.026 0.610 0.078 
Q06033 ITIH3 2 56.25 1.525 0.027 0.297 0.099 
P04196 HRG 5 62.50 -0.996 0.031 -0.093 0.150 
P00450 CP 6 75.00 -2.088 0.032 -0.222 0.019 
P01023 A2M 9 75.00 -0.749 0.035 -0.246 0.112 
P01768 n/a 6 56.25 -1.586 0.036 -0.195 0.100 
P0C0L4 C4A 7 100 -0.656 0.038 -0.235 0.027 
P02647 APOA1 9 93.75 -0.599 0.039 -0.061 0.255 
P04196 HRG 3 68.75 1.205 0.039 0.334 0.034 
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Q14624 ITIH4 1 56.25 1.244 0.041 0.187 0.118 
P02747 C1QC 2 56.25 -0.746 0.043 -0.460 0.095 
P01876 IGHA1 1 93.75 -0.537 0.046 -0.329 0.099 
O14791 APOL1 5 81.25 0.829 0.048 0.731 0.004 
P02790 HPX 6 87.50 0.587 0.049 0.216 0.053 
P01024 C3 8 93.75 -0.569 0.058 -0.480 0.030 
P08519 LPA 1 62.50 0.929 0.062 0.315 0.030 
P04220 n/a 4 62.50 -0.954 0.063 -0.256 0.020 
P19823 ITIH2 4 75.00 -0.762 0.067 -0.294 0.026 
O43866 CD5L 5 75.00 -0.929 0.110 -0.398 0.013 
Q03591 CFHR1 8 87.50 1.667 0.120 0.313 0.008 
P06396 GSN 5 75.00 1.018 0.251 0.174 0.033 
Q92620 DHX38 2 87.50 -0.383 0.351 0.046 0.044 
P01700 n/a 8 68.75 -0.218 0.510 -0.366 0.002 
P25311 AZGP1 7 62.50 0.140 0.681 0.327 0.043 
P01762 n/a 4 68.75 0.018 0.952 -0.273 0.042 
 
Table 3-8: Protein group MW isoforms measured by LC-MS/MS significantly 
associated with NAB as continuous measure, using a “mean of all peptides” method.  
For regressions age, gender and presence of APOE ε4 was used as covariates. Protein 
group MW isoforms that passed a significance of P = <0.05 are highlighted (green). All 
multiple testing corrections = Q > 0.75. 
 















Beta P value Rho P value 
P01876 IGHA1 4 93.75 -0.225 0.002 -0.186 0.116 
P00738 HP 5 100 -0.198 0.005 -0.280 0.013 
P01876 IGHA1 6 100 -0.194 0.005 -0.144 0.209 
P0C0L4 C4A 1 56.25 0.241 0.009 0.160 0.293 
P04196 HRG 5 62.50 -0.228 0.011 -0.238 0.096 
Q14624 ITIH4 1 56.25 0.251 0.013 0.222 0.142 
P02647 APOA1 10 68.75 -0.211 0.013 -0.204 0.136 
P00739 HPR 5 62.50 0.209 0.016 0.232 0.104 
P01768 n/a 6 56.25 -0.209 0.018 -0.124 0.416 
P0C0L4 C4A 7 100 -0.162 0.019 -0.302 0.007 
P02768 ALB 1 100 0.160 0.020 0.100 0.385 
P02647 APOA1 6 100 -0.157 0.023 -0.189 0.098 
P02747 C1QC 2 56.25 -0.201 0.024 -0.210 0.165 
P00738 HP 8 81.25 -0.170 0.026 -0.248 0.047 
P00734 F2 6 68.75 0.190 0.027 0.208 0.135 
P04003 C4BPA 7 100 -0.153 0.028 -0.156 0.173 
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P00450 CP 2 87.50 0.167 0.029 0.000 0.998 
P0CG04 IGLC1 6 68.75 -0.176 0.031 -0.098 0.486 
P04220 n/a 4 62.50 -0.197 0.034 -0.312 0.027 
O14791 APOL1 5 81.25 0.165 0.035 0.308 0.014 
P01024 C3 6 100 -0.148 0.035 -0.107 0.351 
P01023 A2M 9 75.00 -0.196 0.037 -0.092 0.482 
P10909 CLU 6 87.50 -0.159 0.037 -0.102 0.408 
Q92620 DHX38 5 62.50 0.197 0.038 0.144 0.318 
P01700 n/a 3 68.75 0.177 0.044 0.377 0.005 
P01700 n/a 7 81.25 -0.156 0.044 -0.191 0.134 
O75636 FCN3 6 75.00 -0.152 0.044 0.034 0.798 
P04196 HRG 6 56.25 -0.185 0.049 -0.194 0.214 
P02671 FGA 4 100 -0.142 0.052 -0.284 0.012 
P19823 ITIH2 4 75.00 -0.159 0.061 -0.267 0.039 
P04003 C4BPA 4 93.75 -0.127 0.076 -0.248 0.035 
P00751 CFB 1 56.25 0.164 0.081 0.310 0.038 
O43866 CD5L 5 75.00 -0.140 0.088 -0.288 0.028 
P06727 APOA4 6 56.25 -0.144 0.115 -0.389 0.010 
Q03591 CFHR1 8 87.50 0.155 0.178 0.483 0.007 
P02647 APOA1 5 75.00 -0.101 0.229 -0.263 0.046 
P01700 n/a 8 68.75 -0.081 0.378 -0.372 0.005 
O43866 CD5L 6 56.25 0.077 0.400 0.347 0.022 
P25311 AZGP1 7 62.50 0.076 0.461 0.327 0.021 
P01023 A2M 3 100 0.048 0.497 0.290 0.010 
P01768 n/a 9 68.75 0.054 0.600 0.291 0.031 
P02679 FGG 6 62.50 0.044 0.613 -0.331 0.021 
 
Table 3-9: Protein group MW isoforms measured by LC-MS/MS significantly 
associated with NAB groups (PiB-, PiB+) when applying a “median of all peptides” 
method.  For regressions age, gender and presence of APOE ε4 was used as covariates. 
Protein group MW isoforms that passed a significance of P = <0.05 are highlighted 
(green). All multiple testing corrections = Q > 0.75. 
 


















P00738 HP 8 81.25 -1.048 0.018 -0.190 0.030 
P01860 IGHG3 1 93.75 -0.715 0.018 -0.234 0.041 
Q06033 ITIH3 2 56.25 1.267 0.019 0.422 0.013 
P01876 IGHA1 8 100 -0.683 0.020 -0.411 0.109 
P04196 HRG 3 68.75 1.149 0.024 0.611 0.030 
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P01700 n/a 7 81.25 -0.747 0.024 -0.195 0.050 
P02647 APOA1 10 68.75 -0.872 0.025 -0.087 0.087 
P04196 HRG 5 62.50 -0.996 0.031 -0.093 0.150 
P00450 CP 6 75.00 -2.088 0.032 -0.222 0.019 
P01768 n/a 6 56.25 -1.561 0.043 -0.178 0.137 
P02747 C1QC 2 56.25 -0.746 0.043 -0.460 0.095 
P00747 PLG 1 62.50 0.786 0.049 0.409 0.102 
P0C0L4 C4A 7 100 -0.592 0.049 -0.224 0.037 
P01876 IGHA1 4 93.75 -0.559 0.050 -0.224 0.253 
P01860 IGHG3 2 81.25 -0.623 0.050 -0.555 0.042 
P08519 LPA 1 62.50 0.869 0.064 0.222 0.045 
O43866 CD5L 5 75.00 -0.596 0.080 -0.307 0.015 
O14791 APOL1 5 81.25 0.578 0.091 0.795 0.007 
P07357 C8A 5 75.00 -0.539 0.104 -0.474 0.032 
P04003 C4BPA 4 93.75 -0.466 0.106 -0.473 0.038 
P01860 IGHG3 6 81.25 -0.508 0.116 -0.325 0.049 
P02768 ALB 1 100 0.499 0.128 0.229 0.011 
P13671 C6 2 81.25 -0.430 0.145 -0.662 0.048 
P01023 A2M 1 100 0.340 0.181 0.469 0.046 
Q03591 CFHR1 8 87.50 1.414 0.187 0.186 0.019 
P06396 GSN 5 75.00 1.149 0.202 0.151 0.042 
Q92620 DHX38 2 87.50 -0.380 0.351 0.046 0.031 
P02787 TF 1 87.50 0.249 0.372 0.352 0.040 
P08603 CFH 6 87.50 0.190 0.490 0.243 0.041 
P01700 n/a 8 68.75 -0.218 0.510 -0.366 0.002 
P02768 ALB 8 100 0.144 0.565 0.420 0.025 
P25311 AZGP1 7 62.50 0.140 0.681 0.327 0.043 
P01762 n/a 4 68.75 0.018 0.952 -0.273 0.042 
 
Table 3-10: Protein group MW isoforms measured by LC-MS/MS significantly 
associated with NAB as continuous measure, using a “median of all peptides” method.  
For regressions age, gender and presence of APOE ε4 was used as covariates. Protein 
group MW isoforms that passed a significance of P = <0.05 are highlighted (green). All 
multiple testing corrections = Q > 0.75. 
 















Beta P value Rho P value 
P04196 HRG 5 62.50 -0.228 0.011 -0.238 0.096 
P02675 FGB 6 87.50 -0.172 0.016 -0.188 0.125 
P00739 HPR 5 62.50 0.209 0.016 0.232 0.104 
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P02679 FGG 6 62.50 -0.191 0.021 -0.298 0.039 
P0CG04 IGLC1 6 68.75 -0.188 0.021 -0.141 0.313 
P01876 IGHA1 6 100 -0.160 0.022 -0.090 0.435 
P04003 C4BPA 7 100 -0.158 0.023 -0.150 0.189 
P02747 C1QC 2 56.25 -0.201 0.024 -0.210 0.165 
P01768 n/a 6 56.25 -0.200 0.024 -0.094 0.539 
P01024 C3 6 100 -0.156 0.025 -0.119 0.300 
P01860 IGHG3 1 93.75 -0.158 0.026 -0.237 0.043 
P01876 IGHA1 4 93.75 -0.157 0.033 -0.087 0.465 
P02647 APOA1 10 68.75 -0.183 0.035 -0.266 0.049 
P01860 IGHG3 2 81.25 -0.161 0.037 -0.243 0.055 
Q92620 DHX38 5 62.50 0.197 0.038 0.144 0.318 
P02647 APOA1 6 100 -0.143 0.038 -0.236 0.038 
P01860 IGHG3 6 81.25 -0.145 0.039 -0.139 0.277 
P00738 HP 5 100 -0.149 0.041 -0.181 0.112 
P00751 CFB 1 56.25 0.189 0.042 0.363 0.014 
P0C0L4 C4A 7 100 -0.143 0.042 -0.229 0.044 
O43866 CD5L 5 75.00 -0.165 0.042 -0.235 0.076 
P00738 HP 8 81.25 -0.157 0.043 -0.226 0.070 
P01700 n/a 3 68.75 0.177 0.044 0.377 0.005 
P01700 n/a 7 81.25 -0.156 0.044 -0.191 0.134 
O75636 FCN3 6 75.00 -0.152 0.044 0.034 0.798 
P07357 C8A 5 75.00 -0.153 0.073 -0.261 0.048 
P19827 ITIH1 8 62.50 -0.164 0.113 -0.313 0.030 
P06727 APOA4 6 56.25 -0.139 0.128 -0.387 0.010 
P02790 HPX 5 100.00 0.105 0.134 0.228 0.045 
P04003 C4BPA 4 93.75 -0.105 0.154 -0.275 0.018 
Q92620 DHX38 2 87.50 -0.095 0.208 0.243 0.046 
Q03591 CFHR1 8 87.50 0.144 0.217 0.444 0.014 
O43866 CD5L 6 56.25 0.090 0.313 0.369 0.015 
P01700 n/a 8 68.75 -0.081 0.378 -0.372 0.005 
P25311 AZGP1 7 62.50 0.076 0.461 0.327 0.021 
P01023 A2M 2 100 0.048 0.495 0.237 0.037 
P01023 A2M 3 100 0.042 0.559 0.254 0.025 
P02768 ALB 9 100 0.033 0.644 0.242 0.033 







Table 3-11: A summary of protein group MW isoforms significantly associated with 
NAB, ranked by the highest number of statistical tests passed (P <0.05). Protein groups 
that are represented by four separate MW isoforms are highlighted in blue. Protein 














P0C0L4 complement C4-A (C4α) C4A 7 8 Fig 3-12 to 3-13 
P00738 haptoglobin  HP 8 7 Fig 3-14 
P01700 
Ig lambda chain V-I region 
HA 
n/a 7 6 n/a 
P02647 apolipoprotein A-I (apoA1) APOA1 10 5 Fig 3-15 
O14791 apolipoprotein L1 (apoL1) APOL1 5 5 Fig 3-16 to 3-17 
P00738 haptoglobin  HP 5 5 Fig 3-18 to 3-20 
P25311 zinc-alpha-2-glycoprotein  AZGP1 7 4 Appendix 2 
P02747 
complement C1q 
subcomponent subunit C 
C1QC 2 4 Appendix 2 
O43866 CD5 antigen-like CD5L 5 4 Appendix 2 
Q03591 
complement factor H 
related protein 1 (FHR-1) 
CFHR1 8 4 Fig 3-21 to 3-22 
P00450 ceruloplasmin CP 6 4 Appendix 2 
P04196 
histidine-rich glycoprotein  
(HRG) 




HRG 3 4 Fig 3-22 to 3-23 
P01876 Ig alpha-1 chain C region IGHA1 4 4 n/a 
P01860 Ig gamma-3 chain C region IGHG3 1 4 n/a 
P01768 
Ig heavy chain V-III region 
CAM 
n/a 6 4 n/a 
P01700 
Ig lambda chain V-I region 
HA 
n/a 3 4 n/a 
P01700 
Ig lambda chain V-I region 
HA 
n/a 8 4 n/a 
P02647 apolipoprotein A-I (apoA1) APOA1 6 3 Fig 3-24 to 3-29 
P04003 
C4b-binding protein alpha 
chain 
C4BPA 4 3 Appendix 2 
P00751 
complement factor B 
(CFB) 
CFB 1 3 Fig 3-30 to 3-31 
Q92620 pre-mRNA-splicing factor DHX38 2 3 Appendix 2 





inhibitor heavy chain H3 
ITIH3 2 3 Appendix 2 
P04220 
Ig mu heavy chain disease 
protein 








A2M 3 2 Fig 3-34 to 3-40 




APOA4 6 2 Fig 3-41 to 3-42 
P01024 complement C3 (CC3) C3 6 2 Fig 3-43to 3-49 
P04003 
C4b-binding protein alpha 
chain 
C4BPA 7 2 Appendix 2 
P07357 
complement component C8 
alpha chain (CC8α) 
C8A 5 2 Appendix 2 
O43866 CD5 antigen-like CD5L 6 2 Appendix 2 
P08603 
complement factor H 
(CFH) 
CFH 6 2 Fig 3-50 to 3-52 
Q92620 pre-mRNA-splicing factor DHX38 5 2 Appendix 2 
O75636 ficolin 3 FCN3 6 2 Appendix 2 
P06396 gelsolin GSN 5 2 Fig 3-53 to 3-54 
P00739 haptoglobin-related protein HPR 5 2 n/a 
P01876 Ig alpha-1 chain C region IGHA1 6 2 n/a 
P01860 Ig gamma-3 chain C region IGHG3 2 2 n/a 
P01860 Ig gamma-3 chain C region IGHG3 6 2 n/a 
P0CG04 
Ig lambda-1 chain C 
regions 
IGLC1 6 2 n/a 
P19823 
Inter-alpha-trypsin 
inhibitor heavy chain H2 
ITIH2 4 2 n/a 
Q14624 
Inter-alpha-trypsin 
inhibitor heavy chain H4 
ITIH4 1 2 n/a 
P08519 apolipoprotein(a) (apo(a)) LPA 1 2 Fig 3-55 
P01762 
Ig heavy chain V-III region 
TRO 
n/a 4 2 n/a 








A2M 1 1 Fig 3-62 to 3-64 
P02768 albumin ALB 8 1 n/a 
P02768 albumin ALB 9 1 n/a 
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P02647 apolipoprotein A-I (apoA1) APOA1 5 1 Fig 3-65 to 3-66 
P02647 apolipoprotein A-I (apoA1) APOA1 9 1 Fig 3-67 to 3-69 
P01024 complement C3 (CC3) C3 8 1 Fig 3-70 




C6 2 1 Appendix 2 
P10909 clusterin CLU 6 1 Fig 3-72 to 3-74 
P00450 ceruloplasmin CP 2 1 Appendix 2 
P00734 prothrombin F2 6 1 Appendix 2 
P02671 fibrinogen α chain (FGα) FGA 4 1 Fig 3-75 to 3-78 
P02675 fibrinogen β chain (FGβ) FGB 6 1 n/a 
P02790 hemopexin HPX 6 1 Appendix 2 




HRG 6 1 n/a 
P01876 Ig alpha-1 chain C region IGHA1 1 1 n/a 
P01876 Ig alpha-1 chain C region IGHA1 8 1 n/a 
P19827 
Inter-alpha-trypsin 
inhibitor heavy chain H1 
ITIH1 8 1 n/a 
P01768 
Ig heavy chain V-III region 
CAM 
n/a 9 1 n/a 
P02787 serotransferrin (TF) TF 1 1 Fig 3-79 to 3-80 
 
A total of 69 protein group MW isoforms corresponding to 43 separate unique 
protein groups passed at least one statistical test (uncorrected P < 0.05) for 
association with 
11
C-PiB retention in the AIBL-1 imaging cohort. One protein group 
MW isoform, from protein group C4α, passed all eight statistical tests (Table 3-11). 
The most represented protein groups found to be related with 
11
C-PiB were α2m, 
apoA1 and Ig alpha-1 chain C region each having four separate protein group MW 
isoforms having statistical significance (highlighted in blue; Table 3-11). Further 
protein groups having three MW isoforms significant with NAB were histidine-rich 
glycoprotein (HRG), Ig gamma-3 chain C region and Ig lambda chain V-I region HA 
(highlighted in red; Table 3-11). 
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3.4.4 Pathway analysis 
Pathway analysis revealed that these 43 protein groups (Table 3-11) were over-
represented for involvement in the complement and coagulation cascades (P = 3.7 
x10
-22
, Q = 3.3 x 10
-21
), systemic lupus erythematosus (P = 2.65 x 10
-4
, Q = 0.15) 
and prion diseases (P = 5.9 x 10
-3
, Q = 0.051).  
3.4.5 Candidate selection for technical replication  
We sought to translate our LC-MS/MS discovery findings to a simple-to-use 
commercially available immunoassay format more applicable to a clinical setting. A 
technical replication using an orthogonal approach would reduce the number of false 
positives and ensure robust targets for future independent validation. Technical 
replication, by ELISA, was performed on the same 78 AIBL-1 subjects as in 
discovery LC-MS/MS.   
For a technical replication to be feasible, the LC-MS/MS candidate list of 43 unique 
protein groups needed to be prioritised (Figure 3-11). In addition to statistical 
evidence already displayed (summarised in Table 3-11), conformation of the LC-
MS/MS identifications by manual examination of the assigned spectra was 
performed for each candidate (Figure 3-12 to 3-80 and Appendix 2). The 
identifications reported in this study are initially based on automated database 
searching with cut-offs defined by FDR. Routine practice recommends manual 
examination of assigned spectra for a protein group in question or of interest; the 
peptide sequence would typically be confirmed by the presence of a majority of b 
and y ions in a series (described in Chapter 2.4.6). This is of paramount importance 
in discovery experiments when considering protein groups identified by relaxed 
FDR’s or limited PSMs. We also favoured candidates with previous evidence in 




Figure 3-11: Schematic flow diagram to describe the process of prioritising LC-MS/MS 
candidates significantly associated with 
11
C-PiB retention for technical replication. 
 
Statistical Significance
a) Pass at least one statistical test at p-value <0.05
Removal of identifications associated with albumin or IgG’s
Confident annotation & spectral data (Fig 3-12 – Fig 3-80)
a) Identification based on >2 peptides sequences 
b) Peptide identified matches MW of native protein
c) Manual inspection of quantified (TMT) peptides
Evidence of interaction with Amyloid (Table 3-12)
either;
a) Direct Aβ peptide Interaction 
b) Direct Aβ plaques interaction
c) Reasonable hypothesis of amyloid interaction
Technical Replication
43 protein groups 
(69 MW isoforms; 
Table 3-11)
35 protein groups 
(51 MW isoforms; 
Table 3-11)
28 protein groups 
(38 MW isoforms)
17 protein groups 
(25 MW isoforms)
116 protein groups 




Of the 43 protein groups associated with 
11
C-PiB retention, 8 protein groups were 
associated with immunoglobins or albumin. A further 7 candidates were removed 
due poor quality TMT spectra. Of the remaining 28 candidates, which had confident 
TMT spectra, 17 protein groups had existing literature evidence of interacting with 
Aβ and/or highlighted in AD GWAS studies (Table 3-12). Spectral evidence for all 
the 25 MW isoforms for the 17 protein groups selected for technical replication are 
displayed from Figure 3-12 to Figure 3-80, with a figure reference for each protein 
group MW isoforms listed in Table 3-11. Spectral evidence for all other candidate 
protein group MW isoforms not chosen for technical replication can be found in 
Appendix 2. 
Of the 17 candidates selected for technical replication, five protein groups had 
multiple MW isoforms significantly associated with 
11
C-PiB (α2m, apoA1, 
haptoglobin, C4α and CC3; Table 3-11). In the most case, these isoforms were in gel 
fractions adjacent to each other, suggesting that the peptide sequences identified 
were common across these fractions. For α2m, TMT peptide sequences 
“QKDNGCER” and “QLNYKHYDGSYSTFGER” were observed in all significant α2m 
MW isoforms with “TITKLSFVKVDSHFR”, “GEAFTLKATVLNYLPKCIR”, 
“TGKAAQVTIQSSGTFSSKFQVDNNNR” and “VVSMDENFHPLNELIPLVYIQDPKGNR” 
being detected in 2/3 gel fractions. With common peptides quantified across these 
fractions, it is unsurprising the significant α2m peptides in gel fraction 1, 2 and 3 all 
showed an increased expression in the PiB+ group. In addition, apoA1 also had 
common peptides in adjacent fractions and all had a significant decrease in PiB+ 
group. Haptoglobin has a native MW of 18kDa and therefore its presence in gel 
fraction 8 is expected, however a significant peptide profile is also observed in gel 
fraction 5 (40 – 50kDa). Despite a differing location, haptoglobin in gel fraction 5 
and 8 both demonstrated a decrease in the PiB+ group. C4α has a native MW of 
190kDa (expected location gel fraction 1). C4α demonstrated significant MW 
isoforms in gel fractions 1 and 7, with both fractions showing a differing peptide 
profile. C4α in gel fraction 1 increased with PiB+, whereas C4α in gel fraction 7 
decreased with PiB+.  Peptide profiles for all MW isoforms used for protein group 
identification (No TMT) and quantitation (TMT) can be found in Appendix 3.   
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Comments, Interactions, Proposed Hypothesis 
P10909 clusterin CLU 4 1 1 1 1 
Biochemical evidence of clusterin binding to Aβ. Binds to Aβ in CSF 
and found co-localised with Aβ plaques.  Potential to modulate Aβ 
deposition and half-life. 
P01023 α2m A2M 3 1 0 1 1 
Biochemical evidence shows that α2m can interact with Aβ thus 
maintaining its solubility. Shown to bind to Aβ with potential to 
increase or decrease its clearance. 
P02647 apoA1 APOA1 3 1 0 1 1 
Biochemical evidence of apoA1 binding to Aβ with potential to 
modulate Aβ deposition and half-life. 
P02671 FGα FGA 3 1 0 1 1 
Fibrinogen can bind to Aβ and biochemical evidence showing 
fibrinogen may oligomerise in the presence of Aβ. 
P06396 gelsolin GSN 3 1 0 1 1 
Biochemical data shows that gelsolin binds to Aβ and can modulate 
Aβ fibrillisation. 
P08603 CFH CFH 3 0 1 1 1 
Evidence showing CFH binding to Aβ plaques. Possible involvement 
with Aβ plaques being recognized by microglia. 
P00738 haptoglobin HP 2 1 0 0 1 
Biochemical evidence that haptoglobin can interact with prefibrillar 
Aβ thus maintaining its solubility. 
P00751 CFB CFB 2 0 0 1 1 
Biochemical evidence shows that Aβ may indirectly modulate CFB 
expression with potential modulation of downstream markers MCP-1, 
IL-1β, TNF-α. 
P01024 CC3 C3 2 1 0 0 1 
Biochemical evidence that CC3 can accelerate Aβ fibrillisation.  Some 
data showing CC3 mRNA concentrations increase between AD and 
age match controls. 
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P02679 FGγ FGG 2 1 0 0 1 
Fibrinogen can bind to Aβ and biochemical evidence showing 
fibrinogen may oligomerise in the presence of Aβ. 
P02787 TF TF 2 0 0 1 1 
Biochemical binding to iron and transport into brain via TFR.   Data 
showing the binding affinity of CP2 to the transferrin promoter was 
regulated by Aβ. 
P06727 apoA4 APOA4 2 0 0 1 1 apoA4 is expressed in brain but intestines are higher. 
P0C0L4 C4α C4A 2 0 0 1 1 Biochemical evidence shows soluble Aβ can activate C4α 
O14791 apoL1 APOL1 1 0 0 0 1 
apoL1 is expressed in brain and it is a minor apoprotein component of 
HDL. 
P08519 apo(a) LPA 1 0 0 1 0 
apo(a) concentrations can vary significantly between individuals and 
changes may be impacted by inflammatory response. 
Q03591 FHR-1 CFHR1 1 0 0 0 1 Possible involvement with Aβ plaques being recognised by microglia. 
P04196 HRG HRG 1 0 0 0 1 
HRG is a ligand for LRP1b involved in lipoprotein metabolism.  Note 
that other ligands include Aβ precursor protein, fibrinogen, clusterin, 
serum amyloid P-component, and immunoglobulins. 
O43866 CD5 antigen-like CD5L 0 0 0 0 0 Did not find any biochemical studies directly linking protein to Aβ. 
O75636 ficolin-3 FCN3 0 0 0 0 0 Did not find any biochemical studies directly linking protein to Aβ. 
P00450 ceruloplasmin CP 0 0 0 0 0 Did not find any biochemical studies directly linking protein to Aβ. 
P00734 prothrombin F2 0 0 0 0 0 Did not find any biochemical studies directly linking protein to Aβ. 
P02747 C1QC C1QC 0 0 0 0 0 Did not find any biochemical studies directly linking protein to Aβ. 




C4BPA 0 0 0 0 0 Did not find any biochemical studies directly linking protein to Aβ. 
P07357 CC8α C8A 0 0 0 0 0 Did not find any biochemical studies directly linking protein to Aβ. 















Figure 3-12: MS/MS spectrum of m/z 851.41the [M+3H]
3
+ molecular ion for a peptide of 2552.23 Da with corresponding sequence 






Figure 3-13: MS/MS spectrum of m/z 488.91 the [M+3H]
3
+ molecular ion for a peptide of 1464.73 Da with corresponding sequence 




Figure 3-14: MS/MS spectrum of m/z 694.03 the [M+3H]
3+ 
molecular ion for a peptide of 2080.07 Da with corresponding sequence 




Figure 3-15: MS/MS spectrum of m/z 949.82 the [M+3H]
3+ 
molecular ion for a peptide of 2847.43 Da with corresponding sequence 





Figure 3-16: MS/MS spectrum of m/z 377.23 the [M+3H]
3+ 
molecular ion for a peptide of 1129.68 Da with corresponding sequence 





Figure 3-17: MS/MS spectrum of m/z 815.90 the [M+2H]
2+ 
molecular ion for a peptide of 1630.79 Da with corresponding sequence 





Figure 3-18:  MS/MS spectrum of m/z 694.03 the [M+3H]
3+ 
molecular ion for a peptide of 2080.08 Da with corresponding sequence 







Figure 3-19: MS/MS spectrum of m/z 871.45 the [M+4H]
4+ 
molecular ion for a peptide of 3482.78 Da with corresponding sequence 







Figure 3-20: MS/MS spectrum of m/z 396.90 the [M+3H]
3+ 
molecular ion for a peptide of 1188.69 Da with corresponding sequence 






Figure 3-21: MS/MS spectrum of m/z 722.03 the [M+3H]
3+ 
molecular ion for a peptide of 2164.07 Da with corresponding sequence 






Figure 3-22: MS/MS spectrum of m/z 504.93 the [M+3H]
3
+ molecular ion for a peptide of 1512.77 Da with corresponding sequence 





Figure 3-23: MS/MS spectrum of m/z 599.28 the [M+3H]
3
+ molecular ion for a peptide of 1795.83 Da with corresponding sequence 






Figure 3-24: MS/MS spectrum of m/z 514.80 the [M+4H]
4
+ molecular ion for a peptide of 2056.18 Da with corresponding sequence 





Figure 3-25: MS/MS spectrum of m/z 414.59 the [M+3H]
3
+ molecular ion for a peptide of 1241.74 Da with corresponding sequence 






Figure 3-26: MS/MS spectrum of m/z 354.20 the [M+3H]
3
+ molecular ion for a peptide of 1060.50 Da with corresponding sequence 






Figure 3-27: MS/MS spectrum of m/z 463.26 the [M+3H]
3
+ molecular ion for a peptide of 1387.77 Da with corresponding sequence 






Figure 3-28: MS/MS spectrum of m/z 366.90 the [M+3H]
3
+ molecular ion for a peptide of 1098.68 Da with corresponding sequence 






Figure 3-29: MS/MS spectrum of m/z 810.46 the [M+3H]
3
+ molecular ion for a peptide of 2429.37 Da with corresponding sequence 







Figure 3-30: MS/MS spectrum of m/z 441.26 the [M+3H]
3
+ molecular ion for a peptide of 1321.77 Da with corresponding sequence 






Figure 3-31: MS/MS spectrum of m/z 421.92 the [M+3H]
3+ 
molecular ion for a peptide of 1263.75 Da with corresponding sequence 






Figure 3-32: MS/MS spectrum of m/z 870.12 the [M+3H]
3+ 
molecular ion for a peptide of 2608.35 Da with corresponding sequence 








Figure 3-33: MS/MS spectrum of m/z 594.52 the [M+3H]
3+ 
molecular ion for a peptide of 2968.59 Da with corresponding sequence 






Figure 3-34: MS/MS spectrum of m/z 1122.92 the [M+3H]
3+ 
molecular ion for a peptide of 3366.77 Da with corresponding sequence 









Figure 3-35: MS/MS spectrum of m/z 811.68 the [M+4H]
4+ 
molecular ion for a peptide of 3243.72 Da with corresponding sequence 







Figure 3-36: MS/MS spectrum of m/z 574.28 the [M+4H]
4+ 
molecular ion for a peptide of 2294.10 Da with corresponding sequence 







Figure 3-37: MS/MS spectrum of m/z 418.54 the [M+3H]
3+ 
molecular ion for a peptide of 1253.62 Da with corresponding sequence QKDNGCFR 







Figure 3-38: MS/MS spectrum of m/z 663.89 the [M+4H]
4+ 
molecular ion for a peptide of 2652.52 Da with corresponding sequence 






Figure 3-39: MS/MS spectrum of m/z 448.70 the [M+5H]
5+ 
molecular ion for a peptide of 2236.32 Da with corresponding sequence 






Figure 3-40: MS/MS spectrum of m/z 559.66 the [M+3H]
3+ 
molecular ion for a peptide of 1676.97 Da with corresponding sequence 








Figure 3-41: MS/MS spectrum of m/z 534.05 the [M+4H]
4+ 
molecular ion for a peptide of 2133.19 Da with corresponding sequence  







Figure 3-42: MS/MS spectrum of m/z 746.89 the [M+4H]
4+ 
molecular ion for a peptide of 2984.53 Da with corresponding sequence  







Figure 3-43: MS/MS spectrum of m/z 995.49 the [M+4H]
4+ 
molecular ion for a peptide of 2984.45 Da with corresponding sequence  








Figure 3-44: MS/MS spectrum of m/z 520.05 the [M+4H]
4+ 
molecular ion for a peptide of 2077.17 Da with corresponding sequence  






Figure 3-45: MS/MS spectrum of m/z 489.97 the [M+3H]
3+ 
molecular ion for a peptide of 1467.88 Da with corresponding sequence  








Figure 3-46: MS/MS spectrum of m/z 573.56 the [M+4H]
4+ 
molecular ion for a peptide of 2291.21 Da with corresponding sequence  






Figure 3-47: MS/MS spectrum of m/z 547.30 the [M+4H]
4+ 
molecular ion for a peptide of 2186.19 Da with corresponding sequence  






Figure 3-48: MS/MS spectrum of m/z 550.97 the [M+3H]
3+ 
molecular ion for a peptide of 1650.89 Da with corresponding sequence  






Figure 3-49: MS/MS spectrum of m/z 431.52 the [M+4H]
4+ 
molecular ion for a peptide of 1723.06 Da with corresponding sequence  







Figure 3-50: MS/MS spectrum of m/z 763.39 the [M+3H]
3+ 
molecular ion for a peptide of 2288.14 Da with corresponding sequence 






Figure 3-51: MS/MS spectrum of m/z 707.32 the [M+3H]
3+ 
molecular ion for a peptide of 2119.94 Da with corresponding sequence 






Figure 3-52: MS/MS spectrum of m/z 471.24 the [M+3H]
3+ 
molecular ion for a peptide of 1411.72 Da with corresponding sequence QMSKYPSGER 






Figure 3-53:  MS/MS spectrum of m/z 465.60 the [M+3H]
3+ 
molecular ion for a peptide of 1394.78 Da with corresponding sequence 







Figure 3-54:  MS/MS spectrum of m/z 415.52 the [M+4H]
4+ 
molecular ion for a peptide of 1659.06 Da with corresponding sequence 




Figure 3-55: MS/MS spectrum of m/z 710.70 the [M+3H]
3+ 
molecular ion for a peptide of 2130.10 Da with corresponding sequence 







Figure 3-56: MS/MS spectrum of m/z 1122.93 the [M+3H]
3+ 
molecular ion for a peptide of 3366.77 Da with corresponding sequence 







Figure 3-57: MS/MS spectrum of m/z 811.69 the [M+4H]
4+ 
molecular ion for a peptide of 3243.72 Da with corresponding sequence 






Figure 3-58: MS/MS spectrum of m/z 765.37 the [M+3H]
3+ 
molecular ion for a peptide of 2294.10 Da with corresponding sequence 






Figure 3-59: MS/MS spectrum of m/z 418.87 the [M+3H]3
+ 
molecular ion for a peptide of 1254.61 Da with corresponding sequence QKDNGCFR 




Figure 3-60: MS/MS spectrum of m/z 448.10 the [M+5H]5
+ 
molecular ion for a peptide of 2236.32 Da with corresponding sequence 






Figure 3-61: MS/MS spectrum of m/z 559.66 the [M+3H]
3+ 
molecular ion for a peptide of 1676.97 Da with corresponding sequence 





Figure 3-62:  MS/MS spectrum of m/z 418.88 the [M+3H]
3+ 
molecular ion for a peptide of 1240.61 Da with corresponding sequence 







Figure 3-63: MS/MS spectrum of m/z 574.28 the [M+4H]
4+ 
molecular ion for a peptide of 2294.11 Da with corresponding sequence 







Figure 3-64: MS/MS spectrum of m/z 663.89 the [M+4H]
4+ 
molecular ion for a peptide of 2652.53 Da with corresponding sequence 






Figure 3-65: MS/MS spectrum of m/z 584.85 the [M+3H]
3+ 
molecular ion for a peptide of 2336.36 Da with corresponding sequence 






Figure 3-66: MS/MS spectrum of m/z 366.90 the [M+3H]
3+ 
molecular ion for a peptide of 1098.68 Da with corresponding sequence QKVEPLR 






Figure 3-67: MS/MS spectrum of m/z 584.85 the [M+4H]
4+ 
molecular ion for a peptide of 2336.36 Da with corresponding sequence 






Figure 3-68: MS/MS spectrum of m/z 462.93 the [M+3H]
3+ 
molecular ion for a peptide of 1386.79 Da with corresponding sequence LEALKENGGAR 






Figure 3-69: MS/MS spectrum of m/z 366.90 the [M+3H]
3+ 
molecular ion for a peptide of 1098.68 Da with corresponding sequence QKVEPLR 







Figure 3-70: MS/MS spectrum of m/z 520.06 the [M+4H]
4+ 
molecular ion for a peptide of 2077.17 Da with corresponding sequence 




Figure 3-71: MS/MS spectrum of m/z 401.23 the [M+3H]
3+ 
molecular ion for a peptide of 1208.61 Da with corresponding sequence 






Figure 3-72: MS/MS spectrum of m/z 1131.09 the [M+2H]
2+ 
molecular ion for a peptide of 2261.17 Da with corresponding sequence 








Figure 3-73: MS/MS spectrum of m/z 577.93 the [M+4H]
4+ 
molecular ion for a peptide of 2885.62 Da with corresponding sequence 






Figure 3-74: MS/MS spectrum of m/z 387.72552 the [M+4H]
4+ 
molecular ion for a peptide of 1547.882 Da with corresponding sequence 






Figure 3-75: MS/MS spectrum of m/z 670.40 the [M+3H]
3+ 
molecular ion for a peptide of 2009.03 Da with corresponding sequence 






Figure 3-76: MS/MS spectrum of m/z 503.79 the [M+4H]
4+ 
molecular ion for a peptide of 2012.14 Da with corresponding sequence 








Figure 3-77: MS/MS spectrum of m/z 619.07 the [M+4H]
4+ 
molecular ion for a peptide of 2473.27 Da with corresponding sequence 






Figure 3-78: MS/MS spectrum of m/z 481.63 the [M+3H]
3+ 
molecular ion for a peptide of 1442.88 Da with corresponding sequence LEVDIDIKIR 




Figure 3-79: MS/MS spectrum of m/z 676.87 the [M+4H]
4+ 
molecular ion for a peptide of 2704.46 Da with corresponding sequence 




Figure 3-80: MS/MS spectrum of m/z 1086.05 the [M+2H]
2+ 
molecular ion for a peptide of 2171.10 Da with corresponding sequence 
SAGWNIPIGILLYCDLPEPR unique to TF identified in 1DGE fraction 1 as significant (P value <0.05) between PiB+ and PiB- groups. 
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3.4.6 Technical replication of LC-MS/MS candidates by immunoassay  
The 17 candidate proteins from the LC-MS/MS discovery were measured in plasma 
samples from the same 78 AIBL-1 discovery cohort subjects using commercially 
available ELISA kits (Table 2-1). Using Logistic and Linear Regression models 
(including age, gender, APOE status, ELISA assay plate as covariates) we found that 
two proteins – α2m (Figure 3-81) and FGγ (Figure 3-83), replicated our findings 
from the LC-MS/MS discovery study (Table 3-13).  
Table 3-13: Technical replication of plasma protein candidates discovered by LC-
MS/MS in AIBL-1. For regressions age, gender, presence of APOE ε4 and ELISA plate 
were used as covariates. 
  
Logistic regression with 
SUVR >1.5 




Protein Name Beta P value Q value Beta P value Q value 
P01023 α2m 1.000 0.009 0.076 0.200 0.008 0.068 
Q03591 FHR-1 -1.000 0.005 0.076 -0.220 0.006 0.068 
P02679 FGγ -0.700 0.041 0.230 -0.200 0.014 0.081 
P08519 apo(a) 0.480 0.130 0.340 0.180 0.051 0.180 
P06396 gelsolin -0.480 0.110 0.340 -0.140 0.068 0.190 
P00738 haptoglobin -0.380 0.180 0.390 -0.130 0.089 0.190 
P04196 HRG 0.480 0.140 0.340 0.140 0.081 0.190 
P06727 apoA4 -0.630 0.083 0.340 -0.170 0.067 0.190 
P01024 CC3 -0.610 0.250 0.470 -0.210 0.130 0.250 
P0C0L4 C4α -0.550 0.510 0.660 -0.270 0.220 0.380 
P10909 clusterin -0.270 0.360 0.510 -0.091 0.270 0.410 
P02647 apoA1 0.340 0.290 0.470 0.088 0.320 0.460 
P02671 FGα -0.280 0.300 0.470 -0.064 0.390 0.520 
P02787 TF -0.013 0.960 0.960 -0.041 0.600 0.730 
O14791 apoL1 -0.090 0.740 0.890 -0.026 0.730 0.770 
P08603 CFH 0.066 0.800 0.890 0.027 0.700 0.770 






Figure 3-81: Box and whisker plot to show the α2m group differences (P = 0.009) 
between PiB- and PiB+ in the AIBL-1 cohort as a technical replication. 
 
Figure 3-82: Box and whisker plot to show the FHR-1 group differences (P = 0.005) 






















Figure 3-83: Box and whisker plot to show the FGγ group differences (P = 0.041) 
between PiB- and PiB+ in the AIBL-1 cohort as a technical replication. 
After multiple testing comparisons, α2m, FHR-1 and FGγ remained associated with 
NAB (Q value = <0.1).  In the LC-MS/MS discovery study, FHR-1 was increased in 
the PiB+ group. Even though FHR-1 was associated with NAB in the technical 
replication (Table 3-13), an opposite trend was observed (Figure 3-82). Furthermore, 
apo(a), haptoglobin, HRG, apoA4, CC3, C4α, clusterin, FGα, CFH and CFB all 
showed the same directional change as in the LC-MS/MS discovery, although not 
significant at the uncorrected P <0.05 level (Table 3-13). The similarities and 
differences with regards to directional protein change within the PiB+ group between 











11C-PiB PET SUVR status
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Table 3-14: A comparison of directional change in the PiB+ group between LC-MS/MS 
discovery and ELISA technical replication. For LC-MS/MS results one arrow 
represents one MW protein isoform, of which 25 were represent for 17 protein groups. 
Protein 
Name 
Direction of change in 
PiB+ Protein 
Name 
Direction of change in 
PiB+ 
LC-MS/MS ELISA LC-MS/MS ELISA 
α2m≠   C4α   
FHR-1†   clusterin   
FGγ≠   apoA1   
apo(a)   FGα   
gelsolin   TF   
haptoglobin   apoL1   
HRG   CFH   
apoA4   CFB   
CC3   
 ≠ Statistically significant (uncorrected P <0.05 level) in technical replication with the same 
directional change as discovery; † Statistically significant (uncorrected P <0.05) level in technical 
replication with an opposite directional change as discovery.  
3.4.7 Independent replication by immunoassay in the UCSF cohort 
To verify the results from the AIBL-1 cohort (discovery and technical replication), 
the levels of the three proteins significantly associated with NAB in the technical 
replication (α2m, FGγ and FHR-1) were measured using samples from an 
independent cohort with Aβ measures. These proteins were measured by ELISA in 
79 samples from the UCSF cohort (Table 3-2; Figure 3-3). Logistic and Linear 
Regression models were built using the same confounding factors as AIBL-1 
technical replication, with the added variable of PET scanner type.  
FGγ was found to be significantly associated with 11C-PiB positivity, as determined 
both by visual examination of 
11
C-PiB PET scans (Table 3-15, Figure 3-84; P = 
0.002, Q = 0.006) and by applying a threshold of >1.5 to SUVRs (Table 3-16, Figure 
3-85; P = 0.017, Q = 0.051). Assessing 
11
C-PiB PET as a continuous measure there 
was a statistically significant correlation between FGγ and NAB (Table 3-16, Figure 
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3-86; P = <0.001, Q = 0.001). As with LC-MS/MS discovery and technical 
replication, lower plasma FGγ were associated with increased NAB. Despite not 
being significantly associated with NAB, α2m correlated with SUVR positivity in 
the same direction as in the discovery study and technical replication (Table 3-16). 
There was no association found for FHR-1.  
Table 3-15: Independent replication in UCSF of plasma protein candidates discovered 
by LC-MS/MS and technically verified by immunoassay (Visual read to Aβ). For 
regressions age, gender, presence of APOE ε4, ELISA assay plate and PET scanner 
type were used as covariates. 
  






Beta P value Q value 
P01023 α2m -0.013 0.960 0.960 
P02679 FGγ -1.000 0.002 0.006 
Q03591 FHR-1 -0.066 0.790 0.960 
 
Table 3-16: Independent replication in UCSF of plasma protein candidates discovered 
by LC-MS/MS and technical verified by immunoassay (SUVR to Aβ). For regressions 
age, gender, presence of APOE ε4, ELISA assay plate and PET scanner type were used 
as covariates. 
  
Logistic Regression to 
SUVR > 1.5 





Beta P value Q value Beta P value Q value 
P01023 α2m 0.270 0.290 0.440 0.075 0.22 0.33 
P02679 FGγ -0.740 0.017 0.051 -0.210 <0.001 0.001 





Figure 3-84: Box and whisker plot to show the FGγ group differences (P = 0.002; Q = 
0.006) between PiB- and PiB+ according to visual examination of 
11
C-PiB PET in the 
UCSF cohort. 
 
Figure 3-85: Box and whisker plot to show the FGγ group differences (P = 0.017; Q = 
0.051) between PiB- and PiB+ according to an 
11





















Figure 3-86: Scatter plot to show the FGγ correlation (P = <0.001; Q = 0.001) with 11C-
PiB PET SUVR in the UCSF cohort. 
3.4.8 Multivariate analysis 
It is unlikely that a single marker alone will be able to explain heterogeneity 
demonstrated in AD and elevated Aβ. Therefore, a multimodal prediction model was 
attempted to be trained and tested (ELISA data only). Subjects with any missing 
covariates or protein measurements were excluded from the multivariate analysis, 
leaving 70 subjects from AIBL-1 (34 PiB-, 36 PiB+ based on SUVR cut-off >1.3) 
and 78 subjects from UCSF (46 PiB-, 32 PiB+ based on visual inspection). 
Classification models were trained in the AIBL-1 ELISA data to predict SUVR 
positivity (>1.3) and tested in the UCSF ELISA data to predict 
11
C-PiB positivity 
determined by visual inspection (more robust across multiple PET scanners). A 
‘basic’ model (age/gender/APOE ε4) was compared to a ‘basic + proteins’ model 
which used the plasma concentrations of FGγ, α2m and FHR-1. Figure 3-87a and 3-
87b shows a Receiver Operator Characteristic (ROC) analysis, where an Area Under 
the Curve (AUC) was shown to be higher for the ‘basic + protein’ model than for the 
‘basic’ model in the test datasets. The highest test AUC was found using the Random 










Forest approach, where the ‘basic + protein’ model (AUC = 0.70) outperformed the 
‘basic’ model (AUC = 0.46) in the test dataset. The Random Forest ‘basic + 
proteins’ model gave a test set sensitivity of 50% and specificity of 85%.  
 
Figure 3-87: Receiver Operator Characteristic (ROC) for the prediction of 
11
C-PiB 
positivity. A ‘basic’ model (age/gender/APOE4 presence) is compared to a ‘basic + 
proteins’ model also including the ELISA plasma levels of FGγ, α2M and FHR-1. 
Random Forest and Classification and Regression Trees (CART) were used to fit 
models in CARET using default parameters. Area Under the Curve (AUC) is given for 
each model. ROC curves are shown comparing predictive accuracy of models in (A) 
the training dataset (AIBL-1), and (B) the test dataset (UCSF). Classification tree 
trained on AIBL-1 ELISA data to predict NAB positivity and estimated cut-off (C). 
Furthermore, a classification tree was fitted to the ‘basic + proteins’ model, to 
provide a simpler alternative with clear thresholds. The resulting classification tree 
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used just two variables (age/plasma FGγ level; Figure 3-87c) and achieved a 
comparable AUC to the Random Forest model (AUC 0.69, sensitivity 59%, 
specificity 78%).  
3.4.9 The association of plasma FGγ with core CSF biomarkers  
Previous studies have shown a good inverse relationship between 
11
C-PiB PET 
SUVR and CSF Aβ1-42 
474-476
 as well as other Aβ imaging tracers 477. Given this, a 
plasma marker that demonstrates altered 
11
C-PiB should also reflect altered CSF 
Aβ1-42. There has been evidence to support that CSF Aβ biomarkers are altered 
before a global 
11
C-PiB SUVR threshold is reached in affect individual 
242, 246, 478-479
. 
Consequently, surrogate measures of CSF Aβ1-42 maybe a more sensitive measure of 
for preclinical Aβ accumulation and therefore AD. We investigated the association 
of plasma FGγ with CSF Aβ1-42 measures from 489 subjects in the EMIF-AD cohort 
(Table 3-3). We also explored the relationship of plasma FGγ with p-tau, t-tau and a 
CSF Aβ1-42 /tau algorithm 
480
.  
Given the reported inverse relationship of 
11
C-PiB SUVR and CSF Aβ1-42 in AD and 
the negative correlation observed between FGγ and 11C-PiB SUVR, we would expect 
to see a positive correlation between plasma FGγ levels and CSF Aβ1-42 where low 
CSF Aβ1-42- (indicative of PiB+) is associated with reduced FGγ. 
FGγ levels were affected by multi-cohort centres included in the EMIF-AD study (P 
= 0.049, F = 2.165) and ELISA assay plate (P = 9.205 x10
-5
; F = 9.394), therefore 
values were adjusted using a GLM. There was no association between FGγ with age 
or gender. No data was available for time of plasma sample storage. All subsequent 
analysis was performed on the GLM adjusted data. We observed a significant 
association between FGγ and APOE ε4 (P = 0.028), therefore we looked at the 
association of FGγ and core CSF biomarkers with and without adjusting for APOE 
genotype.  
We observed a statistically significant positive relationship between FGγ and CSF 
Aβ1-42 (Table 3-17; Figure 3-88a). When accounting for the effect of APOE (by 
partial correlation), a postivie relationship between FGγ and CSF Aβ1-42 remained 
(Table 3-17; Figure 3-88b). When CSF Aβ1-42 was treated as categorical measure 
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there was again a significant association between FGγ and CSF Aβ1-42 which was 
less significant that then correlation analysis (Table 3-17). However, this became 
non-significant when co-varying for APOE genotype (Table 3-17).  
Table 3-17: The association of FGγ with CSF Aβ1-42 in the EMIF-AD cohort. 
Associations were made using CSF Aβ1-42 as discrete and continuous measures as well 
as investigating the effect APOE genotype. A basic GLM co-varying for cohort centre 





Mann Whitney U 




FGγ 0.151 <0.001 -2.518 0.012 
FGγ (Adjusted for APOE ε4) 0.121 0.008 -1.909 0.056 
  
As CSF Aβ1-42 measures correlate greatly with the CSF algorithm values (Figure 3-8) 
it was unsurprising to finding FGγ significantly associated with the CSF algorithm 
(Table 3-18). However, this was not as significant as the association of FGγ with 
CSF Aβ1-42 alone and this is likely to be confounded by the inclusion of CSF t-tau in 
the algorithm (Table 3-19). 
Table 3-18: The association of FGγ with CSF algorithm in the EMIF-AD cohort. 
Associations were made using CSF algorithm as discrete and continuous measures as 
well as investigating the effect APOE genotype. A basic GLM co-varying for cohort 
centre and ELISA assay was applied in both analysis. 
 
CSF Algorithm  
Spearman Rank 
Correlation 
Mann Whitney U 




FGγ -0.096 0.034 -2.210 0.027 




Figure 3-88: Scatter plots demonstrating the correlations of CSF Aβ1-42 with FGγ co-
varying with APOE genotype (B) and without (A). A basic GLM co-varying for cohort 
centre and ELISA assay was applied in both analysis.  
When examining tau measures individually, a statistically significant but weak 































APOE genotype (Table 3-19). There was no association between FGγ and CSF t-tau 
although a negative trend was observed (Table 3-19). 
Table 3-19: The association of FGγ with CSF t-tau and p-tau in the EMIF-AD cohort. 
Associations were made using CSF t-tau and p-tau as discrete and continuous 
measures as well as investigating the effect APOE genotype. A basic GLM co-varying 





Mann Whitney U 




FGγ -0.090 0.046 -1.586 0.113 





Mann Whitney U 




FGγ -0.130 0.005 -2.170 0.030 
FGγ (Adjusted for APOE) -0.110 0.017 -1.181 0.069 
 
3.4.10 Plasma FGγ to predict elevated NAB for therapeutic trials 
Recent studies have shown that Aβ begins to accumulate ~15 years before the 
clinical onset of AD, leading many to suggest that anti-Aβ trials should begin in 
asymptomatic older individuals with elevated brain Aβ levels. This has led to the 
development of AD prevention trials, such as A4, GAP, TOMORROW and EPAD 
470
. There is some tentative evidence to suggest that anti-Aβ treatments may be more 
affective if given in preclinical or prodromal AD 
481
. These trials will require the 
identification of large populations of Aβ positive asymptomatic individuals, which is 
currently challenging. One of the key challenges is the low prevalence of NAB in 
asymptomatic individuals (~30%), which means that screening is necessary. We 
have found that measuring a single plasma protein – FGγ – with age could allow the 
prediction of individuals with NAB with a sensitivity of 59% and a specificity of 
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78% (Figure 3-87). Here we test the ability of the described cut-off concentrations of 
FGγ to predict elevated Aβ in cohort that included a large number of asymptomatic 
individuals (EMIF-AD). 
Firstly, we compared the raw EMIF-AD FGγ concentrations against the 
immunoassay results from AIBL-1 and UCSF. This demonstrated that there was a 
very consistent measurement of FGγ across all cohorts, with no significant 
differences between the three groups (P = 0.172; Figure 3-89). The largest mean 
difference was between AIBL-1 and EMIF-AD (P = 0.089; Mean difference = 
109.28 ng/mL), however this may be due to the greater variability in the 
substantially larger EMIF-AD cohort. When comparing cohorts of a similar size 
(AIBL-1 versus UCSF), the mean difference was considerably smaller (P = 0.498; 
Mean difference 67.34 ng/mL). This is evidence to show that the classifier and FGγ 
concentration cut-offs built in AIBL-1 and tested in UCSF should be applicable to 
EMIF-AD.   
 
Figure 3-89: Box and whisker plots demonstrating the concentration ranges of FGγ 
(ng/mL) across three independent cohorts; AIBL-1, UCSF and EMIF-AD. 
The classifier was tested in 489 subjects from the EMIF-AD cohort (Table 3-3). The 





















(59% vs. 78%) for predicting elevated Aβ in all subjects than in UCSF. When 
participants were divided into diagnostic groups, the classifier was seen to perform 
best in HEC (i.e. asymptomatic) individuals with a sensitivity of 50% and a 
specificity of 61% (Table 3-20). As the prevalence of elevated Aβ in EMIF-AD 
control individuals was lower than typical asymptomatic AD trial participants (12% 
vs. 30%), we adjusted positive (PPV) and negative predictive values (NPV) to be 
more representative. At a prevalence of 0.3 (as observed in the A4 trial), our 
classifier leads to a PPV of 0.35 but a NPV of 0.74. 
Table 3-20: Accuracy, sensitivity and specificity of the FGγ classifier (Figure 3-82) to 




All            
(n = 489) 
HEC 
 (n = 94) 
MCI 
(n = 234) 
AD          
(n = 161) 
Accuracy 53% 59% 52% 50% 
Sensitivity 44% 50% 37% 48% 
Specificity 59% 61% 59% 57% 






With the serial failure of Aβ based therapeutics in clinical trials compromised by the 
inclusion of substantial numbers of participants without the target pathology the need 
for biomarkers markers of NAB is an essential step in the search for a global 
prevention strategy. Blood-based biomarkers could be used to screen large numbers 
of potential participants, and those predicted to have abnormally high NAB would be 
retested using CSF assays or PET scans, reducing screen failure rates. This could 
reduce recruitment time and costs, as well as allowing eligible subjects to be 
identified more readily, for example from bio-banks with permission for re-contact.  
This work has demonstrated that a blood test consisting of FGγ plasma levels along 
with age could have some potential for predicting NAB, achieving a test set 
sensitivity, specificity and AUC of 59%, 78% and 69% respectively, highlighting its 
potential use in stratifying patients for anti-Aβ trials. The initial replication was 
performed in a mixed dementia cohort (UCSF) with Aβ measures, suggesting that 
FGγ and age may also have utility for distinguishing between Aβ and non-Aβ 
dementias. Additionally, because the classification model was trained in a subset of 
the AIBL-1 cohort containing very few AD subjects, it is more likely that FGγ will 
be able to predict Aβ positivity in the earlier stage of AD. As the UCSF cohort 
contained only few cognitively normal individuals we further examined FGγ in a 
larger cohort, with additional cognitively normal individuals (EMIF-AD). This study 
initially verified that FGγ positively correlates with CSF Aβ1-42. As CSF levels of 
Aβ1-42 are negatively correlated to brain NAB it is encouraging to see this 
relationship and reinforces the connection between FGγ and NAB. The association 
of FGγ with p-tau and not t-tau is also encouraging and links FGγ to a biomarker that 
reflects neuronal degeneration, with a greater sensitivity for AD. There was also a 
significant association of FGγ and a CSF algorithm however this did not outperform 
CSF Aβ1-42. Given the individual associations of FGγ with CSF Aβ1-42 and CSF p-tau 
but not CSF t-tau an algorithm of Aβ1-42 and p-tau may yield greater results.   
Next, we aimed to replicate the classifier trained and tested in AIBL-1 and UCSF, in 
EMIF-AD. We demonstrated that FGγ was consistently measured across these three 
differing cohorts. As these assays were performed within the same laboratory, inter 
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laboratory variability could not be tested. The FGγ classifier was shown to predict 
NAB best in HEC and out perform a demographic model. However, it is worth 
noting that in larger studies, using demographics models reach an accuracy of ~0.6 
across all individuals. While the specificity and sensitivity was lower in EMIF-AD 
than in our previous investigations and lower than a blood test developed by 
Burnham and colleagues 
437
 this is the only blood test whose predictive ability has 
been tested in an asymptomatic population relevant to AD prevention trials. 
Additionally, as it requires the measurement of a single protein, using a 
commercially available ELISA, it could be affordably combined with other markers 
to produce a more accurate test. 
APOE status is a substantial risk factor for AD 
482
 and Aβ 253. While we took APOE 
ε4 status into account during our analyses we were not surprised to find that APOE 
genotype markers did not improve our initial classification model as the study was 
designed to be independent of this effect. However, in EMIF-AD APOE ε4 did have 
an effect on the data and in a general population sample APOE genotype is likely to 
contribute to the prediction of NAB.  
FGγ has been previously associated with NAB 373 436. However, in the study by 
Burnham and colleagues 
437
 total fibrinogen was not found to associate with NAB, 
whereas Kiddle and colleagues 
436
 showed it was negatively associated with NAB. 
Additionally, complementary work to our study demonstrated that plasma measures 
of FGγ considerably improved the predictive ability of a 5 metabolite panel for 
elevated NAB 
445
. Further to this, decreased levels of plasma FGγ have been shown 
to be associated with a smaller whole brain volume in AD subjects 
428
 whereas 
measures of whole fibrinogen in plasma have shown an increase 
404, 483
. 
Discrepancies in these findings may be due to the platform used to measure total 
fibrinogen or highlight the importance of looking at specific fibrinogen chains. FGγ 
is normally rejected from the brain by the blood-brain barrier (BBB), yet has still 
been detected in mice and human brain tissue 
484-485
. This could be due to the 
reported dysfunction of the BBB in mice 
486
 and humans in AD 
487
. However, the 
movement of fibrinogen across a defected BBB seems to be molecule-specific, as 
smaller molecules are not BBB-permeable in AD 
488
. Fibrinogen has been shown to 
accumulate over time as AD pathology progresses 
489





. Ahn and colleagues 
491
 demonstrated that fibrinogen binds to toxic 
Aβ, which enhances aggregation and increases Aβ fibrillisation. Further to this FGγ-
A chain precursor was found to be increased in the CSF in both MCI and AD 
patients compared to normal controls 
492
. 
After FGγ, plasma α2m was the second most promising candidate, shown for the 
first time to associate with NAB, and more recently by Westwood and colleagues 
375
. 
This is noteworthy because, α2m has been found to be one of the most replicable 
markers of other AD-related phenotypes including diagnosis, hippocampal 
metabolism and response to treatment with sodium divalproex. Furthermore, α2m 
has been shown to be present in senile plaques 
493
, binds to Aβ1-42 
494-495
 and prevents 
fibrillogensis and Aβ toxicity 494-495. However, the role of α2m in 
the neurodegenerative process is not clear, given that α2m has been shown to exert 
both neuroprotective and neurotoxic effects on cultured neurons 
496
. Furthermore, 
several polymorphisms in the A2M gene have been associated with AD and result in 
significantly increased accumulation of Aβ plaques 497. It has also been suggested 
that α2m is strongly correlated with AD progression in females and not males 426. 
Technical replication was performed to reduce the number of false positives and to 
ensure robust translation of LC/MS-MS findings using a platform more applicable to 
clinical setting. Using commercially available ELISAs, we confirmed that α2m, FGγ 
and FHR-1 significantly predicted NAB with a 0.1 Q-value significance level. In 
addition to FGγ and α2m a further nine proteins (apo(a), haptoglobin, HRG, apoA4, 
CC3, C4α, clusterin, FGα, CFH and CFB) technically replicated the trend observed 
in the LC-MS/MS discovery without reaching statistical significance. Immunoassays 
cannot always distinguish between sequence variants, proteins modified with 
different PTM, or different truncated forms of a same protein seen by LC/MS-MS. It 
is also possible that the LC-MS/MS peptides used for quantification do not match the 
epitope measured by immunoassay. This could also explain the differences seen in 
significance, association and trend (e.g. FHR-1) between discovery and replication in 
some cases; therefore these candidates should not necessarily be discounted.  
Furthermore, the confounding influence of non-analyte specific interference also 
needs to be considered when immunoassays are the platform of choice. Heterophilic 
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antibodies (HAs) are found in upto 40% of healthy and diseased patient samples 
498
 
and have the ability to bridge between the capture and the detection antibodies in the 
immunometric assay creating a false signal. The influence of heterophilic antibodies 
on the immunoassays utilised in this study was not examined and could be another 
factor in we observed a poor replication between an MS-based discovery and 
ELISA-based replication. Approaches can be taken in sample pre-treatemnt (IgG 
depletion and heat shocking) and assay modification (replacement of monoclonal 
antibodies or HA blocking buffers) to reduce the interaction of HAs 
499
. The 
concentration of HAs is higher in blood samples than in CSF 
392
 and for low 
abundant proteins such as Aβ oligomers, positive signals are eliminated in plasma or 




In addition to these confounding factors, spike and recovery assessments were not 
performed on commercial ELISAs in this study and therefore the absolute accuracy 
of measuring an analyte in a complex sample matrix was not determined. This could 
be contributing to the poor replication from MS to ELISA. The immunoassay 
replication was reliant on an LC-MS/MS discovery phase and there are some 
limitations to this initial technique that needs to be considered. There was clear 
restriction on the number of protein group measured and a restriction dynamic range, 
with only classical plasma proteome targets being analysed. This is likely to due to 
the method of isobaric labelling employed and/or the pre-fractionation for LC-
MS/MS acquisition. These caveats will be discussed further in Chapter 4. 
3.5.1 Conclusions  
Using a well established discovery proteomic technique, this current study 
indentifies numerous cross-sectional candidate biomarkers of NAB. Many of these 
candidates have been previously been reported as AD putative biomarkers in “case 
versus control” cohorts, and this provides further evidence for utility as biomarkers 
in disease. In translation to quantitative assays we further demonstrated a potential 
blood test (plasma FGγ with age) having some ability to predict NAB. This was 
replicated in two independent sample cohorts of 
11
C-PiB imaging and CSF Aβ1-42 
measures. Plasma FGγ was also shown to have utility in preclinical disease by 
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illustrating a modest prediction of elevated NAB in asymptomatic individuals. We 
also demonstrated that plasma FGγ has an association with CSF p-tau but not t-tau. 
This study adds further evidence that differences in the plasma proteome in relation 
to AD and its pathology do exist, and therefore such changes could be used to 
stratify patients for anti-Aβ treatment trials.  
Statement of collaborative work 
Dr. Steven Kiddle (King’s College London) wrote the code for PRQ-1. Dr. Kiddle 




CHAPTER 4  
IN-DEPTH PROTEOMIC PROFILING OF PLASMA: AN 
APPLICATION FOR THE DISCOVERY OF PERIPHERAL 
BIOMARKERS OF NEUROLOGICAL DISEASE 
 
4.1 Introduction  
Protein markers for early detection, accurate diagnosis and prognosis are in great 
demand for a number of diseases, including neurodegeneration. Routine clinical 
practices are utilising blood as their first port of call, due to its minimally invasive 
nature, availability and relatively minimal cost. Moreover, blood is a good indicator 
of an individual’s overall function as it perfuses all body tissues and organs 501 and 
changes in the levels of blood proteins reflect most physical conditions 
502
.  
Immunoassays are frequently the method of choice in a clinical and research setting 
however they pose particular limitations e.g. inability to perform unbiased biomarker 
discovery, sample multiplexing and to detect protein isoforms/modifications. 
Futhermore, immunoassays are susepctible to non-analyte specific interference. In 
contrast a proteomic strategy that utilises Mass Spectrometry (MS) as a discovery 
platform would be able to address these limitations.  
Proteomic analysis of blood (plasma/serum) for the discovery and validation of 
disease related biomarkers by MS is a challenging task. While improving 
instrumentation has been important in advancing the development of shotgun 
proteomics, sample preparation still remains the critical factor. The high complexity 




 causes difficulties in 
deep profiling of the plasma proteome. In addition plasma is comprised of 20 highly 
abundant proteins including albumin, immunoglobulins, transferrin and haptoglobin, 
which make up 99% of the total protein content 
369
. When considering an unbiased 
shotgun proteomics method, peptides derived from highly abundant proteins 
dominate the focus of the analysis.  This leads to the ‘masking’ of lower abundant 
proteins or they simply fall below the detection limits of MS instrumentation because 
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the abundant proteins dictate the volume of plasma that can be injected and analysed 
503
. More recently, the removal of the most abundant proteins (Top2, 6, 12, 14 or 20) 
is employed in shotgun proteomics. By using these strategies it has been shown that 
analytes of low abundance (<100ng/mL) are readily detectable in the plasma 
proteome 
504-505
. A potential concern with immunodepletion strategies, particularly in 
non-denaturing conditions, is the removal of several proteins associated with 
immunocaptured targets that are known to function as carrier proteins 
506-507
. For 
example, the “albuminome” is the term given to intact proteins and fragments that 
are bound to anti-albumin resin during immunocapture process 
508
. This unwanted 
removal of proteome content is only likely to increase when depleting multiple 
analytes.   
The removal of albumin alone has been described as inadequate to achieve the 
sensitivity required to measure the much desired “tissue leakage” portion of the 
plasma proteome 
509
. While improving the coverage of medium abundant proteins, 
other studies have confirmed that the removal of several targets, in addition to 
albumin, does little to improve detection of proteins at low abundance 
142, 507
. 
Furthermore, increasing the number of depletion targets has minimal benefit given 
the additional expenditure 
510
. Importantly, proteins routinely included in multi-
immunocapture columns have been highlighted to be of major importance in several 
disease processes, in particular plasma biomarkers of neurodegeneration
357, 372, 374, 
429
. This is further supported by the observed association of FGγ, α2m, apoA1 and 
haptoglobin with NAB in Chapter 3. Even with the inclusion of a depletion strategy 
the issue of high complexity in plasma remains. This can be overcome by the 
combination of depletion and upstream protein or peptide level fractionation before 
LC-MS/MS. Strong cation exchange or SCX chromatography and 1DGE are highly 
compatible with immunodepletion and LC-MS/MS for peptide and protein 
separation respectively. However, one of the main disadvantages of SCX is the very 
strict buffer requirements needed to get optimal separation; a consistent column set 
up is also required. On the other hand a gel-based approach with 1DGE is robust and 
a popular technique for fractionating proteins based on molecular weight, as 
demonstrated in Chapter 3. However, gel-based techniques are still limited to the 
amount of protein that can be separated and a laborious process of peptide extraction 
from gel for MS analysis is required.  
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The development of the OFFGEL approach that fractionates proteins/peptides based 
on their isoelectric point (pI) has demonstrated superior performance in terms of 
protein identifications 
511-514
 and specifically peptide OFFGEL has been shown to be 
a greater separation technique than SCX 
515
 and 1DGE 
503, 516
 in complex matrices. 
Although in some instances, reports have demonstrated that gel-based separation can 
be superior to OFFGEL in less complex materials 
517-518
. A major drawback of 
having any upstream fractionation in a discovery methodology is the time and cost 
involved in performing the MS acquisition in order to be able to identify targets. 
This cost can be reduced by using multiplex isobaric labelling (TMT or iTRAQ) at 
the protein or peptide level. Protein separation utilising TMT6plex protein labelling 
has already been utilised in Chapter 3. With the recent development of TMT10plex, 
up to nine samples and one study reference can be measured in a single MS 
acquisition with relative quantification. 
The ideal goal of a MS-based plasma discovery would be to capture a wide dynamic 
range of low abundant proteins without losing the coverage of high/medium 
abundances, whilst keeping cost to a manageable level. However, if one is purely 
after the absolute maximum coverage, several studies have performed extensive MS 
approaches to detect total plasma protein numbers 
463, 509
. These studies in effect are 
an excellent reference tool and a valuable source for identifying detectable targets in 
the plasma proteome. However, these approaches could be deemed unrealistic to 
apply in a typical biomarker discovery project; firstly, they are often performed on a 
single sample with multiple techniques and huge number of technical repeats. 
Secondly, the cost, time and effort to apply such strategies is beyond the scope of a 
typical biomarker study in an research setting, which are generally conducted in a 
multi-disciplinary facility, examining >100 biological samples. 
Chapter 3 “Blood protein predictors of neocortical amyloid pathology for 
enrichment in therapeutic trials” presented results using a typical proteomic 
approach utilising 1DGE, TMT protein labelling without immunodepletion. 
Although it was shown to be an extremely useful proteomic technique, this 
methodology does have limitations that need to be addressed when aiming to 
conduct a thorough analysis of the plasma proteome. The main limitation in this 
method places on our biomarker discovery investigation is its restriction on dynamic 
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range, with only classical plasma proteome targets being analysed. Low abundant 
proteins play important roles in major biological processes such as cell cycle control 
and stress response. More recently, CNS proteins have been described in plasma as 
markers of neuronal injury and BBB dysfunction 
519
. Low abundant analytes were 
under represented in the dataset presented in Chapter 3 but are also under 
represented in the wider plasma proteomic literature, particularly for 
neurodegeneration. Highly abundant targets, such as FGγ and α2m, which were 
discovered in relation to NAB have also been attributed to number of other diseases. 
This would mean that alone their disease/phenotype accuracy is unlikely reach a 
level of clinical utility. However, if combined within a multi-analyte model 
alongside novel protein groups of lower abundance, this may foster greater 
sensitivity and specificity to the disease phenotype.      
In this study we have focused only on applying a number of common and widely 
used proteomic approaches to assess the optimum strategy to maximum proteome 
coverage, dynamic range and increase sample cohort size all within a manageable 
cost effective pipeline for typical plasma biomarker research. We also aim to 
examine these datasets for protein groups related to the CNS or neurodegeneration. 
Therefore, we have focused on plasma obtained from elderly subjects with differing 
disease classifications. However, in this Chapter we do not aim to investigate 
differential expression between clinical phenotypes but principally describe the limit 





To investigate a number of plasma proteomic strategies that can be coupled to LC-
MS/MS for the greater detection of lower abundance plasma protein groups. 
Methodologies will investigate immunodepletion, pre-fractionation and isobaric 
quantitation at the protein and peptide level. The plasma protein datasets and MS/MS 
spectra produced will be specifically interrogated for protein groups of low 
abundance (<100ng/mL), brain-specific protein groups and proteins related to 




4.3 Methodological overview  
The proteomic workflows investigated in this study are outlined in Figure 4-1. The 
detailed methodological protocols for each procedure are outlined in Chapter 2.6.  
All methods utilised TMT10plex isobaric tagging at the protein or peptide level for 
LC–MS/MS based quantification. This was applied to increase sample throughput 
and achieve relative quantification against a study reference. Either a gel-based 
method (1DGE) or isoelectric focusing method (OFFGEL (OGE)) of 10 or 20 
fractions was utilised for upfront separation of proteins and peptides respectively. 
This was compared alongside non-fractionated (NF) strategies. All 1DGE methods 
incorporated TMT protein labelling (1DGE-4, 1DGE-5, 1DGE-7 and 1DGE-8) 
whereas OGE (OGE-6 and OGE-9) and NF strategies used TMT peptide labelling 
(NF-1, NF-2 and NF-3). Furthermore, six strategies incorporated an initial 
immunodepletion step.  ProteoPrep
®
 Immunoaffinity removal of albumin and IgG’s 
was applied to methods NF-2, 1DGE-5, OGE-6, 1DGE-8 and OGE-9 whereas 
Pierce™ Top12 depletion was only applied to method NF-3. No depletion strategy 
was applied to methods NF-1, 1DGE-4 and 1DGE-7. The resulting peptide fractions 
for each proteomic methodology were analysed in an identical manner. Peptides 
were resolved using a linear gradient for 115 minutes through a C18 analytical 
column and mass spectra were acquired on a Thermo Scientific LTQ Orbitrap Velos 
instrument. Two different computational MS approaches in Proteome Discoverer 1.4 
for protein group/peptide identification and quantification were performed; 
sequential searching and MudPIT.  
Plasma samples were obtained from the multicentre European study, AddNeuroMed 
(ANM). For each methodology, pools of clinically confirmed healthy elderly (HEC), 
mild cognitive impairment (MCI) and Alzheimer’s disease (AD) plasma occupied 
isobaric labels in each TMT10plex analysis. Each pool consisted of differing HEC, 





Figure 4-1: Schematic flow diagram represents the 15 proteomic workflows investigated in Chapter 4. 








TMT10plex  protein labelling
Plasma samples 





































4.4.1 Protein/peptide metrics  
In total 7,439 unique proteins groups at 5% FDR have been identified across all 
methodologies (Supplementary Material 4), of which only 62.25% have been 
previously reported by the plasma proteome database (PPD; 
www.plasmaproteomedatabse.com) 
369
. A total of 4,404 protein groups were 
identified based on >2 peptides of which 23 were identified as “contaminant protein 
groups” (i.e. trypsin and human epidermal keratins). We also examined the protein 
groups, peptides, PSMs and spectral yield rates of each methodology at 1% FDR and 
contrasted this to 5% FDR (Table 4-1). Typically gel-based methods gave a spectral 
yield of between 45-55% whereas OGE methods returned a yield of between 35-
45% at 5% FDR. As expected there was a reduction in protein groups, peptides, 
PSMs and spectral yield performance when applying a 1% FDR, this was more 
detrimental in methods with a greater number of fractions. For all further analysis 
5% FDR was applied.  
Our initial analysis was to evaluate the total number of protein groups (Figure 4-2a), 
peptides (Figure 4-2b) and peptide spectral matches (PSMs; Figure 4-2c) that were 
detectable with each proteomic methodology. The number of protein groups 
identified using LC–MS/MS exponentially increased with greater pre-fractionation 
of complex matrices. OGE-9 (20 fractions) consistently yielded the greatest number 
of protein group identifications (Mean = 1202, SD = 122.92) whereas the equivalent 
gel-based method (1DGE-8) was significantly lower (Mean = 1049, SD = 91.12). 
However, it was interesting that gel-based method 1DGE-5 (Mean = 720, SD = 
68.8) outperformed the OGE equivalent (OGE-6, Mean = 672, SD = 54.8). In our 
hands non-fractionated (NF) methodologies yielded between 201-319 protein group 




Table 4-1: The performance of each proteomic methodology by number of protein groups, peptides, PSM, and spectral yield at false discovery rates 
(FDR) of 5% and 1%. The mean of 3 biological repeats has been shown for each method.   
  





















NF-1 21256 220 969 6741 31.71% 163 942 6629 31.19% 
NF-2 19565 271 975 7504 38.35% 200 946 7145 36.52% 
NF-3 14555 280 1114 7117 48.89% 213 880 6687 45.94% 
1DGE-4a 75180 487 2033 35759 47.56% 442 1967 25146 33.45% 
1DGE-4b 75180 542 2349 36438 48.47% 422 1972 26167 34.81% 
1DGE-5a 88206 709 3714 48322 54.78% 587 3475 43451 49.26% 
1DGE-5b 88206 730 4031 48433 54.91% 554 3442 48908 55.45% 
OGE-6a 82020 713 2257 30700 37.43% 517 1683 19524 23.80% 
OGE-6b 82020 620 2354 33596 40.96% 425 1648 19855 24.21% 
1DGE-7a 157126 802 4230 72620 46.22% 487 2109 69209 44.05% 
1DGE-7b 157126 874 4321 72110 45.89% 410 2076 69234 44.06% 
1DGE-8a 184943 1058 5699 76055 41.12% 754 4304 69364 37.51% 
1DGE-8b 184943 1041 5478 76736 41.49% 675 4203 70278 38.00% 
OGE-9a 194650 1359 5103 67913 34.89% 739 3872 57239 29.41% 
OGE-9b 194650 1045 4540 66960 34.40% 787 3797 56883 29.22% 
Abbreviations:NF-1, non-fractionated, TMT peptide labelling; NF-2, non-fractionated, Top2 depletion, TMT peptide labelling; NF-3, non-fractionated, Top12 depletion, TMT peptide labelling; 
1DGE-4a, One dimensional gel electrophoresis, 10 fractions, Top2 depletion, TMT protein labelling, sequential database searching; 1DGE-4b, One dimensional gel electrophoresis, 10 
fractions, Top2 depletion, TMT protein labelling, MudPIT database searching; 1DGE-5a, One dimensional gel electrophoresis, 20 fractions, Top2 depletion, TMT protein labelling, sequential 
database searching; 1DGE-5b, One dimensional gel electrophoresis, 20 fractions, Top2 depletion, TMT protein labelling, MudPIT database searching; OGE-6a, OFFGEL fractionation, 10 
fractions, Top2 depletion, TMT peptide labelling, sequential database searching; OGE-6b, OFFGEL fractionation, 10 fractions, Top2 depletion, TMT peptide labelling, MudPIT database 
searching; 1DGE-7a , One dimensional gel electrophoresis, 20 fractions, TMT protein labelling, sequential database searching; 1DGE-7b , One dimensional gel electrophoresis, 20 fractions, 
TMT protein labelling, MudPIT database searching; 1DGE-8a, One dimensional gel electrophoresis, 20 fractions, Top2 depletion, TMT protein labelling, sequential database searching; 
1DGE-8b, One dimensional gel electrophoresis, 20 fractions, Top2 depletion, TMT protein labelling, MudPIT database searching; OGE-9a, OFFGEL fractionation, 20 fractions, Top2 






Figure 4-2: The number of (a) protein groups (b) unique peptides and (c) peptide 
spectral matches (PSM) identified in plasma for 15 proteomic methodologies. White 
shading of the bars illustrates number of entities that can quantify by TMT10plex 
whereas grey shading represents identified protein groups only. The error bars shown 
are the standard deviation of 3 biological repeats. Identification is based on an FDR of 
5%. All 1DGE methods (10 fractions [4a, 4b, 5a, 5b] or 20 fractions [7a, 7b, 8a, 8b]) 
incorporated TMT10plex protein labelling whereas OGE (10 fractions [6a, 6b] or 20 
fractions [9a or 9b]) and NF strategies used TMT10plex peptide labelling. 
Furthermore, 6 strategies incorporated an initial immuodepletion step (2, 3, 5, 6, 8 and 
9). No depletion strategy was applied to methods 1, 4 and 7. For 1DGE-7a and 1DGE-
7b only 1 experimental repeat was performed. 
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Despite a decreased number of protein group identifications, all gel-based 
techniques yielded a greater number of peptides and PSM compared with OGE. To 
assess if this increase in peptide/PSM features equated to greater protein group 
sequence coverage we assessed the protein sequence coverage of several protein 
groups at differing concentrations (Figure 4-3). Protein group sequence coverage 
improved with greater fractionation however this analysis demonstrated that gel-
based techniques produced marginally greater coverage of proteins at higher 
concentrations (>1µg/ml) whereas method OGE-9 revealed greater sequence 
coverage of proteins of lower abundance (<1ng/ml).  
Despite having a fewer number of total PSMs than 1DGE-8, OGE-9 produced a 
1.25-fold increase in unique PSM sequences. Since gel-based proteomics is only 
compatible with TMT protein labelling all OGE methods resulted in a significantly 
higher number of quantified protein groups, peptides and PSMs. All TMT protein 
labelling methods were able to quantify between 52-57% of protein groups whereas 
TMT peptide methods ranged between 91-94% efficiency (white shading; Figure 4-
2). 
In addition, we also performed two different computational MS approaches for 
protein group/peptide identification; sequential searching (1DGE-4a, 1DGE-5a, 
OGE-6a, 1DGE-7a, 1DGE-8a and OGE-9a) and MudPIT (1DGE-4b, 1DGE-5b, 
OGE-6b, 1DGE-7b, 1DGE-8b and OGE-9b). For the most part sequential searching 
yielded a greater number of features, although OGE methods demonstrated a 
noticeable reduction in protein group and peptide identifications in the MudPIT 
methodology (Table 4-1, Figure 4-2). This is likely due to the robust identification in 
MudPIT searching which applies FDR’s across the whole dataset rather than within 
one fraction. Despite this difference both sequential and MudPIT performed equally 







Figure 4-3: Heat map to demonstrate the percentage of protein group sequence 
coverage for each proteomic methodology at three concentration levels; high 
abundance (>10mg/mL), medium abundance (>100ng/mL) and low abundance 
(<1ng/mL). Peptide sequence coverage colour gradient is shown as a percentage of the 
protein coverage identified in each method.Protein concentrations were estimated by 
the plasma proteome database (PPD). 
Gene identifications: APOA1, apoA1; C5, complement C5; FGA, FGα; APOC3, apolipoprotein C-
III; FN1, fibronectin 1; APOE, ApoE; HPR, haptoglobin-related; VWF, von Willebrand factor; 
FCN3, ficolin-3; ATRN, attractin; F10, factor X;  CFL1, cofilin 1; ICAM1, Intercellular Adhesion 
Molecule 1; DCD, dermcidin; MYH7, myosin-7; ITLN1, Intelectin-1; CFI, complement factor I; FLG, 
filaggrin; SNCA, α-synuclein; CRISP3, cysteine-rich secretory protein 3; IL7, Interleukin-7; BDNF, 
























4.4.2 Assessment of proteomic dynamic range 
In order to measure the depth of coverage achieved with the different workflows we 
compared our findings with the Plasma Proteome Database (PPD) that has reported 
the concentrations of >1,200 proteins 
463
. Only 12% of the protein groups observed 
in our data had reported concentration in PPD. The protein concentration ranges for 
each methodology are log2 transformed and are displayed as box and whisker plots 
in Figure 4-4.  
Highly significant mean differences were found between OGE-9 methods and all 
other methods (P = 8.7 x10
-10
). OGE-9a achieved the lowest level of detection 
(LOD, multiple epidermal growth factor-like domains protein 8 [4.3pg/ml]) whereas 
methods 1DGE-8a, 1DGE-8b and OGE-9b achieved an equivalent lowest LOD 
(cysteine-rich secretory protein 3 [6.4pg/ml]). OGE-9a also achieved the lowest 
median level of detection (66ng/ml) compared with OGE-9b (92ng/ml), 8a 
(120ng/ml) and 8b (175ng/ml). Although these methods accomplished a marked 
improvement in lowest LOD, full annotation of protein groups at all concentration 
levels was achieved (Figure 4-4). NF methods (NF-1, NF-2 and NF-3) all showed 
the same lowest LOD (apo(a) [1.4ng/ml]) however NF-1, despite having no 
depletion strategy, surprisingly achieved the lower median concentration (5.2ug/ml).  
Gel-based methods with 10 fractions (1DGE-4 and 1DGE-5) performed similarly 
regardless of depletion (Lowest LOD = kallikrein-10 [440pg/ml], Median = 
210ng/ml) or without depletion (Lowest LOD = kallikrein-10 [440pg/ml], Median = 
290ng/ml). OGE-6 performed poorly in this analysis (Median = 1.28 ug/ml) 
compared with all other fractionated methods despite having a lower LOD of 







Figure 4-4: Assessment of dynamic range achieved by each proteomic methodology. Box and whisker plots demonstrate the range of concentration 
(log2 transformed) identified in all 15 proteomic methods. Vertical bars within each box plot illustrate the frequency of proteins identified at a 


























NF1 1DGE-4a 1DGE-4b 1DGE-5a 1DGE-5b OGE-6a OGE-6b 1DGE-7a 1DGE-7b 1DGE-8a 1DGE-8b OGE-9a OGE-9bNF2 NF3
P = 8.7 x10-10
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To highlight the improved proteomic coverage, we compared protein groups 
identified (not quantified) in the LC-MS/MS discovery study in Chapter 3 with the 
best performing methodology (OGE-9a) presented in this Chapter (Figure 4-5). 
 
Figure 4-5: A proteomic coverage comparison between protein groups identified in 
Chapter 3 (red) and the best performing proteomic methodology in Chapter 4 (OGE-
9a; blue). Each circle represents an individual protein group. Concentrations from the 
plasma proteome database (PPD) have been log2 transformed with an indication 
(dashed line) of calculated concentration level given.     
Identical coverage of the milligram and microgram concentration ranges was 
observed between the two methods (Figure 4-5). However, OGE-9a demonstrated 
comprehensive coverage of the nanogram concentration level of the plasma 
proteome despite only 12% of protein groups being matched to the PPD database.  
Protein groups at the picogram level were also identified, which was not observed in 
protein groups from the results in Chapter 3. This comparison reveals the ability of 
the OGE-9a to identify a larger proportion of low abundance protein groups without 
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Immunodepletion played a considerable role in the improvement of protein group 
identification and three approaches were investigated in this study; non-depleted, 
Top2 depleted and Top12 depleted plasma. A statistically significant increase in 
protein groups between non-depleted (NF-1) and Top2 depletion (NF-2) was 
observed (P = 0.027; Figure 4-6). The addition of an immunodepletion strategy was 
the only difference between these two methodologies and therefore would be the 
principal cause of the significant increase in protein groups.  Conversely, a Top12 
depletion method (NF-3) did not significantly improve the number of observed 
proteins groups compared to NF-2 (P = 0.701; Figure 4-6) although a marginal mean 
increase was observed (Table 4-1; Figure 4-6). This small increase in protein groups 
was no greater than the experimental variation between replicates and therefore it 
was concluded that the Top12 depletion strategy had no further benefit than Top2 
depletion. In addition, other non-depleted methods that were compared to Top2 
depleted method, which included a fractionation step, also demonstrated a 
significant increase in the number of protein groups; 1DGE-4 versus 1DGE-5 (P = 
0.012) and 1DGE-7 versus 1DGE-8 (P = 0.023). This confirms the notable 
advantage of Top2 depletion. Top12 depletion was not performed on fractionated 
samples.  
It was apparent that the target proteins for Top12 immunocapture (NF-3 only) were 
still identified among the most highly abundant proteins groups identified in plasma. 
Table 4-2 demonstrates that 8/12 protein groups targeted for removal by Top12 
depletion still remain as the 25 most abundant protein groups when analysed by LC-
MS/MS. This is a concern for MS-based discoveries as highly abundant peptides, 
which are thought to be significantly reduced in the sample, still dominate the focus 
of analysis. The direct comparison of the abundance of immunocapture proteins 
from NF-3 to their abundance in a non-depleted sample (NF-1) is evident that the 
Top12 depletion column is not optimal in removal of specific analytes (Figure 4-7). 
The Top12 depletion column has been successful in a modest reduction in albumin, 
total fibrinogen, TF, haptoglobin and α2m with almost complete removal of IgA, 
IgG and IgM. On the other hand abundances of apoA2 remained constant with 




Figure 4-6: Box plot to illustrate the number of protein groups identified with each 
non-fractionated methodology. A significant increase between non-depleted (NF-1) and 
Top2 depleted (NF-2) plasma was observed (P = 0.027). No significant increase was 
seen in employing Top12 depletion (NF-3) method. Each method was a result of three 

































Table 4-2: The top 25 abundant proteins in non-fractionated Top12 depleted plasma 
(NF-3) based on the sum of PSMs of 3 technical repeats. Observed are 8/12 protein 
groups (highlighted in green) targeted for immunodepletion that remain as the most 
abundant proteins.    
UniProt ID Protein Name Gene Name 
Sum of 
peptides 
(n = 3) 
Sum of 
PSMs  
(n = 3) 
P02768 albumin ALB 56 2630 
P01024 CC3 C3 108 1893 
P02790 hemopexin HPX 29 1456 





P01009 α1-antitrypsin (A1AT) SERPINA1 46 1130 
P02766 transthyretin TTR 18 1102 
P02647 apoA1 APOA1 40 569 
P02765 α2-HS-glycoprotein AHSG 13 565 
P00450 ceruloplasmin CP 39 536 
P02774 vitamin D-binding protein VDBP 32 531 
Q14624 
Inter-alpha-trypsin inhibitor 
heavy chain H4 
ITIH4 31 474 
P02753 retinol-binding protein 4 RBP4 9 408 
P00738 haptoglobin HP 24 356 
P08603 CFH CFH 43 316 
P01008 antithrombin-III SERPINC1 24 307 
P02652 apoA2 APOA2 10 291 
P02787 TF TF 31 286 
P01011 α1-antichymotrypsin SERPINA3 19 283 
P19827 
Inter-alpha-trypsin inhibitor 
heavy chain H1 
ITIH1 21 272 
P19823 
Inter-alpha-trypsin inhibitor 
heavy chain H2 
ITIH2 21 267 
P01042 kininogen-1 KNG1 21 256 
P0C0L5 complement C4-B C4B 62 250 
P0C0L4 C4α C4A 60 248 
P04217 α1B-glycoprotein A1BG 15 245 




Figure 4-7: Bar chart demonstrating the change in the sum total of PSMs between NF-1 (blue) and NF-3 (red). A reduction was observed for IgA 
(98.1%), IgM (96.9%), IgG (95.2%), TF (71.8%), haptoglobin (64%), albumin (49.8%), α2m (30.3%), total fibrinogen (21.8%) and apoA2 (3.9%). 
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NF-1 (Non-depleted, non-fractionated plasma)
NF-3 (Top12, non-fractionated plasma)
NF-2 (Top2, non-fractionated plasma)
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Top2 immunodepletion was successful in decreasing the albumin and IgG content 
by 76.80% and 95.08% respectively (Table 4-3). Even with this large reduction in 
PSMs, albumin was still the 3
rd
 most abundant protein group in non-fractionated 
Top2 depleted plasma; however this was not the case when examining fractionated 
plasma (Table 4-4). It was also apparent that Top2 depletion was more efficient in 
the removal of albumin whereas IgG removal was comparable across both depletion 
methods (Figure 4-7).  
Table 4-3: Showing the sum of PSMs, rank of abundance and % reduction for both 
albumin and IgG for methods NF-1 and NF-2. A 76.8% and 95.1% reduction in 
albumin and IgG PSMs is observed between non-depleted plasma (NF-1) and Top2 






(Top2 depleted plasma) % 
Reduction 
Sum of PSMs 
(n = 3) 
Rank 
Sum of PSMs 
(n = 3) 
Rank 
albumin 5247 1 1219 3 76.80% 
IgG 1017 3 50 60 95.08% 
 
Unsurprisingly, the addition or increase in fractionation resulted in an increase in the 
number of PSMs attributed to albumin and IgG. At the non-depleted level, 13,521 
and 2,644 total PSMs were observed for albumin and IgG’s respectively for method 
1DGE-4 (non-depleted, 10 fractions). In contrast, 1DGE-7 (non-depleted, 20 
fractions) demonstrated a substantial increase; 30,216 and 3,086 PSMs observed for 
albumin and IgG’s respectively.  
Fractionation had a large influence on immunodepletion performance. Top2 
depletion with both 10 fractions (1DGE-5) and 20 fractions (1DGE-8) demonstrated 
greater “removal percentage” in albumin and IgG content than non-fractionated 
methods (Table 4-4). A reduction in of 82.70% in albumin PSMs was observed in 
1DGE-5 whereas a 93% reduction was measured in 1DGE-8. This is compared to 
76.80% reduction in non-fractionated methods (Table 4-3). A reduction in IgG 
content was also observed (Table 4-4; Figure 4-8). It was also observed that the 
265 
 
overall abundance rank of albumin and IgG fell exponentially with increasing 
fractionation (Table 4-4). Top2 depleted non-fractionated (NF-2) plasma ranked 




 most abundant respectively (Table 4-3). However, 
Top2 10 fraction (1DGE-5) plasma ranked albumin 25
th
 and IgG 115
th
 with Top2 20 
fraction (1DGE-8) plasma ranked albumin 40
th
 and IgG 141
st
 respectively (Table 4-
4). This demonstrates that the reduction of highly abundant proteins is not solely 
dependent on the immunocapture strategy employed and that a complementary 
fractionation step will enhance the impact of immunodepletion further.       
Table 4-4: Showing the sum of PSMs, rank of abundance and % reduction for both 
albumin and IgG for methods 1DGE-4, 1DGE-5, 1DGE-7 and 1DGE-8. An 82.70% 
and 98.30% reduction in albumin and IgG PSMs was observed between non-depleted 
10 fraction plasma (1DGE-4) and Top2 depleted 10 fraction plasma (1DGE-5). A 93% 
and 97.85% reduction in albumin and IgG content was observed between non-depleted 
20 fraction plasma (1DGE-7) and Top2 depleted 20 fraction plasma (1DGE-8). This is 






Sum of PSMs (n = 3) Rank Sum of PSMs (n = 3) Rank 
albumin 13521 1 2330 25 82.70% 






Sum of PSMs (n = 3) Rank Sum of PSMs (n = 3) Rank 
albumin 30216 1 2127 40 93.00% 








Figure 4-8: Bar charts representing of the performance of (A) albumin and (B) IgG 
removal between non-depleted fractionated methods (1DGE-4 and 1DGE-7) and Top2 
depleted fractionated methods (1DGE-5 and 1DGE-8). 
The “albuminome” is a term given to proteins that bind or interact with albumin. 
Experimental evidence has shown that, together with albumin, a number of proteins 
are bound to, and may be released from, an anti-albumin resin after plasma/serum 
immunodepletion. Therefore, we investigated the albumin bound portion of the 
immunodepletion process to identify any significant removal of albumin bound 
proteins (Figure 4-9). Proteins significantly observed in the albumin bound portion 



















































Figure 4-9: Pie chart to demonstrate the content of the albumin bound portion 
(“albuminome”) of the immunodepletion process (Top2 only).  
As expected albumin dominated the analysis in the albumin bound portion (67.12%, 
Figure 4-9). A large portion of contaminant protein groups (trypsin and human 
epidermal keratins) are also found within the albumin bound portion (12.76%, 
Figure 4-9). Furthermore, 15.11% of the albumin bound portion was occupied by 34 
other plasma protein groups (Table 4-5).  
The plasma protein groups found within the albumin bound fraction are displayed in 
Table 4-5 and are compared to the unbound fraction as a ratio. The majority of 
protein groups observed in the albumin bound fraction are a small proportion of the 
total PSMs in unbound fraction (<0.12). However, some protein groups do have a 
higher abundance in the albumin bound compared with the unbound fraction 
suggesting that they are significantly bound to albumin or albumin resin in the 
immunodepletion process (Table 4-5; dermcidin, Immunoglobulin lambda-like 
polypeptide 5, krev interaction trapped protein 1, probable G-protein coupled 
receptor 115, Ig kappa chain V-I region DEE and Ig kappa chain C region). Other 
protein groups have a considerable proportion (>0.40) of PSMs in the albumin 
bound fraction (Table 4-5; Ig lambda-2 chain C regions, Ig lambda-3 chain C 
regions, Ig kappa chain V-III region B6, Ig lambda-1 chain C regions). These protein 
groups should not be considered as disease related biomarkers when analysing 
plasma that has been through a Top2 depletion process as a considerable quantity of 
the PSMs will not be present in the unbound fraction.  
268 
 
Table 4-5: Protein groups observed in the albumin bound fraction (“albuminome”) 
when utilising Top2 immunodepletion. Protein groups are ranked by a PSM ratio 















2 40 20.00 
O00522 krev interaction trapped protein 1 2 22 11.00 
Q8IZF3 
probable G-protein coupled receptor 
115 
4 14 3.50 
P01597 Ig kappa chain V-I region DEE 6 20 3.33 
P01834 Ig kappa chain C region 130 194 1.49 
P0CG05 Ig lambda-2 chain C regions  99 64 0.65 
P0CG06 Ig lambda-3 chain C regions 100 64 0.64 
P01619 Ig kappa chain V-III region B6 51 32 0.63 
P0CG04 Ig lambda-1 chain C regions 99 40 0.40 
P69905 hemoglobin subunit alpha 24 3 0.12 
P01876 Ig alpha-1 chain C region 161 19 0.12 
P01871 Ig mu chain C region 218 22 0.10 
P68871 hemoglobin subunit beta 70 7 0.10 
P02647 apoA1 595 59 0.10 
P01023 α2m 534 47 0.09 
P08603 CFH 265 24 0.09 
P02671 FGα 510 37 0.07 
P00747 plasminogen 149 10 0.07 
P02787 TF 1271 72 0.06 
P02753 retinol-binding protein 4 237 13 0.05 
P02751 fibronectin 111 6 0.05 
P0C0L4 C4α 140 7 0.05 
P0C0L5 C4β 142 7 0.05 
P00751 CFB 111 5 0.05 
P02679 FGγ 641 24 0.04 
P00738 haptoglobin 485 15 0.03 
P01024 CC3 853 25 0.03 
P02675 FGβ 815 23 0.03 
Q14624 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
337 5 0.01 
Q86YZ3 hornerin 488 6 0.01 
P02766 transthyretin 546 4 0.01 
P02652 apoA2 292 2 0.01 
P02790 hemopexin 1014 6 0.01 
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4.4.4 Pathway analysis 
Pathway analysis (KEGG and BIOCARTA) was performed on the protein groups 
identified by each proteomic methodology. This was done to see which pathways, in 
plasma, could be enriched and if this differed depending on which proteomic 
methodology was employed.  Highly significant over-represented pathways were 
common between all methodologies (Table 4-6). This included anticipated pathways 
for blood analysis; complement, metabolic and coagulation pathways as well as 
protein groups related to cardiovascular diseases, inflammation and autoimmune 
diseases (Table 4-6).  
Table 4-6: DAVID pathway analysis of over-represented KEGG and BIOCARTA 
terms common to all plasma proteomic methodologies. 
KEGG pathway term BIOCARTA pathway term 
Complement and coagulation cascades Complement Pathway 
Staphylococcus aureus infection Classical Complement Pathway 
Systemic lupus erythematosus Lectin Induced Complement Pathway 
Prion diseases Extrinsic Prothrombin Activation Pathway 
Glycolysis / Gluconeogenesis Alternative Complement Pathway 
 
Intrinsic Prothrombin Activation Pathway 
 




The number of unique protein groups detected in OGE-9 method demonstrated 
significant over-expression (uncorrected P value level <0.05) of pathways related to 
AD, Huntington’s disease (HD), neurotrophin signalling, MAPK signalling and 
GnRH signalling which were not enriched in any other methodology (KEGG 
pathway analysis, Table 4-7). Furthermore, BIOCARTA pathway analysis 
demonstrated over-representation for synaptic junction proteins (Table 4-8), 
highlighting the sensitivity and potential of OGE-9 over other methods to explore 
the protein groups, within plasma, involved in neurodegenerative disease or CNS 
processes.         
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Table 4-7: DAVID pathway analysis of over-represented KEGG terms in a list of 




P value Q value 
Complement and coagulation cascades 54 7.77 x10-30 1.49 x10-27 
Glycolysis / Gluconeogenesis 26 1.14 x10-06 1.10 x10-04 
Pathogenic Escherichia coli infection 24 5.93 x10-06 3.79 x10-04 
Prion diseases 15 4.49 x10-04 0.021 
Systemic lupus erythematosus 29 9.42 x10-04 0.035 
Focal adhesion 48 0.002 0.075 
Fatty acid elongation in mitochondria 6 0.003 0.091 
Butanoate metabolism 13 0.004 0.091 
Viral myocarditis 21 0.005 n/s 
Alzheimer's disease 33 0.006 n/s 
Gap junction 23 0.007 n/s 
Neurotrophin signaling pathway 31 0.008 n/s 
Pentose phosphate pathway 10 0.011 n/s 
Fructose and mannose metabolism 12 0.013 n/s 
Citrate cycle (TCA cycle) 11 0.017 n/s 
MAPK signaling pathway 47 0.019 n/s 
Propanoate metabolism 11 0.021 n/s 
GnRH signaling pathway 20 0.025 n/s 
Adherens junction 20 0.027 n/s 
Huntington's disease 37 0.032 n/s 
Cell adhesion molecules (CAMs) 30 0.035 n/s 
Regulation of actin cytoskeleton 45 0.039 n/s 
Lysine degradation 13 0.034 n/s 




Table 4-8: DAVID analysis of over-represented BIOCARTA terms in list of protein 




P value Q value 
Complement Pathway 17 5.36 x10-11 1.39 x10-08 
Classical Complement Pathway 12 1.52 x10-07 1.97 x10-05 
Lectin Induced Complement Pathway 12 1.52 x10-07 1.97 x10-05 
Alternative Complement Pathway 10 3.43 x10-06 2.96 x10-04 
Intrinsic Prothrombin Activation Pathway 13 6.91 x10-06 4.47 x10-04 
Extrinsic Prothrombin Activation Pathway 8 0.002 0.086 
Glycolysis Pathway 8 0.002 0.086 
Acute Myocardial Infarction 8 0.006 n/s 
Platelet Amyloid Precursor Protein Pathway 6 0.018 n/s 
Synaptic Proteins at the Synaptic Junction 8 0.047 n/s 
Monocyte and its Surface Molecules 6 0.047 n/s 
Fibrinolysis Pathway 6 0.047 n/s 
Neutrophil and Its Surface Molecules 5 0.047 n/s 
 
4.4.5 The detection of brain-derived proteins and the plasma expression of 
 neurodegeneration and CNS injury. 
With a focus on neurodegeneration and CNS injury with the added indication from 
the pathway analyses (Table 4-7 and Table 4-8), we were interested in assessing if 
brain-derived proteins (BDP) could be measured in plasma. To address this we 
utilised the Human Protein Atlas (HPA) (http://www.proteinatlas.org/) which 
illustrates 1,223 genes with elevated protein expression in the cerebral cortex 
compared with all other tissues 
520
 (download date from HPA 20/10/2016). We also 
chose to only cross-reference this HPA list with protein groups that were only 
detected by methodology OGE-9. OGE-9 was shown to detect a superior number of 
protein groups and quantified protein groups (Figure 4-2), increased plasma 
proteome coverage to include the pg/mL range (Figure 4-4 and 4-5) and have 
pathways over-represented for neurodegeneration and/or CNS processes (Table 4-7 
and 4-8). Therefore this methodology would be the most likely to be utilised for 
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future plasma biomarker studies, compared with the others investigated. OGE-9 
alone (OGE-9a and OGE-9b) detected 3,175 unique protein groups (Supplementary 
Material 4) across three technique repeats and this dataset was mined for suspected 
BDPs highlighted by HPA.       
The OGE-9 plasma dataset demonstrated spectral evidence for 468/1,223 of these 
highly expressed cerebral cortex proteins (Supplementary Material 5) however a 
large percentage of these proteins do show evidence of significant peripheral 
expression. A total of 311/468 proteins have been described as “Group Enriched” (n 
= 88) or “Tissue Enhanced” (n = 223) by HPA (Supplementary Material 5). These 
are proteins that have five-fold higher expression in cerebral cortex but also exhibit 
substantial expression in other tissues. Therefore these protein groups cannot be 
exclusively deemed as a BDP. 
The “Tissue Enriched” category in HPA (>five-fold increased expression in the 
cerebral cortex compared with all other tissues) was used as an indication of a BDP 
candidate, due to high expression in the brain and minimal/no expression in other 
tissues. In this enriched dataset, which contained 381 cerebral cortex proteins, 157 
(99 with >2 PSMs) had detectable expression in our plasma protein list using 
automated database searches (Table 4-9). After manual inspection of the assigned 
spectra, 31 protein groups did not have sufficient b and y ion evidence to be 
considered as a confident identification (Table 4-9, highlighted in red). Glial 
fibrillary acidic protein (GFAP) and oligodendrocytic myelin paranodal and inner 
loop protein (OPALIN) are the highest scoring cerebral cortex specific proteins in 
HPA (download version date 20/10/2016).  There is adequate support to suggest that 
these proteins are present within our plasma dataset and MS/MS spectrum are shown 
(Figure 4-10, 4-11, 4-12 and 4-13). Furthermore, spectral evidence for other high 
scoring cerebral cortex specific proteins in HPA (myelin-oligodendrocyte 
glycoprotein (MOG) and β-synuclein (SNCB)) are also displayed (Figure 4-14 and 
4-15). Evidence for all other candidate BDPs observed in our plasma dataset is 




Table 4-9: Protein groups classified as “Tissue Enriched” by HPA that are detected in OGE-9 plasma dataset. The “Tissue Enriched” category in 
HPA (>five-fold increased expression in the cerebral cortex compared with all other tissues) was used as an indication of a candidate BDP due to 
high expression in the brain and minimal/none expression in other tissues. In this enriched dataset, which contained 381 cerebral cortex proteins, 
157 had detectable expression in the OGE-9 plasma protein list. All MS/MS spectra were manually examined and protein groups that did pass 
automated database criteria but not manual MS/MS spectra validation (n = 31) are highlighted in red.  
Gene symbol 




HPA tissue category 
(Cerebral Cortex) 
HPA Rank  
(Cerebral Cortex) 
HPA TS  
(calculated as the fold change 
to the 2nd highest tissue) 
Cerebral Cortex  
TS score  
GFAP HPRD_00675 160 Tissue enriched 1 1262 cerebral cortex: 1983.8 
OPALIN HPRD_15521 8 Tissue enriched 2 447 cerebral cortex: 44.7 
OMG HPRD_01257 2 Tissue enriched 6 168 cerebral cortex: 72.2 
MOG HPRD_11831 2 Tissue enriched 17 83 cerebral cortex: 103.3 
NCAN HPRD_02897 5 Tissue enriched 18 82 cerebral cortex: 87.4 
SNCB HPRD_03980 10 Tissue enriched 23 62 cerebral cortex: 146.2 
POU3F2 HPRD_02734 1 Tissue enriched 24 60 cerebral cortex: 10.2 
FEZF2 
 
1 Tissue enriched 29 54 cerebral cortex: 5.3 
PLP1 HPRD_02321 26 Tissue enriched 30 49 cerebral cortex: 1662.8 
SLC12A5 HPRD_09469 1 Tissue enriched 33 49 cerebral cortex: 36.6 
CSPG5   1 Tissue enriched 34 48 cerebral cortex: 73.7 
GPR37L1 HPRD_13603 1 Tissue enriched 37 45 cerebral cortex: 17.6 
CACNG8 HPRD_06063 1 Tissue enriched 39 44 cerebral cortex: 12.1 
GABRA1 HPRD_00662 1 Tissue enriched 40 44 cerebral cortex: 60.7 
HPCA HPRD_00811 2 Tissue enriched 41 44 cerebral cortex: 75.9 
SEZ6 
 
1 Tissue enriched 46 40 cerebral cortex: 28.2 
ELAVL3 HPRD_16024 1 Tissue enriched 47 39 cerebral cortex: 31.9 
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MBP HPRD_01158 214 Tissue enriched 48 37 cerebral cortex: 1427.5 
PCDHGC5 HPRD_07318 1 Tissue enriched 49 37 cerebral cortex: 25.4 
GAP43 HPRD_01198 4 Tissue enriched 59 30 cerebral cortex: 188.8 
GPM6B 
 
2 Tissue enriched 62 29 cerebral cortex: 439.1 
SYN2 
 
1 Tissue enriched 64 29 cerebral cortex: 98.6 
TNR 
 
1 Tissue enriched 69 27 cerebral cortex: 36.8 
CASKIN1 HPRD_10809 2 Tissue enriched 77 24 cerebral cortex: 8.4 
GRIN2B HPRD_00697 6 Tissue enriched 78 24 cerebral cortex: 5.8 
SYN1 HPRD_02433 12 Tissue enriched 82 24 cerebral cortex: 115.5 
SNAP25 HPRD_02637 10 Tissue enriched 85 23 cerebral cortex: 916.5 
CNTNAP4 HPRD_13079 2 Tissue enriched 91 21 cerebral cortex: 18.2 
NRXN1 HPRD_11858 3 Tissue enriched 95 20 cerebral cortex: 65.1 
TRIM67 
 
1 Tissue enriched 98 20 cerebral cortex: 4.9 
JPH3 HPRD_05589 2 Tissue enriched 107 18 cerebral cortex: 20.0 
SCN2A HPRD_03133 1 Tissue enriched 110 18 cerebral cortex: 31.4 
SHANK1 HPRD_05413 9 Tissue enriched 111 18 cerebral cortex: 14.6 
SLC4A10   1 Tissue enriched 112 18 cerebral cortex: 31.7 
SV2B 
 
3 Tissue enriched 113 18 cerebral cortex: 23.6 
AK5 HPRD_10472 2 Tissue enriched 115 17 cerebral cortex: 112.6 
LRRTM4   1 Tissue enriched 119 17 cerebral cortex: 10.0 
OLFM1 HPRD_09249 5 Tissue enriched 121 17 cerebral cortex: 346.0 
RPH3A HPRD_15273 4 Tissue enriched 123 17 cerebral cortex: 44.8 
APC2 HPRD_09802 2 Tissue enriched 126 16 cerebral cortex: 24.2 
CTNND2 HPRD_09181 1 Tissue enriched 127 16 cerebral cortex: 67.6 
SLC1A2 HPRD_02625 3 Tissue enriched 134 16 cerebral cortex: 195.0 
ERC2 HPRD_10810 1 Tissue enriched 137 15 cerebral cortex: 14.3 
ACTL6B HPRD_12419 3 Tissue enriched 144 14 cerebral cortex: 21.1 
GABRG1 HPRD_15923 1 Tissue enriched 163 13 cerebral cortex: 13.8 
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HRH3 HPRD_05162 2 Tissue enriched 167 13 cerebral cortex: 4.8 
KIAA1549L 
 
1 Tissue enriched 170 13 cerebral cortex: 16.0 
PCDH9 HPRD_04661 1 Tissue enriched 173 13 cerebral cortex: 36.2 
SLC1A3 HPRD_02523 10 Tissue enriched 175 13 cerebral cortex: 269.2 
CYP46A1 HPRD_04970 5 Tissue enriched 190 12 cerebral cortex: 30.0 
DNM1 HPRD_03851 2 Tissue enriched 191 12 cerebral cortex: 162.5 
PTPN5 HPRD_01472 1 Tissue enriched 198 12 cerebral cortex: 26.5 
C1QL2   1 Tissue enriched 210 11 cerebral cortex: 1.0 
CHN1 HPRD_00319 2 Tissue enriched 211 11 cerebral cortex: 327.1 
CMTM5 HPRD_06986 1 Tissue enriched 213 11 cerebral cortex: 39.5 
GAD2 HPRD_11817 1 Tissue enriched 218 11 cerebral cortex: 11.2 
MYT1L 
 
12 Tissue enriched 223 11 cerebral cortex: 30.8 
NETO1 HPRD_16264 1 Tissue enriched 225 11 cerebral cortex: 28.0 
PCDHA5 HPRD_07323 3 Tissue enriched 229 11 cerebral cortex: 2.0 
SV2A 
 
1 Tissue enriched 234 11 cerebral cortex: 83.1 
APLP1 HPRD_00102 1 Tissue enriched 236 10 cerebral cortex: 198.0 
DSCAM HPRD_03953 2 Tissue enriched 245 10 cerebral cortex: 6.0 
KIF3C HPRD_04164 17 Tissue enriched 253 10 cerebral cortex: 68.9 
NRGN HPRD_03828 43 Tissue enriched 255 10 cerebral cortex: 429.0 
PRKCG HPRD_01502 8 Tissue enriched 256 10 cerebral cortex: 19.6 
RAB3A 
 
1 Tissue enriched 258 10 cerebral cortex: 111.7 
SERPINI1 HPRD_03901 1 Tissue enriched 259 10 cerebral cortex: 172.9 
SLIT1 HPRD_04773 4 Tissue enriched 262 10 cerebral cortex: 28.0 
AMPH HPRD_02687 3 Tissue enriched 267 9 cerebral cortex: 42.4 
ATCAY HPRD_10491 1 Tissue enriched 269 9 cerebral cortex: 56.9 
B4GALNT1 HPRD_03525 2 Tissue enriched 271 9 cerebral cortex: 12.6 
BRINP1   3 Tissue enriched 272 9 cerebral cortex: 30.7 
CNTNAP2 HPRD_05197 3 Tissue enriched 275 9 cerebral cortex: 15.8 
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CPNE6 HPRD_05748 1 Tissue enriched 276 9 cerebral cortex: 41.0 
KIRREL3 HPRD_09679 4 Tissue enriched 287 9 cerebral cortex: 9.6 
LPPR4   5 Tissue enriched 290 9 cerebral cortex: 47.2 
MAP2 HPRD_01140 3 Tissue enriched 292 9 cerebral cortex: 157.0 
PCDHGB1 HPRD_09389 2 Tissue enriched 294 9 cerebral cortex: 9.6 
PRMT8 HPRD_11029 2 Tissue enriched 296 9 cerebral cortex: 9.7 
RLBP1 HPRD_01572 2 Tissue enriched 298 9 cerebral cortex: 2.9 
SCG3 HPRD_11538 3 Tissue enriched 299 9 cerebral cortex: 144.0 
SH3GL2 HPRD_05125 2 Tissue enriched 301 9 cerebral cortex: 89.5 
SHISA7 
 
4 Tissue enriched 302 9 cerebral cortex: 8.8 
SYP HPRD_02435 2 Tissue enriched 306 9 cerebral cortex: 264.6 
TRIM9 HPRD_05947 4 Tissue enriched 307 9 cerebral cortex: 39.5 
ELFN2   2 Tissue enriched 320 8 cerebral cortex: 11.0 
FAM155A   1 Tissue enriched 322 8 cerebral cortex: 7.7 
GRIN3A HPRD_09443 1 Tissue enriched 327 8 cerebral cortex: 6.3 
NEFL HPRD_01206 13 Tissue enriched 336 8 cerebral cortex: 151.6 
PGM2L1 
 
3 Tissue enriched 339 8 cerebral cortex: 35.4 
UNC13A HPRD_19058 1 Tissue enriched 350 8 cerebral cortex: 16.1 
AMER3 HPRD_08241 1 Tissue enriched 352 7 cerebral cortex: 3.5 
AP3B2 HPRD_03699 1 Tissue enriched 353 7 cerebral cortex: 17.7 
C1QL1 HPRD_12712 2 Tissue enriched 357 7 cerebral cortex: 15.5 
CDH10 HPRD_05187 2 Tissue enriched 362 7 cerebral cortex: 18.1 
CNKSR2 HPRD_06473 1 Tissue enriched 369 7 cerebral cortex: 28.3 
CNP HPRD_00448 27 Tissue enriched 370 7 cerebral cortex: 294.9 
FGFBP3   2 Tissue enriched 375 7 cerebral cortex: 8.7 
LHFPL4 
 
1 Tissue enriched 390 7 cerebral cortex: 11.1 
MAP1A HPRD_02549 7 Tissue enriched 392 7 cerebral cortex: 82.9 
NAPB HPRD_17627 1 Tissue enriched 395 7 cerebral cortex: 156.1 
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PTPRZ1 HPRD_01481 4 Tissue enriched 405 7 cerebral cortex: 135.2 
RUNDC3A HPRD_16106 6 Tissue enriched 410 7 cerebral cortex: 91.3 
SCN8A HPRD_09006 2 Tissue enriched 412 7 cerebral cortex: 11.2 
SMIM18 
 
6 Tissue enriched 418 7 cerebral cortex: 4.7 
SOGA3 
 
1 Tissue enriched 420 7 cerebral cortex: 1.3 
STXBP1 HPRD_04235 3 Tissue enriched 426 7 cerebral cortex: 193.7 
TAGLN3 HPRD_12136 1 Tissue enriched 427 7 cerebral cortex: 179.4 
TPPP HPRD_18522 9 Tissue enriched 428 7 cerebral cortex: 74.9 
TUBB2A 
 
133 Tissue enriched 429 7 cerebral cortex: 234.6 
ANKS1B  4 Tissue enriched 435 6 cerebral cortex: 53.9 
ASIC4   5 Tissue enriched 440 6 cerebral cortex: 4.8 
BAI1 HPRD_04062 4 Tissue enriched 443 6 cerebral cortex: 9.2 
BAI3 HPRD_04064 2 Tissue enriched 444 6 cerebral cortex: 30.0 
CAMK2A HPRD_06532 9 Tissue enriched 450 6 cerebral cortex: 136.1 
CHD5 HPRD_10828 7 Tissue enriched 453 6 cerebral cortex: 20.6 
DCLK2 
 
1 Tissue enriched 456 6 cerebral cortex: 46.1 
DLG4 HPRD_04199 1 Tissue enriched 459 6 cerebral cortex: 82.7 
DLGAP1 HPRD_09260 1 Tissue enriched 460 6 cerebral cortex: 46.8 
EFR3B HPRD_13824 1 Tissue enriched 463 6 cerebral cortex: 16.2 
ENO2 HPRD_00573 16 Tissue enriched 464 6 cerebral cortex: 215.7 
FEZ1   1 Tissue enriched 469 6 cerebral cortex: 200.4 
FMN2 HPRD_10449 2 Tissue enriched 471 6 cerebral cortex: 29.8 
GABRA3 HPRD_02375 1 Tissue enriched 473 6 cerebral cortex: 15.2 
GABRA4 HPRD_08839 1 Tissue enriched 474 6 cerebral cortex: 8.0 
GNAO1 HPRD_00757 11 Tissue enriched 476 6 cerebral cortex: 209.4 
GRIK3 HPRD_00691 2 Tissue enriched 481 6 cerebral cortex: 9.7 
GRIN2A HPRD_00698 8 Tissue enriched 482 6 cerebral cortex: 14.2 
GRM2 HPRD_04977 1 Tissue enriched 484 6 cerebral cortex: 2.0 
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HCN1 HPRD_09099 12 Tissue enriched 485 6 cerebral cortex: 10.0 
JAKMIP2 HPRD_11090 1 Tissue enriched 488 6 cerebral cortex: 16.7 
KCNC1 HPRD_15936 3 Tissue enriched 489 6 cerebral cortex: 7.6 
KIAA0513 
 
2 Tissue enriched 496 6 cerebral cortex: 51.8 
LRRC4C HPRD_12303 1 Tissue enriched 503 6 cerebral cortex: 17.2 
NECAB1   2 Tissue enriched 508 6 cerebral cortex: 41.6 
NLGN3 HPRD_02275 3 Tissue enriched 510 6 cerebral cortex: 29.7 
NRXN2 HPRD_11859 3 Tissue enriched 512 6 cerebral cortex: 64.2 
NSF HPRD_03380 1 Tissue enriched 513 6 cerebral cortex: 117.5 
POU3F4 
 
5 Tissue enriched 520 6 cerebral cortex: 3.5 
RAB6B 
 
2 Tissue enriched 526 6 cerebral cortex: 106.1 
SYT16 
 
1 Tissue enriched 536 6 cerebral cortex: 7.2 
VSNL1 HPRD_02890 1 Tissue enriched 545 6 cerebral cortex: 382.8 
YWHAH HPRD_00215 38 Tissue enriched 547 6 cerebral cortex: 462.5 
BEND6 
 
1 Tissue enriched 556 5 cerebral cortex: 18.9 
BSN HPRD_04933 5 Tissue enriched 557 5 cerebral cortex: 14.0 
CELF5 
 
1 Tissue enriched 560 5 cerebral cortex: 17.2 
GAREML  3 Tissue enriched 578 5 cerebral cortex: 10.9 
IBSP 
 
6 Tissue enriched 585 5 cerebral cortex: 0.8 
IDS HPRD_02402 1 Tissue enriched 586 5 cerebral cortex: 233.3 
KIF5C HPRD_18371 2 Tissue enriched 593 5 cerebral cortex: 111.0 
MEGF10 
 
1 Tissue enriched 598 5 cerebral cortex: 7.9 
PPFIA2 HPRD_04392 4 Tissue enriched 607 5 cerebral cortex: 30.2 
SEZ6L HPRD_08449 2 Tissue enriched 613 5 cerebral cortex: 43.3 
SLC24A2   2 Tissue enriched 614 5 cerebral cortex: 27.2 
SPTBN4 HPRD_09372 8 Tissue enriched 617 5 cerebral cortex: 8.4 
UCHL1 HPRD_01877 9 Tissue enriched 625 5 cerebral cortex: 212.5 
BDNF HPRD_00214 18 Tissue enriched 665 5 cerebral cortex: 10.0 







Figure 4-10: MS/MS spectrum of m/z 653.37 the [M+3H]
3+ 
molecular ion for a peptide of 1958.11 Da with corresponding sequence 







Figure 4-11: MS/MS spectrum of m/z 529.64 the [M+3H]
3+ 
molecular ion for a peptide of 1586.91 Da with corresponding sequence 




Figure 4-12: MS/MS spectrum of m/z 549.81 the [M+2H]
2
+ molecular ion for a peptide of 1098.62 Da with corresponding sequence 





Figure 4-13: MS/MS spectrum of m/z 513.80 the [M+2H]
2
+ molecular ion for a peptide of 1026.59 Da with corresponding sequence 







Figure 4-14: MS/MS spectrum of m/z 793.92 the [M+2H]
2
+ molecular ion for a peptide of 1586.83 Da with corresponding sequence 






Figure 4-15: MS/MS spectrum of m/z 437.23 the [M+2H]
2
+ molecular ion for a peptide of 873.46 Da with corresponding sequence 
EGVVAAAEK unique to SNCB. 
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Additionally, mining the OGE-9 plasma dataset revealed evidence for protein groups 
implicated in neurodegenerative pathogenesis. A number of proteins that have 
significant involvement in AD, DLB, PD, other tauopathies, Amyotrophic lateral 
sclerosis (ALS) and Polyglutamine diseases were identified (Table 4-10). 
Furthermore, proteins that been highlighted to have roles in neuronal injury, 
dendritic spines, post/pre-synaptic function as well as blood-brain barrier (BBB) 
breakdown also have been detected (Table 4-10). The spectral MS/MS evidence for 
these protein group identifications are shown from Figure 4-16 to Figure 4-29.  
Table 4-10: Proteins detected in the OGE-9 plasma dataset that are involved in 
neurodegenerative pathogenesis or CNS injury/damage. All MS/MS spectra were 
manually examined and protein groups that did pass automated database criteria but 
not manual MS/MS spectra validation (n = 6) are highlighted in red. 










Protein aggregation in AD, PD, DLB and 
MSA. Preparation of synaptic vesicles in 
pre-synaptic terminals. 
amyloid beta A4 
protein (Aβ) 
57 
Good             
(Fig 4-18, 4-
20) 
Protein aggregation in AD, 
amyloidopathies and DLB. CSF 
biomarker for NAB. Processing 




8 Poor (n/a) Proteolytic processing of APP. 
glial fibrillary acidic 
protein (GFAP) 
160 
Good      
(Fig 4-10, 4-
11, 4-12) 
Implicated in TBI and BBB dysfunction 




13 Poor (n/a) 
Protein aggregation in AD, FTD, PD and 
tauopathies. Hyperphosphorylated tau 






Implicated in Schizophrenia (SZ). A CSF 
biomarker for AD and synaptic loss. 
Post-synaptic protein that binds to 
calcium calmodulin and that may 
regulate calcium influx when neurons 
fire; a substrate for protein kinase C, an 









CSF biomarker in AD and FTD. 




Moderate    
(Fig 4-23) 
Implicated in AD and FTD. Pre-synaptic 
neuronal growth membrane protein that 











Moderate    
(Fig 4-25, 4-
26) 
Autosomal recessive early 
onset Parkinson's disease. PARK7 




Moderate    
(Fig 4-27) 
Synaptic vesicle protein that directs 
membrane trafficking and docking. 
S100B 25 
Moderate    
(Fig 4-29) 






Moderate    
(Fig 4-28) 
Protein aggregation in ALS. SOD1 
provides a defence against oxygen 
toxicity. 
synapsin-1 (SYN1) 12 
Good          
(Fig 4-30) 
Regulation of neurotransmitter release. 
synaptosomal-
associated protein 25 
(SNAP25) 
10 Poor (n/a) 
Marker of functional synapses. A 
component of the SNARE complex. 
synaptophysin (STP) 2 Poor (n/a) 
Pre-synaptic vesicle protein involved in 




5 Poor (n/a) 
Synaptic membrane protein that triggers 
synaptic vesicle fusion. 
TAR DNA-binding 
protein 43 (TDP43) 
2 Poor (n/a) Protein aggregation in ALS. 
Abbreviations: PD, Parkinson’s disease; DLB, Dementia with Lewy Bodies; MSA, Multiple system 
atrophy; SZ, Schizophrenia; TBI, Traumatic brain injury; BBB, Blood-brain barrier; FTD, 
Frontotemporal dementia; ALS, Amyotrophic lateral sclerosis; SNARE, Soluble NSF attachment 






Figure 4-16: MS/MS spectrum of m/z 666.39 the [M+2H]
2+
 molecular ion for a peptide of 1331.79 Da with corresponding sequence 






Figure 4-17: MS/MS spectrum of m/z 705.42 the [M+2H]
2+
 molecular ion for a peptide of 1409.83 Da with corresponding sequence 






Figure 4-18: MS/MS spectrum of m/z 449.48 the [M+4H]
4+
 molecular ion for a peptide of 1794.92 Da with corresponding sequence 






Figure 4-19: MS/MS spectrum of m/z 595.33 the [M+3H]
3+
 molecular ion for a peptide of 1783.99 Da with corresponding sequence 






Figure 4-20: MS/MS spectrum of m/z 617.83 the [M+2H]
2+
 molecular ion for a peptide of 1234.66 Da with corresponding sequence 






Figure 4-21: MS/MS spectrum of m/z 817.45 the [M+2H]
2+
 molecular ion for a peptide of 1633.90 Da with corresponding sequence 






Figure 4-22: MS/MS spectrum of m/z 531.25 the [M+2H]
2+
 molecular ion for a peptide of 1061.51 Da with corresponding sequence 







Figure 4-23: MS/MS spectrum of m/z 550.77 the [M+4H]
4+
 molecular ion for a peptide of 2200.07 Da with corresponding sequence 






Figure 4-24: MS/MS spectrum of m/z 1044.55 the [M+2H]
2+
 molecular ion for a peptide of 2088.09 Da with corresponding sequence 






Figure 4-25: MS/MS spectrum of m/z 829.43 the [M+2H]
2+
 molecular ion for a peptide of 1657.86 Da with corresponding sequence 






Figure 4-26: MS/MS spectrum of m/z 593.42 the [M+2H]
2+
 molecular ion for a peptide of 1185.836 Da with corresponding sequence 




Figure 4-27: MS/MS spectrum of m/z 387.90 the [M+3H]
3+








Figure 4-28: MS/MS spectrum of m/z 957.47 the [M+3H]
3+
 molecular ion for a peptide of 2870.42 Da with corresponding sequence 






Figure 4-29: MS/MS spectrum of m/z 836.71 the [M+4H]
4+
 molecular ion for a peptide of 3343.83 Da with corresponding sequence 






Figure 4-30: MS/MS spectrum of m/z 401.71 the [M+2H]
2+
 molecular ion for a peptide of 802.42 Da with corresponding sequence 
MAQALPR unique to SYN1. 
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4.5 Discussion  
In this study our aim was to investigate proteomic workflows to identify a suitable 
approach for deep profiling of human plasma for a biomarker discovery setting. By 
using a combination of immunodepletion, isobaric labelling and fractionation, we 
optimised a strategy that obtains reproducible metrics, wider proteome coverage and 
wider dynamic range (mg/mL – pg/mL) as well as relative quantification (OGE-9). 
This was designed all within a manageable cost effective pipeline for typical plasma 
biomarker research and could span across several research disciplines. This Chapter 
primarily focused on the content observed by each proteomic technique and the aim 
was not to investigate differential expression between clinical groups (this is 
explored further in Chapter 5). With a focus on neurological disease, we found 
evidence for brain-derived proteins (BDP) circulating in plasma as well as key 
proteins implicated in disease pathogenesis and CNS processes.   
We firstly demonstrated that the inclusion of an upfront immunodepletion step 
improves proteome coverage in complex matrices, which is in agreement with the 
majority of studies in the field 
504, 507, 521
. A commercially available immunoaffinity 
column for the depletion of albumin and IgG (Top2) has been previously shown to 
be reproducible in human plasma 
375
. In all non-fractionated and fractionated 
methodologies the Top2 depletion significantly improved protein group 
identifications compared with non-depleted samples. As expected from previous 
studies, immunodepletion methods did not fully remove their targeted proteins; 
however, this was more apparent in the Top12 depletion strategy. In our hands, a 
Top12 immunodepletion approach had little benefit in increasing protein group 
numbers in non-fractionated samples. It is possible that if greater separation was 
applied to the Top12 method the benefits could have been more apparent but this 
was not investigated. Furthermore, multi-immunocapture columns (including Top12) 
do include analytes of disease interest. Using neurodegenerative disorders as an 
example α2m 372, 374, FGγ 374, 428, CC3 436, α1-acid glycoprotein 357, apoA1 357 and 
transthyretin 
357, 429
 have all been implicated as plasma biomarkers of AD and 
routinely captured in all commercially available multi-immunocapture strategies.  
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Without pre-fractionation, protein groups in the µg/mL range are well annotated with 
sporadic sampling of the ng/mL concentration level. As with all methodologies this 
would be improved with extended liquid chromatography (LC) gradients and the 
implementation of the newest generation of MS technology 
522
. 
As expected the greater pre-fractionation of complex matrices exponentially 
increased the number of protein groups identified and therefore a lower LOD is 
achieved. On average greater fractionation demonstrated a 1.5-fold increase in 
protein identifications and a wider concentration range. Thus methodologies with 
Top2 depletion and 20 fractions were superior (1DGE-8 and OGE-9). Method OGE-
9a, outperformed 1DGE-8 at the protein level consistently identifying ~1,200 
proteins, a median protein concentration of 66ng/mL and a lower LOD of 4.3pg/mL. 
It is important to note that protein concentrations extracted from the plasma protein 
database (PPD) only represent 12% of the protein groups identified in this study. 
Therefore it is possible that protein groups of lower concentrations have been 
identified but remain unreported in terms of their level of abundance. OGE methods 
exhibited a lower spectral yield than gel-based methods. In addition, OGE 
demonstrated a more dramatic reduction in protein group identifications when 
applying a more stringent FDR to the dataset. This was seen to be driven by a large 
number of protein groups being identified with only PSM. Despite this, even at 1% 
FDR, OGE-9 returned greater number of protein group identifications with relative 
quantification than gel-based methods.      
Isobaric labelling is now a critical step in MS biomarker discovery primarily because 
of its application in measuring multiple samples in a single acquisition. This is 
fundamental to drive down cost, reduce analytical time, reduce technical variability 
and increase sample size. In addition, an experimental reference can be added for 
relative quantification and global normalisation across several experiments. An 
increase from TMT6plex to TMT10plex has been made in this study. An isobaric 
labelling strategy is less variable than other MS quantification techniques such as 
label-free, metabolic-labelling and other MS1-based quantification 
523
. When each 
sample is run individually or with limited multiplexing, an ion selected for 
fragmentation on one analytical run may not be selected consistently in subsequent 
acquisitions. This will result in inconsistent observations, affecting identification and 
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quantification. Isobaric labelling overcomes this variability as a common precursor 
ion is fragmented that corresponds to the same peptide species present in all of the 
labelled samples. Quantification is based upon the intensity of unique reporter ions 
generated for each channel (sample) and these are simultaneously measured. 
Here, two variations of isobaric labelling (peptide and protein TMT10plex) were 
investigated and a marked difference in labelling efficiency was observed. TMT 
peptide labelling efficiency quantified between 91-94% of acquired peptides whereas 
TMT protein labelling ranged between 52-57%. This under labelling at the protein 
level has been previously reported 
524
 and was also noted as a limitation in Chapter 3. 
TMT protein labelling is thought to reduce sample variability and have a more 
physico-chemically diverse separation than the derived peptides but is limited to 
labelling of lysine amino acid residues. This restricts protein digestion as well as 
quantitative coverage. Peptide spectra identified in MS/MS acquisition without 
lysine residues will be without quantitative TMT information. Therefore, without 
TMT information these peptides cannot be assigned to individual clinical sample, 
effectively making these peptide identifications irrelevant. Conversely, TMT peptide 
labelling is not restricted to a particular class of peptide and is reactive toward the 
free amino-terminus, allowing quantification of almost all peptide sequences and this 
is evident in our data. The choice of isobaric labelling therefore dictates the choice of 
fractionation that can be used. For TMT peptide labelling, fractionation commences 
after digestion and therefore gel-based techniques (1DGE and 2DGE) are unsuitable. 
Separation at the peptide level would require separation by SCX or Isoelectric 
Focusing (IEF) – IEF by OFFGEL (OGE) as investigated in this study. 
Within the plasma protein group indentifications generated by method OGE-9 we 
observed a number of analytes that are shown to be highly or exclusively expressed 
in the cerebral cortex. Protein groups that are thought to have an origin within the 
CNS are of particular interest as they may indicate loss of blood-brain barrier 
integrity 
519, 525
, neuronal injury 
363, 526-527
, protein aggregation or on-going 
neurodegeneration 
528-529
. It has also recently been shown that CNS or brain-derived 
proteins can be transported into the periphery by neuronally-derived exosomes 
530-
531
. The denaturing conditions of sample preparation required for LC-MS/MS 
methodologies would ensure that any cargo derived from these vesicles would be 
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released and detected, another key advantage over immunoassays. We demonstrated 
automated database evidence for 157 BDPs within our plasma dataset.  Of the top 30 
most exclusively expressed proteins in the cerebral cortex nine were observed in our 
plasma proteomic dataset; GFAP, OPALIN, oligodendrocyte-myelin glycoprotein 
(OMG), myelin oligodendrocyte glycoprotein (MOG), neurocan (NCAN), β-
synuclein (SNCB), brain-specific homeobox/POU domain protein 2 (POU3F2), FEZ 
family zinc finger 2 (FEZF2) and proteolipid protein 1 (PLP1). GFAP is a CNS 
specific protein that is almost entirely expressed in astroglia and has been 
highlighted as a marker of acute injury in Traumatic Brain Injury (TBI) 
532-533
. Injury 
to astroglial cells lead to release of GFAP into the extracellular matrix, which might 
increase levels in both cerebrospinal fluid and blood 
526
, this would be in parallel 
with S100B and a panel of interleukins 
534-535
 also observed within our plasma 
dataset, demonstrating the potential ability of this methodology to assess CNS 
insults. However, limited investigations into GFAP in blood have found no 
association with neurological disease or damage 
536
. OPALIN, OMG, MOG and 
PLP1 are proteins involved in the structure and integrity of the myelin sheath where 
as NCAN is reported to play a role in axon guidance and neurite growth 
537
. SNCB is 
found predominately in the pre-synaptic terminals. Highly homologous to α-
synuclein (SNCA), SNCB is thought to inhibit SNCA aggregation and therefore may 
protect the CNS from the toxic effects of SNCA. To our knowledge, these markers 
(not GFAP) have yet to be described in blood however replication in an independent 
dataset is of importance due to low number of matched PSMs. However, after 
manual inspection of the MS/MS spectra, OMG, NCAN and FEZF2 were seen to be 
not of sufficient quality for a positive identification. Additionally, a further 29/157 
BDPs database matched in our plasma dataset were classified as falsely identified 
after manual MS/MS inspection. Other protein groups hypothesised to reflect brain 













, and NEFL 
363, 526
 are all observed within our plasma dataset. 
Proteins implicated in neurodegenerative pathogenesis have also been detected in 
this study. Although plasma expression of Aβ, MAPT, SNCA, SOD1 and others 
have been observed in plasma previously by immunoassay or MS studies we 
demonstrate a methodology that will simultaneously detect peptides from these 
protein groups in the same subjects in the same experiment. Further to this, pathway 
analysis of the best performing proteomic methodology (OGE-9) revealed over-
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representation of protein groups related to specific neurodegenerative diseases and 
CNS pathways. The neurotrophin signalling pathway is involved in differentiation 
and survival of neural cells plus a significant role in high-order functions such as 
learning and memory. This pathway is regulated by the MAPK signalling pathway, 
which is also over-represented in OGE-9 plasma protein group dataset. Although this 
analysis does not identify a change in plasma protein expression between two 
differing phenotypes it does indicate that CNS specific protein groups and pathways 
can be measured in plasma if the correct methodology is applied. 
The use of OFFGEL (OGE) fractionation, combined with immunodepletion and 
TMT10plex peptide labelling has shown to be a sensitive workflow for 
comprehensive plasma exploration. Proteins of medium and high abundance have 
excellent protein coverage and reproducibility. This method also demonstrates 
peptides derived from proteins of low abundance (<100 pg/mL) and although 
consistent in their measurement across biological repeats, this method may not 
reflect an accurate plasma expression due to variable sequence coverage. 
Nonetheless, this dataset is an indication that low abundant BDPs are circulating in 
plasma with a significant number related to synaptic processes and neuronal injury. 
These proteins would be prime targets to predict CNS insults in the periphery and 
should be further validated and then investigated by an ultra-sensitive targeted assay. 
The identifications reported in this study are largely based on automated database 
searching with cut-offs defined by false discovery rates. Routine practice 
recommends manual examination of assigned spectra for a protein in question or of 
interest; the peptide sequence would typically be confirmed by the presence of an 
overlapping series of b and y ions. This is of paramount importance in discovery 
experiments when considering protein groups identified by relaxed FDR’s or limited 
PSMs. The results reported here are all at 5% FDR and this does increase the 
chances of falsely assigned spectra. However a more stringent biomarker discovery, 
particularly when subtle changes in novel candidates are anticipated, has the 
potential to overlook disease related changes. Manual MS/MS spectra interrogation, 
replication in multiple samples, cohorts and targeted assays are essential to confirm 
identification and expression change.  
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TMT10plex labelling requires a superior level of MS resolution than TMT6plex 
labelling. This is needed to identify TMT reporter channels with only 0.0006 Da 
mass differences, which currently increases MS and MS/MS survey scanning. 
Further developments in mass spectrometer technology continue to improve 
sensitivity and scan rates thereby increasing MS/MS events in a defined period of 
time. This will lead to the detection of more PSMs so that overall experimental 
coverage of a sample is enhanced. This is important in relation to this study because 
sequence coverage of each protein, particularly those of low abundance of 1-2 PSMs, 
can be improved giving more accurate expression levels in relation to disease.  
4.5.1 Conclusions 
In this study, we have highlighted a methodology for plasma protein profiling that 
utilises isobaric TMT10plex peptide labelling, simple immunodepletion and 
OFFGEL fractionation coupled to LC-MS/MS (OGE-9; Figure 4-1). The main aim 
was to maximise proteome coverage, increase concentration range and increase cost 
effective throughput for plasma biomarker research and this has been achieved. 
Using this technique, we can identify >1200 proteins at 5% FDR within a single 
TMT10plex experiment, with relative quantification of >92%. OGE-9 also 
demonstrates a broad dynamic range covering the “classic proteome” with coverage 
of protein proteins within ng/mL and pg/mL region. We have highlighted the 
potential of this method in a neurological setting by identifying a number of brain-
derived proteins, some of which are established markers of neuronal and synaptic 
injury, as well as proteins involved in the pathogenesis of neurodegenerative disease 
circulating within blood. This technique has utility for a range of disease conditions 
and even differing bio-fluids. It could also serve as a “point of interest” reference set 
of what is present in blood for future targeted investigations  
The application of this in-depth profiling methodology will determine if further 
observations can be made between disease phenotypes of AD risk within blood 
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CHAPTER 5  
A MASS SPECTROMETRY-BASED DISCOVERY AND 
REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR 
NEOCORTICAL AMYLOID PATHOLOGY 
 
5.1 Introduction 
Chapter 3 outlined a typical LC-MS/MS proteomic approach that was shown to be a 
particularly useful discovery tool in highlighting plasma biomarkers that are related 
to NAB. Whilst the study produced replicated candidates for predicting Aβ, there 
were limitations that restricted this initial discovery from having further impact. 
Firstly, almost up to 50% of protein groups indentified using this technique could not 
be quantified due the nature of isobaric protein labelling. Even if this was addressed, 
the sensitivity of the workflow could still only report coverage of the “classical 
plasma proteome”. Current hypotheses indicates that biomarkers of disease relevance 
in plasma, particularly of CNS disorders, would mostly be located at the “tissue 
leakage” level (pg/mL – ng/mL) 501. Indeed, levels of Aβ1-42 and p-tau reported by 
immunoassays are estimated to be at picogram level in blood 
359, 377
. More recently, 
CNS proteins (e.g. S100B) have been described at the picogram level in plasma as a 
hypothesised response to BBB impairment 
519, 541
. 
A methodological review of the latest LC-MS/MS proteomic pipelines in Chapter 4 
highlighted a strategy that incorporated high-resolution peptide separation, 
immunodepletion and isobaric peptide labelling (OGE-9). This workflow was shown 
to dramatically increase the number of quantifiable targets and widen plasma 
proteome coverage over all other strategies. Furthermore, it was shown that a subset 
of protein groups identified in plasma had considerable, in some cases exclusive, 
cerebral cortex expression or involvement in neurodegenerative pathogenesis. Given 
these results it is essential to utilise this approach in independent and well 
characterised cohorts, not only to validate findings from Chapter 3 but also to 
discover novel candidates relating to NAB given the improved sensitivity.  
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Chapter 3 also demonstrated the difficulty of translating findings from MS-based 
platform to an orthogonal immunoassay approach. Only 3/17 targets replicated from 
an MS platform to an ELISA approach and it cannot be determined if this was 
because of a false association in the LC-MS/MS discovery or simply the difference 
in proteomic platform. It is inevitable that an immunoassay, similar to an ELISA 
platform, will be at the basis for any future biomarker clinical testing for AD. 
However, in this study, to minimise candidate rejection due to platform variation we 
choose to use an identical LC-MS/MS platform in discovery and replication. As 
previously, this approach was applied to plasma samples from individuals with 
concurrent Aβ PET imaging; discovery (AIBL-2; 11C-PiB) and replication 
(KARVIAH; 
18
FBB). Given the recent focus towards therapeutic intervention at the 
preclinical stages 
218, 470
 the cohorts utilised in this study were more focused toward 





To investigate further plasma proteins predictive of Aβ burden using the improved 
proteomic strategy established in Chapter 4 (Figure 5-1). Furthermore, our dataset 
will be mined to replicate the plasma expression of brain-derived proteins than have 
been previously described, and where possible, relate to Aβ burden. Lastly, we will 
attempt to relate this generated data to further replicate LC-MS/MS candidates 
highlighted in Chapter 3.  
Univariate analysis will be performed to describe single plasma proteins that are 




FBB), and confounding variables by either correlation or a binary 
endophenotype approach. Multivariate analysis will include least absolute shrinkage 
and selection operator (LASSO) as a variable reduction tool and support vector 
machine learning to build a predictive model of elevated Aβ in a discovery cohort 




5.3 Methodology Overview  
The proteomic workflow utilised in this Chapter is outlined in detail in Figure 5-1. 
This method has been shown to produce a superior coverage of the plasma proteome 
over other conventional proteomic methodologies (Chapter 4). This was in terms of 
protein group numbers and identification of low abundant proteins with almost 
complete relative quantification. The detailed methodological protocols for each 
procedure are outlined in Chapter 2.6. 
Plasma samples (30µL) were immunodepleted of albumin and IgG’s prior to 
enzymatic digestion of 100µg of protein from each depleted sample.  Increased 
sample throughput and relative quantification was achieved by TMT10plex peptide 
labelling, using a dynamic global study reference. Each TMT10plex was randomly 
assigned to nine clinical samples, which was a mixture of both cohorts utilised in this 
study (AIBL-2 and KARVIAH). Unlike previous studies the study reference was 
assigned a random TMT label within each TMT10plex. Peptide based fractionation 
was achieved by isoelectric focusing using the OFFGEL system (OGE). A total of 
1mg of digested protein material from the combined clinical samples was separated 
by the OGE system. TMT10plex labelled peptide fractions were focused for 50 kwh 
and collected in 24 fractions. Peripheral fractions were combined to create 20 
peptide fractions for LC-MS/MS acquisition. This was repeated for 32 TMT10plex’s 
which comprised 284 plasma samples. The resulting peptide fractions were analysed 
separately on a Thermo Scientific LTQ Orbitrap Velos instrument for 115 minutes. 
Raw data acquired was processed in Proteome Discoverer (ver. 1.4) for protein 
group/peptide identification and quantification using Mascot and Sequest 
sequentially.   
Plasma samples were obtained from the Australian Imaging, Biomarkers and 
Lifestyle Flagship Study of Ageing imaging sub-cohort (AIBL-2) and McCusker 





Figure 5-1: Methodological Overview: Schematic flow diagram represents the 
proteomic workflow applied to the AIBL-2 and KARVIAH cohorts in Chapter 5. 
  
Plasma samples (30µL) 
Immunodepletion
(ProteoPrep Immunoaffinity Albumin and IgG 
Depletion Kit )
TMT10plex peptide labelling
OGE Fractionation (1mg) 
(24 fractions)
Digestion (100µg)





5.4.1 Demographic characteristics (AIBL-2 and KARVIAH) 
In this study, participants were selected from the Australian Imaging, Biomarkers 
and Lifestyle Flagship Study of Ageing imaging sub-cohort (AIBL-2). AIBL-2 
subjects are different from the AIBL-1 cohort examined in Chapter 3. Furthermore, 
participants from the McCusker Kerr Anglican Retirement Village Initiative in 
Ageing Health Research Centre (KARVIAH) were also utilised. Individuals from 
both cohorts must have undergone Aβ PET at baseline, cognitive assessment 
(MMSE) and APOE genotyping to be included in the study. Furthermore, the AIBL-
2 cohort had longitudinal Aβ PET and cognitive information. To classify NAB as 
positive (Aβ+) or NAB negative (Aβ-) individuals, a study specific SUVR cut-off of 
>1.5 was set for Aβ+ in the AIBL-2 cohort whereas an SUVR cut-off of >1.35 was 
used for Aβ+ the KARVIAH cohort. The difference in SUVR cut-offs is due to the 




FBB) tracer whereas the AIBL-2 
participants were imaged using the “gold standard” 11C-PiB. 18FBB and 11C-PiB 





FBB has been shown to be more sensitive in discriminating other dementias 
from AD 
233, 465
.    
The distribution of SUVR’s can be seen in Figure 5-2. In contrast to Chapter 3, an 
extreme endophenotype approach was not employed but a more continuous 
assessment of SUVR was examined. Consistent with Chapter 3, the greater 
variability in SUVR was found in the Aβ+ group (range = 1.35 – 3.18) whereas the 
Aβ- SUVR ranged from 0.97 – 1.44. Given the overlap in SUVR ranges, due to Aβ 




Figure 5-2: Scatter plot demonstrating the distribution of PET SUVR for the AIBL-2 
and KARVIAH imaging cohorts. The individual SUVR values are coded by Aβ 
classification; Aβ- (blue) or Aβ+ (green). KARVIAH subjects underwent 18FBB 
imaging rather than 
11
C-PiB. KARVIAH subjects classified as Aβ+ but are below the 
11
C-PiB threshold for Aβ+ (>1.5) are displayed in red.   
AIBL-2 and KARVIAH individuals were enriched for cognitively healthy 
individuals (83.5%) for the investigation of preclinical NAB. Although a small 
variation in MMSE, the KARVIAH cohort (n = 94) is clinically defined as 
cognitively normal (HEC). A small proportion of participants from AIBL-2, defined 
clinically as MCI (7.5%) or AD (8.9%), were also included in the study (Figure 5-3). 
The demographic information for the 284 subjects examined in this study is 
















Figure 5-3:  Scatter plot demonstrating the distribution of PET SUVR for the AIBL-2 
and KARVIAH imaging cohorts. The individual SUVR values are coded by clinical 
diagnosis; HEC (Healthy elderly controls, blue), MCI (green) and AD (red). 
Table 5-1: Subject demographics for participant’s classified as Aβ+ or Aβ- by PET 







Number of subjects (n) 170 114 
 
Aβ PET SUVR (mean (S.D)) 1.16 (0.09) 1.99 (0.41) 9.30 x10-76 
Gender; females (n (%)) 95 (56.5) 60 (53.5) 0.624 
Age in years (mean (S.D)) 73.73 (6.94) 75.79 (7.54) 0.036 
Clinical diagnosis (n (%)) 
HEC: 161 (94.7) 
MCI: 8 (4.7) 
AD: 1 (0.6) 
HEC: 77 (67.5) 
MCI: 13 (11.2) 
AD: 24 (21.3) 
1.36 x10
-5 
APOE ε4 carrier (n (%)) 45 (26.5) 68 (59.6) 4.56 x10-4 
MMSE (mean (S.D)) 28.26 (1.42) 26.79 (3.63) 9.30 x10-4 
Abbreviations: HEC, Healthy elderly control; MCI, Mild cognitive impairment; AD, Alzheimer’s 















All subjects were matched for gender but were significantly different in age (P = 
0.036, Table 5-1). As expected, there was a bias towards an AD clinical diagnosis in 
the Aβ+ group (Table 5-1, Figure 5-3). With a larger number of AD subjects present 
in the Aβ+ group, it is expected that a significantly lower MMSE (P = 9.30 x10-4) 
and a greater number APOE ε4 carriers (P = 4.56 x10-4) would be observed (Table 5-
1). However, when examining the HEC group separately (Table 5-2) there is no 
difference between MMSE when comparing Aβ+ and Aβ- groups (P = 0.261) but 
still a highly significant difference in APOE ε4 carriers remains (P = 3.34 x10-4). 
This difference between the two groups needs to be accounted for when interpreting 
the results of the study. 
Table 5-2: Subject demographics for healthy elderly controls (HEC) only participant’s 








Number of subjects (n) 161 77 
 
Aβ PET SUVR (mean (S.D)) 1.16 (0.09) 1.82 (0.27) 9.30 x10-54 
Gender; females (n (%)) 91 (56.5) 42 (54.4) 0.522 
Age in years (mean (S.D)) 73.3 77.3 0.008 
APOE ε4 carrier (n (%)) 34 (21.1) 41 (53.2) 3.34 x10-4 
MMSE (mean (S.D)) 29.2 28.9 0.261 
Abbreviations: HEC, Healthy elderly control; SUVR, Standardized uptake values ratio; S.D; 
Standard deviation; MMSE, Mini mental state examination. 
There is a significantly higher Aβ SUVR in the AIBL-2 cohort (P = 0.001) and a 
significantly lower MMSE in AIBL-2 (P = 0.017; Table 5-3). This is likely due to all 
AD and MCI individuals being from AIBL-2 and a higher percentage of APOE ε4 
carriers in AIBL-2 (Table 5-3). Despite this, there was no statistical difference in the 
proportion of Aβ+ subjects recruited into this study between the two cohorts (P = 
0.445). The subjects in the KARVIAH cohort were seen to be substantially older 
than AIBL-2 (P = 1.07 x10
-7
). Once more, these cohort differences need to be 
considered when looking for protein differences between Aβ+ and Aβ- subjects. 
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Table 5-3: Subject demographics for participants separated by cohorts; AIBL-2 (n = 
190) and KARVIAH (n = 94) imaging cohorts. 
 









Number of subjects (n) 190 94 
 
Aβ Classification; Aβ+ (n (%)) 79 (41.58) 35 (37.24) 0.445 
Aβ PET SUVR (mean (S.D) ) 1.60 (0.54) 1.36 (0.31) 0.001 
Gender; females (n (%)) 94 (49.49) 61 (64.89) 0.022 
Age in years (mean (S.D)) 72.41 (7.35) 78.26 (5.47) 1.07 x10-7 








APOE ε4 carrier (n (%)) 82 (43.15) 21 (22.34) 0.001 
MMSE (mean (S.D)) 27.62 (3.10) 28.43 (1.48) 0.017 
Abbreviations: HEC, Healthy elderly control; MCI, Mild cognitive impairment; AD, Alzheimer’s 
disease; SUVR, Standardized uptake values ratio; S.D; Standard deviation; MMSE, Mini mental state 
examination. 
5.4.2 Protein/peptide metrics  
Our refined plasma proteomic methodology and subsequent LC-MS/MS acquisition 
(Figure 5-1) was performed on plasma samples from 284 subjects from the AIBL-2 
and KARVIAH imaging cohorts, whose full demographics are shown in Table 5-1 
and Table 5-3. Thus each sample followed a proteomic methodology which 
incorporated immunodepletion, TMT10plex peptide labelling and fractionation by 
isoelectric focusing (OGE). The 284 plasma samples were measured in 32 
“TMT10plex groups” (9 clinical samples and 1 study reference). Each TMT10plex 
was fractionated into 20 peptide fractions which were individually analysed by an 
LTQ Orbitrap MS. The number of MS/MS events demonstrated in Table 5-4 
indicates that sample preparation and instrument performance was consistent across 
all experiments.   
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Table 5-4: The number of MS/MS events acquired for each TMT10plex group. Each 
TMT10plex included 9 clinical samples from the AIBL-2 or KARVIAH imaging 




  TMT1 189476 TMT17 170045 
TMT2 148265 TMT18 152142 
TMT3 158778 TMT19 166534 
TMT4 220465 TMT20 166408 
TMT5 186761 TMT21 166851 
TMT6 186761 TMT22 166851 
TMT7 158968 TMT23 180740 
TMT8 159488 TMT24 158102 
TMT9 162580 TMT25 184533 
TMT10 167061 TMT26 165384 
TMT11 161896 TMT27 169418 
TMT12 166723 TMT28 173620 
TMT13 170909 TMT29 174372 
TMT14 144403 TMT30 168967 
TMT15 169559 TMT31 174206 






Variation (CV %) 
169723.2 13934 8.21 
 
We also examined the number of protein groups, peptides, PSMs and spectral yield 
rates of each TMT10plex group at 5% FDR (Table 5-5). In contrast to Chapter 3, due 
to peptide fractionation and not protein fractionation being utilised, each peptide 
identified for a unique protein group was combined to create one protein group score 
regardless of the fraction it was obtained from. On average 1,711 protein groups 
were measured per TMT10plex group and this was moderately consistent across all 
10plex’s (CV = 16.04%, Table 5-5). There was considerable variation in the number 
of PSMs measured and this was also reflected in the spectral yield. TMT10plex 
groups 4, 30, 31 and 32 demonstrated PSMs >70,000 and spectral yields of >3.5, this 
was significantly greater than the mean of the data (Table 5-5). However, this greater 
number of PSMs and spectral yield did not translate to a significantly greater number 
of protein groups.  
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Table 5-5: The performance of each TMT10plex by number of protein groups, 










TMT1 1615 4556 52218 0.28 
TMT2 1377 3536 28520 0.19 
TMT3 1665 3964 33026 0.21 
TMT4 2164 6667 76239 0.35 
TMT5 1510 3814 30408 0.16 
TMT6 1510 3814 32897 0.18 
TMT7 1472 3586 29408 0.18 
TMT8 1941 4981 30064 0.19 
TMT9 1933 4800 29897 0.18 
TMT10 2170 5656 36044 0.22 
TMT11 1763 4081 33443 0.21 
TMT12 1757 4257 33137 0.2 
TMT13 1852 4292 39375 0.23 
TMT14 2117 5355 34059 0.24 
TMT15 1906 4673 38994 0.23 
TMT16 2244 5690 36694 0.21 
TMT17 2055 5102 33468 0.2 
TMT18 1969 4835 31666 0.21 
TMT19 1560 3899 34744 0.21 
TMT20 1823 4626 36320 0.22 
TMT21 1913 4636 31135 0.19 
TMT22 1276 4008 48451 0.29 
TMT23 1315 4635 41456 0.23 
TMT24 1445 4953 42180 0.27 
TMT25 1810 4451 37490 0.2 
TMT26 1316 4699 45321 0.27 
TMT27 1480 4242 47360 0.28 
TMT28 1443 4288 43682 0.25 
TMT29 1451 4801 49144 0.28 
TMT30 1865 5543 74788 0.44 
TMT31 1919 5526 79463 0.46 
TMT32 1860 5578 75008 0.44 
Mean 1734.25 4673.71 41830.25 0.25 
Standard Dev. 278.82 712.26 14847.88 0.08 
Coefficient of 
Variation (CV %) 





In total, 12,572 unique proteins groups at 5% FDR were identified across all 32 
TMT10plex’s. However, these protein groups were not observed across all 
TMT10plex groups. With the increased numbers of samples analysed in this study 
compared with the method development phase (Chapter 4), it was shown that a large 
proportion of protein groups were identified in <50% of subjects (Figure 5-4). 
 
Figure 5-4: Bar chart to represent the frequency of identified protein groups in this 
study.  
For the association of plasma proteins with NAB, only protein groups observed in 
>50% of the data (n = 1,085) were taken forward for further investigation. The full 
list of proteins groups investigated (shown as gene names) are listed in Appendix 4.  
5.4.3 Generation of protein residuals by a generalised linear model (GLM)  
All protein group ratios were log10 transformed to achieve normal distribution. 
Shaprio-Wilks normality tests (P >0.05) and a visual inspection of their histograms 
with Q-Q plots demonstrated that a large majority of the 1,085 protein groups still 
maintained a non-normal distribution. Therefore, further analyses utilised non-
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Covariates investigated included age, gender, cohort and technical variance. Firstly, 
before investigating covariates associated with the sample demographics, technical 
variation was investigated by principle component analysis (PCA). Scatter plot 
(Figure 5-5) demonstrated a clustering of TMT10plex groups, which would have a 
significant effect on protein ratios. A number of experimental factors are connected 
with TMT10plex group; OGE fractionation date, TMT labelling date and date of MS 
acquisition which are subject to significant variation. Therefore, an initial GLM 
correcting for only TMT10plex group was performed before investigating the effect 
of other covariates on protein group ratios (Figure 5-6). 
 
Figure 5-5: PCA analysis demonstrating the association of protein ratios with 
TMT10plex groups. Four examples of TMT10plex clusters are highlighted; TMT 
group 27 (green), TMT group 13 (orange), TMT group 25 (blue) and TMT group 11 
(purple).   
 
Figure 5-6: PCA analysis demonstrating the association of protein ratios with 















































Residuals generated from the GLM (correcting for TMT10plex group variance; 
Figure 5-6) were then used to investigate other potential covariates. Table 5-6 shows 
the number protein groups that were significantly associated (uncorrected P value 
<0.05) with gender, age and cohort. We found that a substantial number of protein 
groups were significantly affected by these covariates. Using a Mann Whitney-U 
test, sample cohort (Table 5-7) and gender (Table 5-7) were associated with 17.06% 
and 15.86% of all protein groups respectively. Participant age (Table 5-9) was 
correlated with 9.85% of the total protein groups with a Spearman Rank Correlation. 
Therefore, a GLM model was reapplied to the original ratios to adjust the data for 
TMT10plex group with the addition of gender, age and sample cohort.  
Table 5-6: The number of protein groups (n) associated with covariates (gender, age 
and cohort) at the uncorrected P value <0.05. A percentage (%) of the total number 
protein groups (n = 1,085) associated with covariates is also shown. 
Covariate n % 
Gender 172 15.86% 
Age 104 9.85% 











Table 5-7: Protein groups ranked by significance (shown as gene names) associated 
with sample cohort differences at the uncorrected P value <0.05. 
Gene Name t df P value 
    ACTB -4.611 282 6.00 x10-06 ABHD10 2.447 178 0.015 
AK -3.651 185 4.57 x10-05 HOXD3 -2.431 210 0.016 
FN1 -5.373 282 4.20 x10-04 MAP3K7 2.433 184 0.016 
STXBP3 4.028 185 4.70 x10-04 MST1 2.431 238 0.016 
TPM3 -4.96 239 5.20 x10-04 TARBP1 2.418 220 0.016 
TPM4 -3.742 211 9.85 x10-04 UACA 2.423 164 0.016 
CDKL2 -3.441 185 0.001 CFHR1 2.401 282 0.017 
NRGN -3.312 274 0.001 MFN1 -2.408 150 0.017 
THG1L 3.256 213 0.001 MICALL2 -2.407 190 0.017 
CFD 3.16 282 0.002 CENPF -2.384 208 0.018 
KRT13 -3.137 210 0.002 FGA -2.334 282 0.02 
F9 3.038 282 0.003 PON3 -2.321 273 0.021 
RAB3GAP2 -2.995 238 0.003 GSE1 -2.271 157 0.024 
EPRS -2.867 265 0.004 IGHG2 -2.252 282 0.025 
KIAA1731 -2.882 168 0.004 C1QB 2.237 282 0.026 
AMBP 2.822 282 0.005 IGFBP3 2.244 239 0.026 
CDH13 -2.844 158 0.005 PPFIBP2 -2.246 172 0.026 
CFP 2.854 264 0.005 FUT8 2.224 185 0.027 
RELA -2.82 177 0.005 PROS1 2.215 282 0.028 
C4BPB 2.764 228 0.006 CDH5 -2.209 167 0.029 
RIMS2 -2.783 211 0.006 CEP290 2.182 176 0.03 
ZNF93 -2.761 158 0.006 RFC4 -2.186 178 0.03 
FCN2 -2.746 141 0.007 PON1 -2.156 282 0.032 
HSP90AA5P -2.729 282 0.007 ANKRD36B 2.145 150 0.034 
KIF4B 2.712 247 0.007 ASH1L 2.141 176 0.034 
MTFMT -2.724 248 0.007 APOB -2.121 282 0.035 
EPPK1 -2.673 238 0.008 IGLC3 2.109 273 0.036 
FGG -2.652 282 0.008 FGB -2.099 282 0.037 
EPB41 -2.631 168 0.009 SHBG -2.091 269 0.037 
RBP4 2.645 282 0.009 SLC16A10 -2.088 175 0.038 
KIAA0753 -2.594 161 0.01 SNX15 -2.09 218 0.038 
NDUFAF6 2.597 165 0.01 SYTL2 -2.089 150 0.038 
APOH 2.569 282 0.011 APOC4 2.065 220 0.04 
RLTPR -2.572 167 0.011 C1orf222 -2.074 167 0.04 
SRRM1 2.566 239 0.011 PCNX -2.048 238 0.042 
ULK2 -2.573 141 0.011 C1S 2.029 282 0.043 
C1R 2.5 282 0.013 FARSB 2.017 141 0.046 
HECTD4 2.508 175 0.013 SYNE2 2.001 259 0.046 
PPBP 2.499 282 0.013 FAM186A 1.981 205 0.049 
VEZT -2.491 175 0.014 
 
   Abbreviations: df, degree of freedom. 
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Table 5-8: Protein groups ranked by significance (shown as gene names) associated 
with participant gender at the uncorrected P value <0.05. 
Gene 
Name 
t df P value 
    STX11 -3.929 274 1.08 x10-04 KIF16B -2.22 256 0.027 
CDK1 3.313 255 0.001 SERPING1 2.222 282 0.027 
KRT222 3.431 213 0.001 KIF21B 2.215 141 0.028 
TRRAP -2.96 176 0.003 BIRC6 -2.195 214 0.029 
CD5L 2.942 282 0.004 LRP1B -2.193 167 0.03 
NPY5R -2.862 248 0.005 TPM4 -2.181 211 0.03 
RB1CC1 -2.836 141 0.005 APOA2 2.162 282 0.031 
FAM81A -2.771 221 0.006 D2 -2.171 204 0.031 
VTN -2.786 282 0.006 ZFC3H1 -2.178 186 0.031 
SIPA1L1 -2.727 164 0.007 DKFZp571N1833 -2.151 203 0.033 
CFHR5 2.681 203 0.008 FCN3 2.128 282 0.034 
MAP2 -2.691 264 0.008 GPSM2 2.136 169 0.034 
TPM3 -2.69 239 0.008 DZIP3 2.114 273 0.035 
HCN2 2.614 168 0.01 GC 2.12 282 0.035 
NCOR2 -2.592 220 0.01 ANK3 -2.118 155 0.036 
DEFA1 -2.569 282 0.011 GFAP -2.102 282 0.036 
RELA -2.586 177 0.011 LRSAM1 -2.114 173 0.036 
IGHM 2.527 282 0.012 SERPI3 2.104 282 0.036 
RG2 -2.534 157 0.012 EIF5B -2.102 163 0.037 
TRAK1 -2.491 221 0.013 CHD5 2.084 194 0.038 
INTS3 2.464 282 0.014 SLC16A10 2.087 175 0.038 
FGA -2.421 282 0.016 VIPAS39 2.094 158 0.038 
NEK3 2.399 274 0.017 DST -2.075 264 0.039 
PIBF1 2.387 282 0.018 NRAP 2.08 247 0.039 
IGKC 2.353 282 0.019 CROCC 2.057 237 0.041 
BLOC1S6 2.352 211 0.02 RAB3GAP2 -2.039 238 0.043 
LRP12 -2.349 264 0.02 C1QC 2.027 221 0.044 
MASP2 -2.356 151 0.02 SCN2A -2.016 168 0.045 
APOB 2.329 282 0.021 ATRN 2.006 282 0.046 
GMFG -2.327 282 0.021 BAZ2B -2.007 195 0.046 
CNNM4 2.305 165 0.022 DAPK1 -2.012 168 0.046 
FN1 -2.255 282 0.025 REST -1.991 282 0.047 
TRIL -2.259 150 0.025 ORM2 1.987 282 0.048 
TTC7B -2.265 176 0.025 PCDHB15 -1.967 222 0.05 
C2 2.229 280 0.027 SNCA -1.97 274 0.05 
HMBOX1 2.24 140 0.027 
    




Table 5-9: Protein groups ranked by significance (shown as gene names) correlating 






   
APOL1 -0.209 2.31 x10-4 SLC16A10 -0.175 0.02 
C7 0.215 2.59 x10-4 VEZT -0.175 0.02 
ABHD10 0.271 3.83 x10-4 ZC3H13 -0.166 0.021 
CFD 0.187 0.002 MUC12 0.172 0.021 
AMBP 0.177 0.003 ACTB -0.136 0.022 
EPB41 -0.226 0.003 EPRS -0.139 0.023 
CDH13 -0.231 0.003 KRT20 -0.133 0.025 
CASC2 0.201 0.006 ZNF106 -0.166 0.025 
HECTD4 0.201 0.007 APOC3 -0.13 0.029 
KIAA0753 -0.206 0.008 TPM3 -0.141 0.029 
DENND3 -0.199 0.01 RELA -0.163 0.029 
ULK2 -0.216 0.01 SERPI6 -0.128 0.031 
MAPK9 -0.18 0.013 TPM4 -0.146 0.033 
KRT18 0.2 0.013 HAUS3 -0.172 0.034 
TXLNG -0.209 0.013 APOB -0.125 0.036 
GSE1 -0.195 0.014 CA5A -0.142 0.037 
SERPINF2 -0.144 0.015 FN1 -0.123 0.039 
IGKC 0.144 0.015 CD163 0.172 0.041 
SPHKAP -0.174 0.015 APOH 0.117 0.048 
FMN2 0.159 0.016 IGLC3 0.119 0.049 
RIMS3 0.144 0.017 CADPS2 -0.116 0.05 
LRSAM1 0.178 0.019 
   
Abbreviations: df, degree of freedom. 
We also examined our GLM adjusted protein group data for association with APOE 
status. As APOE genotype is itself highly correlated with AD and APOE ε4 variants 
influence the clearance of Aβ, it is possible that differences can be entirely or largely 
due to differences in APOE genotype. It was found that 46 protein groups were 
associated with APOE genotype (Table 5-10). This included proteins related to Aβ 
(Amyloid beta A4 protein (Aβ) and amyloid beta A4 precursor protein-binding 
family B member 3 (APBB3)) and the apoE protein itself. ApoE was found to be 
significantly lower in ε4 carriers (P = 0.013). APOE genotype was not included in 
the GLM model because of its contribution in AD. However protein groups found to 
be associated with APOE genotype (Table 5-10) were separately investigated with 
APOE genotype as a covariate.      
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Table 5-10: Protein groups ranked by significance (shown as gene names) associated 
with APOE genotype at the uncorrected P value <0.05. 
Gene name t df P value 
    
NEFL -3.755 256 0.001 BROMI 2.416 194 0.017 
NBEA 3.766 150 0.001 ASPM 2.393 229 0.018 
APP -3.253 282 0.001 TBC1D32 2.389 194 0.018 
APBB3 -3.389 273 0.001 B2M 2.342 247 0.02 
EPPK1 3.277 238 0.001 ABCA6 2.345 174 0.02 
SYTL2 3.28 150 0.001 CEP250 -2.346 167 0.02 
HECTD3 3.276 148 0.001 FGB 2.315 282 0.021 
HABP2 3.039 282 0.003 STXBP3 -2.263 185 0.025 
TMEM131 2.969 155 0.003 DNM3 2.213 159 0.028 
SLBP 2.936 193 0.004 KANSL1 2.207 146 0.029 
KRT1 -2.858 282 0.005 FN1 2.108 282 0.036 
DYNC1H1 -2.724 220 0.007 IL18RAP -2.109 273 0.036 
TRIP11 2.716 194 0.007 HLTF 2.111 168 0.036 
CSDE1 -2.642 256 0.009 KLKB1 2.094 282 0.037 
APOE 2.489 282 0.013 STX11 -2.102 274 0.037 
OBSCN 2.51 202 0.013 AKNA 2.102 185 0.037 
NEUROG2 -2.469 273 0.014 ANKRD36B 2.054 150 0.042 
NEK3 2.44 274 0.015 ATRN 2.03 282 0.043 
KRT9 -2.449 189 0.015 FAN1 2.044 173 0.043 
EPRS 2.435 265 0.016 REV3L -2.046 147 0.043 
KRT8 -2.428 150 0.016 A2M 1.996 282 0.047 
LGALS3BP 2.412 282 0.017 BLOC1S6 1.978 211 0.049 
KRT10 -2.407 282 0.017 FUT8 -1.985 185 0.049 
Abbreviations: df, degree of freedom. 
5.4.4 Plasma proteins correlating with Aβ SUVR as continuous measure  
Spearman Rank Correlations were performed to associate the GLM adjusted values 
of 1,085 protein groups with Aβ SUVR as a continuous measure. A total of 57 
protein groups were found to be significantly associated with SUVR at the 
uncorrected P value of <0.05 (Table 5-11). After multiple testing correction (FDR), 
seven protein groups demonstrated a Q value of <0.1 (amyloid beta A4 protein (Aβ), 
neurofilament light polypeptide (NEFL), neurogenin-2 (NEUROG2), amyloid beta 
A4 precursor protein-binding family B member 3 (APBB3), V-type proton ATPase 
116 kDa subunit (ATP6V0A2), rootletin (CROCC) and isoform 4 of RE1-silencing 
transcription factor (REST). A positive correlation with Aβ SUVR was observed for 
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Aβ, NEFL, NEUROG2, APBB3 and ATP6V0A2 with negative association with 
observed for CROCC and REST (Table 5-11).  
A partial correlation, adjusting for APOE genotype, was only performed on protein 
groups associated with Aβ SUVR that were also previously seen to be influenced by 
APOE genotype (Table 5-10). After adjustment for APOE, seven protein groups 
remained significantly correlated at the uncorrected P value <0.05 with Aβ, NEFL 
and NEUROG2 remaining significant after FDR multiple testing correction.  A total 
of eight protein groups found to be associated with Aβ SUVR lost significance at the 
uncorrected P value <0.05 suggesting that their significance with Aβ was driven by 









Table 5-11: Protein groups significantly associated with Aβ SUVR as a continuous measure (using a Spearman’s Rank Correlation). GLM residuals 
were adjusted for TMT10plex group, age, gender and sample cohort. A partial correlation co-varying for APOE genotype for APOE associated 




Spearman Rank Correlation 
with SUVR 
Partial Correlation with SUVR 






n Rho P value Q value 
Partial 
Correlation 
P value Q value 
P05067 amyloid beta A4 protein (Aβ) APP 284 0.286 1.05 x10-06 5.87 x10-04 0.233 7.50 x10-05 0.024 
P07196 neurofilament light polypeptide (NEFL) NEFL 258 0.29 2.46 x10-06 6.88 x10-04 0.223 3.15 x10-04 0.059 
Q9H2A3 neurogenin-2 (NEUROG2) NEUROG2 275 0.272 5.28 x10-06 9.84 x10-04 0.235 8.63 x10-05 0.024 
O95704 
amyloid beta A4 precursor protein-binding 
family B member 3 (APBB)) 
APBB3 275 0.24 6.59 x10-05 9.21 x10-03 0.177 0.003 0.152 
Q9Y487 
V-type proton ATPase 116 kDa subunit 
(ATP6V0A2)  
ATP6V0A2 143 0.292 3.19 x10-04 3.57 x10-02 
   
Q5TZA2 rootletin (CROCC) CROCC 239 -0.216 0.001 0.080 
   
Q13127 
isoform 4 of RE1-silencing transcription 
factor (REST) 
REST 284 -0.19 0.001 0.080 
   
Q14520 hyaluronan-binding protein 2 HABP2 284 -0.188 0.002 0.124 -0.129 0.030 >0.200 
Q8IVF4 dynein heavy chain 10, axonemal DNAH10 240 0.202 0.002 0.124 
   
P29597 non-receptor tyrosine-protein kinase TYK2 239 -0.188 0.004 0.186 
   
P42356 phosphatidylinositol 4-kinase alpha PI4KA 160 -0.228 0.004 0.186 
   
P15924 desmoplakin DSP 231 0.188 0.004 0.186 
   
O60841 eukaryotic translation initiation factor 5B EIF5B 165 -0.216 0.006 >0.200 
   
Q6ZUS6 coiled-coil domain-containing protein 149  CCDC149 151 0.221 0.007 >0.200 
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Q6P2H3 centrosomal protein of 85 kDa CEP85 169 0.203 0.007 >0.200 
   
A2RUS2 DENN domain-containing protein 3 DENND3 167 -0.211 0.007 >0.200 
   
Q9UQ16 dynamin-3 DNM3 161 -0.212 0.008 >0.200 -0.158 0.046 >0.200 
Q9UKN1 mucin-12 MUC12 179 -0.198 0.009 >0.200 
   
Q13103 secreted phosphoprotein 24 SPP2 179 -0.199 0.009 >0.200 
   
P03952 plasma kallikrein KLKB1 284 -0.155 0.009 >0.200 -0.116 0.052 >0.200 
Q8IWV7 E3 ubiquitin-protein ligase  UBR1 149 0.212 0.010 >0.200 0.172 0.037 >0.200 
Q8IZ81 ELMO domain-containing protein 2 ELMOD2 213 -0.177 0.011 >0.200 
   
O60674 tyrosine-protein kinase JAK2 JAK2 143 0.215 0.012 >0.200 
   
P00734 prothrombin F2 284 -0.15 0.012 >0.200 
   
Q9Y2M0 fanconi-associated nuclease 1 FAN1 175 -0.191 0.012 >0.200 -0.143 0.060 >0.200 
P01861 Ig gamma-4 chain C region IGHG4 284 0.149 0.013 >0.200 




FHAD1 184 0.18 0.013 >0.200 
   
Q15485 ficolin-2 FCN2 143 -0.206 0.013 >0.200 
   
Q9NSD9 phenylalanine--tRNA ligase beta subunit FARSB 143 0.214 0.013 >0.200 
   
P0DJI8 serum amyloid A-1 protein SAA1 284 0.148 0.013 >0.200 
   
Q92686 neurogranin NRGN 276 0.147 0.015 >0.200 
   
Q15047 histone-lysine N-methyltransferase SETDB1 SETDB1 160 0.195 0.015 >0.200 
   
P51956 serine/threonine-protein kinase NEK3 276 -0.147 0.015 >0.200 -0.098 0.104 >0.200 
Q8TDY2 RB1-inducible coiled-coil protein 1 RB1CC1 143 0.202 0.017 >0.200 
   
Q8N139 
ATP-binding cassette sub-family A member 
6 
ABCA6 176 -0.179 0.019 >0.200 -0.121 0.110 >0.200 
Q09666 neuroblast differentiation-associated protein AHNAK 230 -0.154 0.021 >0.200 
   
P35249 replication factor C subunit 4 RFC4 180 -0.173 0.022 >0.200 
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P49454 centromere protein F CENPF 210 -0.162 0.022 >0.200 
   
Q12830 nucleosome-remodeling factor subunit BPTF BPTF 142 -0.186 0.025 >0.200 
   
Q5T447 E3 ubiquitin-protein ligase HECTD3 150 -0.181 0.026 >0.200 -0.087 0.293 >0.200 
Q9NTJ3 
structural maintenance of chromosomes 
protein 4 
SMC4 169 0.171 0.027 >0.200 
   
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 284 0.13 0.029 >0.200 
   
P81274 G-protein-signaling modulator 2 GPSM2 171 -0.171 0.030 >0.200 
   
P35542 serum amyloid A-4 protein SAA4 284 0.128 0.032 >0.200 
   
Q6RI45 
bromodomain and WD repeat-containing 
protein 3 
BRWD3 195 -0.154 0.034 >0.200 
   
Q9NQW8 cyclic nucleotide-gated cation channel beta-3 CNGB3 239 -0.137 0.037 >0.200 
   
Q8TBY8 
polyamine-modulated factor 1-binding 
protein 1 
PMFBP1 196 0.148 0.037 >0.200 
   
P08571 monocyte differentiation antigen CD14 CD14 263 0.129 0.037 >0.200 
   
P02647  apoA1 APOA1 284 -0.124 0.037 >0.200 
   
P17936 insulin-like growth factor-binding protein 3 IGFBP3 241 -0.134 0.038 >0.200 
   
P21549 serine-pyruvate aminotransferase AGT 284 0.123 0.039 >0.200 
   
O95256 interleukin-18 receptor accessory protein IL18RAP 275 0.123 0.041 >0.200 0.08 0.188 >0.200 
P23142 fibulin-1 FBLN1 275 0.123 0.042 >0.200 
   
Q8IX21 
SMC5-SMC6 complex localization factor 
protein 2 
FAM178A 182 -0.15 0.042 >0.200 
   
P05787 keratin, type II cytoskeletal 8 KRT8 152 0.166 0.043 >0.200 0.098 0.232 >0.200 
Q8N7X0 androglobin ADGB 198 -0.139 0.045 >0.200 
   
P02751 fibronectin FN1 284 -0.118 0.049 >0.200 -0.075 0.211 >0.200 
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Among our 284 subjects, a proportion had received a diagnosis of either MCI or AD 
(n = 46). With the pressing need for a biomarker at the preclinical stage of disease, 
we decided to investigate Aβ SUVR correlations in the cognitively normal 
individuals only. Demographics of the cognitively normal individuals (HEC) can be 
found in Table 5-2. In removing MCI and AD individuals from the analysis we 
found that 25 protein groups lost statistical association with Aβ at the uncorrected P 
<0.05 (Table 5-12). It is possible that these proteins are more associated with an 
MCI/AD diagnosis than Aβ SUVR. However, it is more likely the reduction in 
significance is due to loss of statistical power as 95% of AD and 61% MCI 
individuals are found in the Aβ+ group. 
Table 5-12: Protein groups (shown as gene names) that lost statistical significance (at 
the uncorrected P <0.05) when removing individuals with a clinical diagnosis of MCI 
and AD. 
Gene Name 
CROCC APOA1 HECTD3 
IL18RAP FCN2 NEK3 
ELMOD2 AGT CENPF 
SETDB1 DSP TYK2 
EIF5B UBR1 FARSB 
AHNAK RB1CC1 MUC12 
FAM178A IGHG4 KRT8 




In addition, a further 19 protein groups became significantly correlated with Aβ 
SUVR when examining just the cognitively normal group (Table 5-13, highlighted 
green), most notably brain mitochondrial carrier protein 1 (SLC25A14). None of 
these 19 protein groups passed multiple testing corrections or were seen to be 
associated with APOE genotype. It was also apparent that Aβ (Figure 5-7), 
NEUROG2 (Figure 5-8) and NEFL (Figure 5-9) were more associated with Aβ 
SUVR in the cognitively normal group (Table 5-13) whereas APBB3, REST, 
CROCC and ATP6V0A2 became less significant. DENN domain-containing protein 
3 (DENND3) became highly significant with Aβ SUVR when removing AD and 
MCI subjects and also passed multiple testing correction (Q = 0.004).  
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Table 5-13: Protein groups significantly associated with Aβ SUVR as a continuous measure (using a Spearman’s Rank correlation) in cognitively 
normal subjects only. A total of 25 protein groups lost association with Aβ at the uncorrected P <0.05. An additional 19 protein groups became 
significantly correlated with Aβ SUVR in the cognitively normal group (highlighted in green). GLM residuals adjusted for TMT10plex group, age, 
gender and sample cohort. Benjamini-Hochberg Q values were calculated for multiple testing correction. 
Uniprot 
ID 
Protein Description  
Gene 
Name 
n Rho P value Q value 
P05067 amyloid beta A4 protein (Aβ) APP 238 0.336 1.09 x10-07 3.84 x10-05 
Q9H2A3 neurogenin-2 (NEUROG2) NEUROG2 230 0.339 1.37 x10-07 3.84 x10-05 
P07196 neurofilament light polypeptide (NEFL) NEFL 215 0.327 9.73 x10-07 1.82 x10-04 
A2RUS2 DENN domain-containing protein 3 (DENND3) DENND3 143 -0.343 2.70 x10-05 0.004 
O95704 amyloid beta A4 precursor protein-binding family B member 3 (APBB3) APBB3 230 0.249 1.35 x10-04 0.02 
Q8IVF4 dynein heavy chain 10, axonemal DNAH10 202 0.213 0.002 0.16 
Q9UQ16 dynamin-3 DNM3 134 -0.267 0.002 0.16 
Q13127 isoform 4 of RE1-silencing transcription factor (REST) REST 238 -0.179 0.006 >0.200 
Q6ZUS6 coiled-coil domain-containing protein 149  CCDC149 128 0.237 0.007 >0.200 
Q8TBY8 polyamine-modulated factor 1-binding protein 1 PMFBP1 168 0.209 0.007 >0.200 
O95258 brain Mitochondrial Carrier Protein 1 (SLC25A14) SLC25A14 223 0.177 0.008 >0.200 
Q12830 nucleosome-remodeling factor subunit BPTF BPTF 113 -0.242 0.01 >0.200 
Q9Y487 V-type proton ATPase 116 kDa subunit (ATP6V0A2) ATP6V0A2 120 0.231 0.011 >0.200 
P00734 prothrombin F2 238 -0.165 0.011 >0.200 
Q9Y2M0 fanconi-associated nuclease 1 FAN1 152 -0.207 0.011 >0.200 
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P23142 fibulin-1 FBLN1 230 0.168 0.011 >0.200 
Q6P2H3 centrosomal protein of 85 kDa CEP85 144 0.204 0.014 >0.200 
P08571 monocyte differentiation antigen CD14 CD14 222 0.163 0.015 >0.200 
P0CF74 Ig lambda-6 chain C region IGLC6 183 0.18 0.015 >0.200 
Q92686 neurogranin NRGN 231 0.158 0.016 >0.200 
Q9NQW8 cyclic nucleotide-gated cation channel beta-3 CNGB3 199 -0.168 0.018 >0.200 
P20742 pregnancy zone protein PZP 238 0.152 0.019 >0.200 
 B1AJZ9 forkhead-associated domain-containing protein 1 FHAD1 163 0.181 0.021 >0.200 
Q14520 hyaluronan-binding protein 2 HABP2 238 -0.149 0.021 >0.200 
Q6RI45 bromodomain and WD repeat-containing protein 3 BRWD3 171 -0.173 0.024 >0.200 
P32189 glycerol kinase GK 164 0.175 0.025 >0.200 
Q659A1 little elongation complex subunit 2 NARG2 131 -0.195 0.026 >0.200 
P35249 replication factor C subunit 4 RFC4 146 -0.185 0.026 >0.200 
Q8N139 ATP-binding cassette sub-family A member 6 ABCA6 154 -0.177 0.028 >0.200 
Q08379 golgin subfamily A member 2 GOLGA2 186 -0.161 0.029 >0.200 
P03952 plasma kallikrein KLKB1 238 -0.142 0.029 >0.200 
Q9BQG0 myb-binding protein 1A MYBBP1A 149 -0.179 0.029 >0.200 
Q8IYT8 serine/threonine-protein kinase ULK2 ULK2 123 0.196 0.03 >0.200 
P02765 alpha-2-HS-glycoprotein AHSG 238 -0.138 0.033 >0.200 
Q8NDH2 coiled-coil domain-containing protein 168 CCDC168 140 -0.177 0.036 >0.200 
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Q9NTJ3 structural maintenance of chromosomes protein 4 SMC4 141 0.175 0.038 >0.200 
P31483  nucleolysin TIA-1 isoform p40 TIA1 134 -0.179 0.038 >0.200 
O60674 tyrosine-protein kinase JAK2 JAK2 118 0.19 0.039 >0.200 
Q8IVF2 protein AHNAK2 AHNAK2 136 0.176 0.041 >0.200 
Q96RV3 pecanex-like protein PCNX 203 0.143 0.042 >0.200 
Q9NQ66 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 PLCB1 117 -0.187 0.043 >0.200 
P42356 phosphatidylinositol 4-kinase alpha PI4KA 134 -0.174 0.044 >0.200 
Q13103 secreted phosphoprotein 24 SPP2 153 -0.163 0.044 >0.200 
O15078 centrosomal protein of 290 kDa CEP290 151 -0.163 0.045 >0.200 
Q0VDD8 dynein heavy chain 14, axonemal DNAH14 137 -0.172 0.045 >0.200 
P27816 microtubule-associated protein 4 MAP4 162 -0.156 0.048 >0.200 
Q14524 sodium channel protein type 5 subunit alpha NAV1 231 0.13 0.049 >0.200 






Figure 5-7: Scatter plot to show the correlation between amyloid beta A4 protein (Aβ) 
and Aβ SUVR in cognitively normal individuals (P = 1.09 x10-07; Q = 3.84 x10-05). 
 
Figure 5-8: Scatter plot to show the correlation between neurogenin-2 (NEUROG2) 








































































Figure 5-9: Scatter plot to show the correlation between neurofilament light 




5.4.5 Plasma proteins associated with Aβ classification 
Aβ SUVR measures from the 284 individuals were categorised as Aβ- or Aβ+. The 
AIBL-2 cohort underwent 
11
C-PiB PET neuroimaging and an Aβ+ cut-off was 
defined as >1.5. The KARVIAH cohort underwent 
18
FBB PET imaging and Aβ+ 
cut-off was defined as >1.35. The distribution of Aβ- or Aβ+ individuals is shown in 
Figure 5-2. The 1,085 GLM adjusted protein groups were analysed for their 
association with pathology endophenotypes (Aβ- versus Aβ+) using a Mann 
Whitney-U test. A total of 57 protein groups were found be statistically different 
between Aβ- and Aβ+ groups at the uncorrected P value <0.05 (Table 5-14). After 
correction for multiple testing nine protein groups remained associated with Aβ 
classification (Q = <0.1, Table 5-14). Once more Aβ (Figure 5-10), NEUROG2 
(Figure 5-11), NEFL (Figure 5-12), APBB3 (Figure 5-13) and REST (Figure 5-14) 
were the most significant protein groups associated NAB classification.   
Unsurprisingly, there was a large overlap (43/57) between the candidate protein 










































protein group that was most associated with Aβ classification without being 
associated with Aβ SUVR was serotransferrin (TF; P = 0.0009, Figure 5-15). 
Furthermore, protein groups previously associated with APOE genotype (Table 5-
10) were further investigated with APOE being added to the GLM model and 
subsequent Mann Whitney-U analysis performed. This demonstrated consistent 
findings with Table 5-11 with a number of protein groups association with Aβ 
attributed to APOE genotype. Aβ, NEUROG2, NEFL and APBB3 still passed FDR 
multiple testing corrections after adjustment for APOE genotype.      
 
Figure 5-10: Box and whisker diagram to show the amyloid beta A4 (Aβ) protein 
group differences (P = 1.26 x10
-08
; Q = 7.06 x10
-06















































Figure 5-11: Box and whisker diagram to show the neurogenin-2 (NEUROG2) protein 
group differences (P = 1.20 x10
-07
; Q = 3.36 x10
-05) between Aβ- and Aβ+ groups. 
 
Figure 5-12: Box and whisker diagram to show the neurofilament light polypeptide 
(NEFL) protein group differences (P = 2.26 x10
-07
; Q = 4.22 x10
















































































Figure 5-13: Box and whisker diagram to show the amyloid beta A4 precursor protein-
binding family B member 3 (APBB3) protein group differences (P = 1.54 x10
-06
; Q = 
2.16 x10
-04) between Aβ- and Aβ+ groups. 
 
Figure 5-14: Box and whisker diagram to show the RE1-silencing transcription factor 






















































































































Figure 5-15: Box and whisker diagram to show the serotransferrin (TF) protein group 
differences (P = 0.0009) between Aβ- and Aβ+ groups. 
In cognitively normal subjects we demonstrated a reduced group of 32 protein 
groups being associated with Aβ classification (Table 5-15). A total of eight protein 
groups were exclusively associated with Aβ classification when excluding MCI and 
AD participants. These protein groups were probable methyltransferase (TARBP1), 
proline-glutamic acid-leucine-rich protein 1 (PLEP1), ninein (NIN), pecanex-like 
protein 1 (PCNX), CC5, dickkopf-like protein 1 (DKKL1), nucleolysin TIA-1 
isoform p40 (TIA1) and cilia- and flagella-associated protein 43 (WDR96). None of 
these protein groups were associated with APOE genotype not did they pass FDR 
correction. There seemed to be little change in the association of Aβ classification 
and Aβ, NEUROG2, NEFL, APBB3 and REST whereas TF, cyclic nucleotide-gated 
cation channel beta-3 (CNGB3), neurogranin (NRGN) and DENN3 all passed 



































Table 5-14: Protein groups significantly associated with Aβ classification (Aβ- or Aβ+) using a Mann Whitne-U test. GLM residuals adjusted for 
TMT10plex group, age, gender and sample cohort. An additional GLM was performed adjusting for APOE genotype. Benjamini-Hochberg Q values 
were calculated for multiple testing correction. 
   
Mann Whitney-U for group 
differences (Aβ- versus Aβ+) 
Mann Whitney-U for group 
differences (Aβ- versus Aβ+) 
adjusted for APOE genotype 
UniProt 
ID 
Protein Description Gene Name Z P value Q value Z P value Q value 
P05067 amyloid beta A4 protein (Aβ) APP -6.319 1.26 x10-08 7.06 x10-06 -4.866 1.00 x10-06 1.20 x10-05 
Q9H2A3 neurogenin-2 (NEUROG2) NEUROG2 -5.668 1.20 x10-07 3.36 x10-05 -4.564 5.00 x10-06 3.00 x10-05 
P07196 neurofilament light polypeptide (NEFL) NEFL -5.717 2.26 x10-07 4.22 x10-05 -4.33 1.50 x10-05 6.00 x10-05 
O95704 
amyloid beta A4 precursor protein-binding family B 
member 3 (APBB3) 
APBB3 -5.338 1.54 x10-06 2.16 x10-04 -3.513 4.42 x10-04 0.001 
Q13127 
Isoform 4 of RE1-silencing transcription factor 
(REST) 
REST -4.670 8.03 x10-05 0.009 
   
Q9Y487 V-type proton ATPase 116 kDa subunit (ATP6V0A2) ATP6V0A2 -3.544 0.001 0.055 
   
 B1AJZ9 forkhead-associated domain-containing protein 1 FHAD1 -3.815 0.001 0.076 
   
Q14520 hyaluronan-binding protein 2 HABP2 -2.495 0.001 0.076 -0.96 0.337 >0.200 
Q8IVF4 dynein heavy chain 10, axonemal DNAH10 -2.643 0.001 0.076 
   
Q92686 neurogranin NRGN -3.600 0.003 0.135 
   
O60674 tyrosine-protein kinase JAK2 JAK2 -2.374 0.003 0.135 
   
Q13103 secreted phosphoprotein 24 SPP2 -2.827 0.003 0.135 
   
Q15485 ficolin-2 FCN2 -2.841 0.003 0.137 
   
Q6ZUS6 coiled-coil domain-containing protein 149  CCDC149 -2.597 0.004 0.176 
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Q8IWV7 E3 ubiquitin-protein ligase  UBR1 -1.957 0.005 0.178 -1.164 0.244 >0.200 
P81274 G-protein-signaling modulator 2 GPSM2 -2.373 0.005 0.178 
   
P51956 serine/threonine-protein kinase NEK3 -2.807 0.006 0.195 -1.572 0.116 0.199 
Q5TZA2 rootletin (CROCC) CROCC -2.617 0.007 >0.200 
   
Q8TBY8 polyamine-modulated factor 1-binding protein 1 PMFBP1 -2.239 0.007 >0.200 
   
O95256 interleukin-18 receptor accessory protein IL18RAP -2.019 0.008 >0.200 -1.031 0.303 >0.200 
Q9Y2M0 fanconi-associated nuclease 1 FAN1 -2.362 0.009 >0.200 -1.773 0.076 0.152 
P02787 serotransferrin (TF) TF -3.301 0.009 >0.200 
   
P42356 phosphatidylinositol 4-kinase alpha PI4KA -2.038 0.009 >0.200 
   
Q6P2H3 centrosomal protein of 85 kDa CEP85 -1.845 0.010 >0.200 
   
Q9UQ16 dynamin-3 DNM3 -2.808 0.010 >0.200 -1.78 0.075 0.152 
Q8N7X0 androglobin ADGB -2.279 0.011 >0.200 
   
Q5T447 E3 ubiquitin-protein ligase HECTD3 -1.965 0.011 >0.200 -0.687 0.492 >0.200 
P15924 desmoplakin DSP -1.793 0.011 >0.200 
   
A2RUS2 DENN domain-containing protein 3 (DENN3) DENND3 -2.640 0.012 >0.200 
   
Q8IZ81 ELMO domain-containing protein 2 ELMOD2 -2.348 0.012 >0.200 
   
O60292 
signal-induced proliferation-associated 1-like protein 
3 
SIPA1L3 -1.997 0.012 >0.200 
   
O60841 eukaryotic translation initiation factor 5B EIF5B -2.041 0.013 >0.200 
   
P08571 monocyte differentiation antigen CD14 CD14 -1.985 0.013 >0.200 
   
P03952 plasma kallikrein KLKB1 -2.084 0.013 >0.200 -1.135 0.256 >0.200 
Q9UKN1 mucin-12 MUC12 -2.349 0.017 >0.200 
   
P0DJI8 serum amyloid A-1 protein SAA1 -1.763 0.019 >0.200 
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P00488 coagulation factor XIII F13A1 -2.035 0.020 >0.200 
   
Q12830 nucleosome-remodeling factor subunit BPTF BPTF -1.923 0.021 >0.200 
   
P00734 prothrombin F2 -2.068 0.022 >0.200 
   
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 -1.685 0.027 >0.200 
   
Q8TDY2 RB1-inducible coiled-coil protein 1 RB1CC1 -2.567 0.031 >0.200 
   
P09871 complement C1s subcomponent C1S -2.167 0.032 >0.200 
   
Q9NQW8 cyclic nucleotide-gated cation channel beta-3 CNGB3 -3.174 0.033 >0.200 
   
Q86TU7 histone-lysine N-methyltransferase SETD3 SETD3 -2.421 0.036 >0.200 
   
Q8N139 ATP-binding cassette sub-family A member 6 ABCA6 -2.655 0.036 >0.200 -1.874 0.061 0.141 
P00742 coagulation factor X F10 -1.950 0.037 >0.200 
   
Q15047 Histone-lysine N-methyltransferase SETDB1 SETDB1 -1.515 0.037 >0.200 
   
Q5VTT5 myomesin-3 MYOM3 -1.630 0.038 >0.200 
   
Q9NTJ3 structural maintenance of chromosomes protein 4 SMC4 -1.022 0.040 >0.200 
   
Q6RI45 bromodomain and WD repeat-containing protein 3 BRWD3 -1.460 0.040 >0.200 
   
Q14493 histone RNA hairpin-binding protein SLBP -1.173 0.041 >0.200 
   
P0DJI9 serum amyloid A-2 protein SAA2 -1.477 0.042 >0.200 
   
Q9UGM5 fetuin-B FETUB -2.504 0.042 >0.200 
   
P08185 corticosteroid-binding globulin SERPINA6 -2.222 0.042 >0.200 
   
P35353 corticotropin-releasing factor receptor 1 CRHR1 -2.296 0.045 >0.200 
   
P02765 alpha-2-HS-glycoprotein AHSG -1.481 0.045 >0.200 
   
Q13651 interleukin-10 receptor subunit alpha IL10RA -1.829 0.047 >0.200 
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Table 5-15: Protein groups significantly associated with Aβ classification (Aβ- or Aβ+) in the cognitively normal individuals only. An additional 8 
protein groups became significantly associated with Aβ classification in the cognitively normal group (highlighted in green). GLM residuals adjusted 
for TMT10plex group, age, gender and sample cohort. Benjamini-Hochberg Q values were calculated for multiple testing correction. 
UniProt 
ID 
Protein Description  Gene Name Z P value Q value 
P05067 amyloid beta A4 protein (Aβ) APP -5.686 1.30 x10-08 7.28 x10-06 
Q9H2A3 neurogenin-2 (NEUROG2) NEUROG2 -5.305 1.12 x10-07 3.14 x10-05 
P07196 neurofilament light polypeptide (NEFL) NEFL -4.706 3.00 x10-06 5.60 x10-04 
O95704 amyloid beta A4 precursor protein-binding family B member 3 (APPB3) APBB3 -4.451 9.00 x10-06 0.001 
Q13127-4 isoform 4 of RE1-silencing transcription factor (REST) REST -3.935 8.30 x10-05 0.009 
P02787 serotransferrin (TF) TF -3.55 3.85 x10-04 0.037 
Q92686 neurogranin (NRGN) NRGN -3.266 0.001 0.062 
Q9NQW8 cyclic nucleotide-gated cation channel beta-3 (CNGB3) CNGB3 -3.425 0.001 0.062 
A2RUS2 DENN domain-containing protein 3 (DENN3) DENND3 -3.329 0.001 0.062 
 B1AJZ9 forkhead-associated domain-containing protein 1 FHAD1 -3.009 0.003 0.168 
Q9Y487 V-type proton ATPase 116 kDa subunit (ATP6V0A2) ATP6V0A2 -2.827 0.005 >0.200 
Q9UQ16 dynamin-3 DNM3 -2.595 0.009 >0.200 
Q8IVF4 dynein heavy chain 10, axonemal DNAH10 -2.504 0.012 >0.200 
Q9UGM5 fetuin-B FETUB -2.471 0.013 >0.200 
P51956 serine/threonine-protein kinase NEK3 -2.408 0.016 >0.200 
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Q8TBY8 polyamine-modulated factor 1-binding protein 1 PMFBP1 -2.399 0.016 >0.200 
Q86TU7 histone-lysine N-methyltransferase SETD3 SETD3 -2.359 0.018 >0.200 
Q13395 probable methyltransferase (TARBP1) TARBP1 -2.349 0.019 >0.200 
Q8N139 ATP-binding cassette sub-family A member 6 ABCA6 -2.35 0.019 >0.200 
Q6ZUS6 coiled-coil domain-containing protein 149  CCDC149 -2.278 0.023 >0.200 
Q8IZL8 proline-, glutamic acid- and leucine-rich protein 1 (PELP1) PELP1 -2.259 0.024 >0.200 
Q8N4C6 ninein (NIN) NIN -2.237 0.025 >0.200 
Q8N7X0 androglobin ADGB -2.223 0.026 >0.200 
Q96RV3 pecanex-like protein 1 (PCNX) PCNX -2.217 0.027 >0.200 
Q15485 ficolin-2 FCN2 -2.151 0.031 >0.200 
Q8TDY2 RB1-inducible coiled-coil protein 1 RB1CC1 -2.068 0.039 >0.200 
O95256 interleukin-18 receptor accessory protein IL18RAP -2.057 0.04 >0.200 
P01031 complement C5 (CC5) C5 -2.005 0.045 >0.200 
Q9UK85 dickkopf-like protein 1 (DKKL1) DKKL1 -2.00 0.045 >0.200 
P81274 G-protein-signaling modulator 2 GPSM2 -1.988 0.047 >0.200 
P31483 nucleolysin TIA-1 isoform p40 (TIA1) TIA1 -1.983 0.047 >0.200 





5.4.6 Summary of protein groups related to Aβ SUVR and Aβ classification  
A total of 95 unique protein groups have been associated with Aβ (Table 5-16). This 
has been examined as a correlation or a group-wise difference. Furthermore, we 
have also examined the full dataset (including MCI and AD individuals) and the 
cognitively normal subjects alone in regards to Aβ SUVR and classification. Table 
5-16 summarises these findings by displaying the protein group and its association 
with an endophenotype (shown as P value). We have also displayed any relationship 
found with APOE genotype (Table 5-16). 
APBB3, Aβ, NEFL and NEUROG2 are highly associated with all SUVR variables 
and are also related to APOE genotype. When adjusting for APOE all four of these 
protein groups remain highly significant with Aβ and also after applying FDR. A 
further 11 protein groups were significantly associated with all four analysis, 
including REST and NRGN. 
Interestingly, TIA1 and PCNX were the only protein groups exclusively associated 
with both analyses that included only cognitively normal individuals. A large 
number of protein groups were only associated with Aβ when MCI and AD 
individuals were included in the analysis. This suggests that these proteins are 
related to other AD processes and not necessarily a reflection of NAB.   
Table 5-16: A summary of protein groups associated (uncorrected P value) with Aβ in 
this study. Association with APOE genotype is shown when significant.  
 
Correlation with Aβ 
SUVR (P value) 
Group-wise association 















APBB3 6.59 x10-05 1.35 x10-04 1.54 x10-06 9.00 x10-06 0.001 
APP 1.05 x10-06 1.09 x10-07 1.26 x10-08 1.30 x10-08 0.001 
ABCA6 0.019 0.028 0.036 0.019 0.02 
CCDC149 0.007 0.007 0.004 0.023 n/s 
CNGB3 0.037 0.018 0.033 0.001 n/s 
DENND3 0.007 2.70 x10-05 0.012 0.001 n/s 
DNM3 0.008 0.002 0.010 0.009 0.028 
DNAH10 0.002 0.002 0.001 0.012 n/s 
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FHAD1 0.013 0.021 0.001 0.003 n/s 
REST 0.001 0.006 8.03 x10-05 8.30 x10-05 n/s 
NEFL 2.46 x10-06 9.73 x10-07 2.26 x10-07 3.00 x10-06 0.001 
NEUROG2 5.28 x10-06 1.37 x10-07 1.20 x10-07 1.12 x10-07 0.014 
NRGN 0.015 0.016 0.003 0.001 n/s 
PMFBP1 0.037 0.007 0.007 0.016 n/s 
ATP6V0A2 3.19 x10-04 0.011 0.001 0.005 n/s 
ADGB 0.045 n/s 0.011 0.026 n/s 
BRWD3 0.034 0.024 0.040 n/s n/s 
CEP85 0.007 0.014 0.010 n/s n/s 
FAN1 0.012 0.011 0.009 n/s 0.043 
FCN2 0.013 n/s 0.003 0.031 n/s 
GPSM2 0.030 n/s 0.005 0.047 n/s 
HABP2 0.002 0.021 0.001 n/s 0.003 
IL18RAP 0.041 n/s 0.008 0.04 0.036 
CD14 0.037 0.015 0.013 n/s n/s 
BPTF 0.025 0.01 0.021 n/s n/s 
PI4KA 0.004 0.044 0.009 n/s n/s 
KLKB1 0.009 0.029 0.013 n/s 0.037 
RB1CC1 0.017 n/s 0.031 0.039 n/s 
SPP2 0.009 0.044 0.003 n/s n/s 
NEK3 0.015 n/s 0.006 0.016 0.015 
SMC4 0.027 0.038 0.040 n/s n/s 
JAK2 0.012 0.039 0.003 n/s n/s 
AHSG n/s 0.033 0.045 n/s n/s 
DSP 0.004 n/s 0.011 n/s n/s 
HECTD3 0.026 n/s 0.011 n/s 0.001 
UBR1 0.010 n/s 0.005 n/s n/s 
ELMOD2 0.011 n/s 0.012 n/s n/s 
EIF5B 0.006 n/s 0.013 n/s n/s 
FETUB n/s n/s 0.042 0.013 n/s 
FBLN1 0.042 0.011 n/s n/s n/s 
SETD3 n/s n/s 0.036 0.018 n/s 
SETDB1 0.015 n/s 0.037 n/s n/s 
ITIH4 0.029 n/s 0.027 n/s n/s 
MUC12 0.009 n/s 0.017 n/s n/s 
TIA1 n/s 0.038 n/s 0.047 n/s 
PCNX n/s 0.042 n/s 0.027 n/s 
F2 0.012 0.011 n/s n/s n/s 
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RFC4 0.022 0.026 n/s n/s n/s 
CROCC 0.001 n/s 0.007 n/s n/s 
TF n/s n/s 0.009 3.85 x10-04 n/s 
SAA1 0.013 n/s 0.019 n/s n/s 
PLCB1 n/s 0.043 n/s n/s n/s 
APOA1 0.037 n/s n/s n/s n/s 
SLC25A14 n/s 0.008 n/s n/s n/s 
CENPF 0.022 n/s n/s n/s n/s 
CEP290 n/s 0.045 n/s n/s n/s 
WDR96 n/s n/s n/s 0.048 n/s 
F10 n/s n/s 0.037 n/s n/s 
F13A1 n/s n/s 0.020 n/s n/s 
CCDC168 n/s 0.036 n/s n/s n/s 
C1S n/s n/s 0.032 n/s n/s 
C5 n/s n/s n/s 0.045 n/s 
SERPINA6 n/s n/s 0.042 n/s n/s 
CRHR1 n/s n/s 0.045 n/s n/s 
DKKL1 n/s n/s n/s 0.045 n/s 
DNAH14 n/s 0.045 n/s n/s n/s 
FN1 0.049 n/s n/s n/s 0.036 
GK n/s 0.025 n/s n/s n/s 
GOLGA2 n/s 0.029 n/s n/s n/s 
SLBP n/s n/s 0.041 n/s 0.004 
IGHG4 0.013 n/s n/s n/s n/s 
IGLC6 n/s 0.015 n/s n/s n/s 
IGFBP3 0.038 n/s n/s n/s n/s 
IL10RA n/s n/s 0.047 n/s n/s 
KRT8 0.043 n/s n/s n/s 0.016 
NARG2 n/s 0.026 n/s n/s n/s 
MAP4 n/s 0.048 n/s n/s n/s 
MYBBP1A n/s 0.029 n/s n/s n/s 
MYOM3 n/s n/s 0.038 n/s n/s 
AHNAK 0.021 n/s n/s n/s n/s 
NIN n/s n/s n/s 0.025 n/s 
TYK2 0.004 n/s n/s n/s n/s 
FARSB 0.013 n/s n/s n/s n/s 
PZP n/s 0.019 n/s n/s n/s 
TARBP1 n/s n/s n/s 0.019 n/s 
PELP1 n/s n/s n/s 0.024 n/s 
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AHNAK2 n/s 0.041 n/s n/s n/s 
SRRM1 n/s 0.049 n/s n/s n/s 
ULK2 n/s 0.03 n/s n/s n/s 
AGT 0.039 n/s n/s n/s n/s 
SAA2 n/s n/s 0.042 n/s n/s 
SAA4 0.032 n/s n/s n/s n/s 
SIPA1L3 n/s n/s 0.012 n/s n/s 
FAM178A 0.042 n/s n/s n/s n/s 
NAV1 n/s 0.049 n/s n/s n/s 
 
5.4.7 Pathway analysis  
Pathway analysis revealed that these 96 significantly associated protein groups 
(Table 5-16) were over-represented for involvement in complement and coagulation 
cascades (P = 2.9 x10
-5
, Q = 0.032) and platelet degranulation (P = 7.2 x10
-6
, Q = 
0.012). Other pathways included the intrinsic prothrombin activation pathway (P = 
0.028) and the Stat3 signalling pathway (P = 0.034) however these pathways did not 
pass multiple testing correction.  
5.4.8 Comparisons with LC-MS/MS performed on AIBL-1 (Chapter 3)  
In Chapter 3 “Blood protein predictors for neocortical amyloid pathology for 
enrichment in therapeutic trials” we presented an initial LC-MS/MS discovery that 
demonstrated 43 protein groups that were found to be significantly different between 
PiB+ and PiB- subjects (Table 3-11). Only 17 of these protein groups were taken 
forward for replication (Table 3-13) via immunoassay of which only α2m, FHR-1 
and most prominently FGγ were replicated. Here, we have compared only the LC-
MS/MS findings from Chapter 3 to the LC-MS/MS discovery performed in this 
Chapter as a way of independent validation (Table 5-17). Firstly, 42/43 protein 
groups from AIBL-1 were measured in AIBL-2 and KARVIAH with only pre-
mRNA-splicing factor (DHX38) not being identified. We found that only four 
protein groups that were significantly associated with Aβ in the AIBL-1 cohort were 
significantly associated with Aβ in AIBL-2 and KARVIAH cohorts. It was shown 
that TF and prothrombin (F2) were related with Aβ in conflicting directions with 
AIBL-1 whereas apoA1 and Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) 
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replicated the LC-MS/MS finding with AIBL-1. CD5 antigen-like (CD5L) was also 
approaching significance (P = 0.052) with the same direction of association. Ficolin-
2 was found to be significantly reduced with Aβ+ individuals in AIBL-2/KARVIAH 
datasets whereas ficolin-3 was significantly reduced in AIBL-1. Ficolin-3 shares 
50% amino acid homology with ficolin-2 
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 and therefore the small number of 
significant peptides identified as ficolin-3 in AIBL-1 could be attributed to ficolin-2. 
Albeit not significant, a number of protein groups did replicate the direction of 
association with Aβ+ groups (Table 5-17), this included FGγ and α2m. FGγ was 
found to be significantly reduced in AIBL-1, UCSF and EMIF-AD in Chapter 3. 
Here we show that FGγ is minimally reduced in Aβ+ group (Rho = -0.058, P = 
0.382). α2m has been shown to be increased in AIBL-1, UCSF, EMIF-AD and now 
AIBL-2/KARVIAH. However, statistical significance was not achieved in AIBL-2 
and KARVIAH cohorts (Rho = 0.028, P = 0.700). When examining HEC subjects 
only, α2m was found to be approaching statistical significance (Rho = 0.108, P = 
0.082) and co-varying for APOE genotype became statistical significant (P = 0.042). 
The poor overlap with the findings from Chapter 3 is unsurprising given the 
methodological differences. The method employed in this Chapter has been shown 
to have greater protein sequence coverage and therefore is likely to be a better 
reflection of overall protein expression. Furthermore, the study design that includes 
a continuum of Aβ SUVR rather than an extreme endophenotype, as in Chapter 3, is 
less likely to be biased towards markers of an AD diagnosis. However, as apoA1 and 
ITIH4 are replicated across these two methodologies, and given these differences, 
should be considered as robust indicators for NAB.   
Table 5-17: Protein groups found to be significantly associated using LC-MS/MS in 















P02768 albumin† ALB   
P01023 α2m A2M   
P02647 apoA1 APOA1  ≠ 
P06727 apoA4 APOA4   
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O14791 apoL1 APOL1   
P08519 apo(a) LPA   
P04003 C4b-binding protein alpha chain C4BPA   
O43866 CD5 antigen-like CD5L  ^ 
P00450 ceruloplasmin CP   
P10909 clusterin CLU   
P02747 complement C1q subcomponent  C1QC   
P01024 CC3 C3   
P0C0L4 C4α C4A   
P13671 CC6 C6   
P07357 C8α C8A   
P00751 CFB CFB   
P08603 CFH CFH   
Q03591 FHR-1 CFHR1   
P02671 FGα FGA   
P02675 FGβ FGB   
P02679 FGγ FGG   
O75636 ficolin-3 FCN3   
P06396 gelsolin GSN  - 
P00738 haptoglobin  HP   
P00739 haptoglobin-related protein HPR   
P02790 hemopexin HPX   
P04196 HRG HRG  - 
P01876 Ig alpha-1 chain C region IGHA1   
P01860 Ig gamma-3 chain C region† IGHG3   
P01768 Ig heavy chain V-III region CAM n/a   
P01762 Ig heavy chain V-III region TRO n/a   
P01700 Ig lambda chain V-I region HA n/a   
P0CG04 Ig lambda-1 chain C regions IGLC1   
P04220 Ig mu heavy chain disease protein n/a   
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1   
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2   
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 ITIH3   
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4  ≠ 
P00747 plasminogen PLG   
Q92620 pre-mRNA-splicing factor DHX38  n/a 
P00734 prothrombin (F2) F2  ≠ 
P02787 TF TF  ≠ 
P25311 zinc-alpha-2-glycoprotein  AZGP1   
≠ Statistically significant (P = < 0.05) in one or more tests in Chapter 5; † Protein group deleted 
from Chapter 5 analysis; ^ Protein group approaching statistical significance. 
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5.4.9 Plasma protein classifier for Aβ positivity 
Univariate analysis has shown that a number of single plasma protein groups have 
the ability to predict Aβ classification. However, it is unlikely that a single marker 
would achieve the sensitivity or specificity required for clinical implementation. 
Therefore, we have attempted to build a multi-analyte classifier that can accurately 
predict Aβ status. 
The data was divided into a train (AIBL-2) and test (KARVIAH) sets. As the two 
cohorts were analysed separately, the covariate “cohort” was removed from the 
GLM model. This is also important to demonstrate how a plasma protein classifier 
will perform in an independent cohort. Missing values were imputed by using the 
average score of the protein group. Support Vector Machine (SVM) classifiers were 
built from n = 2 to n = 560 in the order they were ranked by LASSO. LASSO is a 
feature selection regression analysis that produces a simpler and more interpretable 
model by applying L1 regularisation. In practice, LASSO implicitly assesses the 
correlation between variables, removing from each correlated group those proteins 
that less significantly improve the accuracy of the prediction model. Performance of 
the classification method in the training set was assessed using a 100 repeats of a 5-
fold cross validation (blue graph in Figure 5-16). While, in the training set, every 
repeat and fold of the cross validation may select a slightly different set of proteins 
when applying LASSO (each one of the 100 repeats, randomly divides the training 
set into 5 folds for cross-validation), sets of 10-20 proteins obtained the maximum 
Area Under the Curve (AUC), with an average of  90.0 + 0.01 (s.d.). Meanwhile, 
training the model in the whole training set (all samples from AIBL-2) selected the 
panel of proteins shown in Table 5-18 with LASSO. When this already trained 
model was then tested in KAVIRAH, the panel of Table 5.18 produced the AUCs 
shown in Figure 5-16 (red graph), with maximum value at 14 protein groups (AUC 
86.6).  
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Table 5-18: Protein groups (listed by feature number) included in the classifier model 





Protein description  
Gene 
Name 
1 P00734 prothrombin F2 
2 P07196 neurofilament light polypeptide NEFL 
3 Q9Y487 V-type proton ATPase 116 kDa subunit  ATP6V0A2 
4 Q15485 ficolin-2 FCN2 
5 P05067 amyloid beta A4 protein APP 
6 B1AJZ9 forkhead-associated domain-containing protein 1 FHAD1 
7 Q9H2A3 neurogenin-2 NEUROG2 
8 Q8IZ81 ELMO domain-containing protein 2 ELMOD 
9 Q13127 isoform 4 of RE1-silencing transcription factor  REST 
10 O95704 
amyloid beta A4 precursor protein-binding family 
B member 3 
APBB3 
11 Q8IVF4 dynein heavy chain 10, axonemal DNAH10 
12 Q8IWV7 E3 ubiquitin-protein ligase  UBR1 
13 Q8IZF3 adhesion G protein-coupled receptor F4 GPR115 
14 P81274 G-protein-signaling modulator 2 GPSM2 
15 Q13103 secreted phosphoprotein 24 SPP2 
16 Q14520 hyaluronan-binding protein 2 HABP2 
17 Q04206 transcription factor p65 RELA 
18 Q5TZA2 rootletin CROCC 
19 Q14493 histone RNA hairpin-binding protein SLBP 






Figure 5-16: Plasma biomarker classifier for Aβ classification. A twenty-protein set 
with optimal AUC for classifying PET Aβ positivity was built in AIBL-2 with stability 
selection with LASSO and with 100 repeats of 5-fold cross validation. This classifier 
was tested in KARVIAH with a maximum AUC of 86.6. 
As mentioned in previous Chapters, it is important to gather spectral evidence for 
automated database assignments in MS discovery projects. This is of particular 
importance here when an LC-MS/MS dataset has been used to train a prediction 
model, with an independent LC-MS/MS dataset used for testing. Peptides used to 
generate protein group scores for the classifier model are shown in Table 5-19. To 
our knowledge, this is the first time this has been done in the development of a 






















Table 5-19: LC-MS/MS identified and matched peptides contributing to the overall score of each protein group included in the 20 plasma protein 










of b ions 
Number 
of y ions 
1 prothrombin F2 ENLDRDIALMK 521.61 7 4 
  
  
YTACETAR 600.79 6 5 
  
  
ANTFLEEVR 654.36 7 5 
  
  
ELLESYIDGR 712.38 7 6 
  
  
RGDACEGDSGGPFVMK 714.35 12 8 
  
  
KSPQELLCGASLISDR 744.75 11 10 
  
  
TFGSGEADCGLRPLFEK 781.41 9 9 
  
  
NPDSSTTGPWCYTTDPTVR 795.37 8 8 
  
  
IVEGSDAEIGMSPWQVMLFR 832.09 12 14 
  
  
DKLAACLEGNCAEGLGTNYR 891.11 15 13 
  
  
TATSEYQTFFNPR 896.44 9 11 
  
  
GDACEGDSGGPFVMK 992.97 11 7 
      SEGSSVNLSPPLEQCVPDR 1150.71 9 11 
2 neurofilament light NEFL LAAEDATNEK 531.25 8 4 
  
  
ALYEQEIR 625.85 5 5 
  
  
QNADISAMQDTINK 688.1 6 5 
  
  
EYQDLLNVK 700.94 3 4 
  
  
LLEGEETR 712.32 3 3 
      VQSLQDEVAFLR 817.45 4 4 
3 V-type proton ATPase 116 kDa subunit ATP6V0A2 FYVGAGTK 536.96 5 5 
  
  
ETPPTRIRTNK 591.23 7 4 
  
  
QSFLELTELK 718.23 2 5 
      QDQIHSSIVSTLLALMDGLDSR 806.39 9 9 





GEAGTNGK 596.83 4 4 
  
  
VADEAEK 610.35 3 4 
  
  
GTHGSFANGINWK 616.66 5 8 
  
  
MVGLEGSDKLTILR 664.06 3 3 
  
  
GYNYSYK 676.86 5 5 
      VDLVDFEDNYQFAK 721.04 7 5 
5 amyloid beta A4 protein APP HFEHVRMVDPKK 
   
  
  
HDSGYEVHHQK 449.48 4 7 




FHAD1 SLHLPK 462.29 1 5 
  
  
EISESNIAYEK 504.59 4 4 
  
  
QHAQTIVSLEEK 537.96 5 2 
  
  
QKMELEQNVVLVQQQSK 565.8 3 7 
      MTTEGGPPPAPLRR 570.32 3 2 
7 neurogranin NRGN GGAGGGPSGD 480.37 2 5 
      GRKGPGPGGPGGAGVARGGAGGP 698.58 5 4 
8 ELMO domain-containing protein 2 ELMOD2 KRPYDSDNLQHEELLMKLWNLLMPTK 574.64 5 7 
9 RE1-Silencing Transcription factor REST EPVQMELSPPMEVVQK 685.37 7 7 
  
  
LLNTGEGNKEAPLQK 691.39 7 4 
  
  
IKGDVAGKKNEKSVK 722.35 5 4 
      QVHNGPKPLNCPHCDYK 841.76 5 5 
10 
amyloid beta A4 precursor protein-
binding, family B, member 3 
APBB3 CLVASAAR 359.53 3 4 
      SRSQPPDGAWGEGQNMLMLLK 930.5 5 6 
11 dynein heavy chain 10, axonemal DNAH10 DCLSWPR 581.79 4 3 
      SSQFWK 658.18 5 6 
12 E3 ubiqutin-protein ligase UBR1 KSQQAGPSYVQNCVK 481.99 5 2 
  
  





QWIALLQRGNCTFKEK 613.83 6 9 
      LLLKQNVDVEAEDK 692.07 8 4 
13 adhesion G protein-coupled receptor F4 GPR115 QVNGLVLSVVLPER 508.95 8 8 
      KTKSPSSESTKTTK 580.33 3 3 
14 G-protein-signaling modulator 2 GPSM2 IGEGRACWSLGNAYTALGNHDQAMHFAEK 863.4 4 6 
      VQNWNSEILAKQKPLIAKPSAK 631.18 9 8 
15 secreted phosphoprotein 24 SPP2 VSAQQVQGVHAR 503.62 5 7 
      VNSQSLSPYLFR 820.45 2 6 
16 hyaluronan-binding protein 2 HABP2 TEIAER 474.27 4 2 
  
  
VVLGDQDLKKEEFHEQSFR 599.13 12 15 
  
  
HLKVVLGDQDLK 608.7 2 6 
  
  
VQNTCKDNPCGR 636.32 6 4 
  
  
LIANTLCNSR 695.88 6 4 
  
  
YSHYNERDEIPHNDIALLK 697.36 10 10 
  
  
LKPVDGHCALESK 714.4 11 11 
      FTCACPDQFK 866.43 6 5 
17 transcription factor p65 RELA IQTNNNPFQGDSAGPIR 515.75 12 12 
      DLEQAISQR 645.34 4 4 
18 rootletin CROCC RAAEAQLGGLR 457.6 4 8 
  
  
ELQELR 509.29 4 4 
  
  
QQIIATQEK 530.28 5 4 
      KTFPNSEANPLNAYYLK 607.84 9 8 
19 histone RNA hairpin-binding protein  SLBP QINYGK 590.85 4 4 
  
  
TESQKTKSK 374.72 5 4 
      LVQHGLQVRLQLFK 636.73 6 7 
20 olfactory receptor 52I2 OR52I2 CQQILR 410.2 6 4 
  
  
NKDVHVALK 494.96 4 7 
      MLQNQDTMEILSNSTSK 729.35 4 5 
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5.4.10 Replication of brain-derived proteins observed within human plasma 
In Chapter 4, we described a group of 157 (99 with >2 PSMs; Table 4-9) proteins 
(termed brain-derived proteins (BDPs)) observed and measured within human 
plasma. These proteins are described in the Human Protein Atlas (HPA, 
http://www.proteinatlas.org/) to have a >five-fold increased expression in the 
cerebral cortex compared with all other tissues. This was used as an indication of a 
BDP due to high expression in the brain and minimal/none expression in other 
tissues. These protein groups were identified based on 5% FDR with some protein 
groups such as GFAP, PLP1 and MBP having substantial PSMs evidence. 
Conversely, proteins such as POU3F2, FEZF2 and GPR37L1 were based upon <2 
PSMs (Table 4-9). Manual inspection of the MS/MS spectra demonstrated that some 
protein group identifications were based upon moderate-to-poor quality spectra. 
Therefore, we utilised the AIBL-2 and KARVIAH cohorts to replicate the presence 
of these protein groups within plasma and where possible examine these BDPs 
relationship with NAB.  
Mining the AIBL-2 cohort we demonstrated that 120/157 BDPs described in 
Chapter 4 were again identified at 5% FDR, with further confirmation of their 
occurrence in the KARVIAH cohort (Table 5-20). However, only 12 of these BDPs 
in Table 5-20 were included in the main analysis above. This was because a majority 
of BDPs in our dataset occur in <50% of the dataset and therefore were removed 
from further statistical analysis by our criteria. It was encouraging to observe that 
BDPs GFAP, BDNF, NEFL, NRGN, synaptosomal-associated protein, 25kDa 
(SNAP25) and formin 2 (FMN2) were measured in >80% of individuals included in 
this study. Of the BDPs that did not replicate in this dataset 15 protein groups were 
based upon 1 PSMs and 20 protein groups were grouped as “poor spectral evidence” 
in the discovery data (Table 4-9), this emphasises the importance of manual spectral 
interrogation to avoid false database identifications. Furthermore, we examined if 
additional cerebral cortex “Tissue Enriched” proteins, described in HPA, but not 
observed in our discovery data were present in the AIBL-2 and KARVIAH cohorts, 
given the larger cohort sizes. We demonstrated evidence that a further 52 cerebral 
cortex “Tissue Enriched” proteins were measured in AIBL-2 and then KARVIAH 
plasma samples (Table 5-21). As above, very few of these additional BDPs were 
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included in the main analysis and only amyloid beta (A4) precursor protein-binding, 
family A, member 2 (APBA2) and regulating synaptic membrane exocytosis 3 




Table 5-20: ID replication of 120/157 brain-derived proteins discovered in Chapter 4. The evidence generated from the discovery dataset is shown as 
PSMs with evidence of the identification in AIBL-2 and KARVIAH shown as a percentage of individuals the BDP was observed in. Protein groups 
that did not replicate (37) are shown in the table with 0% for both AIBL-2 and KARVIAH.  The “Tissue Enriched” category in HPA (>five-fold 
increased expression in the cerebral cortex compared with all other tissues) was used as an indication of a candidate BDP due to high expression in 
























GFAP glial fibrillary acidic protein 1 160 100.00% 100.00% 
BDNF brain-derived neurotrophic factor 665 18 98.95% 94.68% 
NEFL neurofilament, light polypeptide 336 13 90.53% 91.49% 
NRGN neurogranin  255 43 86.32% 89.36% 
SNAP25 synaptosomal-associated protein, 25kDa 85 10 81.05% 75.53% 
FMN2 formin 2 471 2 81.05% 80.85% 
CHD5 chromodomain helicase DNA binding protein 5 453 7 68.95% 69.15% 
MYT1L myelin transcription factor 1-like 223 12 62.63% 62.77% 
MAP2 microtubule-associated protein 2 292 3 62.11% 51.06% 
SCN2A sodium channel, voltage-gated, type II, alpha subunit 110 1 60.00% 59.57% 
SYT16 synaptotagmin XVI 536 1 59.47% 59.57% 
SHANK1 SH3 and multiple ankyrin repeat domains 1 111 9 51.58% 51.06% 
DSCAM down syndrome cell adhesion molecule 245 2 44.21% 44.68% 
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MBP myelin basic protein 48 214 43.16% 22.34% 
JPH3 junctophilin 3 107 2 41.05% 39.36% 
PCDH9 protocadherin 9 173 1 34.21% 35.11% 
BSN bassoon presynaptic cytomatrix protein 557 5 34.21% 32.98% 
SYN1 synapsin I 82 12 32.63% 31.91% 
KIF5C kinesin family member 5C 593 2 31.58% 29.79% 
NRXN1 neurexin 1 95 3 31.05% 31.91% 
NRXN2 neurexin 2 512 3 31.05% 31.91% 
SOGA3 SOGA family member 3 420 1 28.95% 26.60% 
KIRREL3 kin of IRRE like 3 (Drosophila) 287 4 28.42% 28.72% 
SLC24A2 solute carrier family 24 (sodium/potassium/calcium exchanger), member 2 614 2 28.42% 28.72% 
SPTBN4 spectrin, beta, non-erythrocytic 4 617 8 28.42% 28.72% 
ERC2 ELKS/RAB6-interacting/CAST family member 2 137 1 25.26% 25.53% 
CMTM5 CKLF-like MARVEL transmembrane domain containing 5 213 1 25.26% 24.47% 
ANKS1B ankyrin repeat and sterile alpha motif domain containing 1B 435 4 25.26% 25.53% 
NSF N-ethylmaleimide-sensitive factor 513 1 22.63% 21.28% 
LRRTM4 leucine rich repeat transmembrane neuronal 4 119 1 22.11% 22.34% 
MAP1A microtubule-associated protein 1A 392 7 22.11% 21.28% 
PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 405 4 22.11% 22.34% 
ELAVL3 ELAV like neuron-specific RNA binding protein 3 47 1 21.58% 19.15% 
CNTP4 contactin associated protein-like 4 91 2 21.58% 22.34% 
CASKIN1 CASK interacting protein 1 77 2 21.05% 21.28% 
SLIT1 slit homolog 1 262 4 20.00% 19.15% 
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CNKSR2 connector enhancer of kinase suppressor of Ras 2 369 1 20.00% 20.21% 
SNCB synuclein, beta 23 10 18.95% 19.15% 
UNC13A Unc-13 homolog A (C. elegans) 350 1 18.95% 12.77% 
JAKMIP2 janus kinase and microtubule interacting protein 2 488 1 18.95% 18.09% 
PPFIA2 
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 2 
607 4 18.95% 19.15% 
UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 625 9 18.42% 19.15% 
IDS iduronate 2-sulfatase 586 1 17.89% 19.15% 
KIAA1549L KIAA1549-like 170 1 15.79% 15.96% 
GRIK3 glutamate receptor, ionotropic, kainate 3 481 2 15.79% 15.96% 
YWHAH 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
eta 
547 38 15.79% 15.96% 
APC2 adenomatosis polyposis coli 2 126 2 15.26% 15.96% 
KIF3C kinesin family member 3C 253 17 15.26% 14.89% 
EFR3B EFR3 homolog B (S. cerevisiae) 463 1 15.26% 13.83% 
OMG oligodendrocyte myelin glycoprotein 6 2 14.21% 19.15% 
PLP1 proteolipid protein 1 31 26 14.21% 19.15% 
SLC12A5 solute carrier family 12 (potassium/chloride transporter), member 5 33 1 14.21% 19.15% 
ACTL6B actin-like 6B 144 3 13.16% 11.70% 
PGM2L1 phosphoglucomutase 2-like 1 339 3 12.63% 12.77% 
CNP 2',3'-cyclic nucleotide 3' phosphodiesterase 370 27 12.63% 12.77% 
LRRC4C leucine rich repeat containing 4C 503 1 12.63% 11.70% 
TRIM67 tripartite motif containing 67 98 1 12.11% 12.77% 
DLG4 discs, large homolog 4 (Drosophila) 459 1 12.11% 12.77% 
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ENO2 enolase 2 (gamma, neuronal) 464 16 11.58% 8.51% 
NETO1 neuropilin (NRP) and tolloid (TLL)-like 1 225 1 10.00% 9.57% 
ELFN2 extracellular leucine-rich repeat and fibronectin type III domain containing 2 320 2 10.00% 8.51% 
CSPG5 chondroitin sulfate proteoglycan 5 (neuroglycan C) 34 1 9.47% 9.57% 
DNM1 dynamin 1 191 2 9.47% 9.57% 
CHN1 chimerin 1 211 2 9.47% 9.57% 
B4GALNT1 beta-1,4-N-acetyl-galactosaminyl transferase 1 271 2 9.47% 8.51% 
LPPR4 lipid phosphate phosphatase-related protein type 4  290 5 9.47% 9.57% 
PCDHGB1 protocadherin gamma subfamily B, 1 294 2 9.47% 9.57% 
SCG3 secretogranin III 299 3 9.47% 9.57% 
TPPP tubulin polymerization promoting protein 428 9 9.47% 7.45% 
TUBB2A tubulin, beta 2A class IIa 429 133 9.47% 9.57% 
SEZ6 seizure related 6 homolog (mouse) 46 1 8.95% 8.51% 
BAI1 brain-specific angiogenesis inhibitor 1 443 4 8.95% 3.19% 
DCLK2 doublecortin-like kinase 2 456 1 8.95% 9.57% 
GABRA4 gamma-aminobutyric acid (GABA) A receptor, alpha 4 474 1 8.95% 9.57% 
PRKCG protein kinase C, gamma 256 8 7.37% 7.45% 
CTNND2 catenin (cadherin-associated protein), delta 2 127 1 6.84% 5.32% 
SEZ6L seizure related 6 homolog (mouse)-like 613 2 6.84% 5.32% 
OLFM1 olfactomedin 1 121 5 6.32% 6.38% 
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 175 10 6.32% 6.38% 
RAB3A RAB3A, member RAS oncogene family 258 1 6.32% 6.38% 
GRIN3A glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 327 1 6.32% 6.38% 
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SCN8A sodium channel, voltage gated, type VIII, alpha subunit 412 2 6.32% 6.38% 
STXBP1 syntaxin binding protein 1 426 3 6.32% 6.38% 
TAGLN3 transgelin 3 427 1 6.32% 6.38% 
GABRA3 gamma-aminobutyric acid (GABA) A receptor, alpha 3 473 1 6.32% 6.38% 
HCN1 hyperpolarization activated cyclic nucleotide-gated potassium channel 1 485 12 6.32% 6.38% 
CELF5 CUGBP, Elav-like family member 5 560 1 6.32% 6.38% 
GRIN2B glutamate receptor, ionotropic, N-methyl D-aspartate 2B 78 6 5.79% 6.38% 
PCDHA5 protocadherin alpha 5 229 3 5.79% 6.38% 
CPNE6 copine VI (neuronal) 276 1 5.26% 5.32% 
FEZ1 fasciculation and elongation protein zeta 1 (zygin I) 469 1 5.26% 6.38% 
GAP43 growth associated protein 43 59 4 4.74% 3.19% 
SH3GL2 SH3-domain GRB2-like 2 301 2 3.68% 1.06% 
AP3B2 adaptor-related protein complex 3, beta 2 subunit 353 1 3.68% 3.19% 
VSNL1 visinin-like 1 545 1 3.68% 6.38% 
OPALIN oligodendrocytic myelin paranodal and inner loop protein 2 8 3.16% 3.19% 
MOG myelin oligodendrocyte glycoprotein 17 2 3.16% 3.19% 
POU3F2 POU class 3 homeobox 2 24 1 3.16% 3.19% 
AK5 adenylate kinase 5 115 2 3.16% 3.19% 
RPH3A rabphilin 3A 123 4 3.16% 3.19% 
PTPN5 protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched) 198 1 3.16% 3.19% 
SERPINI1 serpin peptidase inhibitor, clade I (neuroserpin), member 1 259 1 3.16% 2.13% 
AMPH amphiphysin 267 3 3.16% 3.19% 
ATCAY ataxia, cerebellar, Cayman type 269 1 3.16% 3.19% 
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PRMT8 protein arginine methyltransferase 8 296 2 3.16% 3.19% 
RLBP1 retinaldehyde binding protein 1 298 2 3.16% 3.19% 
TRIM9 tripartite motif containing 9 307 4 3.16% 3.19% 
AMER3 APC membrane recruitment protein 3 352 1 3.16% 3.19% 
C1QL1 complement component 1, q subcomponent-like 1 357 2 3.16% 3.19% 
LHFPL4 lipoma HMGIC fusion partner-like 4 390 1 3.16% 3.19% 
BAI3 brain-specific angiogenesis inhibitor 3 444 2 3.16% 3.19% 
CAMK2A calcium/calmodulin-dependent protein kinase II alpha 450 9 3.16% 3.19% 
DLGAP1 discs, large homolog-associated protein 1 460 1 3.16% 3.19% 
GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A 482 8 3.16% 3.19% 
KCNC1 potassium voltage-gated channel, Shaw-related subfamily, member 1 489 3 3.16% 4.26% 
GAREML GRB2 associated, regulator of MAPK1-like 578 3 3.16% 3.19% 
IBSP integrin-binding sialoprotein 585 6 3.16% 3.19% 
MEGF10 multiple EGF-like-domains 10 598 1 3.16% 3.19% 
GABRG1 gamma-aminobutyric acid (GABA) A receptor, gamma 1 163 1 2.63% 1.06% 
C1QL2 complement component 1, q subcomponent-like 2 210 1 2.63% 3.19% 
NCAN neurocan 18 5 0.00% 0.00% 
FEZF2 FEZ family zinc finger 2 29 1 0.00% 0.00% 
GPR37L1 G protein-coupled receptor 37 like 1 37 1 0.00% 0.00% 
CACNG8 calcium channel, voltage-dependent, gamma subunit 8 39 1 0.00% 0.00% 
GABRA1 gamma-aminobutyric acid (GABA) A receptor, alpha 1 40 1 0.00% 0.00% 
HPCA hippocalcin 41 2 0.00% 0.00% 
PCDHGC5 protocadherin gamma subfamily C, 5 49 1 0.00% 0.00% 
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GPM6B glycoprotein M6B 62 2 0.00% 0.00% 
SYN2 synapsin II 64 1 0.00% 0.00% 
TNR tenascin R 69 1 0.00% 0.00% 
SLC4A10 solute carrier family 4, sodium bicarbonate transporter, member 10 112 1 0.00% 0.00% 
SV2B synaptic vesicle glycoprotein 2B 113 3 0.00% 0.00% 
SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 134 3 0.00% 0.00% 
HRH3 histamine receptor H3 167 2 0.00% 0.00% 
CYP46A1 cytochrome P450, family 46, subfamily A, polypeptide 1 190 5 0.00% 0.00% 
GAD2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 218 1 0.00% 0.00% 
SV2A synaptic vesicle glycoprotein 2A 234 1 0.00% 0.00% 
APLP1 amyloid beta (A4) precursor-like protein 1 236 1 0.00% 0.00% 
BRINP1 bone morphogenetic protein/retinoic acid inducible neural-specific 1 272 3 0.00% 0.00% 
CNTNAP2 contactin associated protein-like 2 275 3 0.00% 0.00% 
SHISA7 shisa family member 7 302 4 0.00% 0.00% 
SYP synaptophysin 306 2 0.00% 0.00% 
FAM155A family with sequence similarity 155, member A 322 1 0.00% 0.00% 
CDH10 cadherin 10, type 2 (T2-cadherin) 362 2 0.00% 0.00% 
FGFBP3 fibroblast growth factor binding protein 3 375 2 0.00% 0.00% 
NAPB N-ethylmaleimide-sensitive factor attachment protein, beta 395 1 0.00% 0.00% 
RUNDC3A RUN domain containing 3A 410 6 0.00% 0.00% 
SMIM18 small integral membrane protein 18 418 6 0.00% 0.00% 
ASIC4 acid-sensing (proton-gated) ion channel family member 4 440 5 0.00% 0.00% 




GRM2 glutamate receptor, metabotropic 2 484 1 0.00% 0.00% 
KIAA0513 KIAA0513 496 2 0.00% 0.00% 
NECAB1 N-terminal EF-hand calcium binding protein 1 508 2 0.00% 0.00% 
NLGN3 neuroligin 3 510 3 0.00% 0.00% 
POU3F4 POU class 3 homeobox 4 520 5 0.00% 0.00% 
RAB6B RAB6B, member RAS oncogene family 526 2 0.00% 0.00% 









Table 5-21: ID discovery of an additional 52 BDPs in AIBL-2 and KARVIAH that were not initially observed in the discovery study in Chapter 4. 
Evidence of the identification in AIBL-2 and KARVIAH is shown as a percentage of individuals the BDP was observed in. The “Tissue Enriched” 
category in HPA (>five-fold increased expression in the cerebral cortex compared with all other tissues) was used as an indication of a candidate 
BDP due to high expression in the brain and minimal/none expression in other tissues. 
Gene name Protein description 
Plasma Evidence 





Cerebral Cortex TS 
score 
ADCY1 adenylate cyclase 1 (brain) 18.42% 17.78% cerebral cortex: 17.8 
APBA2 
amyloid beta (A4) precursor protein-binding, family A, 
member 2 
100.00% 100.00% cerebral cortex: 32.6 
ARNT2 aryl-hydrocarbon receptor nuclear translocator 2 8.42% 10.00% cerebral cortex: 77.9 
BAI2 brain-specific angiogenesis inhibitor 2 3.16% 3.33% cerebral cortex: 33.7 
C4orf50 chromosome 4 open reading frame 50 22.11% 23.33% cerebral cortex: 1.5 
CA10 carbonic anhydrase X 12.63% 13.33% cerebral cortex: 33.2 
CACNG2 calcium channel, voltage-dependent, gamma subunit 2 9.47% 10.00% cerebral cortex: 7.1 
CACNG3 calcium channel, voltage-dependent, gamma subunit 3 8.95% 10.00% cerebral cortex: 22.2 
CAMKV caM kinase-like vesicle-associated 6.32% 6.67% cerebral cortex: 44.6 
CHRNB2 cholinergic receptor, nicotinic, beta 2 (neuronal) 5.79% 5.56% cerebral cortex: 11.0 
DRP2 dystrophin related protein 2 15.79% 16.67% cerebral cortex: 6.1 
ERMN ermin, ERM-like protein 10.53% 10.00% cerebral cortex: 116.4 
FRMPD4 FERM and PDZ domain containing 4 22.11% 23.33% cerebral cortex: 8.0 
GABBR2 gamma-aminobutyric acid (GABA) B receptor, 2 14.21% 13.33% cerebral cortex: 45.8 
GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5 10.00% 7.78% cerebral cortex: 43.1 
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GRIA2 glutamate receptor, ionotropic, AMPA 2 10.00% 8.89% cerebral cortex: 98.2 
GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 18.95% 18.89% cerebral cortex: 71.9 
GRM3 glutamate receptor, metabotropic 3 9.47% 8.89% cerebral cortex: 32.9 
GRM5 glutamate receptor, metabotropic 5 12.63% 13.33% cerebral cortex: 11.6 
HTR2A 
5-hydroxytryptamine (serotonin) receptor 2A, G protein-
coupled 
6.84% 5.56% cerebral cortex: 16.9 
IL1RAPL1 interleukin 1 receptor accessory protein-like 1 6.32% 6.67% cerebral cortex: 2.9 
KCNH1 potassium voltage-gated channel, subfamily H member 1 6.32% 6.67% cerebral cortex: 5.6 
KCNH7 potassium voltage-gated channel, subfamily H member 7 22.11% 22.22% cerebral cortex: 2.4 
KCNIP1 KV channel interacting protein 1 9.47% 10.00% cerebral cortex: 22.0 
KCNK12 potassium channel, subfamily K, member 12 24.74% 26.67% cerebral cortex: 2.5 
KIF1A kinesin family member 1A 14.74% 15.56% cerebral cortex: 136.1 
KIF5A kinesin family member 5A 22.11% 23.33% cerebral cortex: 163.0 
LGI1 leucine-rich, glioma inactivated 1 7.89% 10.00% cerebral cortex: 23.0 
LMTK3 lemur tyrosine kinase 3 9.47% 10.00% cerebral cortex: 8.5 
MAST1 microtubule associated serine/threonine kinase 1 6.32% 6.67% cerebral cortex: 16.0 
MEPE matrix extracellular phosphoglycoprotein 12.63% 13.33% cerebral cortex: 2.3 
OLFM3 olfactomedin 3 14.74% 14.44% cerebral cortex: 13.7 
PAQR6 progestin and adipoQ receptor family member VI 12.63% 13.33% cerebral cortex: 48.1 
PDZD4 PDZ domain containing 4 9.47% 10.00% cerebral cortex: 56.7 
PMP2 peripheral myelin protein 2 8.95% 10.00% cerebral cortex: 148.4 
RIMS3 regulating synaptic membrane exocytosis 3 96.84% 101.11% cerebral cortex: 30.4 
RIT2 ras-like without CAAX 2 17.37% 18.89% cerebral cortex: 11.3 
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RTN1 reticulon 1 9.47% 10.00% cerebral cortex: 178.7 
SLC17A7 
solute carrier family 17 (vesicular glutamate transporter), 
member 7 
9.47% 10.00% cerebral cortex: 291.7 
SLC35F1 solute carrier family 35, member F1 8.95% 10.00% cerebral cortex: 24.7 
SLC39A12 solute carrier family 39 (zinc transporter), member 12 12.63% 13.33% cerebral cortex: 12.9 
SLC7A14 solute carrier family 7, member 14 12.63% 13.33% cerebral cortex: 13.8 
SLCO1C1 solute carrier organic anion transporter family, member 1C1 11.58% 13.33% cerebral cortex: 13.6 
STX1A syntaxin 1A (brain) 12.63% 13.33% cerebral cortex: 83.6 
STX1B syntaxin 1B 10.00% 8.89% cerebral cortex: 43.2 
SYNGR3 synaptogyrin 3 9.47% 10.00% cerebral cortex: 38.9 
SYT1 synaptotagmin I 6.32% 6.67% cerebral cortex: 272.2 
SYT11 synaptotagmin XI 12.63% 12.22% cerebral cortex: 209.7 
TMEM132B transmembrane protein 132B 12.63% 13.33% cerebral cortex: 11.9 
TMEM132D transmembrane protein 132D 21.58% 21.11% cerebral cortex: 6.7 




We have thus gathered strong evidence to suggest that suspected BDPs are 
circulating within human plasma. A total of 120 BDPs were discovered and then 
independently identified in two larger cohorts (AIBL-2 and KARVIAH). A large 
majority of the protein groups have moderate-to-good spectral evidence to support 
their identifications. In addition, a further 52 probable BDPs were discovered in 
AIBL-2 and then observed in KARVIAH. Despite their confirmation in multiple 
cohorts all but 14 BDP protein groups were excluded from the main analysis due to 
their inconsistent measurement in both cohorts. It is likely that the very low 
abundances of these protein groups, expected to be at the limit of sensitivity for MS 
analysis, are the cause for the inconsistent measurement. Furthermore, if these 
protein groups are truly “brain-derived” biological and disease state will influence 
their abundances within plasma.  We have examined the association of these BDP 
with NAB as a continuous and binary measure. 
Of the 172 replicated BDPs only 119 were investigated. We chose to examine only 
protein groups with data present in >18 participants. Furthermore, protein groups 
GFAP, BDNF, NEFL, NRGN, SNAP25, FMN2, SH3 and multiple ankyrin repeat 
domains 1 (SHANK1), sodium channel, voltage-gated, type II, alpha subunit 
(SCN2A), APBA2, chromodomain helicase DNA binding protein 5 (CHD5), 
microtubule-associated protein 2 (MAP2), RIMS3, synaptotagmin XVI (SYT16) and 
myelin transcription factor 1-like (MYT1L) were not examined here due to their 
inclusion in the main analysis. NEFL and NRGN (Table 5-11, Table 5-13, Table 5-
14 and Table 5-15) were shown to have an associated with NAB. RIMSA and FMN2 
were associated with age (Table 5-9) whereas SHANK1, CHD5 and MAP2 were 
associated with gender (Table 5-8). Using a Spearman Rank Correlation we found 
five BDPs to be nominally associated with Aβ SUVR at the uncorrected <0.05 P 
value (Table 5-22). No proteins groups were found to be statistically significant 
when applying a multiple testing correlation. Furthermore, only two protein groups 
demonstrated significance when adding APOE genotype as an additional covariate; 
TAGLN3 (P = 0.026) and SLC1A3 (P = 0.006). Additionally, seven protein groups 
were found to be associated with Aβ classification at the uncorrected <0.05 P value 
(Table 5-23). Box plots demonstrating the group separation of the most significant 
BDP protein groups (DLG4 and SNCB) are shown in Figure 5-17 and Figure 5-18. 
BDPs found to be associated with NAB in this study are underpowered with a 
373 
 
number of candidates found in <50 participants. Replication using an MS-MRM 
assay utilising the peptides discovered in study or an ultra-sensitive targeted assay 
would be necessary. However, from the initial discovery in Chapter 4 and 
identification in AIBL-2 and KARVIAH we have good evidence to conclude a 
number of potentially disease relevant BDPs are circulating and measurable in 
plasma.  
Table 5-22: Protein groups termed as “brain-derived” associated with Aβ SUVR as 
continuous measure using Spearman’s Rank correlation. GLM residuals were created 
by adjusted for TMT10plex group, age, gender and sample cohort. Benjamini-
Hochberg Q values were all >0.3. 
Protein Name Gene name Rho n P value 
postsynaptic density protein 95 DLG4 -0.482 35 0.003 
adenylyl cyclase type 1 ADCY1 0.574 18 0.013 
ERC protein 2 ERC2 -0.295 71 0.013 
mylein basic protein MBP 0.520 118 0.027 
DS Cell Adhesion Molecule DSCAM -0.168 126 0.049 
neurexin 1 NRXN1 -0.195 89 0.067 
CKLF Like MARVEL Transmembrane 
Domain Containing 5 
CMTM5 -0.207 72 0.08 
solute Carrier Family 1 Member 3  SLC1A3 -0.408 18 0.092 
CASK Interacting Protein 1 CASKIN1 0.217 59 0.099 
SNCB SNCB -0.248 44 0.099 
Table 5-23: Protein groups termed as “brain-derived” associated with Aβ classification 
using Mann Whitney-U test. GLM residuals were created by adjusted for TMT10plex 




Gene name Total Aβ- Aβ+ Z P value 
postsynaptic density protein 95 35 13 22 -2.868 0.004 
SNCB 44 30 14 -2.621 0.009 
ERC protein 2 71 37 34 -2.371 0.018 
transgelin 3 18 9 9 -2.163 0.031 
tubulin Beta 2A Class IIa 27 17 10 -2.159 0.031 
kinesin Family Member 3C 44 29 15 -2.117 0.034 
iduronate 2-Sulfatase 52 30 22 -2.037 0.042 
adenylyl cyclase type 1 18 12 6 -1.873 0.061 




Figure 5-17: Box and whisker diagram to show the postsynaptic density protein 95 
(DLR4) group differences (P = 0.004) between Aβ- and Aβ- (n = 35). 
 
Figure 5-18: Box and whisker diagram to show the β-synuclein (SNCB) group 










































































In Chapter 4, we also described a group of proteins that were implicated in 
neurodegenerative pathogenesis or CNS injury/damage (Table 4-10). Of the 18 
protein groups highlighted in Table 4-10, a total of 14 were once again identified in 
AIBL-2 and KARVIAH. Protein groups that were not replicated in this study 
demonstrated poor spectral evidence in the discovery dataset. Seven of these protein 
groups were included in the main analysis with Aβ, NRGN and NEFL exhibiting an 
association with NAB. Eight other protein groups were not included in the main 
analysis due to being measured in only <50% of the dataset (BACE1, GAP43, 
ENO2, PARK7, RAB43, SOD1 and SYN1) therefore these protein groups were 
investigated for their association with NAB separately (Table 5-24). It was observed 
that only neuron specific enolase (ENO2 or NSE) demonstrated a significant but 
weak positive correlation with NAB (P = 0.036, Spearman’s Rho = 0.346; Figure 5-
19).    
Table 5-24: Protein groups involved in neurodegenerative pathogenesis discovered in 
plasma in Chapter 4 and the replication of discovery in Chapter 5.    
 










alpha-synuclein 218 Good 44 
amyloid beta A4 protein 57 Good 284 
β-secretase 1  8 Poor 18 
glial fibrillary acidic protein  160 Good 284 
microtubule-associated protein tau 13 Poor 284 
neurogranin  43 Moderate  276 
neurofilament light polypeptide 13 Good/Moderate  257 
neuromodulin  4 Moderate     12 
neuron specific enolase  10 Moderate 30 
protein DJ-1  26 Moderate     25 
ras-related protein Rab-3A  2 Moderate     18 
S100B  25 Moderate    n/a 
superoxide dismutase [Cu-Zn]  3 Moderate     18 
synapsin-1  12 Good           90 
synaptosomal-associated protein 25  10 Poor 257 
synaptophysin  2 Poor n/a 
synaptotagmin  5 Poor  n/a 




Figure 5-19: Scatter plot to show the correlation between neuron specific enolase 








































5.5 Discussion  
In this study we employed a deep proteomic profiling technique to discover, in some 
instances, novel plasma biomarkers of Aβ pathology assessed by either 11C-PiB or 
18
FBB PET imaging. Using an endophenotype design and an LC-MS/MS workflow 
we have described a substantial number of single plasma proteins significantly 
related to Aβ. Furthermore, we also detail a twenty-plasma protein panel, which was 
discovered and replicated by LC-MS/MS with 81% accuracy, increasing to 86.6%, in 
an independent cohort. 
In previous blood-based biomarkers studies, we and others have first utilised LC-
MS/MS as a hypothesis-generating tool to identify plasma protein biomarkers of AD 
pathology 
372-375
. An attempt was then made to replicate these markers by an 
orthogonal platform, typically ELISA. In most cases, this translation has been 
disappointing and this is likely due to key platform differences. Mass spectrometry 
involves the analysis of peptides resulting from denatured protein, whilst ELISA 
measures native protein, or more precisely the region of the intact protein where the 
epitope recognized by the antibody resides. It is possible, therefore, that the 
measurement of different protein regions and the introduction of non-analyte 
interference in ELISAs will affect these results. To our knowledge, this is the first 
time a multi-analyte plasma biomarker for an AD related phenotype has been 
discovered and independently replicated by LC-MS/MS and the commonality in 
platform between discovery and replication has certainly aided this successful 
replication.    
At the univariate level, a large number of protein groups were associated with Aβ 
pathology in correlation or group-wise analysis. Pathway analysis, as in Chapter 3, 
demonstrated that the coagulation and complement cascade pathways were 
overrepresented in this group. A total of 16 protein groups were associated with all 
statistical analysis in both the full dataset and cognitively normal individuals and 10 
protein groups passed multiple testing corrections (Aβ, NEFL, NEUROG2, APBB3, 
ATPVOA2, CROCC, REST, DENND3, FHAD1, CNGB3 and NRGN (Table 5-16)). 
Of these highly associated protein groups, only three were not included in our 
multivariate classifier. DENN domain-containing protein 3 (DENND3) was found to 
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be decreased in relation to elevated NAB and interestingly was found to be more 
associated with elevated NAB in the cognitively normal individuals (Q = 0.004). In 
the same manner, cyclic nucleotide gated channel beta 3 (CNGB3) was found to 
have a more significant negative correlation in the cognitively normal individuals. 
DENND3 and CNGB3 have not been previously linked to AD although have been 
implicated to C9orf72 related ALS 
543
 and macular degeneration 
544
 respectively. On 
the other hand, the link between AD and neurogranin (NRGN) has been widely 
reported. NRGN is a post-synaptic protein thought to have a major role in synaptic 
plasticity and it is hypothesised that synaptic degradation releases NRGN into the 
CSF. Consequently, increased levels of CSF NRGN have been extensively reported 
in AD 
528, 545-547
 but more encouragingly are seen to be specific for AD 
548
. 
Kvartsberg and colleagues 
528
, using MS, have been able to categorise NRGN 
peptides from CSF and plasma. While showing significant increases in NRGN CSF, 
that also correlate to Aβ1-42, they report no difference in plasma NRGN related to AD 
phenotypes and this has been verified by others 
549
. Furthermore, subgroups of 
NRGN peptides have been shown to be specific to plasma and not CSF as well as 
CSF specific peptides and those that are identified in both compartments 
528
. 
Kvartsberg and colleagues found there to be no correlation between CSF and plasma 
NRGN peptides. In our data, peptides that make up our NRGN protein score 
correspond with plasma specific peptides reported by Kvartsberg and colleagues 
528
 
and therefore confirming that our NRGN expression is exclusively peripheral. 
NRGN expression in the spleen, bone marrow, platelets and lung tissue has been 
previously reported 
550
 and this is our likely source. Nonetheless, in contrast to the 
studies mentioned, we report for the first time a highly significant positive 
correlation between plasma NRGN and Aβ SUVR. Increased levels of serum NRGN 
have been previously attributed to TBI 
551
. 
We also attempted to use the LC-MS/MS discovery findings from Chapter 3. This 
was largely unsuccessful with only 2/43 protein groups replicating a significant 
directional change in the Aβ (apoA1 and ITIH4). Significant methodological 
differences could explain this poor replication. Firstly, in Chapter 3, upfront 
fractionation was performed at the protein level by 1DGE. IDGE gel fractions were 
analysed and statistically examined separately. Identical protein groups found in 
separate gel fractions were considered as differing protein group MW isoforms as 
379 
 
protein modifications or proteolytic cleavage seemingly have altered structure to the 
native molecular MW of the protein. Therefore, protein groups identified by this 
method are likely to be fragment specific. In contrast, the LC-MS/MS methodology 
applied in this Chapter incorporated enzymatic digestion prior to fractionation. All 
peptides from a protein group were merged together for analysis; therefore, this 
method is a more global representation of overall protein levels in plasma. Further to 
this, Chapter 3 employed TMT protein labelling to be compatible with 1DGE 
separation. As previously described TMT protein labelling can only quantify 
between 52-57% of the identified peptides as TMT protein labelling is limited to 
lysine residues. Conversely, TMT peptide labelling utilised in this Chapter 
chemically labels each peptide toward the free amino-terminus, allowing 
quantification of almost all peptide sequences. Again, this points towards the 
methodology applied in this Chapter being a more accurate and global estimation of 
plasma protein expression. 
Many candidate biomarkers of AD pathology were identified in this study. Of these, 
20 protein groups (Table 5-18) were found by a combination of variable reduction 
analysis and support vector machine learning together to accurately predict elevated 
NAB. This plasma protein model was trained in the full AIBL-2 cohort and tested in 
the KARVIAH cohort. It is encouraging that a model of NAB trained in a mixed 
diagnosis cohort (AIBL-2) has good predictability in a cognitively normal cohort 
(KARVIAH) and demonstrates potential use as population screening tool. Using the 
univarite analysis as a guide, a differing protein panel may have been observed if 
only cognitively normal individuals in AIBL-2 were used to build the classifier. This 
is based upon CROCC, UBR1, ELMOD2 and ficolin-2 being only associated with 
Aβ when MCI and AD subjects were included in the study. Furthermore, targets not 
included in the model such as CNGB3, TF, DENN3, TIA and PCNX were more 
associated with cognitively normal individuals at the univariate level. Nonetheless, 
the observed high accuracy of predicting NAB by this panel (AUC 86.6%; Figure 5-
16) is of greater accuracy then previous blood-biomarker studies 
374, 437, 552
 and 
nearing the predictive ability of core CSF biomarkers. 
It must be noted that although entirely independent cohorts, AIBL-2 and KARVIAH 
plasma samples were prepared and analysed concurrently with one another. This 
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reduces the technical variability between the cohorts and therefore may inflate the 
result of our replication. Furthermore, a key advantage of employing an isobaric 
labelling technique for sample multiplexing is that it overcomes analytical variability 
that is introduced by single sample acquisition.  Quantitative TMT10plex reporter 
ions arise from a common fragmented precursor ion present in the sample. In most 
cases the precursor ion intensity will be a combined signal from all samples in a 
TMT10plex group. However, in our data, which has two different cohorts 
multiplexed together, it is possible that the precursor ion intensity maybe driven by 
one cohort of samples forcing a TMT reporter ion values in the other cohort.  
The protein groups included in the predictive panel are included in Table 5-18 and 
are discussed below, in terms of their biological function and relation or possible link 
to AD and Aβ pathology.   
5.5.1 APP processing 
The most significant protein group in all univariate level analysis was amyloid beta 
A4 protein (Aβ). Here, we observed a positive correlation between plasma Aβ and 
Aβ PET SUVR as well as a highly significant increase of plasma Aβ in Aβ+ 
individuals (Table 5-16). This highly significant association remained when 
examining just the cognitively normal group.  
The APP gene codes for a protein 770 amino acids in length. Alternative proteolysis 
in this protein group generates several fragments including Aβ peptides that are the 
principle composition of senile plaques in AD brains. The LC-MS/MS data 
presented here identified three unique Aβ peptides that were consistently measured 
in all subjects and were database matched to Aβ (Table 5-25). The sequences 
identified highlight peptides located within the C99 region (672-770) of the amyloid 
beta A4 protein. Proteolytic cleavage of C99 by γ-secretase results in the production 
of toxic Aβ1-40 and Aβ1-42. Peptide sequences “HDSGYEVHHQK” and 
“LVFFAEDVGSNK” fall within the region of Aβ1-40 and Aβ1-42 peptides (Table 5-
25). However, without further supporting evidence it cannot be determined if these 




Table 5-25: Peptide sequences and amino acid positions identified by LC-MS/MS 






HFEHVRMVDPKK 510-522 sAPPα/ sAPPβ 
HDSGYEVHHQK 676-687 sAPPα/C99/Aβ1-40/Aβ1-42 
LVFFAEDVGSNK 688-699 C99/Aβ1-40/Aβ1-42/C83 
 
Almost all of the investigations of Aβ in plasma have been performed by antibody-
based immunoassays. Mass Spectrometry efforts for the detection of Aβ in plasma 
have been limited to selected reaction monitoring (SRM) studies 
553-554
 or 
immunoprecipitation MS (IP-MS) 
555. The difficulties in detecting Aβ variants in 
plasma are due to the concentrations of Aβ1-40 and Aβ1-42 in human plasma being 
approximately 50-fold lower than in human CSF but the total protein concentration 
being 100-fold higher in plasma 
556
. We have shown that an unbiased and untargeted 
MS approach can be utilised to consistently measure Aβ peptides, although it is not 
as extensively measured as the aforementioned SRM and IP-MS studies. As 
previously discussed, the association of plasma Aβ peptides to AD and AD 






 or unchanged 
350, 377, 379, 381, 384, 557
 in relation to an AD 
diagnosis or elevated NAB. Rembach and colleagues 
380
 concluded that plasma Aβ 
species have limited diagnostic utility alone but do have utility as part of a peripheral 
panel, as Aβ is influenced by a number of peripheral age-related analytes 380. 
Burnham and colleagues 
437
 have previously described the validity of including 
plasma Aβ1-42 in a multi-analyte panel and our data, without being able to determine 
the species of Aβ, comes to a similar conclusion.  
A hypothesised theory in the field suggests that the clearance of CSF A into the 
blood gives the reasonable assumption that plasma A levels would follow the same 
disease related trend as CSF. However, it is important to consider and not over 
simplify the source of circulating Aβ fragments. APP processing occurs in a wide 
variety of tissues in both the CNS and periphery 
558
 with skeletal muscle, platelets 
and vascular walls generating Aβ peptides in the heart, pancreas, liver and kidneys 
559
. These compartments may allow for an active exchange of Aβ peptides between 
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the brain and periphery but undoubtedly contribute to the pool of circulating Aβ 
peptides 
558
. Studies have demonstrated that Aβ processing in the periphery does 
differ from the CNS and therefore distinctions can be made 
560
. Conversely, 
increased platelet Aβ peptide levels with associated reduced α-secretase and 
increased β-secretase activities indicates that blood platelet Aβ is processed by the 
same amyloidogenic and non-amyloidogenic pathways as the CNS 
561
. An increased 
Aβ blood platelet levels associated with clinical AD have been previously shown 561-
563
 and is in concordance with the results we demonstrate.  
We also reported the significant positive association of the amyloid beta A4 
precursor protein-binding, family B, member 3 (APBB3) and Aβ SUVR. APBB3 is a 
member of the FE65 protein family (with APBB1 and APBB2), adaptor and 
scaffolding proteins that mediate complexes through a variety of protein interactions 
including Aβ 564. FE65 proteins are highly expressed in the brain; however APBB2 
and APBB3 have been shown to be expressed in a variety of tissues. All FE65 
proteins have similar structures; however, they diverge in their N-termini. Peptides 
identified in our study show exclusivity to APBB3 and these exact peptides 
sequences have been previously identified in a large MS plasma study giving further 
validity to their assignment 
565
. To our knowledge, APBB3 has not been shown to be 
differentially expressed in blood for any disease modality. In cellular models, 
APBB3 has been shown to promote Aβ production 566. A polymorphism in 
the APBB3 gene was shown to be a risk factor for EOAD 
567
 whereas a deletion in 
the APBB1 gene has been reported to have a protective effect in individuals over 75 
years 
568
. However, the role for FE65 proteins in the adult brain is not fully 
understood, particularly with regard to their individual effects on APP processing. 
The presence of APBB3 in blood plasma, it’s highly significant association with 
NAB and peripheral Aβ peptides revealed here suggest a mirrored role of alternative 
Aβ processing in blood.       
5.5.2 Coagulation and complement pathways 
Interestingly, prothrombin and hyaluronan-binding protein 2 (HABP2) were 
included in our protein classifier and at the univariate level were shown to be 
decreased in relation to elevated NAB. The identification of prothrombin and 
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HABP2 once again highlights the importance of fibrinogen production, fibrin 
cleavage products and the coagulation cascade in AD 
484, 489
. It also supports the 
growing body of evidence for the physical interaction between coagulation factors, 
APP processing and Aβ peptides 484-485, 489. The coagulation cascade activates a 
series of events that lead to the production of thrombin (a serine protease) from 
prothrombin; this mediates the conversion of fibrinogen to fibrin. In the brain, 
thrombin affects several processes that are directly relevant for AD. Thrombin (also 
code by the F2 gene) in vitro can stimulate production of APP and cleavage of APP 
into fragments 
569
. Furthermore, thrombin is also important for the proteolytic 
processing of tau 
570
. On the other hand, HABP2 is another serine protease that does 
not act upon F2 but directly cleavages α and β chains of fibrinogen at multiple sites. 
This action prevents thrombin’s action in creating cleavage products (fibrinopeptide 
A and B) and therefore disrupts the formation of clots pointing towards HABP2 
being an inhibitor of coagulation 
571
. In blood, AD subjects often show increased clot 
formation, decreased fibrinolysis, and elevated levels of thrombin, fibrinogen and 
coagulation factors 
371, 404, 483, 572-576
. A decrease expression of an inhibitor of the 
coagulation process, such as HABP2, would be in line with this theory. However, we 
have extensively demonstrated the negative relationship of coagulation activators 
and products F2, factor Xa (F10), plasma kallikrein (KLKB1), factor XIII (F13A-1) 
and fibrinogen chains (Chapter 3) with NAB. An explanation for this observed 
decrease in response to AD pathology could be that coagulation factors also act upon 
the complement system 
577-578
. An overactive complement system is often reported in 
AD and this would correspond to a reduction in complement inhibitors that include 
fibrinogen (α, β, γ) and F2.  
In the brain, a bidirectional association between the complement and coagulation 
systems occurs. Complement proteins are the target for several coagulation factors 
and therefore the levels of coagulation factors present in the AD brain could enhance 
the activation of the complement cascade 
484, 579
. On the other hand, complement 
activation might lead to coagulation and fibrin deposition 
484
. Aβ and tau are potent 
activators of the complement pathway 
580-581
 and therefore in AD, after Aβ and tau 
activation, a complement response may induce a prothrombic state. With 
complement and coagulation factors prominent in blood it is likely that this 
interaction between these systems occurs in the periphery. This is supported by both 
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LC-MS/MS discovery investigations in this thesis demonstrating significant protein 
groups that were over-represented for involvement in complement and coagulation 
cascades simultaneously. 
The complement system is critical in both the innate and adaptive immune system, 
and has been previously associated in the pathogenesis of many neurodegenerative 
diseases, including AD 
582-583
. The complement system is divided into three main 
pathways (Figure 5-20). The classical pathway primarily acts to lyse cells and 
bacteria already recognised then signalling these cells for immunological clearance. 
The alternate pathway acts independently of plasma antibodies and binds to cells and 
bacteria that do not express complement decay accelerating factor (DAF). The 
mannose-binding lectin (MBL) pathway recognises lectins and ficolins, common 
bacterial surface proteins and acts primarily to lyse bacteria and target them for 
immunological clearance. Furthermore, in relation to coagulation, another 
complement activation pathway, named the extrinsic pathway that is driven by 








Complement C3 (CC3) is a central component in the complement system, where all 
three major pathways converge. CC3 is one of the most common plasma proteins to 
be reported as an AD biomarker (reviewed by 
354, 552
) and Aβ pathology 373, 375, 436 but 
conflicting results suggested both a protective role and causal role for CC3. In 
Chapter 3, we found a significant decrease of CC3 (42% protein sequence coverage) 
in relation to elevated Aβ using LC-MS/MS however here we found a non-
significance increase of CC3 with Aβ (87% protein sequence coverage). The 
differences in protein sequence coverage and directional change of CC3 between 
these studies suggest that CC3 isoform/fragment specific association with Aβ should 
be investigated. At the univariate level we have shown increased complement C1s 
(C1s) and CC5 are nominally associated with elevated NAB. CC5 is only associated 
with Aβ in the cognitively normal groups only, suggesting it is an early event in 
relation to Aβ deposition. However, our main finding in relation to the complement 
pathway is the highly significant association and inclusion of ficolin-2, an activator 
of the lectin complement pathway, in our twenty-plasma prediction model.  ficolin-2 
was found to be significantly negatively correlated with Aβ+ individuals and was 
more significant in an endophenotype approach. Ficolin-3 shares 50% amino acid 
homology with ficolin-2 
129
 and was also found to be significantly reduced with Aβ+ 
subject in AIBL-1. Ficolin-2 has previously been associated with type 2 diabetes 
585-
586
, diabetic peripheral neuropathy 
146
 and more recently plasma ficolin-2 was 
discovered to be associated with CSF Aβ1-42 measures in an endophenotype LC-
MS/MS study (Baird AL et al., under review). 
5.5.3 Transcription factors 
REST (Repressor Element 1-Silencing Transcription factor) is a protein that 
modulates neuronal differentiation and gene expression, and more recently been 
found to play an important role in AD 
587
. Though highly expressed during 
development, REST was not thought to be expressed in the adult brain. However, 
recent observations indicate REST expression increases in the aging brain. REST 
expression has been shown to protect mature hippocampal neurons from toxic 
insults, e.g., hyperexcitation, and to play a key role in regulating the ageing brain’s 
response to stress 
588
. Furthermore, preclinical and clinical evidence demonstrate that 





. Recently, the peripheral expression of REST, in relation to 
AD, has become of great interest. REST has been identified in neuronally-derived 
exosomes circulating in plasma and that levels are reduced in AD and MCI subjects 
530, 589
. Furthermore, unpublished data has also demonstrates that reduce levels of 
REST is found in AD and converting MCI plasma using an immunoassay approach 
(Ashton NJ et al., under review). Here, we have also demonstrated a reduction in 
REST but for the first time in relation to Aβ pathology. It is possible that the 
denaturing conditions of LC-MS/MS methodologies would ensure that cargo from 
neuronally-derived exosomes and peripherally circulating REST would be measured 
as one entity. Commercial immunoassay analysis often does not allow for 
identification of protein epitopes measured. Database probability matching in this 
study has identified four peptide sequences to isoform 4 of REST (Table 5-26). 
Isoform 4 of REST differs to the canonical sequence by having amino acids 304-326 
deleted from the sequence. However, sequence information obtained from our LC-
MS/MS data cannot differentiate between isoform 1 or isoform 4 of REST. We can 
conclude that isoforms 2 and 3 of REST are not present in our sample as the peptide 
sequences identified are deleted from those isoforms sequences (Table 5-26).  
Table 5-26: Peptide sequences and amino acid positions identified by LC-MS/MS 









Neurogenins are a family of basic helix-loop-helix (bHLH) transcription 
factors involved in specifying neuronal differentiation 
590
. In the developing cerebral 
cortex, neurogenin-1 and neurogenin-2 are expressed exclusively in the cortical 
ventricular zone during embryonic neurogenesis 
591
. Contrasting to neurogenin-1, 
which is only expressed in the developing brain, neurogenin-2 (NEUROG2) is 
expressed in both embryonic brains as well as in adult hippocampal neural 
progenitor cells 
592-593
. Hippocampal neurogenesis is thought to be essential in 
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maintaining hippocampus related cognitive abilities 
594
 and if impaired adds to the 
progression of AD 
595
. In animal models of AD, the regeneration of hippocampal 
neurones is decreased in the presence of toxic Aβ peptides 596 supporting the notion 
that AD related pathology directly affects neurogenesis. Further to this, studies have 
shown that a potential normal function of APP regulates NEUROG2 to increase 
hippocampal neurogenesis 
597
. In this study, we have identified two unique peptide 
sequences consistently measured in >94% of individuals that are unique to 
NEUROG2. Together these plasma peptides have highly significant correlations with 
Aβ and increases in Aβ+ individuals, even after statistical correction for multiple 
testing. We also demonstrate that NEUROG2 is more associated with Aβ in the 
cognitively normal group and is highly correlated with Aβ peptides that have been 
detected by the same approach. It is unclear if this increased expression of 
NEUROG2 is related to adult neurogenesis in response to NAB or even if these 
NEUROG2 peptides are brain-derived. However, NEUROG2 is a putative novel 
peripheral marker that has established mechanistic connections with cognitive 
decline and AD pathology. The presence of NEUROG2 in plasma has only been 
described in one large-scale plasma profiling study 
565
 despite having evidence of 
peripheral tissue expression. Interestingly, NEUROG2 was not identified in our 
proteomic profiling study in Chapter 4, even though the same methodology and 
analytical apparatus was applied. This would point towards cohort differences and 
analytical variation having an impact on the detection of NEUROG2.  
Inflammation and oxidative stress is a well-documented event in ageing and AD 
(reviewed in 
598-599
) and these processes have been shown to stimulate the NF-κB 
family. NF-κB transcriptionally regulates genes involved in cytokine expression, 
chemokine expression and adhesion molecules. In addition, NF-κB regulates both 
pro-apoptotic and anti-apoptotic genes 
600
. The role of an abnormal NF-κB signalling 
system is well described in a number of age-associated diseases 
601-602







 and atherosclerosis 
606-607
. We 
have identified a key member of the NF-κB family, transcription factor p65 (RELA), 
to be decreased in the plasma of individuals with elevated Aβ SUVR. Although 
nominally associated at the univariate level, RELA was highlighted by variable 
reduction analysis and included in our twenty-plasma protein panel. NF-κB, via 
RELA, regulates IL-1β and TNFα and these key inflammatory proteins are found at 
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increased levels in the brains of AD patients 
608
. The decreased levels of RELA we 
observe could suggest an aberrant NF-κB modulation leading to increased peripheral 
inflammation. Evidence suggests that overstimulation and chronic activation of NF-
κB plays not only a critical role in AD related inflammation and cytokine signalling 
but also senile plaque formation 
609-610
. Further to this, in PD, a 70-fold increase in 
RELA activation is found in dopaminergic neurons 
611
 with NF-κB inhibitors 
improving motor function in PD animal models 
612
. Many have postulated the NF-κB 
system as a possible therapeutic target for AD 
613
. The peripheral measurement of 
NF-κB, by RELA, offers the opportunity to track NF-κB activation in relation to 
disease and in response to therapy, although, the connection of how plasma 
expression of RELA relates to CNS RELA needs to be determined.   
5.5.4 Axonal injury 
Neurofilaments (NF) are the most abundant neuronal cytoskeletal proteins in the 
CNS and are crucial to the structure of axons and transport. NF’s are composed of 
three subunits based on the molecular weight; high (NFEH), medium (NFEM), and 
light (NFEL). NF subunits, mainly NEFL, are actively involved in the pathogenesis 
of axonal injury and degeneration both as causative agents and progression markers 
for a number of neurological diseases.  NEFL is expressed in neurons in both the 
CNS and peripheral nervous system (PNS) 
614
 and therefore neuronal damage is seen 
to release into the extracellular compartment resulting in increased CSF NEFL levels 
615
. High CSF levels of NEFL have been suggested to be consequence of normal 
ageing 
348, 616-617






, progressive supranuclear palsy (PSP) 
623
 
and multiple sclerosis 
624
. More recently, CSF NEFL levels have been shown to be a 
marker of accelerated cognitive decline and shorter survival time across several 
neurodegenerative diseases 
348
. The substantial overlap of CSF measures of NEFL 
across neurological disease has attributed this marker to one of disease integrity, 
progression and not to be disease specific marker 
625
. NEFL is detectable and 
quantifiable in blood and shown to be more than 50-fold lower in concentration than 
in the CSF using an ultra-sensitive assay 
363
, although we have demonstrated NEFL 
measures using an untargeted MS approach. Similar findings have been described in 









An encouraging finding is that NEFL CSF and plasma concentrations seem to be 
correlated in a number of studies 
363, 627-628
 supporting the notion that plasma NEFL 
is a reflection of CNS damage.  
We have identified six unique peptides that correspond to NEFL in plasma (Table 5-
27); although two peptide sequences cannot be distinguished from NEFM we believe 
that there is good supporting evidence to conclude they are peptides from NEFL 
(Table 5-27). NEFL, after Aβ, was the most statistically significant finding in our 
study. We demonstrate that a highly significant correlation exists between NEFL and 
Aβ, which reveals increased NEFL with Aβ+ individuals.   
Table 5-27: Peptide sequences and amino acid positions identified by LC-MS/MS 
matched to neurofilament light chain (NEFL). 
Peptide Sequence 
Amino acid positions 
NEFL NEFM 
ALYEQEIR 137-144 n/a 
LAAEDATNEK 148-158 n/a 
QNADISAMQDTINK 340-353 n/a 
EYQDLLNVK 370-379 383-391 
LLEGEETR 392-399 404-411 
VQSLQDEVAFLR n/a 224-236 
 
Our finding is in keeping with previous studies, although we do not find an age 
related increase of plasma NEFL. In contrast to other NEFL investigations we found 
a significant association between APOE ε4 and plasma NEFL, however a partial 
correlation to account for APOE genotype did not change our overall NEFL 
association. As previously hypothesised, it is possible that observed elevation of 
plasma NEFL is a reflection of CNS injury and not that of Aβ SUVR itself. It has 
been shown that CSF concentrations of NEFL (and therefore plasma NEFL) are not 
driven by pathological Aβ 625. In support of this, the small number of AD and MCI 
subjects with low Aβ SUVR (Suspected Non Amyloid Pathology; SNAP) in our 
study continued to demonstrate high levels of NEFL (data not shown). Moreover, in 
other studies, NEFL measures have been seen to correlate with cognitive decline and 
therefore our finding maybe driven by the significant difference of MMSE between 
our Aβ- and Aβ+ groups (Table 5-1). However, our result still remained significant 
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when correlating NEFL with Aβ SUVR in only cognitively normal individuals 
where no difference in cognition is observed. As the Aβ cascade hypothesis suggests 
that Aβ deposition is the main initiator behind events that result in neuronal death, a 
clear link between elevations of NEFL in response to NAB can be made. Therefore, 
our data indicates that plasma NEFL could be an early marker of CNS injury that is 
consequence of preclinical Aβ deposition.  
5.5.5 G protein coupled receptors  
G protein coupled receptors (GPCRs) are essential membrane proteins that convert 
extracellular signals into intracellular responses, including responses to hormones, 
neurotransmitters, vision, olfaction and taste signals 
630
. Substantial evidence points 
towards GPCRs and GPCR related proteins in the pathogenesis of AD, notably Aβ 
plaques formation 
631
 as well as α-secretase, β-secretase and γ-secretase activity 632-
633
. Our data highlights the association of four GPCRs (probable G-protein coupled 
receptor 115 (GPR115), olfactory receptor 52I2 (OR52I2), ELMO domain 
containing 2 (ELOMD2) and G protein signalling modulator (GPSM2)) to have 
decreased peripheral expression in related to elevated Aβ SUVR. Although these 
specific GPCR’s have not been directly related to AD pathology, it does indicate a 
more global alteration of GPCRs in response to NAB.  
GPR3, a close relative of GPR115, participates in the mediation of Aβ generation by 
affecting the activity of the γ-secretase complex 634-635. GPR3 is strongly expressed 
in neurons in the hippocampus, entorhinal cortex and thalamus in the normal human 
brain and its expression is increased in patients with sporadic AD 
634
. Furthermore, 
olfactory disruption is a well-documented event in dementia 
146
 and has been 
considered to be an early clinical event in AD 
636
. Olfactory function impairment 
tests alone or as part of battery of clinical examinations has been shown to predict 
MCI conversion to AD with high accuracy 
637
. Furthermore, evidence from Tg2576 
AD mouse model studies suggest that olfactory deficits may stem from non-fibrillar 
Aβ toxicity 638. OR52I2 is a GPCR olfactory receptor that acts to initiate a neuronal 
response that perceives smell. It is therefore interesting that our plasma data 
demonstrates a decrease in those with elevated Aβ. Unlike GPR115, ELOMD2 and 
GPSM2, OR52I2 has been described as a part of the plasma proteome previously 
565
.      
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5.5.6 Other plasma protein groups of the multi-analyte classifier  
V-type proton ATPase 116kDA subunit (ATP6V0A2), forkhead-associated domain-
containing protein 1 (FHAD1) and dynein heavy chain 10 (DNAH10) were all 
significantly associated with Aβ SUVR in all univariate analysis and were all seen to 
have increased expression in the Aβ+ group.  
ATP6V0A2 is involved in pH homeostasis and intracellular transport and has been 
described to reside in endosomes and in a compartment overlapping with the trans-
Golgi network, a major secretory pathway that directs newly synthesised proteins. A 
mutation in the gene encoding for ATP6V0A2 causes autosomal recessive cutis laxa 
type II, which has major disruption of the golgi trafficking system 
639
. Golgi 




 and more 
recently has been hypothesised to underpin abnormal accumulation of Aβ 642.  
The specific role of FHAD1 has not been elucidated however the family of forkhead-
associated (FHA) domains have been shown to have major roles in a range of 
biological functions such as cell cycle controls and DNA damage repair 
643
. More 
recently, FHA has been linked to immune responses and the signalling pathways 
leading to NF-κB activation 643. Therefore, our observation of increase plasma 
expression of FHAD1 in conjunction with the decreased expression of RELA, 
described above, could indicate faulty NF-κB activity.   
DNAH10 and as well as rootletin (CROCC) were included in the twenty-plasma 
protein panel for Aβ prediction. Interestingly, both these proteins are components of 
the primary ciliary root structure. Moreover, cilia and flagella associated protein 43 
(WDR96) also primary cilia root protein was significant with Aβ at the univariate 
level. Primary cilia are solitary organelles that protrude from the cell surface in most 
mammalian cell types and the ciliary rootlet links the base of the cilium to the cell 
body. Increasing evidence suggests that primary cilia are key coordinators of 
homeostasis and signalling pathways and when defective are a major cause of human 
diseases and developmental disorders 
644-645
. Several studies have implicated ciliary 
and basal body proteins in the regulation of Wnt signalling. The Wnt-planar cell 
polarity (Wnt-PCP) pathway has been shown to mediate many of the major 
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neurotoxic effects of Aβ and many aspects of AD neuropathology, including synapse 
loss and subsequent cognitive decline 
646
. Although the structural components of the 
ciliary rootlet have been described very little is known about their function 
647
. A 
hypothetical function suggests a role as a critical support structure for the cilia, 
especially in situations where mechanical stress is expected to be high 
648
. Therefore, 
a deficit in the support structure of cilia could lead to the neurotoxic effects of Aβ 
via the Wnt-PCP pathway. Although CROCC is the major component of the cilia 
root, we found a stronger association of DNAH10 and Aβ. DNAH10 is primarily 
linked to respiratory cilia, although its expression has been observed in the brain. A 
variant in the DNAH10 gene has been linked to Charcot Marie Tooth disease, an 
inherited peripheral neuropathy 
649
.   
E3 ubiquitin-protein ligase (UBR1) was shown to be increased in Aβ+ subjects 
however; this association was lost when examined in cognitively normal subjects 
only. Ubiquitin-protein ligases, like UBR1, are of particular importance in disease as 
they determine the targeting specificity of the ubiquitin system 
650
. Such molecules 
have been found to be mutated, absent or malfunction in some hereditary forms of 
neurodegenerative disorders and indeed the presence of ubiquitin-positive, intra or 
extracellular inclusion are found in a number of neurodegenerative diseases 
651
. In 
the same manner, secreted phosphoprotein 24 (SPP2) and histone RNA hairpin-
binding protein (SLBP) were not associated with the cognitively normal group but 
decreased in relationship was observed with NAB as a whole group. This suggests 
that these three protein groups are more associated with NAB in established disease. 
SPP2 is a member of the cystatin superfamily with a genetic link to degeneration of 
the retina 
652
 whereas SLBP is an essential RNA binding protein essential for the 
coordination of histone gene expression with DNA synthesis. 
5.5.7 Identification and replication of brain-derived proteins in plasma 
Cerebrovascular pathology is common in normal aging and this is often marked by 
noticeable damage at the BBB. This process seems to be exacerbated and accelerated 
during AD and other dementias where vascular impairment is common 
487
. Various 
mechanisms have been suggested as a source of the BBB dysfunction in AD, with 





. Under normal conditions, processes at the BBB endothelial cells are 
meant to prevent the unregulated leakage of plasma proteins into the CNS. Several 
alterations in a dysfunctional BBB are observed at these endothelial cells, such as, 
loosening of the tight junctions, increased pinocytosis and subsequent increased 
barrier permeability 
487
. Therefore, ion balance, nutritional transport and the 
modulation of peripheral extravasation are impaired leading to secondary neuronal 
injury and neurodegeneration.   
We have already hypothesised this peripheral extravasation by observing decreased 
plasma FGγ in AD vulnerable individuals. We believe, supported by others, that the 
movement of FGγ (and other coagulation by-products) into the CNS (Chapter 3), in 
response to a dysfunctional BBB, enhances the aggregation of Aβ fibrillisation and 
inflammation by depositing as insoluble fibrin 
490-491, 654
. As well as the influx of 
potentially neurotoxic peripheral molecules into the CNS, it has been suggested that 
there is a bidirectional movement of proteins across the dysfunctional BBB 
655
. It 
must be noted that even under normal physiological conditions, substances are still 
able to cross the vascular BBB, and blood-CSF barrier, into the blood circulation by 
a variety of mechanisms 
655
. Therefore, plasma could be a rich source of brain-
derived proteins (BDP) that have the potential for being biomarkers of CNS injury 
related to neurodegeneration and/or BBB integrity. 
There has been some effort to target hypothesised BDPs in the plasma as alternative 
non-invasive assessment of BBB dysfunction. Currently, the gold standard 
measurement for BBB damage is the calculation of the CSF/plasma albumin ratio 
(Qalb) and this has been widely reported to be increased in AD (reviewed in 
350
). 
S100B has been the leading candidate of BBB integrity in the periphery 
519, 525
. 
S100B is primary synthesised in the brain by the end feet process of the astrocytes 
and is quickly released from the brain into the blood when the BBB is disrupted 
656
. 
However, we describe no detection of S100B in the AIBL-2/KARVIAH cohorts 
despite its identification in the method development phase. This may be attributed to 
AIBL-2/KARVIAH being a predominantly cognitively normal cohort and therefore 
minimal BBB dysfunction has occurred. In support of this, Qalb has been shown to 
be unchanged in preclinical and prodromal AD as well as having no relation to Aβ 
SUVR 
657
. We were able to measure other candidates of BBB integrity (GFAP and 
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ENO2) which are also seen to be markers of astroglial and neuronal injury 
respectively. We found no difference in detectable GFAP between Aβ- and Aβ+ 
individuals, which is in line with more recent evidence 
536
. However, a significant 
increase of γ-Enolase (ENO2, also known as NSE) with increased Aβ and this in 





 and other neurodegenerative disorders 
658
. However, this finding needs to be 
taken with caution; 1) the participant numbers with measured ENO2 in this study 




We utilised the Human Protein Atlas (HPA) as a guide to generate a list of protein 
groups highly expressed in the CNS and hypothesised these to be primarily brain-
derived. Cross referencing with our plasma data we generated evidence of 157 
“BDP” protein groups circulating in plasma (Chapter 4) and here we replicate the 
peripheral expression of 120 protein groups, and due to increased sample size a 
further 52 BDP groups were identified in the AIBL-2 and KARVIAH cohorts. 
However, peripheral expressions of these protein groups were inconsistently 
measured in these cohorts. It was observed that only 14/172 were present in >50% of 
the data (Table 5-20 and Table 5-21) and these included axonal neuronal, astrocytic, 
and synaptic protein groups, of which, NEFL and NEUROG2 were found be 
associated with increased Aβ SUVR. The inconsistent measurement of BDP in this 
plasma dataset is not surprising given their likely low concentration levels being at 
the limits of detection for this MS methodology Furthermore, the inclusion of only a 
small number of MCI/AD subjects infers a small number individuals with active 
BBB impairment. Nonetheless, we have consistently identified the existence of a 
number of suspected BDPs, within plasma, across two independent studies and three 
distinct cohorts.  
BDPs that fell below the 50% cut-off for the inclusion into statistical analysis 
pipeline were analysed separately for their association with Aβ. Postsynaptic density 
protein 95 (DLG4) was the protein group most significant this analyse. DLG4 (also 
known as PSD-95) is a post-synaptic protein, which plays an important role 
in synaptic plasticity and synaptic changes during long-term potentiation 
660
. We 





. β-synuclein (SNCB) was also found to be significantly decreased 
in the Aβ+ group (Figure 5-18). As described in Chapter 4, SNCB is found 
predominately in the pre-synaptic terminal and highly homologous to α-synuclein. 
SNCB is thought to inhibit SNCA aggregation and therefore may protect the CNS 
from the toxic effects of SNCA. It is also interesting to find Down syndrome cell 
adhesion molecule protein (DSCAM) associated with NAB. Although no previous 
association made with AD or Aβ, DSCAM is associated with patients that develop 
Down’s syndrome (DS). Individuals with DS have an extremely high incidence of 
early-onset dementia with an age dependant accumulation of A. Another protein 
group found to be associated with Aβ is myelin basic protein (MBP). MBP has been 
hypothesised as a marker of axonal injury 
359
 and has been shown to co-localise with 
Aβ plaques in the AD brain 662-663. MBP has been detected in the CSF and plasma 565 
however these levels have yet to be associated with disease.   
The detection of suspected BDP groups in plasma is encouraging and we propose 
that selected BDPs should be further investigated, even if not to be associated with 
Aβ in this current study. Protein groups which have an origin at or in neurones, 
axons, dendrites or synapses should be investigated as a priority (Table 5-28). There 
will be two significant challenges in investigating these BDP in more detail. Firstly, 
it is clear that the methodology applied here it not sensitive enough to measure BDP 
consistently in all subjects, although it is was successful in uncovering plasma 
expression of BDPs. A more targeted approach should be employed for the 
consistent measurement of these protein groups. Targeted MS-SRM derived from the 
peptide data generated here would be possible and the opportunity to identify 
multiple targets simultaneously is a major advantage. However, MS-SRM is largely 
dependent on the quality and number of peptides previously identified. An approach 
that is more likely to be successfully would be a custom ultra-sensitive single 
molecule digital array, such as SIMOA or Singulex, although the quality of this 
assay would be determine on paired antibodies available for a given target. Secondly, 
evidence presented in Table 4-9, Table 5-20 and Table 5-21 clearly demonstrate a 
number of BDPs have evidence for peripheral tissue expression, despite being 
minimal in most cases.  Therefore, it is critical to elucidate the origin of the 
peripheral signal and to determine if it is truly brain-derived. Lastly, the sample 
cohort used to measure BDPs is likely to be a confounding factor. The stage of 
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dementia, age, APOE genotype, BBB integrity, TBI, vascular disease and 
autoimmune diseases are all likely influence the level of BDP in the periphery.         
Table 5-28: Examples of BDP detected in plasma in this study that should be further 





structure that could 






Beta-Synuclein SCNB Synapse No 
Chromosome 4 open reading frame 50 C4orf50 Unknown No 
Growth Associated Protein 43 GAP43 Synapse Yes 
Kinesin-like protein 1A KIF1A Axon No 
Microtubule-associated protein 2 MAP2 Dendrite No 
Mylein Basic Protein  MBP Axon Yes 
Neurone Specific Enolase ENO2 Neuron Yes 
Oligodendrocyte-myelin glycoprotein OMG Axon No 
Oligodendrocytic Myelin Paranodal 
And Inner Loop Protein 
OPALIN Axon No 
Postsynaptic density protein 95  DLG4 Synapse Yes 
Proteolipid Protein 1 PLP1 Axon Yes 
Spectrin Breakdown Products n/a Neuron No 
Synapsin I SYN1 Synapse Yes 
Synaptosome Associated Protein 25 SNAP-25 Synapse Yes 
Synaptotagmin 1 SYT1 Synapse No 
Syntaxin 1A STX1A Synapse No 
Tropomodulin 2 (neuronal) TMOD2 Neuron No 
Ubiquitin C-Terminal Hydrolase L1 UCHL1 Neuron Yes 
 
5.5.8 Conclusion  
Plasma proteins associating with brain Aβ burden have previously been shown to 
have the potential to act as biomarkers of early AD related pathology. However, 
attempts in profiling plasma for AD endophenotypes related species have been 
limited to pathway driven immunoassays and gel-based proteomics, which lack 
statistical power and proteome coverage. Using an unbiased LC-MS/MS profiling 
technique, this investigation identifies biomarker signatures, in plasma, that differ 
between individuals with and without neuropathological hallmarks of AD. At the 
single analyte level we identified numerous candidate biomarkers, which continued 
397 
 
to point towards activation of the coagulation system in relation to AD and Aβ 
burden. AD related proteins such as Amyloid beta A4 protein, Neurofilament light 
and RE1-silencing transcription factor were also readily quantified and found to be 
statistically related to Aβ SUVR. Furthermore, a large number of novel putative 
markers were correlated with Aβ pathology in cognitively normal individuals as well 
as the identification of protein groups proposed to be exclusively brain-derived that 
warrant further investigation. 
Using a variable reduction analysis and support vector machine learning analysis, a 
twenty-plasma protein classifier was built and was able to predict Aβ positive 
individuals with a high accuracy (86.6%) in an independent cohort that consisted of 
cognitively normal individuals. This panel most likely needs to be refined, simplified 
and certainly validated in independent cohort by independent laboratories.  
Furthermore, efforts need to be made to successfully translate this panel to a 
simplified assay suitable for population screening. At the very least, the prediction of 
Aβ by these biomarkers in healthy elderly individuals, nearing comparable levels of 
core CSF measures, offers potential in preclinical stratification for clinical trials and 
early intervention targets worthy of further investigation.  
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CHAPTER 6  
DISCUSSIONS AND CONCLUSIONS 
 
6.1 Overall summary 
Recently, research has shown that it is possible to detect a peripheral signal of AD or 
AD related pathology. Whilst it remains unclear if these signals are causative factors, 
a direct reflection of AD pathology or secondary factors in response to CNS changes, 
it is now apparent that plasma is a valuable source of potential biomarkers of the 
disease. The majority of research has focused upon the predictability of differentially 
expressed proteins to classify diagnostic groups. These studies have highlighted 
candidate biomarkers and pathways that have high sensitivity and specificity; 
however these approaches have inherent limitations. The clinical heterogeneity in 
AD and active neuropathology in “healthy controls” is overlooked with these 
approaches. It is therefore possible that a “case versus control” design may reflect 
secondary changes derived from cohort specific variables, with limited involvement 
in the primary disease. A recent adjustment in the approach for plasma biomarkers 
has seen the use of established surrogate markers of AD as the primary outcome 
measurement. This includes stratification of studies based upon APOE genotype, 
cognitive decline, brain atrophy and more recently neocortical Aβ burden (NAB).  
The primary aim of this work was to discover and validate plasma biomarkers of in 
vivo NAB, as a preclinical and/or prodromal surrogate risk for developing clinical 
AD. Recent evidence from anti-Aβ therapeutic trials suggest that intervention at only 
the earliest stages will be beneficial for those at risk. Phase III trials targeting Aβ 
reported that approximately 20% of trial participants actually had little or no A 
when studied retrospectively and this is likely to increase substantially in studies 
involving only cognitively normal individuals. Therefore, biomarkers that can 
accurately identify suitable participants for such trials and track pathological 
progression would be of critical value. The considerable progress in the development 
of Aβ PET tracers and the standardisation of CSF sampling in evaluating in vivo 
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NAB has seen their routine implementation within research, therapeutic and clinical 
settings. However, a blood-based biomarker that is cost-effective and more broadly 
available than these techniques would be more practical and of use to the wider 
research community. Prior to this work only a small number of studies had 
investigated a blood-based signature for NAB 
373, 437, 552
. These initial studies were 
restricted to predefined assay panels or 2DGE, a lengthy technique limited to 
identifying only a small number of candidates in limited sample sets. This thesis 
aimed to expand upon these two proteomic approaches; firstly, an unbiased 1DGE 
proteomic screen examined 78 subjects with either high or low Aβ pathology with 
surrogate measurements by 
11
C-PiB (Chapter 3). Despite this preliminary study 
being the largest MS proteomic screen of Aβ related blood-biomarkers to date, with 
replicated candidates being discovered, it became apparent that limitations existed. 
Therefore, a methodical review aimed to investigate the weaknesses of this study and 
to identify suitable improvements while maintaining its strengths. A refined unbiased 
proteomic methodology which incorporated immunodepletion, TMT10plex peptide 
labelling and high-resolution peptide separation (rather than protein) demonstrated 
significantly improved number of quantifiable targets and increase plasma 
concentration detection (Chapter 4). It was also apparent that this methodology had 
the sensitivity to detect hypothesised brain-derived proteins and proteins with known 
involvement in neurodegenerative pathogenesis centrally, typically at the pg/mL 
concentration level. Following this huge methodological improvement, a secondary 
discovery and replication phase was performed on two independent cohorts with the 
focus on Aβ pathology in more cognitively normal cohorts (Chapter 5). 
This project has thus used two discovery proteomic strategies for the identification of 
biologically relevant plasma biomarkers of Aβ. Being similar in strategy and the 
considerable overlap of analytes being measured between the two techniques, they 
could each provide a form of replication. However, inherent differences would 
render them complementary. The first discovery phase (Chapter 3) primarily focused 
on the classical plasma proteome (>1µg/mL) and fractionation was based at the 
protein level. This ensured that potential protein modifications and fragments 
observed by differing MW on a 1DGE could be measured as separate entities. The 
second discovery phase (Chapter 5) was a more comprehensive screen, not only 
covering the “classical plasma proteome” but inclusive of the much desired “tissue 
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leakage” level (pg/mL – ng/mL) as described by Anderson and colleagues 501. 
Furthermore, the use of peptide fractionation and peptide labelling in this technique 
ensured that individual protein coverage was considerably higher and expression was 
considered to be a global view and not from a fragment or MW specific entity.    
The first discovery phase (Chapter 3) highlighted a number of protein targets which 
were able to distinguish (uncorrected P value <0.05) between extreme high and low 
Aβ pathology, with the complement and coagulation pathways being a prominent 
feature. An MS 1DGE workflow is a discovery methodological tool and currently 
would not be suitable for a clinical setting. Therefore, an assay-based approach more 
applicable to a clinical setting was utilised as a replication tool. To minimise the loss 
of putative candidates due to cohort differences and to remove false positives, we 
performed a “technical replication” where the same LC-MS/MS subjects were re-
analysed using an ELISA method. Three proteins technically replicated the findings 
from the LC-MS/MS discovery (FGγ, α2m and FHR-1). The large number of protein 
groups that did not pass technical replication highlights the importance to recognise 
the intrinsic differences between MS and antibody approaches in biomarker research. 
Most importantly, it is feasible that the LC-MS/MS peptides used for protein 
identification and quantification does not match the epitope measured by 
immunoassay. Next, the confounding influence of heterophilic antibodies generating 
false or elevated signal within immunoassays was not investigated in this study and 
lastly, spike/recovery tests need to determine the accuracy of commercial 
immunoassays. Furthermore, immunoassays cannot always distinguish modified or 
truncated forms of a same protein as seen by our MS 1DGE approach.  
Only FGγ remained significantly related to Aβ in two independent cohorts; firstly, in 
the UCSF cohort (subject stratification by 
11
C-PiB) and also in the EMIF-AD cohort 
where patients were stratified according to CSF Aβ1-42 measures. This was the first 
blood-based study that utilised core CSF biomarkers as an endophenotype 
stratification. Further to this, a model with defined concentration cut-offs for FGγ 
was proposed. The model, which included only FGγ ng/mL and age, had a sensitivity 
59%, specificity 78% for neocortical Aβ positivity, when initially tested. However, 
the same model, with exact concentration FGγ ng/mL cut-offs, was used to predict 
Aβ positivity in EMIF-AD with disappointing findings (sensitivity 44%, specificity 
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59%). Interestingly, the performance of the classifier seemed to improve in 
asymptomatic individuals (sensitivity 50%, specificity 61%). Further still, if the 
EMIF-AD cohort was adjusted to be more representative of elevated NAB found in 
the normal ageing population, reported by recent Aβ therapeutic trials (A4 and 
EPAD), a reasonable negative predictive value (NPV) of 74% was observed. The 
small positive predictive value (PPV = 32%) indicates that many of the positive 
results from an FGγ test are possibly false positives. It would be essential to follow 
up any positive result with a more reliable test (PET/CSF biomarkers) to obtain a 
more accurate assessment of Aβ. The strength in this FGγ blood test seems to rest in 
the superior performance of specificity and NPV suggesting that an FGγ blood test 
would be more useful in rejecting participants for Aβ therapeutic trials rather than 
selection.     
The second discovery phase (Chapter 5) again highlighted a number of single analyte 
targets for the prediction of in vivo Aβ. Firstly, a number of plasma proteins 
demonstrated an association with Aβ in the presence of cognitively impaired 
individuals whereas subsets of proteins were exclusively or more significantly 
associated with asymptomatic subjects with elevated Aβ. Many protein groups 
displayed opposite direction of coefficients to those described in the first discovery 
phase. It is common to find conflicting relationships reported in blood-biomarker 
studies and this highlights the complexity of the relationship of these proteins may 
have with disease and the peripheral ageing processes. It is important to determine 
exactly which form of the protein is being measured and also to consider disease 
status used as the primary outcome measure as well as pre-analytical cohort 
differences. Despite these discrepancies, apoA1 and ITIH4 were protein groups 
found to be commonly associated with Aβ between the two LC-MS/MS studies. LC-
MS/MS analysis in the AIBL-2 and KARVIAH cohorts continued to support the 
significant involvement of the coagulation and complement pathways with NAB as 
well as verification of brain-derived proteins circulating in plasma. The variable 
measurement of these brain-derived proteins across a large cohort meant that a 
reliable association with Aβ could not be concluded. Instead, this dataset is a 
valuable reference source of potential CNS related biomarkers that are detectable in 
blood and therefore hypothesis-driven investigation using targeted assays should be 
conducted to investigate the meaning of their peripheral expression.  
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The prominent finding in Chapter 5 was the independent replication of a multi-
protein panel for NAB. Given the complexity of AD and AD-related pathology, it is 
likely a multi-analyte panel would be more accurate in addressing the heterogeneity 
of the disease. However, a trade-off between number of analytes to explain disease 
complexity and a reduced panel for biomarker simplicity would need to be 
negotiated. As with Chapter 3, we aimed to build the simplest model to predict Aβ 
pathology. In the AIBL-2 cohort, an SVM learning technique performed multivariate 
classification to train a predictive model. In addition to this, LASSO was used to 
remove correlating variables, while retaining the most significant protein group to 
represent certain clusters. The trained twenty-plasma protein model was then tested 
in the KARVAIH cohort achieving an accuracy of 81%, increasing to 86.6% using 
just the first 14 features. The most encouraging aspect of this discovery panel was 
the ability to predict elevated Aβ in purely asymptomatic individuals. If one was to 
train the predictive panel in only the asymptomatic individuals from AIBL-2 not 
only an anticipated reduction in variables but a potential increase in predictive 
accuracy when tested in the KARVIAH cohort. As previously discussed, certain 
considerations need to be addressed with this panel. Firstly, analytical variability was 
considerably reduced in this study with two cohorts being simultaneously measured 
and therefore future replication is unlikely to gain the same level of accuracy. 
Secondly, this panel would need to be translated to a more applicable platform for 
more general research and clinical use. As this has been previously shown to be 
troublesome, more effort and attention in tailoring assay panels based upon the 
epitopes and peptide data recognised by the LC-MS/MS discoveries would yield 
greater success. At the very least, the presence of this putative panel of biomarkers in 
the asymptomatic group indicates that there is potential in blood-based screening at 
preclinical stage of AD and highlights early intervention targets and pathways 
worthy of further investigation.               
6.1.1 FGγ as peripheral marker for AD pathology  
Unbiased LC-MS/MS has highlighted a number of coagulation factors in both 
discovery studies. The initial discovery highlighted FGγ, FGβ, FGα, plasminogen 
and prothrombin all to be nominally associated with elevated Aβ. In the second 
discovery phase coagulation related protein groups included kallikrein, factor XIII 
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and factor X. Prothrombin and HABP2 were statistically related to Aβ SUVR and 
were included in the multi-analyte model for Aβ prediction. Although the replication 
of a single analyte was not possible between these two LC-MS/MS studies the 
significant involvement of coagulation and fibrinolysis is evident. 
The relationship between decreased plasma FGγ and Aβ surrogate markers was 
extensively replicated by immunoassay. FGγ and its relationship to AD related 
phenotypes is not a novel finding 
373, 417, 436, 664
 with Kiddle and colleagues 
552
 
reporting it to be among an elite list of plasma candidates consistently related to AD. 
Further to this, a systematic review demonstrated that plasma FGγ was most likely to 
be specific to AD 
665
. Given this evidence, more recent studies 
375
 and our data that 
demonstrates the unbiased discovery and replication in a further three independent 
cohorts, we believe that FGγ is the most replicated putative blood-biomarker for AD 
related phenotypes.  
However, even within our own laboratory, FGγ is not always found to be related to 
AD phenotypes. The second discovery phase (Chapter 5) did not find FGγ or any 
fibrinogen chains related to Aβ and this could well be attributed to methodological 
differences between the two studies. Further to this, the incorporated 
immunodepletion strategy demonstrated that a small percentage of FGγ peptides are 
removed from plasma in the “albuminome” (Table 4-5). Encouragingly, the serine 
protease (prothrombin or thrombin (F2)) that converts fibrinogen to fibrin was found 
to be highly associated with Aβ. Furthermore, a recent targeted approach failed to 
find any association of plasma FGγ with Aβ as measured by F18 flutemetamol (Baird 
AL et al., in review). This inconsistency is likely to be confounded by the cross 
sectional examination of different disease stages studied in these investigations and 
also the differing methods of sample collection and storage. However, the 
relationship of cardiovascular risk and AD should also be considered. Elevated levels 
of fibrinogen and other coagulation factors have been related to a number of 
cardiovascular diseases which are secondary risk factors for AD 
666-669
 and also 
normal ageing (reviewed in 
670
), whereas our data indicates a decreased level in 
association of NAB. Indeed, there have been a few reports of whole fibrinogen levels 
being increased with cognitive decline 
404, 483
. These contradictory findings may 
point towards specific cleavage products for fibrinogen having a bidirectional 
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association with AD and Aβ. Yet, our data demonstrates that all coagulation factors 
measured, regardless of significance, have a negative coefficient with NAB. The role 
of cardiovascular risk will inevitably have a large influence on coagulation factor 
levels which was not accounted for in these studies. This could be partially 
responsible for the low sensitivity and specificity in FGγ in predicting Aβ. It would 
therefore be advised to assess plasma FGγ with AD phenotypes taking into account 
cardiovascular risk factors.   
The direct relationship of fibrinogen and Aβ in the CNS and in vitro studies would 
still support the notion that our peripheral signal, in part, could be a reflection of 
NAB. However, evidence from the literature would deem this relationship to be fully 
dependable on a dysfunctional blood-brain barrier. It is widely reported that 
fibrinogen is an exclusive plasma protein that is excluded from the CNS by the BBB; 
however, there is a rapid movement of fibrinogen across a dysfunctional BBB which 
is converted by thrombin and in-turn deposited as insoluble Fibrin in the CNS 
484, 671
. 
This deposition of fibrin has been shown to have a spatial relationship with Aβ, with 
many studies demonstrating co-deposition in the AD brain 
484-486, 654, 672
. Fibrinogen 
also binds strongly to Aβ in vitro and increases fibrinogen aggregation and Aβ 
fibrillisation 
484, 486
. It is evident that Aβ accumulation in the CNS can be both a 
cause and consequence of BBB dysfunction. The deposition of Aβ in the vessel 
walls of arteries, arterioles and capillaries from the toxic presence and incomplete 
clearance of Aβ can lead to blood vessel weakening and BBB impairment (reviewed 
in 
673
). Furthermore, neurotoxicity, activated microglia and perivascular astrocytic 
damage induced by Aβ accumulation are all reported to cause injury to the BBB 653. 
Therefore, a case can be made for a disruption of BBB initiated by NAB causing the 
extravasation of fibrinogen into the CNS that induces further Aβ deposition and 
neuronal damage. Nonetheless, various mechanisms for BBB dysfunction have been 
reported (reviewed in 
654
) and therefore the influx of fibrinogen into the CNS can be 
induced by a number of mechanisms in response to a number of neurological 
conditions and events. Studies reporting measures of FGγ in the CSF have been 
limited. Acute neuroinflammatory conditions have reported elevated fibrinogen in 
the CSF but no change between chronic conditions (e.g. Multiple Sclerosis) and 
healthy controls 
674
. Interestingly, a splicing variant of FGγ (FGγ A precursor) has 
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been previously reported as elevated in the CSF of AD and MCI subjects 
492
. This 
could almost point to the breakdown of the blood-CSF barrier as well as the BBB. 
It is evident that the movement of fibrinogen can only happen in response to an event 
that alters the BBB and that it could be concluded that our observed reduction of 
FGγ could be in response to BBB abnormality. BBB studies in AD have led to 
conclude that a subset, but not all AD patients, have disruptions of the BBB and for 
that reason plasma FGγ may not be specific for AD. However, it is also clear that 
once inside the CNS fibrinogen has a considerable amount of interaction with AD 
pathology and exacerbates its development. We hypothesise that the decrease of 
plasma FGγ is initially an early marker in response to BBB permeability (Figure 6-
1). Furthermore, if substantial neocortical Aβ pathology is present within the CNS, a 
decrease in plasma FGγ would be more dramatic (Figure 6-1). The FGγ 
concentration cut-offs we presented (<944ng/mL) would only be applicable for these 
cohorts and that longitudinal baseline assessment of FGγ should be made on an 
individual basis due to various confounding influences. A sustained deviation away 








Figure 6-1: Hypothetical curve of plasma FGγ in response to BBB damage with Aβ+ 
and Aβ- individuals. The hypothesis presented assumes BBB dysfunction. Over time an 
expected increase in plasma FGγ due to age-related cardiovascular involvement. This 
trajectory is likely to continue if no BBB impairment is apparent. In response to an 
event that causes BBB dysfunction we would expect an immediate decrease in plasma 
FGγ. In Aβ+ individuals the influx of fibrinogen (FGγ) would interact and exacerbate 
the already increasing levels of neocortical Aβ observed in typical AD development, 
this would reflect in a more dramatic decrease in levels of plasma FGγ (red solid line). 
In Aβ- individuals an anticipated reduction in plasma FGγ may still be expected in 
response to BBB dysfunction however, with less NAB in the CNS the decrease in 
plasma FGγ would be less dramatic (red dashed line).   
6.1.2 Multi-analyte marker of Aβ pathology 
It is unlikely that a single marker alone will be able to explain heterogeneity 
demonstrated in AD in response to elevated Aβ. As previously discussed, a single 
marker, such as FGγ, has the potential to be confounded by a number of factors. A 
multivariate signature approach has been taken by many research groups and two 
studies have reported a multivariate model for Aβ prediction 436-437. Here, we have 
presented a prediction model which seems to outperform these previously described 
models, although the studies cannot be directly compared. It is likely that the 
differences in platforms used between these studies will account for the differences 
in proteins included for prediction models. However, plasma Aβ was a common a 
feature. Burnham and Kiddle both utilised immunoassays to specifically target Aβ1-42 
Time/Age
Plasma FGγ (Aβ+)
Neocortical Aβ Burden (Aβ+)
Plasma FGγ (Aβ-)




in plasma and although it cannot be determined, our MS/MS data suggests peptides 
that are located within the region of toxic Aβ fragments are associated with NAB. 
This supports the concept of many in the biomarker field that the levels of plasma 
Aβ alone are not themselves diagnostic but has a role to play as part of a multi-
analyte panel.  
Using unbiased MS, this panel converges plasma proteins of varying abundances, 
differing mechanisms and novel or previously reported putative candidates for AD. 
As mentioned before, APP processing and the coagulation cascade are represented in 
this panel. Further to this, inflammation and complement proteins, transcription 
factors and GPCR’s are deemed to be important in Aβ prediction. There is also the 
inclusion of CNS protein groups, NEFL and NEUROG2, the former being widely 
reported as a marker for axonal injury in a number of diseases. The broad diversity 
of this panel would have a greater opportunity to explain the variability in AD and its 
pathology. Although this panel has been described for elevation of NAB and tested 
in cognitively normal individuals, the cohorts utilised in this study are enriched for 
future AD risk and therefore this panel may well be more specific for Aβ in relation 
to AD. This would be of great use in therapeutic trials that continue to target Aβ in 
relation to AD. As further replication in similar cohorts would be necessary, the 
performance of this panel in suspected non-Aβ pathology (SNAP) AD subjects and 
other dementias of elevated Aβ would be valuable to determine the biomarker 
specificity for AD. 
An ideal biomarker for AD has been previously described as being able to; detect a 
fundamental pathological feature, be validated in neuropathologically confirmed 
cases, have a sensitivity and specificity >80%, be reliable, reproducible, non-
invasive, simple to perform and inexpensive 
675
. While at the early stages, the 
biomarker panel presented in Chapter 5 would follow this outlined criterion. In 
reality, the further replication in differing cohorts of this biomarker panel would 
most likely reduce in accuracy for a number of factors (preanalytical, platform and 
cohort differences). A blood-based signature for AD and AD pathology is not 
expected to outperform or replace CSF or neuroimaging biomarkers but act as the 
first-step in a multi-stage diagnosis which will inevitably include further 
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confirmation by these modalities. However, higher accuracy at the initial stage is 
critical in reducing costs, recruit time and false positives for a clinical trial setting.      
APOE status is a substantial risk factor for AD and Aβ accumulation. The 
association of several plasma proteins with NAB was shown to be partly confounded 
by the number of APOE ε4 individuals included in this study. However, at the 
univariate level plasma proteins included in this panel were found to be still highly 
associated with Aβ when accounting for APOE status. We conclude that the addition 
of APOE genotype in our model is unlikely to improve prediction accuracy however 
other genetic risk factors have not yet been explored. Although it was chosen for 
APOE not to be statistically corrected for, age and gender were included in a GLM 
adjustment. In a clinical setting, it is highly likely that these variables, particularly 
age, will have an effect on a number if not all protein levels included in this model. 
Although not possible in this study, further investigations should determine 





6.2 Ethical implications for preclinical testing of AD 
Conducting preclinical AD trials presents a variety of novel ethical and policy 
challenges. An issue that is particularly relevant for this study would be revealing 
biomarker status (particularly healthy individuals) to participant’s active in research 
studies. The suitable use of this information is much debated and while disease 
modifying treatments for AD currently do not exist a screening tool appears to have 
limited benefits to currently affected individuals. Therefore, many would argue that 
preclinical testing should remain within research protocols and the results should not 
be shared with subjects until suitable intervention become known. 
From an ethical position, the knowledge of one’s biological status could induce 
considerable stress, which could significantly affect the individual’s well-being 676. 
This will also have implications for the research or clinical study they are actively 
participating in.  Using genetic biomarkers as an example, the REVEAL study has 
demonstrated that the knowledge of APOE status did not have a significant increase 
in anxiety compared with those who did not learn their APOE status 
677
. However, 
those who were informed of being carriers of APOE ε4 demonstrated higher levels of 
distress over a one-year period 
677
. The impact of knowing and the constant reminder 
of one’s genetic risk or biomarker status for AD over a longer period would need to 
be studied and elucidated further. There was also a clear link that individuals who 
demonstrated emotional stress prior to enrolment were more likely to have 
difficulties after disclosure of biomarker status 
677
. This finding points towards a 
cognitive pre-assessment and biomarker status being given on an individual basis.  
In contrast to these standpoints, the REVEAL study also demonstrated that APOE ε4 
aware individuals made efforts to introduce risk reducing interventions into their 
daily lives with significant benefits 
678
. A further argument for the transparency in 
biomarker disclosure is that it would better replicate the actual clinical practice for 
future drug prescription for at risk individuals 
676
. Currently, the A4 and API 
intervention trials have or intend to disclose biomarker status prior to trial participant 
inclusion 
677, 679
. A European-wide study presented a positive public response to 
preclinical AD testing, demonstrating 2/3 people would receive a medical test if it 
would reveal if they would develop AD at later stage (http://www.alzheimer-
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europe.org/Research/Value-of-Knowing). However, in contrast to this, reports from 
the DIAN study for those at risk for familial AD often do not want to learn the 
results from genetic testing 
680
. Preclinical screening can help relieve uncertainty in 
individuals who have ageing concerns, particularly those with suspected inherited 
risks for AD. For some individuals the stress of uncertainty may be more 
considerable than the stress of knowing. Furthermore, an early diagnosis of definite 
AD (if made possible) will help individuals to implement future plans, whether this 
is obtaining relevant care packages and altering educational/career or family plans. 
While it is clear that identifying individuals in the preclinical/prodromal stage of the 
disease will drastically aid AD research and clinical trials, it is imperative to 
carefully consider the individuals involved in these studies. Informed consent should 
always be obtained with appropriate support, counselling and advice being available 
not only throughout the studying but also after its conclusion. Currently, there are no 
guidelines for the disclosure of biomarkers status in such studies however recent 
recommendations 
676
 point towards the study type dictating the acceptable approach. 
Observational research studies should avoid disclosure as it is likely to impact on the 
cognitive performance on the participant having an impact on future research 
developments. Disclosure should be considered in intervention studies to protect 
biomarker negative subjects from preventable risks and stress, although the 





6.3 Future Studies 
Despite the first studies searching for putative plasma markers for AD occurring over 
10 years ago, blood-based biomarkers that reflect dementia and its pathology is still 
an emerging field. As technology and longitudinal ageing cohorts continue to 
develop, large scale discovery and candidate replication studies will need to be 
repeated. The results from these studies have provided more evidence in a growing 
body of literature. This includes the conformation of previously identified single 
markers, offering novel candidates and novel classifiers. More work is clearly 
needed and suggestions for future studies are outlined below. 
6.3.1 Independent verification of LC-MS/MS classifier 
The most promising result from this body of work was the high accuracy of 
predicting NAB using a multi-analyte panel in a cognitively normal cohort. As 
previously discussed there are various aspects to consider in the replication of this 
classifier. Firstly, the reduced analytical variance has likely contributed to increased 
accuracy and secondly, it could be argued that this panel would to need to be 
converted to a more accessible platform to increase participant numbers and 
determine individual protein concentration cut-offs. If the analytical platform is 
altered then a technical replication in the AIBL-2 and KARVIAH participants would 
be required to ensure that the classifier is still performing to a high accuracy. If this 
was to be successful, the validation in independent cohorts and preferably by 
independent users would be essential. Independent cohorts that actively utilise Aβ 
biomarkers (imaging or CSF) in cognitively normal individuals are limited, however 
the Baltimore Longitudinal Study of Ageing (BLSA, www.blsa.nih.gov), the 
Swedish BIOFINDER (www.biofinder.se) and European Medical Informatics 
Framework (www.emif.eu) are well characterised cohorts where this classifier could 
be rigorously tested.  
It is recommended that a proposed classifier should be tested in its exact form to 
produce an unbiased assessment of its performance and therefore careful 
considerations of this classifier should be made before the attempt of validation. 
Firstly, the training of the classifier was performed in a mixed diagnosis cohort 
(AIBL-2) and therefore re-analysis using only cognitively healthy subjects, suitable 
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to the validation cohorts mentioned above, may foster opportunity for greater 
validation.  Secondly, a total of 14 candidates were used to gain 86.6% accuracy in 
NAB prediction. It would be anticipated that the reduction in classifier size, at the 
cost of a small decrease in accuracy, may also have a greater chance of validation.     
6.3.2 Longitudinal assessment of plasma protein classifier(s)  
Both models proposed in this work come from cross-sectional investigations and this 
has utility for participant entry for clinical trials. However, there is also a need for a 
plasma biomarker that can track AD pathology over longer periods or in response to 
a clinical or therapeutic intervention. This has been assessed at the single analyte 
level 
375, 430
 but a panel of multiple markers, each reflecting different mechanisms, is 
likely to be better at tracking the disease course.  
The AIBL study is a longitudinal cohort and since the initial baseline measures were 
obtained in 2009, seven years worth of imaging, clinical and cognitive assessments 
have been collected. The global assessment of the plasma proteome in AIBL-1 and 
AIBL-2 subjects also offers the opportunity to use baseline protein measures to 
predict future conversion. This may be based upon a change in Aβ status or a change 
in clinical classification determined by longitudinal assessment      
The model proposing plasma FGγ and age as a predictor for Aβ demonstrated a 
modest level of accuracy in its replication and its limitation has been previously 
discussed. However, given the simplicity of the model and a successful conversion to 
an assay based platform it would be easy to implement it in a longitudinal study and 
test the proposed hypothesis (Figure 6-1). Recently, substantial evidence has 
accumulated that fibrinogen moves across a dysfunctional BBB and co-deposits (as 
Fibrin) with various pathologies, including Aβ, and inflicts a CNS autoimmune 
response. We propose to utilise the MRC London Neurodegenerative Disease Brain 
Bank which has collected longitudinal plasma samples and with corresponding post 
mortem tissue. We aim to measure the trajectory of plasma FGγ (and other 
coagulation factors) up to the time of death and blindly predict Aβ status (determined 
by Braak staging) using our FGγ test. Furthermore, we will correlate the final plasma 
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FGγ measure with neocortical Aβ/FGγ and utilise immunohistochemistry to 
determine the location FGγ deposition in relation to Aβ plaques.        
6.3.3 Across neurodegeneration classifier  
The accumulation of Aβ is not only associated with AD but also a number of other 
dementias. Single and multi-analyte putative biomarkers highlighted throughout 
these studies should be examined in cohorts that include a range of dementias with 
differing neuropathology. This would determine which biomarkers are specific for 
Aβ, AD or neurodegeneration as a whole.  
6.3.4 Blood-brain barrier models to assess plasma FGγ curve 
There are currently a number of animal models that mimic BBB dysfunction 
681
. 
Their advantage is the reduced confounding variables that are found in human 
disease and also their estimated age of BBB impairment is documented. Therefore, a 
longitudinal assessment of plasma FGγ before, during and after known BBB 
dysfunction in these models would help to elucidate the trajectory of plasma FGγ. 
Post mortem analysis would determine if the levels of plasma FGγ correlate with 
severity of AD pathology.        
6.3.5 Cellular models of novel blood-based biomarkers 
Pathway analysis and individual proteins indicate a number of mechanisms 
highlighted in the multi-analyte prediction for Aβ. Efforts should be made to clarify 
the association of these plasma biomarkers roles in the disease process, or what 
mechanistic relationship it is to Aβ. The effects of biomarker proteins should be 
determined on an Aβ pathway activity in cell lines and in primary rodent neuronal 
cultures.  
6.3.6 Interrogation of plasma expression of brain-derived proteins   
The finding of a large collection of brain-derived proteins circulating within plasma 
warrants further investigation. These brain-derived proteins have the potential to be 
biomarkers not only of NAB or AD but they could be markers for BBB integrity or 
other neurodegenerative diseases if examined in appropriate cohorts. Firstly, 
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knowing that their peripheral expression does exist, investigation of expression using 
sensitive targeted assay is likely to be more successful than LC-MS/MS. Given their 
low abundance the use of the single molecule array (SiMoA) assays would be the 
ideal choice of platform. The SiMoA platform has been shown to successfully detect 
plasma tau at 0.02pg/mL 
359
. Secondly, it should be explored if a suspected brain-
derived protein has significant protein expression in range of peripheral tissues. 
Furthermore, an endophenotype approach stratified by CSF/plasma albumin ratio or 
even plasma FGγ as proposed here could be utilised do determine if these brain-
derived protein are a reflection of BBB integrity.  Lastly, the recent development of 
methods for isolation of neuronal-derived exosomes (NDEs) from plasma has 
allowed quantification of neuronal proteins contained as a part of their cargo 
530
. The 
transport of brain-derived proteins via neuronal exosomes could be an alternative 
explanation for their expression in plasma other than BBB dysfunction or peripheral 
tissue expression.          
6.3.7 Post translational modification and protein fragments  
One of the major advantages of LC-MS/MS over other discovery platforms is the 
detailed peptide structural data that is generated. Our 1DGE experiments and 
numerous 2DGE experiments in the field have demonstrated that the same protein 
groups can be identified at various locations on a gel and this is indicative of 
multiple forms of the protein (modified and/or cleaved). The extensive LC-MS/MS 
data generated here offers the opportunity for the assessment of post-translational 
modification biomarkers in blood. In the same manner as Chapter 5, a discovery in 
AIBL-2 cohort can conduct global expression or protein specific expression of 
modifications such as phosphorylation, acetylation and glycosylation. Any observed 
differences could be assessed in KARVIAH cohort. A specific glycosylated peptide 




6.3.8 Cost benefit analysis of a blood-based classifier  
It is widely accepted that, at this point, blood-based biomarkers are not viewed as 
potentially diagnostic but rather as a first in line for a multi-stage diagnostic process. 
In a clinical trial scenario, blood-based biomarkers are seen to increase access to 
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potential participants while simultaneously reducing the time burden and cost in 
screening. While the former is certainly true, the reduction in cost has yet to be 
proven. Firstly, the cost of a multi-analyte panel(s) is unknown and secondly, the 
anticipated lower accuracy for a fully validated blood-based biomarker would 
require substantially larger pool of testable subjects to achieve the desired number of 
“positive” participants for a clinical trial. Therefore, a side-by-side assessment of 
blood-based biomarker performance against an actual clinical trial population that 
was pre-screened by Aβ imaging and/or CSF Aβ would determine if the cost savings 





6.4.1 Concentration thresholds 
Threshold values for biomarkers must be determined for them to be of use as a 
diagnostic and/or screening tool. An attempt has been made to apply an ng/mL 
threshold for Aβ positivity using FGγ in Chapter 3, with modest results. This cut-off 
was based upon a single cohort and would need to be adjusted after testing multiple 
cohorts that differed in age, ethnicity and disease state to provide a more accurate 
estimate. In Chapter 5 proteomic profiling utilised TMT isobaric labelling as 
discovery and replication tool. This provided only relative quantification of proteins 
levels, therefore estimation of optimal thresholds could not be computed for the 
twenty-protein classifier. Using an MS calibrator or successful conversion to a 
quantifiable platform would be needed to determine concentration cut-offs, as well 
as boundaries for age and gender differences.   
6.4.2 Cross-sectional analysis 
All observations in this study have been cross-sectional, in that protein levels are 
representation at the specific point in time. Cross-sectional analyses are excellent 
hypothesis generating studies that can include large number of participants because it 
is not limited by the need for follow-up data, patient drop-outs or variables 
introduced between time-points. A drawback to cross-sectional analysis is that it 
cannot be determined, unless well documented, if these relative abundances of 
individual plasma proteins are stable or sensitive to dynamic change over time. 
“Short-term” longitudinal analysis would determine how these plasma proteins 
respond to circadian rhythm and cycles over a few a weeks. This would also help 
with the determination of concentration cut-offs and obvious outliers that may affect 
the result. Our multivariate classifier was replicated, with high accuracy, in an 
independent cohort and therefore we would cautiously conclude that these plasma 
proteins remain stable. In both cohorts, blood draws were made in the morning after 
fasting but small variations in other preanalytics did occur. 
Longitudinal analysis over multiple time-points throughout a disease course would 
determine how this classifier performs in relation to disease progression.  
417 
 
6.4.3 Comorbidities and lifestyle risk factors 
Ageing, independently of AD, has numerous associated comorbidities and lifestyle 
risk factors. A number of blood protein levels are likely to be sensitive to these 
conditions. Although exclusion criteria were implemented into the research cohorts 
the affect of our candidate protein markers with cardiovascular risk, secondary 
diseases or diet was not investigated.    
6.4.4 Specificity of Aβ PET   
Post mortem neuropathology analysis is still considered the most accurate indicator 
of AD; in this study predominantly in vivo Aβ PET was used as a surrogate for early 
development for AD. As previously discussed measures of NAB are not generally 
specific for AD and are often described in other dementias and mixed pathology 
dementias. Although plasma signatures presented here are discovered in AD 
enriched cohorts, they should be considered only as markers of Aβ deposition 




6.5 Future perspectives on the field  
6.5.1 Standardisation  
Undoubtedly the greatest challenge for the field of AD blood-biomarkers is the 
agreement and implementation of preanalytical guidelines that can be universally 
employed across cohorts and research laboratories. There is a large concern with the 
lack of reproducibility of findings across independent laboratories and within 
laboratory settings 
683
. Initial guidelines in sample collection, processing and storage 
have been outlined 
440
, replicating the actions taken by the Global Biomarker 
Standardisation Consortium of CSF biomarkers 
324, 684
. This step is arguably more 
critical for blood-based biomarkers and potentially analytical guidelines should be 
even stricter than those set out for CSF analysis. Blood is a highly complex 
biological system and there are numerous confounders that influence levels of 
potential candidate markers. Furthermore, because of its distance to the disease 
organ, the field of AD blood-based biomarkers (including lipidomics and 
metabolomics) currently does not have a gold standard biomarker in which 
standardisation can be extensively examined and referred to.  
These initial guidelines are a promising advancement in the AD field. If widely 
adopted, cohort and inter-laboratory variability can be reduced and the prospect of 
discovering a reproducible blood-based biomarker for AD and its pathology will be 
significantly increased.        
6.5.2 Endophenotype strategies for blood-based biomarkers for AD risk 
The eventual aim for the AD blood-biomarker field would be to have a test that is 
specific for AD. In this study, we have used Aβ PET and CSF Aβ1-42 as surrogates 
for AD risk and this has potential utility for anti-Aβ trials which mainly target AD 
subjects. However, it has been discussed how elevated Aβ biomarkers are not 
necessarily indicative of AD development. The use of MRI imaging also has 
limitations as an endophenotype design for AD. The emergence of tau PET tracers 
offers new avenues for blood-based biomarker research and should be explored 
alone and in combination with Aβ PET; however, lack of disease specificity is again 
liable to be a confounding factor. The AD genetics field are beginning to look 
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closely at “polygenic risk scores” 685-686 where joint effects of multiple previously 
identified genetic variants are weighted to give a single score. Polygenic risk scores 
have recently been proven to be successful in schizophrenia research 
687
. In the same 
manner, and with the emergence of large longitudinal cohorts that are well 
characterised, the convergence of various imaging (Aβ, tau, FDG and structural 
MRI), CSF analysis, genetic risks, epigenetics, psychological assessment, 
comorbidities and lifestyle risk factors could be used create a single “polybiomarker 
risk score” for AD. An endophenotype study that is stratified based upon a single 
score of multiple modalities might not only identify a blood-based biomarker of 
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Appendix 1. LC-MS/MS protein group identifications extracted by PRQ-1 pre-
processing pipeline for Chapter 3 
Protein group MW isoforms (n = 381) identified by LC-MS/MS with TMT6plex 
protein quantification. These protein groups were extracted using the statistical 
pipeline PRQ-1 and post-PRQ-1 clean up. 
UniProt 
ID 






P42684 Abelson tyrosine-protein kinase 2 ABL2 7 62.50 
P60709 Actin, cytoplasmic 1 ACTB 5 68.75 
P43652 Afamin AFM 3 93.75 
P43652 Afamin AFM 4 87.50 
P43652 Afamin AFM 5 87.50 
P02768 Albumin ALB 1 100 
P02768 Albumin ALB 2 100 
P02768 Albumin ALB 3 100 
P02768 Albumin ALB 4 100 
P02768 Albumin ALB 5 100 
P02768 Albumin ALB 6 100 
P02768 Albumin ALB 7 100 
P02768 Albumin ALB 8 100 
P02768 Albumin ALB 9 100 
P02768 Albumin ALB 10 68.75 
P19652 Alpha-1-acid glycoprotein 2 ORM2 5 87.50 
P19652 Alpha-1-acid glycoprotein 2 ORM2 6 75.00 
P01011 Alpha-1-antichymotrypsin SERPINA3 1 87.50 
P01011 Alpha-1-antichymotrypsin SERPINA3 2 100 
P01011 Alpha-1-antichymotrypsin SERPINA3 3 75.00 
P01011 Alpha-1-antichymotrypsin SERPINA3 4 87.50 
P01011 Alpha-1-antichymotrypsin SERPINA3 5 100 
P01011 Alpha-1-antichymotrypsin SERPINA3 6 62.50 
P01011 Alpha-1-antichymotrypsin SERPINA3 7 100 
P01011 Alpha-1-antichymotrypsin SERPINA3 8 81.25 
P01011 Alpha-1-antichymotrypsin SERPINA3 9 81.25 
P04217 Alpha-1-B Glycoprotein A1BG 4 81.25 
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P04217 Alpha-1-B Glycoprotein A1BG 5 81.25 
P08697 Alpha-2-antiplasmin SERPINF2 5 75.00 
P01023 Alpha-2-Macroglobulin (α2m) A2M 1 100 
P01023 Alpha-2-Macroglobulin (α2m) A2M 2 100 
P01023 Alpha-2-Macroglobulin (α2m) A2M 3 100 
P01023 Alpha-2-Macroglobulin (α2m) A2M 4 62.50 
P01023 Alpha-2-Macroglobulin (α2m) A2M 5 100 
P01023 Alpha-2-Macroglobulin (α2m) A2M 6 75.00 
P01023 Alpha-2-Macroglobulin (α2m) A2M 7 100 
P01023 Alpha-2-Macroglobulin (α2m) A2M 8 87.50 
P01023 Alpha-2-Macroglobulin (α2m) A2M 9 75.00 
P01008 Antithrombin-III SERPINC1 4 81.25 
P01008 Antithrombin-III SERPINC1 5 100 
P01008 Antithrombin-III SERPINC1 6 68.75 
P01008 Antithrombin-III SERPINC1 7 62.50 
P01008 Antithrombin-III SERPINC1 8 81.25 
P01008 Antithrombin-III SERPINC1 9 100 
P01008 Antithrombin-III SERPINC1 10 81.25 
P02647 Apolipoprotein A-I (ApoA1) APOA1 2 100 
P02647 Apolipoprotein A-I (ApoA1) APOA1 3 75.00 
P02647 Apolipoprotein A-I (ApoA1) APOA1 5 75.00 
P02647 Apolipoprotein A-I (ApoA1) APOA1 6 100 
P02647 Apolipoprotein A-I (ApoA1) APOA1 7 93.75 
P02647 Apolipoprotein A-I (ApoA1) APOA1 8 100 
P02647 Apolipoprotein A-I (ApoA1) APOA1 9 93.75 
P02647 Apolipoprotein A-I (ApoA1) APOA1 10 68.75 
P06727 Apolipoprotein A-IV (ApoA4) APOA4 5 93.75 
P06727 Apolipoprotein A-IV (ApoA4) APOA4 6 56.25 
P04114 Apolipoprotein B (ApoB) APOB 1 100 
P04114 Apolipoprotein B (ApoB) APOB 2 93.75 
P04114 Apolipoprotein B (ApoB) APOB 3 93.75 
P04114 Apolipoprotein B (ApoB) APOB 5 75.00 
P55056 Apolipoprotein C-IV APOC4 8 87.50 
P55056 Apolipoprotein C-IV APOC4 9 93.75 
P05090 Apolipoprotein D APOD 6 87.50 
P05090 Apolipoprotein D APOD 7 87.50 
P02649 Apolipoprotein E APOE 6 93.75 
P02649 Apolipoprotein E APOE 7 68.75 
P02649 Apolipoprotein E APOE 8 100 
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P02649 Apolipoprotein E APOE 9 93.75 
P02649 Apolipoprotein E APOE 10 56.25 
P02749 Apolipoprotein H APOH 5 62.50 
O14791 Apolipoprotein L-1 (ApoL1) APOL1 5 81.25 
O14791 Apolipoprotein L-1 (ApoL1) APOL1 6 68.75 
O95445 Apolipoprotein M APOM 7 87.50 
O95445 Apolipoprotein M APOM 8 87.50 
O95445 Apolipoprotein M APOM 9 50.00 
P08519 Apolipoprotein(a) LPA 1 62.50 
P08519 Apolipoprotein(a) LPA 2 68.75 
O75882 Attractin ATRN 2 62.50 
P61769 Beta-2-microglobulin B2M 9 87.50 
P04003 C4b-binding protein alpha chain C4BPA 1 100 
P04003 C4b-binding protein alpha chain C4BPA 2 100 
P04003 C4b-binding protein alpha chain C4BPA 3 100 
P04003 C4b-binding protein alpha chain C4BPA 4 93.75 
P04003 C4b-binding protein alpha chain C4BPA 5 100 
P04003 C4b-binding protein alpha chain C4BPA 6 93.75 
P04003 C4b-binding protein alpha chain C4BPA 7 100 
P04003 C4b-binding protein alpha chain C4BPA 9 50.00 
P15169 Carboxypeptidase N catalytic chain CPN1 5 56.25 
P15169 Carboxypeptidase N catalytic chain CPN1 9 68.75 
O43866 CD5 antigen-like CD5L 5 75.00 
O43866 CD5 antigen-like CD5L 6 56.25 
O43866 CD5 antigen-like CD5L 9 81.25 
P00450 Ceruoplasmin CP 2 87.50 
P00450 Ceruoplasmin CP 3 100 
P00450 Ceruoplasmin CP 4 81.25 
P00450 Ceruoplasmin CP 5 81.25 
P00450 Ceruoplasmin CP 6 75.00 
P06276 Cholinesterase BCHE 3 50.00 
P10909 Clusterin CLU 5 62.50 
P10909 Clusterin CLU 6 87.50 
P12259 Coagulation factor V F5 1 62.50 
P00742 Coagulation factor X F10 5 75.00 
P02747 
Complement C1q subcomponent 
subunit C 
C1QC 1 87.50 
P02747 
Complement C1q subcomponent 
subunit C 
C1QC 2 56.25 
P02747 
Complement C1q subcomponent 
subunit C 




Complement C1q subcomponent 
subunit C 
C1QC 7 87.50 
P00736 Complement C1r subcomponent C1R 3 62.50 
P09871 Complement C1s subcomponent C1S 3 81.25 
P09871 Complement C1s subcomponent C1S 4 50.00 
P06681 Complement C2 C2 3 87.50 
P01024 Complement C3 C3 1 100 
P01024 Complement C3 C3 2 100 
P01024 Complement C3 C3 3 100 
P01024 Complement C3 C3 4 100 
P01024 Complement C3 C3 5 100 
P01024 Complement C3 C3 6 100 
P01024 Complement C3 C3 7 100 
P01024 Complement C3 C3 8 93.75 
P01024 Complement C3 C3 9 87.50 
P0C0L4 Complement C4-A C4A 1 56.25 
P0C0L4 Complement C4-A C4A 2 93.75 
P0C0L4 Complement C4-A C4A 3 100 
P0C0L4 Complement C4-A C4A 4 93.75 
P0C0L4 Complement C4-A C4A 5 100 
P0C0L4 Complement C4-A C4A 6 100 
P0C0L4 Complement C4-A C4A 7 100 
P0C0L4 Complement C4-A C4A 8 100 
P0C0L4 Complement C4-A C4A 9 100 
P0C0L4 Complement C4-A C4A 10 50.00 
P01031 Complement C5 C5 1 100 
P01031 Complement C5 C5 2 87.50 
P13671 Complement component C6 C6 2 81.25 
P13671 Complement component C6 C6 3 100 
P13671 Complement component C6 C6 5 62.50 
P10643 Complement component C7 C7 3 56.25 
P07357 
Complement component C8 alpha 
chain 
C8A 5 75.00 
P07360 
Complement component C8 gamma 
chain 
C8G 8 87.50 
P02748 Complement component C9 C9 1 56.25 
P02748 Complement component C9 C9 2 56.25 
P02748 Complement component C9 C9 4 75.00 
P00751 Complement factor B CFB 1 56.25 
P00751 Complement factor B CFB 2 68.75 
P00751 Complement factor B CFB 3 100 
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P00751 Complement factor B CFB 6 81.25 
P00751 Complement factor B CFB 8 68.75 
P00751 Complement factor B CFB 9 75.00 
P00751 Complement factor B CFB 10 50.00 
P00746 Complement factor D CFD 7 75.00 
P08603 Complement factor H (CFH) CFH 1 87.50 
P08603 Complement factor H (CFH) CFH 2 100 
P08603 Complement factor H (CFH) CFH 3 100 
P08603 Complement factor H (CFH) CFH 4 62.50 
P08603 Complement factor H (CFH) CFH 5 87.50 
P08603 Complement factor H (CFH) CFH 6 87.50 
P08603 Complement factor H (CFH) CFH 7 87.50 
P08603 Complement factor H (CFH) CFH 8 93.75 
P08603 Complement factor H (CFH) CFH 9 100 
P08603 Complement factor H (CFH) CFH 10 68.75 
P05156 Complement factor I CFI 6 62.50 
Q03591 
Complemet Factor H related protein 1 
(FHR-1) 
CFHR1 5 87.50 
Q03591 
Complemet Factor H related protein 1 
(FHR-1) 
CFHR1 6 68.75 
Q03591 
Complemet Factor H related protein 1 
(FHR-1) 
CFHR1 8 87.50 
Q03591 
Complemet Factor H related protein 1 
(FHR-1) 
CFHR1 9 68.75 
P36980 Complemet Factor H related protein 2 CFHR2 6 75.00 
P02741 C-reactive protein CRP 1 50.00 
P02679 Fibrinogen γ chain (FGγ) FGG 3 81.25 
P02679 Fibrinogen γ chain (FGγ) FGG 5 93.75 
P02679 Fibrinogen γ chain (FGγ) FGG 6 62.50 
P02671 Fibrinogen-α-Chain (FGα) FGA 1 93.75 
P02671 Fibrinogen-α-Chain (FGα) FGA 2 100 
P02671 Fibrinogen-α-Chain (FGα) FGA 3 100 
P02671 Fibrinogen-α-Chain (FGα) FGA 4 100 
P02671 Fibrinogen-α-Chain (FGα) FGA 5 100 
P02671 Fibrinogen-α-Chain (FGα) FGA 6 100 
P02671 Fibrinogen-α-Chain (FGα) FGA 7 100 
P02671 Fibrinogen-α-Chain (FGα) FGA 8 100 
P02671 Fibrinogen-α-Chain (FGα) FGA 9 87.50 
P02671 Fibrinogen-α-Chain (FGα) FGA 10 50.00 
P02675 Fibrinogen-β-Chain (FGβ) FGB 1 81.25 
P02675 Fibrinogen-β-Chain (FGβ) FGB 2 93.75 
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P02675 Fibrinogen-β-Chain (FGβ) FGB 3 93.75 
P02675 Fibrinogen-β-Chain (FGβ) FGB 4 87.50 
P02675 Fibrinogen-β-Chain (FGβ) FGB 5 100 
P02675 Fibrinogen-β-Chain (FGβ) FGB 6 87.50 
P02675 Fibrinogen-β-Chain (FGβ) FGB 7 100 
P02675 Fibrinogen-β-Chain (FGβ) FGB 8 87.50 
P02675 Fibrinogen-β-Chain (FGβ) FGB 9 87.50 
P02675 Fibrinogen-β-Chain (FGβ) FGB 10 50.00 
P02751 Fibronectin FN1 1 100 
P02751 Fibronectin FN1 2 93.75 
P02751 Fibronectin FN1 3 93.75 
Q15485 Ficolin-2 FCN2 6 81.25 
O75636 Ficolin-3 FCN3 6 75.00 
P06396 Gelsolin GSN 2 56.25 
P06396 Gelsolin GSN 3 93.75 
P06396 Gelsolin GSN 4 56.25 
P06396 Gelsolin GSN 5 75.00 
P06396 Gelsolin GSN 6 56.25 
P22352 Glutathione Peroxidase 3 GPX3 7 87.50 
P22352 Glutathione Peroxidase 3 GPX3 8 56.25 
P00738 Haptoglobin (HP) HP 2 68.75 
P00738 Haptoglobin (HP) HP 3 75.00 
P00738 Haptoglobin (HP) HP 5 100 
P00738 Haptoglobin (HP) HP 6 93.75 
P00738 Haptoglobin (HP) HP 7 81.25 
P00738 Haptoglobin (HP) HP 8 81.25 
P00739 Haptoglobin-related protein HPR 5 62.50 
P00739 Haptoglobin-related protein HPR 6 81.25 
P00739 Haptoglobin-related protein HPR 9 68.75 
P02790 Hemopexin HPX 1 62.50 
P02790 Hemopexin HPX 2 87.50 
P02790 Hemopexin HPX 3 100 
P02790 Hemopexin HPX 4 93.75 
P02790 Hemopexin HPX 5 100 
P02790 Hemopexin HPX 6 87.50 
P02790 Hemopexin HPX 7 87.50 
P02790 Hemopexin HPX 8 87.50 
P02790 Hemopexin HPX 9 56.25 
P05546 Heparin cofactor 2 SERPIND1 4 68.75 
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P04196 Histidine-rich glycoprotein  HRG 1 75.00 
P04196 Histidine-rich glycoprotein  HRG 3 68.75 
P04196 Histidine-rich glycoprotein  HRG 4 75.00 
P04196 Histidine-rich glycoprotein  HRG 5 62.50 
P04196 Histidine-rich glycoprotein  HRG 6 56.25 
P01876 Ig alpha-1 chain C region IGHA1 1 93.75 
P01876 Ig alpha-1 chain C region IGHA1 2 93.75 
P01876 Ig alpha-1 chain C region IGHA1 3 87.50 
P01876 Ig alpha-1 chain C region IGHA1 4 93.75 
P01876 Ig alpha-1 chain C region IGHA1 5 93.75 
P01876 Ig alpha-1 chain C region IGHA1 6 100 
P01876 Ig alpha-1 chain C region IGHA1 7 100 
P01876 Ig alpha-1 chain C region IGHA1 8 100 
P01876 Ig alpha-1 chain C region IGHA1 9 93.75 
P01877 Ig alpha-2 chain C region IGHA2 2 75.00 
P01877 Ig alpha-2 chain C region IGHA2 3 81.25 
P01877 Ig alpha-2 chain C region IGHA2 4 81.25 
P01877 Ig alpha-2 chain C region IGHA2 5 87.50 
P01877 Ig alpha-2 chain C region IGHA2 6 56.25 
P01860 Ig gamma-3 chain C region IGHG3 1 93.75 
P01860 Ig gamma-3 chain C region IGHG3 2 81.25 
P01860 Ig gamma-3 chain C region IGHG3 3 100 
P01860 Ig gamma-3 chain C region IGHG3 4 87.50 
P01860 Ig gamma-3 chain C region IGHG3 5 100 
P01860 Ig gamma-3 chain C region IGHG3 6 81.25 
P01860 Ig gamma-3 chain C region IGHG3 7 100 
P01768 Ig heavy chain V-III region CAM n/a 3 50.00 
P01768 Ig heavy chain V-III region CAM n/a 4 50.00 
P01768 Ig heavy chain V-III region CAM n/a 5 68.75 
P01768 Ig heavy chain V-III region CAM n/a 6 56.25 
P01768 Ig heavy chain V-III region CAM n/a 8 62.50 
P01768 Ig heavy chain V-III region CAM n/a 9 68.75 
P01781 Ig heavy chain V-III region GAL n/a 2 56.25 
P01781 Ig heavy chain V-III region GAL n/a 3 81.25 
P01781 Ig heavy chain V-III region GAL n/a 5 68.75 
P01781 Ig heavy chain V-III region GAL n/a 6 62.50 
P01781 Ig heavy chain V-III region GAL n/a 8 68.75 
P01781 Ig heavy chain V-III region GAL n/a 9 68.75 
P01780 Ig heavy chain V-III region JON n/a 5 87.50 
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P01762 Ig heavy chain V-III region TRO n/a 1 50.00 
P01762 Ig heavy chain V-III region TRO n/a 2 81.25 
P01762 Ig heavy chain V-III region TRO n/a 3 93.75 
P01762 Ig heavy chain V-III region TRO n/a 4 68.75 
P01762 Ig heavy chain V-III region TRO n/a 5 100 
P01762 Ig heavy chain V-III region TRO n/a 6 100 
P01762 Ig heavy chain V-III region TRO n/a 8 68.75 
P01762 Ig heavy chain V-III region TRO n/a 9 75.00 
P01762 Ig heavy chain V-III region TRO n/a 10 50.00 
P01834 Ig kappa chain C region IGKC 3 62.50 
P01834 Ig kappa chain C region IGKC 6 56.25 
P01834 Ig kappa chain C region IGKC 7 100 
P06310 
Ig kappa chain V-II region RPMI 
6410 
n/a 7 75.00 
P06310 
Ig kappa chain V-II region RPMI 
6410 
n/a 8 62.50 
P04206 Ig kappa chain V-III region GOL n/a 7 87.50 
P18135 Ig kappa chain V-III region HAH IGKV3-20 7 87.50 
P18135 Ig kappa chain V-III region HAH IGKV3-20 8 50.00 
P01620 Ig kappa chain V-III region SIE n/a 7 93.75 
P04433 Ig kappa chain V-III region VG IGKV3D-11 7 87.50 
P04433 Ig kappa chain V-III region VG IGKV3D-11 8 62.50 
P01700 Ig lambda chain V-I region HA n/a 3 68.75 
P01700 Ig lambda chain V-I region HA n/a 7 81.25 
P01700 Ig lambda chain V-I region HA n/a 8 68.75 
P01700 Ig lambda chain V-I region HA n/a 9 62.50 
P0CG04 Ig lambda-1 chain C regions IGLC1 2 56.25 
P0CG04 Ig lambda-1 chain C regions IGLC1 6 68.75 
P0CG04 Ig lambda-1 chain C regions IGLC1 7 75.00 
P0CG04 Ig lambda-1 chain C regions IGLC1 8 68.75 
P0CG04 Ig lambda-1 chain C regions IGLC1 9 56.25 
P0CF74 Ig lambda-6 chain C region IGLC6 7 50.00 
A0M8Q6 Ig lambda-7 chain C region IGLC7 7 75.00 
P01871 Ig mu chain C region IGHM 5 56.25 
P01871 Ig mu chain C region IGHM 6 75.00 
P01871 Ig mu chain C region IGHM 7 56.25 
P01871 Ig mu chain C region IGHM 8 50.00 
P04220 Ig mu heavy chain disease protein n/a 1 50.00 
P04220 Ig mu heavy chain disease protein n/a 2 62.50 
P04220 Ig mu heavy chain disease protein n/a 3 68.75 
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P04220 Ig mu heavy chain disease protein n/a 4 62.50 
P01591 Immunoglobulin J chain IGJ 7 50.00 
P19827 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
ITIH1 1 100 
P19827 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
ITIH1 2 87.50 
P19827 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
ITIH1 3 100 
P19827 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
ITIH1 4 62.50 
P19827 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
ITIH1 5 50.00 
P19827 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
ITIH1 8 62.50 
P19827 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
ITIH1 9 62.50 
P19823 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
ITIH2 1 100 
P19823 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
ITIH2 2 93.75 
P19823 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
ITIH2 3 100 
P19823 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
ITIH2 4 75.00 
P19823 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
ITIH2 5 75.00 
P19823 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
ITIH2 8 56.25 
Q06033 
Inter-alpha-trypsin inhibitor heavy 
chain H3 
ITIH3 1 75.00 
Q06033 
Inter-alpha-trypsin inhibitor heavy 
chain H3 
ITIH3 2 56.25 
Q06033 
Inter-alpha-trypsin inhibitor heavy 
chain H3 
ITIH3 3 75.00 
Q14624 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
ITIH4 1 56.25 
Q14624 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
ITIH4 2 87.50 
Q14624 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
ITIH4 3 100 
Q14624 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
ITIH4 5 93.75 
Q14624 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
ITIH4 6 56.25 
P29622 Kallistatin SERPINA4 1 75.00 
P29622 Kallistatin SERPINA4 5 56.25 
P01042 Kininogen-1 KNG1 3 81.25 
P02750 Leucine-rich alpha-2-glycoprotein LRG1 5 87.50 
Q9H8L6 Multimerin-2 MMRN2 8 50.00 
P32119 Peroxiredoxin-2 PRDX2 7 62.50 
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GPLD1 3 68.75 
P36955 Pigment epithelium-derived factor SERPINF1 5 81.25 
P03952 Plasma kallikrein KLKB1 3 93.75 
P00747 Plasminogen PLG 1 62.50 
P00747 Plasminogen PLG 2 93.75 
P00747 Plasminogen PLG 3 100 
P00747 Plasminogen PLG 4 62.50 
P00747 Plasminogen PLG 5 87.50 
P00747 Plasminogen PLG 6 81.25 
P00747 Plasminogen PLG 7 93.75 
P00747 Plasminogen PLG 9 62.50 
P02775 Platelet basic protein PPBP 9 87.50 
Q92620 Pre-mRNA-splicing factor DHX38 2 87.50 
Q92620 Pre-mRNA-splicing factor DHX38 3 81.25 
Q92620 Pre-mRNA-splicing factor DHX38 5 62.50 
P02760 Protein AMBP AMBP 6 75.00 
Q92954 Proteoglycan 4 PRG4 9 50.00 
P00734 Prothrombin F2 3 81.25 
P00734 Prothrombin F2 4 87.50 
P00734 Prothrombin F2 5 68.75 
P00734 Prothrombin F2 6 68.75 
A6NIZ1 
Ras-related protein Rap-1b-like 
protein 
RAP1BL 7 62.50 
P02753 Retinol-binding protein 4 RBP4 9 62.50 
P02753 Retinol-binding protein 5 RBP4 7 87.50 
P02753 Retinol-binding protein 6 RBP4 8 87.50 
Q13103 Secreted phosphoprotein 24 SPP2 8 50.00 
P02787 Serotransferrin TF 1 87.50 
P02787 Serotransferrin TF 2 100 
P02787 Serotransferrin TF 3 100 
P02787 Serotransferrin TF 4 93.75 
P02787 Serotransferrin TF 5 100 
P02787 Serotransferrin TF 6 100 
P02787 Serotransferrin TF 7 100 
P02787 Serotransferrin TF 8 100 
P02787 Serotransferrin TF 9 100 
P02787 Serotransferrin TF 10 75.00 
P35542 Serum amyloid A-4 protein SAA4 8 100 
488 
 
P35542 Serum amyloid A-4 protein SAA4 9 93.75 
P35542 Serum amyloid A-4 protein SAA4 10 56.25 
P02743 Serum amyloid P-component APCS 7 93.75 
P27169 Serum paraoxonase/arylesterase 1 PON1 5 56.25 
Q9H299 
SH3 domain-binding glutamic acid-
rich-like protein 3 
SH3BGRL3 9 68.75 
Q9H299 
SH3 domain-binding glutamic acid-
rich-like protein 3 
SH3BGRL3 10 50.00 
P02549 Spectrin alpha chain, erythrocytic 1 SPTA1 7 56.25 
P35443 Thrombospondin-4 THBS4 8 68.75 
P02766 Transthyretin TTR 6 56.25 
P02766 Transthyretin TTR 8 93.75 
P02766 Transthyretin TTR 9 93.75 
P02766 Transthyretin TTR 10 56.25 
P07225 Vitamin K-dependent protein S PROS1 3 81.25 
P04004 Vitronectin VTN 9 50.00 
P04275 von Willebrand factor VWF 1 68.75 
P04275 von Willebrand factor VWF 2 75.00 
P25311 Zinc-alpha-2-glycoprotein AZGP1 5 87.50 
P25311 Zinc-alpha-2-glycoprotein AZGP1 6 75.00 












Appendix 2. MS/MS spectra assignments for protein groups not selected for technical replication in Chapter 3. 
 
 
MS/MS spectrum of m/z 627.33 the [M+3H]
3+ 
molecular ion for a peptide of 1879.97 Da with corresponding sequence AKAYLEEECPATLR unique 







MS/MS spectrum of m/z 523.30 the [M+3H]
3+ 
molecular ion for a peptide of 2090.21 Da with corresponding sequence YKQKFQSVFTVTR unique 







MS/MS spectrum of m/z 593.64 the [M+3H]
3+ 
molecular ion for a peptide of 1778.91 Da with corresponding sequence KPIWLSQMSCSGR unique 







MS/MS spectrum of m/z 408.22 the [M+3H]
3+ 
molecular ion for a peptide of 1222.65 Da with corresponding sequence KCYGPGVGR unique to CD5 









MS/MS spectrum of m/z 628.35 the [M+4H]
4+ 
molecular ion for a peptide of 2510.40 Da with corresponding sequence 








MS/MS spectrum of m/z 380.48 the [M+4H]
4+ 
molecular ion for a peptide of 1518.91 Da with corresponding sequence RPYLKVFNPR unique 







MS/MS spectrum of m/z 381.56 the [M+3H]
3+ 
molecular ion for a peptide of 1142.67 Da with corresponding sequence KPELVNGR unique to C4b-





MS/MS spectrum of m/z 616.60 the [M+4H]
4+ 
molecular ion for a peptide of 2463.38 Da with corresponding sequence 








MS/MS spectrum of m/z 368.23 the [M+3H]
3+ 
molecular ion for a peptide of 1102.69 Da with corresponding sequence LKVFNPR unique to pre-






 MS/MS spectrum of m/z 358.85 the [M+3H]
3+ 
molecular ion for a peptide of 1074.55 Da with corresponding sequence FAHNVVTMR unique 







MS/MS spectrum of m/z 381.56 the [M+3H]
3+ 
molecular ion for a peptide of 1142.67 Da with corresponding sequence KPELVNGR unique to C4b-






MS/MS spectrum of m/z 681.31 the [M+3H]
3+ 
molecular ion for a peptide of 2041.93 Da with corresponding sequence 
QAQCGQDFQCKETGR unique to complement component C8 alpha chain identified in 1DGE fraction 5 as significant (P value <0.05) between 







MS/MS spectrum of m/z 408.22 the [M+3H]
3+ 
molecular ion for a peptide of 1222.65 Da with corresponding sequence KCYGPGVGR unique to CD5 








MS/MS spectrum of m/z 368.23 the [M+3H]
3+ 
molecular ion for a peptide of 1102.69 Da with corresponding sequence LKVFNPR unique to pre-








MS/MS spectrum of m/z 761.05 the [M+3H]
3+ 
molecular ion for a peptide of 2281.15 Da with corresponding sequence 






MS/MS spectrum of m/z 782.75 the [M+3H]
3+ 
molecular ion for a peptide of 2346.25 Da with corresponding sequence 








MS/MS spectrum of m/z 628.35 the [M+3H]
3+ 
molecular ion for a peptide of 2510.40 Da with corresponding sequence 








MS/MS spectrum of m/z 814.39 the [M+3H]
3+ 
molecular ion for a peptide of 2441.17 Da with corresponding sequence 







MS/MS spectrum of m/z 492.49 the [M+5H]
5+ 
molecular ion for a peptide of 2458.42 Da with corresponding sequence NIEKISMLEKIYIHPR unique 







MS/MS spectrum of m/z 588.65 the [M+3H]
3+ 
molecular ion for a peptide of 1763.94 Da with corresponding sequence WKNFPSPVDAAFR unique 








MS/MS spectrum of m/z 775.15 he [M+4H]
4+ 
molecular ion for a peptide of 3097.61 Da with corresponding sequence 








MS/MS spectrum of m/z 588.65 the [M+3H]
3+ 
molecular ion for a peptide of 1763.94 Da with corresponding sequence WKNFPSPVDAAFR unique 
to hemopexin identified in 1DGE fraction 5 as significant (P value <0.05) between PiB+ and PiB- group. 
511 
  
Appendix 3. Peptide profiles used for protein group MW isoforms identification (No TMT) and quantification (TMT) significantly 
associated with Aβ SUVR in Chapter 3.  
Peptide sequences for protein group MW isoforms significantly associated with Aβ SUVR. Peptide identifications (No TMT) were used as supporting 








Peptide Identifications Quantified (TMT) Peptides Identifications 
P01023 alpha-2-Macroglobulin (α2m) A2M 1 ATVLNYLPKCIR GEAFTLKATVLNYLPKCIR 
    
  
KPKMCPQLQQYEMHGPEGLR QKDNGCFR 
    
  
NQGNTWLTAFVLKTFAQAR QLNYKHYDGSYSTFGER 












P01023 alpha-2-Macroglobulin (α2m) A2M 2 GEAFTLKATVLNYLPKCIR ATVLNYLPKCIR 
  
   
GHFSISIPVKSDIAPVAR QKDNGCFR 
  
   
KDTVIKPLLVEPEGLEK QLNYKHYDGSYSTFGER 
  
   
KPKMCPQLQQYEMHGPEGLR TGKAAQVTIQSSGTFSSKFQVDNNNR 
  
   
NQGNTWLTAFVLKTFAQAR TITKLSFVKVDSHFR 
    
   
VVSMDENFHPLNELIPLVYIQDPKGNR 
P01023 alpha-2-Macroglobulin (α2m) A2M 2 KEYEMKLHTEAQIQEEGTVVELTGR GEAFTLKATVLNYLPKCIR 
    
  
KPKMCPQLQQYEMHGPEGLR QKDNGCFR 
    
  
VSVQLEASPAFLAVPVEKEQAPHCICANGR QLNYKHYDGSYSTFGER 
    
   
TGKAAQVTIQSSGTFSSKFQVDNNNR 
    
   
TITKLSFVKVDSHFR 
    




P02647 apolipoprotein A-I (apoA1) APOA1 5 EQLGPVTQEFWDNLEKETEGLR QKVEPLR 
    
   
VKDLATVYVDVLKDSGR 
P02647 apolipoprotein A-I (apoA1) APOA1 6 EQLGPVTQEFWDNLEKETEGLR AKPALEDLR 
    
  
LAARLEALKENGGAR LAEYHAK 
    
  
LHELQEKLSPLGEEMR LEALKENGGAR 
    
  
LLDNWDSVTSTFSKLR QKVEPLR 
    
  
QGLLPVLESFKVSFLSALEEYTKKLNTQ VSFLSALEEYTKKLNTQ 








P02647 apolipoprotein A-I (ApoA1) APOA1 9 
 
LEALKENGGAR 
    
   
QKVEPLR 
    
   
VKDLATVYVDVLKDSGR 
P02647 apolipoprotein A-I (apoA1) APOA1 10 LEALKENGGAR EQLGPVTQEFWDNLEKETEGLR 
P06727 apolipoprotein A-IV (apoA4) APOA4 6 RVEPYGENFNKALVQQMEQLR GNTEGLQKSLAELGGHLDQQVEEFR 
    
  
QKLGPHAGDVEGHLSFLEKDLR LLPHANEVSQKIGDNLR 
O14791 apolipoprotein L1 (apoL1) APOL1 5 LKSELEDNIR KALDNLAR 
    
   
VTEPISAESGEQVER 
P08519 apolipoprotein(a) LPA 1 NPDSGKQPWCYTTDPCVR TPAYYPNAGLIKNYCR 
P04003 C4b-binding protein alpha chain C4BPA 4 GVGWSHPLPQCEIVK FKTGTTLKYTCLPGYVR 
    
   
KPELVNGR 
    
   
QSTLDKEL 
P04003 C4b-binding protein alpha chain C4BPA 7 WTPYQGCEALCCPEPKLNNGEITQHR KPELVNGR 
O43866 CD5 antigen-like CD5L 5 
 
KCYGPGVGR 
    
   
KPIWLSQMSCSGR 
    




    
   
VEVEQKGQWGTVCDDGWDIKDVAVLCR 
O43866 CD5 antigen-like CD5L 6 
 
KCYGPGVGR 
    
   
KPIWLSQMSCSGR 
P00450 ceruloplasmin CP 2 FNKNNEGTYYSPNYNPQSR LYKKALYLQYTDETFR 
    
  
KERGPEEEHLGILGPVIWAEVGDTIR RPYLKVFNPR 








P10909 clusterin CLU 6 
 
EILSVDCSTNNPSQAKLR 
    
   
KNPKFMETVAEKALQEYR 
    
   
RPHFFFPKSR 
P02747 





P01024 complement C3 C3 6 AEDLVGK EGVQKEDIPPADLSDQVPDTESETR 
    
  
FISLGEACKKVFLDCCNYITELR IFTVNHKLLPVGR 
    
  
ISLPESLKR KVLLDGVQNPR 
    
  
KCCEDGMR QPVPGQQMTLKIEGDHGAR 
    
  
LDKACEPGVDYVYKTR TKKQELSEAEQATR 
    
  
QPSSAFAAFVKR VELLHNPAFCSLATTKR 
    
  
SSKITHR YYTYLIMNKGR 








P01024 complement C3 C3 8 IFTVNHKLLPVGR TKKQELSEAEQATR 




P0C0L4 complement C4-A C4A 1 CSVFYGAPSKSR DKGQAGLQR 






P0C0L4 complement C4-A C4A 7 GQVVKGSVFLR LLATLCSAEVCQCAEGKCPR 
    
  
NNVPCSPKVDFTLSSER MKFACYYPR 




P13671 complement component C6 C6 2 GEVLDNSFTGGICKTVKSSR IGESIELTCPKGFVVAGPSR 





















complement component C8 alpha 
chain 
C8A 5 HTSLGPLEAKR KVQTQAC 
P00751 complement factor B CFB 1 DAQYAPGYDKVKDISEVVTPR DLLYIGKDR 
    
  
STGSWSTLKTQDQKTVR QKQVPAHAR 
P08603 complement factor H (CFH) CFH 6 KGEWVALNPLR FQYKCNMGYEYSER 
    
   
TTCWDGKLEYPTCAK 
    
   
QMSKYPSGER 
Q03591 
complement factor H related protein 
1 (FHR-1) 
CFHR1 8 TTCWDGKLEYPTCAK ITCTEEGWSPTPKCLR 
    
   
TGESAEFVCKR 
P02671 fibrinogen α chain (FGα) FGA 4 AQLVDMKR GKSSSYSKQFTSSTSYNR 
    
  
EVDLKDYEDQQKQLEQVIAKDLLPSR LEVDIDIKIR 
    
  
HQSACKDSDWPFCSDEDWNYKCPSGCR MKGLIDEVNQDFTNR 
    
  
KVIEKVQHIQLLQKNVR TGKEKVTSGSTTTTR 
P02679 fibrinogen γ chain (FGγ) FGG 6 VGPEADKYR KMLEEIMKYEASILTHDSSIR 
    
   
TSTADYAMFKVGPEADKYR 





P06396 gelsolin GSN 5 IEGSNKVPVDPATYGQFYGGDSYIILYNYR LKATQVSKGIR 
    
   
LFACSNKIGR 
P00738 hapoglobin HP 5 FTDHLKYVMLPVADQDQCIR NANFKFTDHLKYVMLPVADQDQCIR 
    
   
QKVSVNER 
    
   
VMPICLPSKDYAEVGR 
P00738 hapoglobin HP 8 NYYKLR VMPICLPSKDYAEVGR 
P02790 hemopexin  HPX 5 
 
LEKEVGTPHGIILDSVDAAFICPGSSR 
    
   
WKNFPSPVDAAFR 
P02790 hemopexin  HPX 6 
 
WKNFPSPVDAAFR 
P04196 histidine-rich glycoprotein (HRG) HRG 3 
 
KYWNDCEPPDSR 
    
   
RPSEIVIGQCKVIATR 
P19827 
Inter-alpha-trypsin inhibitor heavy 
chain H3 
ITIH3 2 DYIFGNYIER FAHNVVTMR 
    
  
KLEQTKEALLR LWAYLTIEQLLEKR 
Q92620 pre-mRNA-splicing factor DHX38 2 
 
LKVFNPR 
Q92620 pre-mRNA-splicing factor DHX38 5 
 
LKVFNPR 
P00734 prothrombin F2 6 ETAASLLQAGYKGR DKLAACLEGNCAEGLGTNYR 
    
  
KSPQELLCGASLISDR NIEKISMLEKIYIHPR 
P02787 serotransferrin TF 1 GKKSCHTAVGR NTYEKYLGEEYVKAVGNLR 
    
  
MDAKMYLGYEYVTAIR SAGWNIPMGLLYNKINHCR 











Appendix 4. Full list of protein groups (n = 1085) identified in >50% of samples 
and used for statistical association with neocortical Aβ burden in Chapter 5 
(listed as gene names). 
A1BG AKNA APOC1 ATR C10orf68 
A2M ALB APOC2 ATRN C12orf40 
ABCA1 ALKBH8 APOC3 ATRX C17orf100 
ABCA12 ALMS1 APOC4 AZGP1 C1orf168 
ABCA13 ALMS1P APOD B2M C1orf173 
ABCA6 ALOXE3 APOE B3GALT2 C1orf222 
ABCC1 ALS2CR11 APOF B3GNT9 C1orf65 
ABCC8 AMBP APOH BAIAP2 C1QA 
ABHD10 ANK1 APOL1 BAZ2B C1QB 
ABHD6 ANK2 APOM BCHE C1QC 
ABL1 ANK3 APP BCORL1 C1R 
ABL2 ANKRD12 ARAP1 BDNF C1RL 
ACACB ANKRD18A ARFGAP2 BDP1 C1S 
ACADVL ANKRD26 ARFGEF1 BICD1 C2 
ACCSL ANKRD32 ARFGEF2 BIRC2 C2orf16 
ACTB ANKRD36B ARHGAP21 BIRC3 C2orf78 
ACVRL1 ANKRD62 ARHGAP39 BIRC6 C3 
ADAM28 ANPEP ARHGEF1 BLOC1S6 C4A 
ADAMTSL1 AP4E1 ARHGEF25 BNC2 C4B 
ADAT1 APBA2 ARID4B BOD1L1 C4BPA 
ADGB APBB3 ARID5B BPTF C4BPB 
AFM APC ASH1L BRCA1 C4orf21 
AGT APCS ASNSD1 BRCA2 C5 
AHNAK APLP2 ASPM BROMI C5orf42 
AHNAK2 APMAP ASXL1 BRWD3 C6 
AHSG APOA1 ATAD2 BSN C6orf10 
AIFM3 APOA2 ATAD5 BTAF1 C6orf163 
AK9 APOA4 ATF7IP2 BTD C7 
AKAP6 APOB ATP13A2 BTK C8A 




C8G CD163 CFI CPN1 DHX32 
C9 CD44 CFL2 CPN2 DHX34 
C9orf126 CD5L CFP CPS1 DIP2B 
CA5A CDC42EP4 CGNL1 CRABP2 DISP1 
CADPS2 CDH13 CHD1 CRHR1 DKFZp571N1833 
CAGE1 CDH2 CHD3 CRISP3 DKK3 
CAMP CDH5 CHD5 CROCC DKKL1 
CAPRIN2 CDK1 CHD7 CRTAC1 DMD 
CASC2 CDK5RAP2 CHIT1 CRYAA DMXL1 
CASP8AP2 CDKL2 CHL1 CSDE1 DNA2 
CBR3 CECR2 CKAP5 CSMD2 DNAH1 
CCDC101 CENPE CLEC3B CST3 DNAH10 
CCDC146 CENPF CLIP1 CTAGE5 DNAH12 
CCDC147 CENPQ CLIP4 CTIF DNAH14 
CCDC149 CEP112 CLU CUL3 DNAH17 
CCDC152 CEP128 CMYA5 CUL9 DNAH2 
CCDC157 CEP135 CNDP1 CUX1 DNAH3 
CCDC168 CEP152 CNGB3 CWF19L2 DNAH5 
CCDC18 CEP250 CNNM4 CYC1 DNAH6 
CCDC180 CEP290 CNOT1 CYP2W1 DNAH8 
CCDC30 CEP350 CNTLN DAPK1 DNAH9 
CCDC39 CEP85 CNTRL DARS DNAJC16 
CCDC66 CEP89 COBLL1 DDX10 DNASE1L3 
CCDC73 CFB COL24A1 DDX19B DNHD1 
CCDC77 CFD COL6A5 DDX47 DNM1L 
CCDC88C CFH COLEC12 DDX49 DNM2 
CCDC9 CFHR1 COMP DEAF1 DNM3 
CCDC91 CFHR2 COPS7B DEFA1 DOCK10 
CCT3 CFHR3 CP DENND3 DOCK4 





DOPEY2 EPB41 FARSB FYTTD1 GSN 
DOT1L EPHB2 FAT1 G6PD GVINP1 
DPP9 EPPK1 FAT2 GANC HABP2 
DSC1 EPRS FAT4 GART HACE1 
DSCAM ERBB4 FBLN1 GBF1 HAUS3 
DSP ERC1 FBXO3 GC HBA1 
DST EVPL FCGR3B GCC2 HBB 
DTX3L EYS FCN2 GCSAM HBD 
DUOX1 F10 FCN3 GFAP HCN2 
DYNC1H1 F11 FDXACB1 GINS1 HDAC3 
DYNC2H1 F12 FER1L6 GIT2 HDAC9 
DZIP3 F13A1 FES GK HEATR1 
ECM1 F13B FETUB GLIPR1L1 HEATR3 
ECM29 F2 FEZ2 GMFG HECTD3 
EDF1 F5 FGA GNN HECTD4 
EDRF1 F9 FGB GOLGA1 HEG1 
EFCAB5 FAF1 FGF14 GOLGA2 HELZ 
EFCAB6 FAM111B FGG GOLGA3 HERC1 
EFEMP1 FAM160A2 FHAD1 GOLGA4 HERC2 
EFHC2 FAM178A FHOD3 GOLGA6C HERC6 
EFHD2 FAM179A FLNC GOLGB1 HGFAC 
EHBP1L1 FAM184A FMN2 GPLD1 HGS 
EHD1 FAM184B FN1 GPR115 HK1 
EIF2AK2 FAM186A FREM1 GPR126 HLTF 
EIF5B FAM188A FRMPD1 GPR155 HMBOX1 
ELMOD2 FAM76A FRY GPR98 HMGB4 
EMILIN2 FAM81A FSIP2 GPS1 HMGXB3 
EML5 FAM83B FUT8 GPSM2 HMMR 
ENTHD1 FAN1 FYB GPX3 HOXC13 





HP IGKC ITIH5 KIAA2026 LAMA3 
HPR IGLC2 ITPR1 KIDINS220 LAMA4 
HPS5 IGLC3 ITPR2 KIF15 LATS2 
HPX IGLC6 IVL KIF16B LBP 
HRG IGLC7 IZUMO1 KIF20B LCAT 
HRNR IGLL5 JAG1 KIF21B LCP2 
HSP90AA5P IGSF9 JAK1 KIF3B LDHA 
HSPA5 IL10 JAK2 KIF4A LDHB 
HSPD1 IL10RA JARID1B KIF4B LGALS3BP 
HYDIN IL13RA1 JMJD1C KIF5C LIMK1 
IAH1 IL17RA JPH1 KLKB1 LNPEP 
IBTK IL18RAP JPH3 KMT2C LOXHD1 
ICA1 IL19 KALRN KMT2D LOXL4 
IFI44 IL1RAP KANK1 KNG1 LPA 
IFT74 IL2 KANK2 KNTC1 LRG1 
IGF1 IL3 KANSL1 KPNA7 LRP1 
IGF2 ILF2 KCNH4 KRT1 LRP12 
IGFALS INCENP KCNJ8 KRT10 LRP1B 
IGFBP3 INPP4A KDM2B KRT13 LRP2 
IGFN1 INPP5B KDM3A KRT18 LRP5 
IGHA1 INPP5D KDM5A KRT2 LRP6 
IGHA2 INTS3 KIAA0100 KRT20 LRRC43 
IGHD INTU KIAA0196 KRT222 LRRC59 
IGHG1 INVS KIAA0753 KRT36 LRRC66 
IGHG2 ISPD KIAA1109 KRT5 LRRIQ3 
IGHG3 ITGAM KIAA1217 KRT6B LRRK1 
IGHG4 ITIH1 KIAA1328 KRT8 LRRN1 
IGHM ITIH2 KIAA1430 KRT9 LRSAM1 
IGHMBP2 ITIH3 KIAA1524 KTN1 LTF 





LUZP1 MMRN2 MYO1E NKRF PAEP 
LUZP2 MOCOS MYO5A NKTR PAK6 
LYST MPHOSPH8 MYO5B NOL8 PAPD4 
MACF1 MPZL3 MYO9A NOLC1 PARP11 
MAN1A1 MRAS MYOM3 NPHP1 PARP4 
MAP1B MRPS28 MYT1L NPY2R PARPBP 
MAP2 MST1 N4BP2 NPY5R PBRM1 
MAP3K19 MST1L NALCN NRAP PCCA 
MAP3K7 MTBP NARG2 NRCAM PCDH9 
MAP4 MTDH NAV1 NRGN PCDHA3 
MAPK7 MTFMT NAV2 NRXN1 PCDHB15 
MAPK9 MTHFR NAV3 NRXN2 PCF11 
MAPKAPK5 MTOR NBEA NSD1 PCLO 
MAPT MTRF1 NCAM1 NSRP1 PCNT 
MASP1 MTX2 NCOR2 NUMA1 PCNX 
MASP2 MUC12 NDUFAF6 NUP153 PCYOX1 
MAT1A MUC16 NEB NUP214 PDS5A 
MCM3AP MUC2 NEFL OBSCN PELP1 
MDGA1 MXRA5 NEFM ODF2L PEPD 
MDN1 MYBBP1A NEK1 OPHN1 PGAM2 
MED14 MYCBP2 NEK3 OR4D9 PGLYRP2 
MED22 MYH10 NEK9 OR52I2 PHLDB1 
MED30 MYH11 NEMF OR8G5 PI16 
MED30S MYH13 NEO1 ORC2 PI4KA 
MET MYH15 NEUROG2 ORM1 PIBF1 
MFN1 MYH7 NF1 ORM2 PIEZO2 
MFSD6 MYH7B NHSL1 OSBPL10 PIGR 
MGA MYH9 NIN OTOF PIK3C2A 
MICALL2 MYLK NINL P4HA3 PIK3C2B 





PITPNA PRKCQ RB1CC1 RRBP1 SERPINA7 
PIWIL1 PRKDC RBM44 RSF1 SERPINC1 
PKD1L2 PROC RBP4 RTTN SERPIND1 
PKHD1 PROS1 RC3H1 RUFY2 SERPINF1 
PKP4 PRPH RCOR3 RYR1 SERPINF2 
PLCB1 PRSS1 RELA RYR2 SERPING1 
PLCB2 PRSS3 RERGL RYR3 SETD2 
PLCH1 PSMD1 REST SAA1 SETD3 
PLCL1 PSMD6 REV1 SAA2 SETDB1 
PLD2 PTPN13 REV3L SAA4 SF3B2 
PLEC PTPN22 RFC4 SACS SGCA 
PLEKHA7 PTPN23 RHBDF2 SAMD9 SGOL2 
PLG PTPRG RIMBP3C SARS SH3GL1 
PLXDC2 PZP RIMS2 SBSN SHANK1 
PLXNA2 QSOX1 RIMS3 SCAPER SHBG 
PLXND1 R3HDM2 RIN2 SCARB1 SHROOM3 
PMFBP1 RAB17 RLTPR SCEL SIGLEC16 
POLQ RAB3GAP2 RNASE4 SCN2A SIPA1L1 
POM121L2 RABEP1 RNF20 SCN7A SIPA1L3 
PON1 RAD18 RNF213 SCYL2 SIRPB2 
PON3 RAD54B RNH1 SELL SLBP 
PPBP RALGAPA2 RNMTL1 SEMA3F SLC16A10 
PPFIBP2 RANBP2 ROBO1 SENP5 SLC25A14 
PPL RAPGEF2 ROCK2 SEPP1 SLC29A1 
PPP1R12A RAPGEF4 RPAP3 SERPINA1 SLC4A1AP 
PPP1R26 RAPGEF6 RPL37A SERPINA10 SLC4A7 
PRDM4 RARA RPL7 SERPINA3 SLC6A2 
PRDX2 RARRES2 RPRD2 SERPINA4 SLK 
PRG4 RASA2 RPS6KA3 SERPINA5 SLMAP 





SLX4IP SRRM1 TET1 TPR UNC45A 
SMC2 SSRP1 TET2 TRAK1 UNKL 
SMC3 ST18 TET3 TRANK1 UPF1 
SMC4 STAB2 TF TRIL URB1 
SMEK2 STAG1 TFRC TRIM65 USO1 
SMTN STARD9 TGFBI TRIO USP18 
SNAP25 STAT1 THBS1 TRIP11 USP20 
SNCA STIM1 THBS3 TRPC1 USP21 
SND1 STK31 THG1L TRPM3 USP42 
SNRPB2 STOX2 THUMPD2 TRRAP USP43 
SNX15 STX11 TIA1 TSEN2 UTP14C 
SOGA1 STXBP3 TIAM2 TSHZ3 UTP20 
SOGA2 STXBP5L TIE1 TSLP UTRN 
SORBS1 SUPT6H TIFA TTC17 VASN 
SORBS3 SYCP1 TIGD1 TTC28 VCAM1 
SOX15 SYMPK TIGD2 TTC7B VCAN 
SPAG17 SYN1 TLN1 TTLL6 VCL 
SPAG9 SYNE1 TLN2 TTN VEZT 
SPATA16 SYNE2 TMEM131 TTR VIL1 
SPATA21 SYT16 TMEM57 TXLNG VIM 
SPEF2 SYTL2 TMF1 TYK2 VIPAS39 
SPERT TARBP1 TMPRSS11A UACA VPS11 
SPG11 TBC1D16 TMTC3 UBA6 VPS13A 
SPHKAP TBC1D32 TNFRSF10C UBR1 VPS13B 
SPP2 TBC1D9 TNKS UBR4 VPS13C 
SPTA1 TBX18 TNXB UBR5 VPS13D 
SPTB TCHH TOP2A UCHL5 VPS16 
SPTBN1 TDRD1 TP63 UGGT1 VPS33B 
SPTBN2 TDRD15 TPM3 ULK2 VTN 





WAPAL XIRP2 ZNF114 ZNF806 
WDFY3 YTHDC2 ZNF292 ZNF835 
WDR33 ZAR1L ZNF454 ZNF92 
WDR87 ZC3H12C ZNF462 ZNF93 
WDR96 ZC3H13 ZNF496 ZNF99 
WFDC3 ZCCHC6 ZNF518A ZPBP2 
WNK3 ZFC3H1 ZNF536 ZRANB3 
XIAP ZFHX4 ZNF683 ZZEF1 
XIRP1 ZNF106 ZNF804B 
 
 
 
